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II. Structure of this thesis 
The following paragraph provides general information about the structure of this work. 
This thesis generally consists of six main chapters, comprising Introduction, Objectives, 
Results, Summarising Discussion, Outlook and Appendix all written in English. Furthermore, 
a Summary is provided in English and German. 
The aim of the introduction is to familiarise the reader with the field of carbohydrates, 
especially sialic acids but also oligosaccharides and the fundamental processes of protein 
glycosylation, as well as to the field of sialic acid binding and processing proteins, including 
siglecs and trans-sialidases (TS). Although the main focus directs on the latter, whereas 
associated aims of this thesis are elucidated in the subsequent objectives chapter. 
The following results chapter is divided into five subchapters, two representing 
accepted publications (Chapter 3.1 and 3.2), one accepted manuscript (Chapter 3.4) and two 
manuscripts in preparation (Chapter 3.3 and 3.5). The first two chapters (3.1 and 3.2) describe 
the identification, cloning, expression and partial characterisation of 14 different, active TS 
from Trypanosoma congolense (T. congolense, TconTS) and their ability to transfer sialic 
acids from donor to acceptor glycoconjugates. Contents of chapter 3.3 comprise a detailed 
characterisation of TconTS regarding their pH optimum and enzymatic activities on blood 
glycoconjugates (serum glycoproteins) and fetuin. The following two chapters (3.4 and 3.5) 
focus on the lectin-like domain (LD) of TconTS and describe its carbohydrate binding 
activities and specificities (Chapter 3.4), as well as the influence on enzymatic catalysis 
(Chapter 3.5). Chapter 3.4 represents a manuscript, which has been recently accepted by the 
editorial board of PLOS-NTD and is currently in press. Chapter 3.3 and 3.5 are manuscripts 
under preparation, whereas latter has been prepared for future submission at PLOS-NTD, 
according to journal guidelines. 
A summary of all publications and manuscripts is given in the fourth chapter termed 
summarising discussion, which generally represents an evaluation bringing all findings and 
conclusions of each publication/manuscript together, subsequently followed by chapter 5, 
representing a short outlook for further research and possible applications. 
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III. Summary 
The study presented here addresses structural and functional relations of trans-sialidases 
(TS) from the African parasite Trypanosoma congolense and their biochemical 
characterisation. Parts of this work have already been published (Chapter 3.1, 3.2 and 3.4).  
TS are unusual enzymes found in the flagellate protozoan parasite Trypanosoma and 
catalyse the stereo and region specific transfer of terminal sialic acid (Sia) from donor sialo-
glycoconjugates to terminal galactose residues of suitable acceptor substrates, resulting in 
α2,3-sialylated glycoconjugates. Major research on trypanosomal TS has been done on 
Trypanosoma cruzi, the causative agent of Chagas’ disease in Latin America. However, only 
little has been known about TS from the African Trypanosoma congolense (TconTS), the 
prevalent causative agent of African animal Trypanosomiasis (AAT) in livestock and 
domestic animals also termed nagana.  
Preliminary search of the Welcome Trust Sanger Institute (WTSI) database using partial 
TconTS sequences revealed 11 closely related gene members termed TconTS1 sharing over 
90 % amino acid sequence identity, as well as 3 additional, more distantly related TconTS 
family members sharing only 40 % sequence identity and therefore termed TconTS2, 
TconTS3 and TconTS4, respectively. Besides these TconTS genes, encoding active enzymes, 
3 further gene members have been identified exhibiting only about 25 % amino acid sequence 
identity compared to TconTS1 and assumed to encode for inactive enzymes due to the lack of 
an tyrosine residue at the catalytic centre, known to be essential for catalysis and enzyme 
activity. All 11 TconTS1 variants as well as TconTS2, TconTS3 and TconTS4 were cloned, 
expressed as recombinant proteins in mammalian fibroblasts and subsequently biochemically 
analysed regarding their specific enzymatic activities. Significantly distinct catalytic activities 
and substrate affinities for all 14 active recombinant TconTS have been determined using a 
variety of several natural and synthetic substrates, as well as different reaction conditions 
(Chapter 3.1 – 3.3). Experimental results determined TconTS1 and TconTS2 as highly active 
TS, whereas TconTS3 and TconTS4 showed significant reduced enzymatic activities. One 
major exception constitutes TconTS1g, which exhibited a drastically lower Sia transfer 
activity compared to the other 10 TconTS1 variants, most likely due to the natural mutation 
R144C found at the catalytic centre in TconTS1g, proposed to be involved in substrate 
binding (Chapter 3.1).  
In silico homology models of TconTS1, TconTS2, TconTS3 and TconTS4 have been 
generated to investigate a potential relation between the amino acid composition at the 
catalytic centre of each TconTS and the corresponding observed specific enzymatic activities, 
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also in respect to the catalytic mechanism published for other trypanosomal TS. However, no 
clear predictions regarding the differences in enzymatic properties of these four TconTS could 
be concluded, indicating the involvement of structural regions distant from the catalytic centre 
influencing the specific enzymatic activities. The most obvious candidate represents the C-
terminal lectin-like domain (LD) of TconTS following the catalytic domain (CD). Therefore, 
a major aim of this study comprises the biochemically characterisation of TconTS-LDs 
including its carbohydrate binding ability and ligand specificity. LDs from all four TconTS 
were cloned and expressed as recombinant proteins. In cooperation with Dr. Joe Tiralongo 
and Dr. Thomas Haselhorst from the Institute for Glycomics (Griffith University Gold Coast, 
Australia) specific lectin activities for TconTS-LDs have been determined utilising several 
analytical methods specific to investigate protein-carbohydrate interactions, such as glycan 
array and saturation transfer difference nuclear magnetic resonance (STD NMR) spectroscopy 
(Chapter 3.4). In addition, a microtitre plate-based binding/inhibition assay was established to 
further characterise the lectin activity of TconTS-LD on glycoproteins (Chapter 3.4). In 
summary, specific binding activities of TconTS-LD to several galactose-, lactose- and 
mannose-containing glycans, as well as to high-mannose N-glycans of glycoproteins have 
been determined (Chapter 3.4). Furthermore, STD-NMR data provided strong evidence for 
simultaneous binding of both, lactose and α1-3,α1-6-mannotriose to two distinct binding sites 
on TconTS2-LD. 
The fact that mannose is not a substrate for the catalytic domain of TconTS suggests a 
different, yet unknown function of TconTS. Experimental data obtained from size exclusion 
chromatography analysis of recombinant TconTS1 demonstrated its oligomerisation and that 
high-mannose N-glycans are essential for this process (Chapter 3.4). Although the 
glycosylation pattern of native TconTS still has remained unknown, this finding indicates a 
potential biological function of TconTS-LD in the organisation of cell surface glycoproteins 
on the parasites surface. 
To further investigate a possible direct influence of TconTS-LD on enzymatic activity a 
strategy was established allowing the exchange and recombination of CDs and LDs from 
different recombinant TconTS. Chimeric, domain-swapped TconTS enzymes have been 
cloned and expressed in bacteria and fibroblasts and analysed for their specific catalytic 
activities (Chapter 3.5). Although clear Sia transfer activity has been determined for domain-
swapped TconTS constructs, the overall enzymatic activities drastically differs relative to that 
determined for wild type TconTS. It has been demonstrated that if TconTS3-LD was 
recombined with TconTS1a-CD the corresponding domain swapped TconTS1a/TS3 enzyme 
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exhibit enhanced sialidase activity when expressed by E. coli and suppressed sialidase activity 
when expressed by fibroblasts relative to that observed for wild type TconTS1a, indicating the 
influence of LD on enzymatic activity (Chapter 3.5). Along this line, additional experimental 
results revealed strong evidence that N-glycosylation of TconTS-LD potentially influences 
enzymatic activities (Chapter 3.5). It will be of interest to investigate which precise structural 
factors are responsible for the observed modulation of enzyme activities and to decipher the 
underlying mechanisms. 
Zusammenfassung 
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IV. Zusammenfassung 
Die hier vorliegende Arbeit befasst sich mit Untersuchungen zu Struktur- und 
Funktionsbeziehungen von Trans-Sialidasen (TS) des afrikanischen Parasiten Trypanosoma 
congolense und deren biochemischer Charakterisierung. Teile dieser Arbeit (Kapitel 3.1, 3.2 
und 3.4) wurden bereits veröffentlich. 
TS sind ungewöhnliche Enzyme, die in Flagellaten (Protozoen) Parasiten der Gattung 
Trypanosoma gefunden wurden und den stereo- und regiospezifischen Transfer von 
endständigen Sialinsäuren (Sia), sialylierter Donor-Glykokonjugate, auf terminale 
Galaktosereste entsprechender Akzeptormoleküle katalysieren. Produkte dieses Sia-Transfers 
sind α2,3-sialylierte Glykokonjugate. Der Großteil der trypanosomalen TS Forschung 
konzentrierte sich bislang hauptsächlich auf die TS des Parasiten Trypanosoma cruzi 
(TconTS), der Verursacher der lateinamerikanischen Chagas-Krankheit. Nur wenig ist 
hingegen über die TS des afrikanischen Parasiten Trypanosoma congolense bekannt, einer der 
Hauptverursacher der afrikanischen Schlafkrankheit (Animal African Trypanosomiasis AAT) 
bei Haus- und Nutztieren, lokal auch unter dem Namen Nagana bekannt.  
Erste Untersuchungen der Welcome Trust Sanger Institute (WTSI) Datenbank, unter 
Verwendung von TconTS Teilsequenzen, ergaben insgesamt 14 verwandte Gensequenzen. 
Davon wurden 11 TconTS Gene mit einer Sequenzähnlichkeit von über 90 % und 3 weitere 
mit Sequenzähnlichkeiten von nur 40 %, relative zu ersteren, identifiziert und daher als 
TconTS1 und entsprechend TconTS2, TconTS3 und TconTS4 bezeichnet. Zusätzlich zu 
diesen 14 Gensequenzen, die für aktive TconTS Enzyme codieren, wurden 3 weitere 
gefunden, die jedoch nur etwa 25 % Sequenzähnlichkeit mit TconTS1 teilen und für inaktive 
Enzyme codieren, da diesen unter anderem ein für die Katalyse essentielles Tyrosin im 
aktiven Zentrum fehlt. Alle Gensequenzen der 11 TconTS1 Varianten sowie von TconTS2, 
TconTS3 und TconTS4 wurden kloniert, als rekombinante Proteine in Säuger-Fibroblasten 
exprimiert und anschließend die spezifischen Enzymaktivitäten biochemisch charakterisiert. 
Dabei wurden teilweise deutliche Unterschiede in den katalytischen Aktivitäten, sowie in den 
Substratspezifitäten, unter der Verwendung verschiedener, natürlicher und synthetischer 
Substrate und Reaktionsbedingungen, für alle 14 rekombinanten TconTS Enzyme beobachtet 
(Kapitel 3.1 – 3.3). Experimentelle Ergebnisse zeigten, dass TconTS1 und TconTS2 
hochaktive TS sind, wohingegen sowie für TconTS3 als auch für TconTS4 relativ stark 
reduzierte Enzymaktivitäten im Vergleich zu ersteren bestimmt wurden. Eine Ausnahme 
bildet dabei die Variante TconTS1g, bei der eine deutlich geringere Sia Transfer-Aktivität, 
relative zu denen der anderen TconTS1 Varianten, gezeigt werden konnte. Die Ursache für 
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die reduzierte Enzymaktivität von TconTS1g ist vermutlich auf die natürliche Mutation 
R144C zurückzuführen, wobei angenommen wird, dass der durch Cystein ersetzte 
Argininrest, im aktiven Zentrum, direkt an der Substratbindung beteiligt ist und diese 
stabilisierende Wechselwirkung in TconTS1g fehlt (Kapitel 3.1).  
In silico berechnete Homologiemodelle von TconTS1, TconTS2, TconTS3 und 
TconTS4 wurden erstellt, um mögliche Zusammenhänge zwischen der Zusammensetzung der 
katalytisch-essentiellen Aminosäuren im aktiven Zentrum der TconTS und den ent-
sprechenden, beobachteten spezifischen Enzymaktivitäten zu erkennen, auch in Hinblick auf 
den, in der Literatur beschriebenen katalytischen Mechanismus anderer Trypanosoma TS. 
Allerdings konnten diesbezüglich keine klaren Aussagen zu den unterschiedlichen, 
enzymatischen Verhalten der vier TconTS Varianten gemacht werden. Diese Ergebnisse 
deuten jedoch darauf hin, dass noch andere Regionen, außer dem katalytischen Zentrum des 
Enzyms, scheinbar einen erheblichen Einfluss auf die katalytischen Aktivitäten der TS haben. 
Dabei bildet die C-terminale Lektin-ähnliche Domäne (LD), die der katalytischen Domäne 
(CD) direkt über einen α-Helix angeschlossen ist und der bisher keine funktionelle Bedeutung 
zugewiesen werden konnte, die plausibelste Region. Daher bestand ein wesentlicher Teil 
dieser Arbeit in der biochemischen Charakterisierung der TconTS-LD und dessen Potential 
als kohlenhydratbindende Domäne, sowie die damit verbundenen Ligandspezifitäten zu 
untersuchen. Dazu wurden die LDs aller vier TconTS kloniert und als rekombinante Proteine 
exprimiert. In Kooperation mit Dr. Joe Tiralongo und Dr. Thomas Haselhorst, vom Institute 
for Glycomics (Griffith Universität, Gold Coast, Australien), wurden mit Hilfe einer Reihe 
von analytischen Methoden wie z.B. Glycan-Array und Sättigungs-Transfer-Differenz(STD) 
Kernresonanz(NMR)-Spektroskopie, speziell für die Analyse von Protein-Kohlenhydrat 
Wechselwirkungen, die spezifischen Lektinaktvitäten der TconTS-LDs experimentell 
bestimmt (Kapitel 3.4). Zusätzlich dazu wurde ein Microtiter-Platten basierter 
Bindungs/Inhibitions-Test entwickelt, mit dessen Hilfe die Lektinaktivitäten der TconTS-LD 
mit immobilisierten Glykoproteinen weiter im Detail untersucht wurden (Kapitel 3.4). 
Zusammenfassend konnten die spezifischen Bindungsaktivitäten der rekombinanten TconTS-
LD an verschiedene Galaktose-, Laktose- und Mannose-haltige Glykane sowie mit 
oligomannosidischen N-Glykanen von Glykoproteinen erfolgreich nachgewiesen werden 
(Kapitel 3.4). Zusätzlich ergaben experimentelle Ergebnisse der STD NMR Analysen einen 
deutlichen Hinweis auf eine mögliche simultane Bindung von Laktose und α1-3,β1-6-
Mannotriose an zwei unterschiedliche Bindungsstellen in der TconTS-LD. 
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Die Tatsache, dass Mannose kein Substrat der TconTS-CD ist, deutet auf eine neue, 
bisher unbekannte Funktion der TconTS hin. Experimentelle Daten von Größenausschluss-
chromatographie-Untersuchungen mit rekombinanten TconTS demonstrierten die N-Glykan-
abhängige Oligomerisierung von TconTS1a (Kapitel 3.4). Auch wenn das Glyko-
sylierungsmuster der nativen TconTS bis jetzt nicht bekannt ist, weisen diese Ergebnisse 
bereits auf eine mögliche biologische Funktion der TconTS-LD bei der Organisation der 
Zelloberflächen-Glykoproteine des Parasiten hin. 
Um einen potentiellen, direkten Einfluss der TconTS-LD auf die Enzymaktivitäten zu 
untersuchen, wurde eine Strategie entwickelt, die den Austausch von CDs und LDs der 
verschiedenen TconTS ermöglicht. Enzym-Chimären bestehend aus den Domänen 
unterschiedlicher TconTS wurden kloniert, in Bakterien und Fibroblasten exprimiert und 
bezüglich ihrer katalytischen Aktivitäten analysiert (Kapitel 3.5). Eindeutige Sia-Transfer-
aktivitäten der TconTS-Chimären wurden detektiert, wobei sich das generelle, katalytische 
Verhalten der Chimären deutlich von denen der Wildtyp TconTS unterscheidet. Dabei konnte 
gezeigt werden, dass, wenn TconTS3-LD mit TconTS1a-CD rekombiniert wurde, die 
resultierende TconTS1a/TS3-Chimäre relativ zu TconTS1a, eine erhöhte Sialidase-Aktivität 
aufwies, wenn das Enzym von Bakterien exprimiert wurde und eine deutlich verringerte 
Sialidase-Aktivität aufwies, wenn es von Fibroblasten exprimiert wurde. Dies war bereits ein 
Hinweis auf einen möglichen Einfluss der LD auf die Enzymaktiviäten (Kapitel 3.5). Weitere 
experimentelle Ergebnisse führten zu der Annahme, dass auch die N-Glykosylierung der 
TconTS-LD einen möglichen Einfluss auf die katalytische Aktivität der Enzyme hat (Kapitel 
3.5). Daher besteht großes Interesse daran, die genauen, strukturellen Faktoren zu bestimmen, 
die für die beobachteten regulatorischen Effekte der Enzymaktivitäten verantwortlich sind 
und damit die zugrundeliegenden Mechanismen aufzuklären. 
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V. Abbreviations 
 
aa amino acids 
AAT Animal African Trypanosomiasis (Nagana) 
bp base pair 
BSA bovine serum albumin 
BSF bloodstream form 
CD catalytic domain 
CMP-Neu5Ac citidine-5’-monophosphate N-acetylneuraminic acid 
Da dalton 
DANA 2-deoxy-2,3-didehydro-N-acetylneuraminic acid 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide 5’-triphosphate 
DTT dithiotreitol 
E.coli Escherichia coli 
FCS fetal calf serum 
Gal galactose 
GalNAc N-acetylgalactosamine 
GARP glutamic acid-alanine-rich protein 
Glc glucose 
GlcNAc N-acetylglucosamine 
GPI glycosylphosphatidylinositol 
HAT Human African Trypanosomiasis (sleeping sickness) 
HPAEC-PAD high performance anion exchange chromatography – pulsed amperometric detection 
IC50 half maximal inhibitor concentration 
Ig immunoglobulin 
IPTG isopropylthiogalactoside 
KM Michaelis-Menten constant 
Lac lactose (β-D-galactopyranosyl(1,4)-D-glucose) 
LD lectin domain 
mAb monoclonal antibody 
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Man mannose 
MU 4-methylumbelliferone 
MUGal 2’(4-methylumbelliferyl)galactoside 
MUNeu5Ac 2’(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 
Neu5Ac N-acetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
NMR nuclear magnetic resonance 
ORF open reading frame 
PARP procyclic acidic repetitive protein 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
RT room temperature 
SA sialidase 
SAPA shed acute phase antigen 
SDS sodium dodecyl sulfate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
Sia sialic acid 
Siglec sialic acid binding immunoglobulin-like lectin 
SPR surface plasmon resonance 
STD saturation transfer difference 
3’SL 3’-sialyllactose (Neu5Acα2,3-lactose) 
6’SL 6’-sialyllactose (Neu5Acα2,6-lactose) 
TBS tris-buffered-saline 
TS trans-sialidase 
TbruTS Trypanosoma brucei trans-sialidase 
TconTS Trypanosoma congolense trans-sialidase 
TcruTS Trypanosoma cruzi trans-sialidase 
TranTS Trypanosoma rangeli trans-sialidase 
TvivTS Trypanosoma vivax trans-sialidase 
Tris 2-amino-2(hydroxymethyl)-1,3-propanediol 
vmax maximum velocity 
VSG variable surface protein 
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Abbreviations for amino acids 
Amino acid 
 
One-letter 
symbol 
Three-letter 
abbreviation 
Amino acid 
 
One-letter 
symbol 
Three-letter 
abbreviation 
Alanine A Ala Leucine L Leu 
Arginine R Arg Lysine K Lys 
Asparagine N Asn Methionine M Met 
Aspartic acid D Asp Phenylalanine F Phe 
Cystein C Cys Proline P Pro 
Glutamine Q Gln Serine S Ser 
Glutamic acid E Glu Threonine T Thr 
Glycine G Gly Tryptophan W Trp 
Histidine H His Tyrosine Y Tyr 
Isoleucine I Ile Valine V Val 
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1 Introduction 
1.1 Carbohydrates 
1.1.1 Structure 
Approximately 100 years ago, naturally occurring substances with the empirical 
formula Cn(H2O)n (n ≥ 3 to 9) were termed “carbon of hydrates” or “carbohydrates” due to the 
suggesting that the carbon atoms are in some way covalently attached to water [1,2]. The 
major group of carbohydrates comprise the family of saccharides or sugars, in which hexoses, 
besides pentoses, determine the most common and relevant constituents with related chemical 
structures. All hexoses in general consist of a six carbon atom chain as backbone, including a 
core of four hydroxymethylen groups, as well as a hydroxymethyl group on one end and 
either an aldehyde group (aldose) or an α-hydroxy ketone (ketose) on the other (Figure 1). 
Each carbon of the four hydroxylmethylene groups is bound to four chemically distinct 
substituents and therefore represents a chiral centre. However, the substituents around each 
optical active carbon can be arranged in two different ways, generating a total of 16 (24, mk: 
m = configurations, k = chiral centres) possible hexoses (stereoisomers). If two hexoses differ 
in the stereochemical configuration of only one chiral centre, they are also referred to as 
epimers, for example in the case of D-glucose (Glc) and D-galactose (Gal, C-4 epimer to 
Glc). According to the rules of nomenclature for organic molecules, the numbering starts at 
the aldehyde carbon, which is the highest oxidised carbon in the structure and also referred to 
as the anomeric C-1. The configuration at the stereogenic centre furthest from the C-1 (C-5 
for hexoses) determines the overall configuration of each sugar to either L or D. In solution, 
hexoses are usually found as an equilibrium mixture of linear and cyclic forms (Figure 1). The 
common cyclic six-ring conformation (pyranose) is created by the nucleophilic addition of the 
C-5 hydroxyl group to the aldehyde group (C-1) forming a hemiacetal structure with two 
possible configurations at the C-1, thus inducing a new asymmetric centre. The addition at C-
2 leads to the appropriate cyclic five-ring hemiacetal structure (furanose). Depending on the 
direction of the nucleophilic attack, the hydroxyl group at C-1 in the cyclic form can either be 
oriented axial or equatorial.  
These two possible configurations at the C-1 are distinguishable by the designations α 
(axial) and β (equatorial) anomers, as shown for D-glucose (Figure 1). Furthermore, in 
contrast to the other stereogenic centres on the cyclic hexose, the anomeric C-1 can undergo 
an interconversion of the stereoisomer, due to the permanent transition between the linear and 
cyclic form, termed mutarotation (fast swap in optical rotation, Figure 1). 
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The distribution between the open chain and the two anomeric cyclic forms depends on 
the chemical structure/stability of each sugar, in which former is only present in minor 
amounts less then 0.01 % [1]. 
Only a few of the theoretically possible hexoses are commonly found in nature, whereas 
many of them can be derived from glucose, the most frequently occurring hexose, with only a 
single epimerisation and/or substitution. Substitutions often comprise modifications at C-6, 
such as oxidation to a carboxyl group (sugar acid, glucuronic acid, GlcA) or even the removal 
of C-6 to the resulting pentose, e.g. xylose (Xyl). Furthermore substitution of the C-2 
hydroxyl group of glucose and galactose with an acetylated amino group leads to the 
frequently occurring N-acetylated hexoses N-acetylglucosamine (GlcNAc) and N-
acetylgalactosamine (GalNAc). However, all of these common hexoses are normally found in 
D configuration. 
Monosaccharides are able to form polymeric oligosaccharide structures through the 
bond formation between the anomeric carbon of one monosaccharide and the hydroxyl group 
Figure 1. Stereochemistry of common hexoses. Monosaccharides are shown in Fischer 
projection (top row), Haworth projection (middle row) and as sterical stick-structures (bottom 
row). The reversible cyclisation of the linear hexose to the respective α or β pyranose ring is 
termed mutarotation and exemplarily shown for Glc. Stereogenic centres are indicated (*). 
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of another sugar (condensation). This fundamental glycosidic bond, which formally involves 
the reaction of a hemiacetal and an alcohol group to an acetal, represents the basis for a 
variety of different oligosaccharides formed from the broad monosaccharide building block. 
The combinatorial aspect of this molecular diversity can, in context to glycan structure, 
exceed those for peptides by orders of magnitude [3]. As an example for the vast increase in 
complexity of oligosaccharides, a simple disaccharide made of two identical glucose units 
will be compared to a dipeptide comprising two glycerine molecules. In principle, 11 different 
disaccharides are possible (5 reactive hydroxyl groups and 1 carbonyl group for each Glc) in 
contrast to only a single dipeptide. However, the increase in heterogeneity is even more 
drastically illustrated when going to lager scale. For example, four different amino acids lead 
to 24 different tetrapeptides but four different hexose monosaccharides can theoretically form 
35,560 possible tetrasaccharides [4-6]. This high diversity derives from the variety in 
glycosidic linkages, including α and β configuration of the glycosidic bond resulting in two 
stereoisomers, the amount of hydroxyl groups on each monosaccharide leading to several 
possible regioisomers and the fact that one monosaccharide can exhibit more than two 
glycosidic bonds, therefore representing a branching point in the oligosaccharide as seen in 
glycoproteins [7,8]. An intriguing fact is that such a huge repertoire of biologically essential 
information is not encoded by the genome [9]. Two of the most common and extensively 
studied oligosaccharides are starch and glycogen, comprising of numerous glucose units 
linked to form a large biopolymer, which is utilised as an “energy-reservoir” in plants and 
animals, respectively. Cellulose serves as a constituent of the cell wall of plants and is 
composed of multiple β-1,4-linked glucose units. In contrast to that, glycosidic bonds of 
glucose monosaccharides in starch and glycogen are mainly formed by α-1,4-linkages, 
whereas also α-1,6-linkages are present in glycogen [2]. 
1.1.2 Carbohydrates, not only just an energy supplier 
In general, four major classes of repeating biopolymers, being part of all living things 
on the planet, can be differentiated in oligonucleotides (DNA and RNA), lipids, proteins and 
carbohydrates. Latter present the most predominant component of biomasses formed on earth, 
since they are integrant of animals, plants and bacteria [1]. In contrast to the other three, on 
the molecular level well understood biopolymers mentioned above, biological functions of 
carbohydrates mainly have remained relative poorly understood, not at least because of their 
large and complex structural diversity in nature. Main important biological functions of 
carbohydrates, besides their role as energy supplier for cellular processes such as protein 
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synthesis, movement and transport, are particularly the involvement in cell-cell and cell-
matrix interactions of complex cell-systems (organs) and organisms, also as a potent 
communication system. 
All cells in nature are covered with a dense layer of a variety of carbohydrates on their 
plasma membrane termed glycocalyx, which can reach an intraluminal thickness of up to 300 
– 500 nm [10]. It was primarily discovered in the early 1940s [11] and subsequently further 
investigated in the following years [12-14], accompanied with an increasing importance as an 
essential factor in vascular physiology, homeostasis and pathology [15-17]. This 
supramembrane carbohydrate coat comprises of single sugars molecules (monosaccharides) 
and extended sugar chains (oligosaccharides), which are in general specified as glycans, 
covalently linked (glycosidic linkage) to amino acid residues of soluble free or membrane 
bound polypeptides (glycoproteins). In addition it was estimated that half of all proteins in 
nature, known so far, are glycosylated [18]. 
However, the composition of proteoglycans, with their associated glycosaminoglycan 
(GAG) side chains forming the major constituent on the plasma membrane, and glycoproteins 
on the cell surface cannot be considered as a static overall picture, rather as a highly dynamic 
system exhibiting a permanent exchange of glycoconjugates [15]. Proteoglycans are 
considered to be the most important functional glycoconjugate species of the glycocalyx, 
comprising of a high number of different glycosaminoglycans attached, varying in length and 
type. The main five types of GAGs are: chondroitin/dermatan sulphate [19], heparan sulphate 
[20], keratan sulphate [21] and hyaluronic acid (hyaluronan) [22]. Structurally GAGs are linear 
dispersed hetero-oligosaccharides containing a repetitive core disaccharide, made of a 
hexosamine and an uronic acid (hexoses in which the C-6 is oxidised to a carboxyl group), 
which can vary between 50 and 150 units [23,24]. Further specifications are made regarding 
the type of hexosamine incorporated and other modifications, such as sulfation and 
acetylation. 
Besides the class of proteoglycans, with their linear hetero-polysaccharide side chains, a 
large number of glycoproteins are present on the cell surface comprising of smaller but highly 
branched oligosaccharides in contrast to the former (further discussed in the following 
chapter). 
The glycosylation pattern of glycoconjugates of a cell is determined by the activity 
levels of the different glycan modulating enzymes such as glycosyltransferases and 
glycosidases in cytosol, endoplasmic reticulum (ER), the Golgi apparatus and on the cell 
surface [25-27]. Significant changes of the glycoconjugate composition and glycosylation 
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pattern are associated with fundamental processes like embryogenesis, tissue development, 
stem-cell differentiation, growth, cell contact inhibition, cell-cell recognition (trans-
interaction), host-pathogen interaction, cell signalling, host immune response, inflammation, 
pathogenesis, metastasis, intracellular trafficking, membrane stability and several fatal 
diseases such as cancer and diabetes [1,4,7,25-39]. The involvement in such a huge variety of 
different biological processes, clearly demonstrate the importance of carbohydrates in nature. 
1.1.3 N- and O-linked glycosylation 
The connection of two monosaccharides via formation of a glycosidic linkage requires 
energy, since it is an enthalpic and entropically unfavourable process [40]. This free energy 
needed for sugar oligomerisation is obtained from the hydrolysis of high-energy phosphate 
anhydride bonds in additional reactions, which hence are coupled to the former. As seen for 
many other energy consuming biological processes, adenosine triphosphate (ATP) is used to 
drive the formation of a nucleotide sugar donor, such as uridine diphosphate (UDP)-
monosaccharide, although other nucleotide sugar donors are also present. The activated 
“high-energy” nucleotide sugar is then transported via specific nucleotide sugar transporter 
(NST, antiporter) into the ER or Golgi [41], where it can be transferred to another mono- or 
oligosaccharide. This reaction is catalysed via a substrate specific glycosyl-transferase, which 
hydrolyses the phosphoester bond of the activated nucleotide sugar donor and forms the new 
glycosidic linkage between the monosaccharides [42]. Different glycan modifying enzymes 
such as glycosyl-transferases and glycosidases exhibit substrate affinity specific to a certain 
sugar donor or acceptor, thus contributing to a broad regulatory glycosylation system [1] 
As discussed in the previous chapter, glycans exhibit a tremendous structural 
heterogeneity, which is transmitted when glycans are for example attached to proteins. Thus 
forming a system of gylcoconjugates, modulated with a very high amount of information, 
providing the contribution to a wide range of biological processes. In general, two possible 
types of glycosidic linkages between a glycan and the polypeptide chain in glycoproteins can 
be differentiated. The first involves a covalent bond between the N-acetylglucosamine residue 
of the oligosaccharides reducing end, and the amide side chain of an asparagine residue (N-
linked) in the polypeptide backbone. This N-linked glycosylation incorporates the essential 
amino acid sequence motif Asn-X-Ser/Thr (N-glycosylation site), whereas X represents any 
amino acid except proline [8]. The second type of linkage is determined by the glycosidic 
bond of N-acetylgalactosamine to the hydroxyl group of serine or threonine side chains (O-
linked) of the polypeptide backbone [38,43]. Most glycoproteins containing O-linked glycans 
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are often also substituted with one or more N-linked oligosaccharides and the other way 
around [44].  
N-glycosylation in eukaryotes starts simultaneously with the translocation of the newly 
synthesised polypeptide chain into the ER, thus determining it as a co-translational event. The 
oligosaccharide moiety of the lipid (Dolichol, Dol)-linked N-glycan precursor with the 
constitution Glc3Man9GlcNAc2-PP(pyrophosphate)-Dol is transferred to the unfolded, nascent 
polypeptide chain, via a membrane-associated oligosaccharyl-transferase (OST). In vivo 
studies on cultured cells with depleting Glc3Man9GlcNAc2-PP-Dol, revealed loss of cell 
viability as a consequence of disabled N-linked oligosaccharide synthesis [45,46]. This 
precursor also defines the basis of three types of N-glycans, namely high-mannose type 
oligosaccharides, hybrid oligosaccharides and complex oligosaccharides [47]. Further 
modifications of the oligosaccharide, including primal removal of three Glc and one Man 
residue to generate high-mannose type N-glycans (Man8GlcNAc2), occur in the ER via certain 
glucosidases and mannosidases, respectively. After transfer of the preliminary glycoprotein to 
the Golgi apparatus (cis-, medium- and trans-Golgi), subsequent modifications of the high-
mannose type N-glycan through several different glycosidases and transferases lead to either 
hybrid or complex N-linked glycans [33]. This processing comprise the addition of terminal 
fucose (Fuc), Glc, GlcNAc, Gal, GalNAc and sialic acids (Sia), exhibiting different glycosidic 
linkages as well as the introduction of further branching and bisecting structures [48-55]. 
However, efficient and controlled N-linked glycan synthesis requires a strict and defined 
order, in which the participating glycosidases and glycosyl-transferases act. This is provided 
by the localisation of enzyme activities and the expression levels of the appropriate enzymes 
[42]. 
In addition, N-linked oligosaccharide structures processed in the ER generate substrates, 
which support enzymatic reglucosylation in the case of improper protein folding (unfolded 
protein response, UPR) [56,57]. Appropriate improperly or partially folded proteins will not 
be allowed to continue molecular trafficking and remain in the ER until proper folding is 
completed (or the improperly folded protein is degraded) and the glycoprotein may proceed to 
the next step along secretory pathways [58,59]. Several studies have demonstrated a causal 
role of deficient N-glycosylation in human congenital disorders of glycosylation (CDG) 
[60,61]. 
In contrast to N-glycans, O-linked oligosaccharides appear to be much more diverse in 
both, structure and function, since the former share at least a common central glycan-protein 
core and can be classified into a few structurally related types, whereas a different situation is 
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found for latter [34]. O-glycans provide glycosidic linkages involving Gal, GalNAc, Fuc, 
GlcNAc, Man or Xyl and serine, threonine or hydroxylysine residues of the polypeptide 
backbone [38,43]. In addition, there are numerous transferases available, which catalyse the 
glycosidic bond formation of GalNAc to serine or threonine residues [62] compared to only a 
single oligosaccharyl-transferase for N-glycosylation (OST). 
O-glycosylation is a posttranslational modification catalysed by a variety of processing 
enzymes in the Golgi apparatus [43,63], including the addition of monosaccharides such as 
Gal, GlcNAc, Fuc and Sia after the addition of O-linked GalNAc [64,65]. These modifications 
are similar or identical to that of N-glycans, providing evidence for a possible overlap 
between both types of glycosylation, in which corresponding enzymes might be shared, also 
indicating their possible co-evolution [42]. However, O-glycans exhibit a very high 
heterogeneity and were demonstrated to effectively modulate enzyme activities by regulating 
transcription, protein-protein interactions, protein degradation and protein localization 
[34,66,67]. In addition, Zachara and Hart demonstrated that O-phosphorylation (another 
posttranslational modification involved in regulating protein function) and O-glycosylation 
compete for the same threonine or serine residues in the polypeptide chain, thus modifying 
the biological function of the mature protein by varying its phosphorylation pattern [34]. 
Furthermore, the fact that O-GlcNAc modified glycoproteins were shuttled from the 
cytoplasm to the nucleus of see slug Aplysia neurons, either indicates a potential role of the 
posttranslational modification as a alternative nuclear localizing signal (NLS) or as a retention 
signal, respectively [34,67]. 
Human congenital disorders of glycosylation (CDGs) for 12 defects in N-linked and 4 in 
O-linked glycosylation have been described so far [33,60,61,68]. For example latter include the 
Walker-Warburg syndrome, characterized by an congenital muscle dystrophy and complex 
brain and eye abnormalities (induced by an O-mannosylation defect [69]) and the hereditary 
multiple exostosis, which is characterised by bone and generalised somatic overgrowth 
(caused by an O-xylosylation defect [70]). In summary, N-linked and O-linked glycans have 
been associated with different unique functions and were demonstrated to be involved in a 
variety of essential biological processes and diseases, however many still remain to be 
explored. 
1.2 Sialic acids 
Glycoconjugates of all vertebrates commonly consist of hexoses and their derivatives. 
The only known fundamental exception constitutes the group of sialic acids (Sia), which 
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incorporate a number of unusual features compared to other common monosaccharides. Sia 
describes a family of 9-carbon α-keto acidic amino-monosaccharides [71] mainly found 
glycosidically linked to terminal Gal, GalNAc or Sia residues of complex oligosaccharide 
chains of glycoproteins or glycolipids. These are predominantly found on eukaryotic cell 
surfaces of vertebrates and Deuterostomia (e.g. Asterias rubens, starfish [72]) or secreted to 
extracellular medium [73,74]. Sia is also found as capsular polysaccharides or 
lipooligosaccharides of some pathogenic bacteria, such as Escherichia coli (E. coli) K1 [75]. 
The name sialic acid/neuraminic acid derived from the fundamental discovery of Sia in 
brain matter (neuramine, Blix in 1936) and on bovine submaxillary mucins (BSM, Klenk in 
1941), a sialoglycoprotein from salivary glands of cows (salios: Greek word for saliva) 
[75,76]. The first conclusive structure of Neu5Ac was proposed by Gottschalk [77] and clearly 
illustrated the main specifications of these unique class of monosaccharides. So far over 62 
naturally existing Sia forms have been identified, including the two most abundant occurring 
in eukaryotes, N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) 
(Figure 2) [76,78-80]. Interestingly the hydroxylase catalysing the reaction which generates the 
N-glycolyl goup in Neu5Gc is absent in humans, due to a mutation in the appropriate gene 
coding for the enzyme, after the evolutionary divergence of human from the great apes [75]. 
Similar gene defects occur in other species, including chicken [81,82]. 
 Finally, one last unusual feature related exclusively to neuraminic acids is determined 
by their synthesis in eukaryotes, which incorporates the condensation of N-
Figure 2. Structure of neuraminic acid and its most common derivatives. N-acetylneuraminic 
acid (Neu5Ac); N-glycolylneuraminic acid (Neu5Gc); 2-keto-3-deoxy-nonulosonic acid (KDN); 
5,7-diamino-3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic acid (legionaminic acid); 
5,7-diamino-3,5,7,9-tetradeoxy-L-glycero-L-manno- nonulosonic acid (pseudaminic acid). 
 
Introduction 
 11 
acetylmannosamine-6-phosphate (C-4 to C-9 of Neu5Ac) and pyruvate (C-1 to C-3 of 
Neu5Ac) followed by dephosphorylation to Neu5Ac catalysed by Neu5Ac-9-phosphate 
synthase (NANS) and Neu5Ac-9-phosphate phosphatase (NANP), respectively [3,42]. Both 
reactions occur in the cytosol, whereas the activation of Neu5Ac to cytosine monophosphate 
(CMP)-Neu5Ac via CMP-sialic acid synthetase (CSS) occurs in the nucleus [83,84]. After 
transport of CMP-Neu5Ac into the Golgi apparatus, further modifications as well as the 
transfer of Neu5Ac to terminal monosaccharide units, catalysed by numerous different sialyl-
transferases (ST), are made, followed by subsequent shuttling to the plasma membrane 
[83,85]. These STs represent key enzymes in the biosynthesis of sialylated oligosaccharides, 
glycoproteins and glycolipids [86], transferring Sia from the activated nucleotide sugar donor 
to terminal Gal, GalNAc or Sia residues of glycoconjugates [74]. The nomenclature of STs 
refers to the stereochemistry of the glycosidic linkage formed. For example the ST, which 
catalyses the transfer of Sia to another terminal Sia residue (polysialic acids, PSA), forming a 
new α2,8 glycosidic linkage is termed ST8Sia [74]. In addition, these polysialic acids 
(polySia) oligosaccharides, commonly found in vertebrates and Deuterostomia [87,88], can 
exceed 60 Sia units and were found to be involved in cell adhesion of eukaryotic cells, 
regeneration of the adult nervous system (neural cell adhesion molecule, NCAM [89]), cell 
trafficking and development of several essential organs, such as hart, brain, kidney, pancreas 
and respiratory tract [90-97]. Weinhold et al. demonstrated that double knockout of ST8SiaII 
and ST8SiaIV genes in mice, essential for PSA synthesis, resulted in a phenotype exhibiting 
several tissue defects accompanied by precocious death [98]. This clearly demonstrates the 
importance of such sialyl-transferases and their crucial function in cell development. 
Besides common sialyl-linkages found in eukaryotes including α2,3 linkage to Gal, 
α2,6-linkage to Gal and GalNAc as well as α2,8 linkage to additional Sia, also more rarely 
occuring linkages such as α2,3 linkage to GalNAc, α2,6 linkage to Glc and GlcNAc, α2,4 
linkage to Gal and GlcNAc and α2,9 linkage to additional Sia and Neu5Gc have been 
identified [72,99-107]. 
Furthermore, the nonulosonic acid family also comprise the common 2-keto-3-deoxy-
nonulosonic acid (KDN), 5,7-diamino-3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic 
acid (legionaminic acid) and 5,7-diamino-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic 
acid (pseudaminic acid), whereas latter two are C-4-epimers (Figure 2) [76]. Besides these 
neuraminic acid derivates, a variety of substitutions mainly at the C-5 position (e.g. N-acetyl, 
N-glycolyl) [108] but also at the C-4, C-7, C-8 and C-9 hydroxyl groups are known, 
incorporating modifications such as O-methylation, O-acetylation, O-sulfation, as well as O-
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acylation (formation of lactyl-esters) [76,109]. Furthermore, Bulai et al. demonstrated that 
20% of the sialic acids bound to surface molecules of human red blood cells (RBC) are others 
than Neu5Ac or the unacetylated neuraminic acid [110]. These findings clearly demonstrate 
the wide chemical diversity of neuraminic acids, which goes beyond that of every other 
known monosaccharide [76,82]. The reasons for that still remain not entirely clarified, but 
some suggestions were made, regarding a potential result of an permanent evolutionary 
selection by host-pathogen interactions [74,109,111]. Sia are involved in a variety of biological 
processes, for example nervous system embryogenesis, cancer metastasis, immunological 
regulation, bacterial, viral and parasitic infections and the involvement in several serious 
diseases [39,76]. One of the well-known human disorders in Sia metabolism is called Sialuria 
(OMIM 269921). A extreme rare inborn disease, caused by a mutation in the gene encoding 
for the bifunctional enzyme GNE (uridine diphosphate (UDP)-GlcNAc 2-epimerase/ 
ManNAc kinase) [112-114], which catalyses formation of the precursor N-acetylmannos-
amine-6-phosphate. Due to this defect an excessive synthesis and accumulation of free Sia in 
body fluids is observed, caused by defects in allosteric feedback inhibition of GNE [115,116]. 
Features of Sialuria incorporate hepatosplenomegaly (unusual enlargement of liver and 
spleen) and varying degrees of developmental delays [117]. Other disorders comprise the 
lysosomal storage disorder sialidosis (OMIM 256550), a neuraminidase 1 (NEU1) deficiency 
[118,119] and the xenosialitis, causing chronic inflammation, which is due to the generation of 
antibodies against Neu5Gc and Neu5Gc-containing glycans in human tissue (xeno-
autoantigens), induced by the uptake of nonhuman Neu5Gc from dietary sources (red meat) 
[73,120]. 
1.2.1 Biological function and relevance 
Together with the negatively charged GAGs, sialic acids mainly contribute to the 
overall negative charge of surface glycoproteins of the glycocalyx. This property is known to 
protect cells, such as the highly sialylated RBCs (more than 10 million Sia molecules per 
erythrocyte [1]), against immune response, therefore considered to be members of the innate 
immune system [82], and underlying glycoproteins from proteolytic degradation [121]. 
Furthermore, sialylation generates repulsive interactions between two negatively charged cells 
or sialylated molecules such as mucins [122], indicating the role of Sia in cell-cell interactions 
(adhesion) and involvement in cell signalling (e.g. hormone induced cell activation) [81,82]. 
Also its terminal positioning supported several hypotheses that Sia participate in modulating 
interactions with the environment. Along this line, Sia was reported to effectively mask 
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receptors, antigenic sites and not at least the directly underlying Gal, GalNAc residues [123]. 
This effect can be abolished by sialidases (unmasking of Gal), in which the subsequent 
binding of molecules or cells, such as macrophages, to exposed Gal residues can occur, for 
example via Gal-recognising receptors (Hepatocytes-asialoglycropotein receptor [121]). On 
the other hand, Sia itself can also serve as target molecule for hormones, antibodies and sialic 
acid specific carbohydrate binding proteins (lectins), expressed on several cell surfaces and 
also known as siglecs (sialic acid-binding immunoglobulin (Ig)-like lectin) [111]. They were 
found in human and animals [124] and demonstrated to be involved in many physiological and 
pathological processes [82,111,125-127]. 
1.3 Lectins 
Lectins are defined as carbohydrate recognising and binding proteins [7,8,128]. Derived 
from the Latin word legere, synonymous for the English word “select”, lectins have been 
generalised to comprise all non-immune carbohydrate binding agglutinins without enzymatic 
functions, also termed hemagglutinins or phytoagglutinins due to their discovery from plant 
extracts, irrespective of blood-type specificity or source [129]. One intensively investigated 
example is ricin, a plant lectin isolated from seeds of the castor oil plant (Ricinus communis). 
It was suggested that ricin was the very first characterised hemagglutinin, described by Peter 
Hermann Stillmark (German-Baltic pharmacologist) 127 years ago (reviewed by Hartmut 
Franz 1988 [130]). Ricin is a highly toxic lectin, recognising terminal galactosyl residues of 
cell surface glycoconjugates. After attachment and following vesicular transport into the cell 
and to the ER, where it is able to avoid proteolytic destruction, ricin folds into an active 
conformation, which inactivates localised ribosomes. Consequences are the collapse of 
protein biosynthesis and subsequent cell death by initiated apoptosis [131]. The United States 
military developed a ricin bomb during World War II, which was tested by the British 
military, but fortunately never used as a mass destruction weapon [129]. 
With increasing knowledge about agglutination and hemagglutinins, multiple lectins 
were isolated and characterised from several organisms, such as plants, microorganisms and 
animals [129]. Interestingly, even though lectins from plants and animals exhibit similar 
carbohydrate binding specificities, they do not show any primary structural homology, which 
might be due to potential co-evolution [8], indicating a fundamental role of carbohydrate-
lectin interactions. With the use of x-ray crystallographic methods, tertiary structures of 
numerous lectins could be solved over the last decades. It was observed that despite several 
differences in primary sequence of many lectins, significant similarities in their tertiary 
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structures exist [129]. Furthermore, additional structural studies regarding carbohydrate-lectin 
interaction suggested the involvement of only particular amino acids at a well-defined 
location in the protein, termed as carbohydrate-recognition domain (CRD). These domains 
commonly recognise the terminal sugar residues of an oligosaccharide, but also lectins with 
extended or even multiple thermodynamically distinct CRDs have been described, in which 
more than one monosaccharide of the same glycoconjugate interacts simultaneously with the 
lectin [129,132]. 
Lectins are classified in families and superfamilies according to structural relations and 
type of carbohydrate recognition [47,133]. L-type lectins represent the first carbohydrate-
binding protein family discovered from seeds of leguminous plants [134], sharing structural 
conserved motifs which were also found in several animal lectins [47]. The family of L-type 
lectins has been intensively investigated, whereas many different members have been 
isolated, characterised and employed as practical tools in a variety of biochemical, analytical 
and biomedical processes, such as affinity purification of glycoconjugates, for specific glycan 
detection, or as diagnostic and therapeutic tools [7,47,135,136]. Other lectin families comprise 
M-type lectins, which are closely related to α-mannosidases of the ER and Golgi, recognising 
high-mannose-type glycans (Man8); P-type lectins exhibiting unique β-rich structures and 
selective binding to phosphorylated Man-6-P; C-type lectins, which require Ca2+-ions for 
carbohydrate recognition, include among others collectins and selectins (mannose-binding 
protein, MBP); S-type lectins (later termed galectins due to preferred βGal binding), which 
require free thiols for structure stability and binding activity (β-sandwich structure) and R-
type lectins, exhibiting a CRD similar to that of ricin and binding affinities to various 
carbohydrate ligands [132,137-145]. Due to various carbohydrate-binding specificities of 
lectins listed above, they are involved in a variety of biological processes, such as ER 
associated protein degradation, protein sorting in the ER and post-Golgi, cell adhesion, rolling 
of lymphocytes on endothelial cell surface, B-cell activation (innate immune system), 
phagocytosis, glycan cross-linking in the extracellular matrix, enzyme targeting (glycoprotein 
hormone turnover) and are involved in human immunodeficiency virus (HIV) infection of T-
cells [146-154]. However, lectins cannot be exclusively classified by their carbohydrate-
binding properties, since some CRDs share similar features, for example C-type and L-type 
lectins both facilitate divalent Ca2+-ions for carbohydrate recognition, respectively. However, 
they significantly differ in their protein overall structure, in which they are clearly 
distinguishable. In addition, in some cases also the oligosaccharide-ligands recognised by a 
specific type of CRD are remarkable similar in structure, whereas in other cases relatively 
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high structure diversity was observed [42,47]. These various and complex lectin-carbohydrate 
interactions generate a tremendous biological diversity of receptor-ligand recognition, also in 
respect to the heterogeneity of glycans itself. To discuss all these very interesting phenomena 
in detail goes beyond the scope of this thesis, but at this point it should be referred to some 
excellent publications and reviews available, for further reading 
 [8,42,47,111,126,129,132,133,145,155-158]. 
1.3.1 Siglecs 
Besides the previous discussed lectin families another very important group of 
carbohydrate binding proteins comprise the I-type lectins. This family belongs to the 
immunoglobulin (Ig)-superfamily, comprising over 500 mammalian members besides 
antibodies, in which a define set of Sia-binding proteins were identified forming a structural 
closely related group of CRDs termed siglecs (Sia-binding immunoglobulin-like lectins) 
[124,159]. They represent the most intensively and well-characterised group of I-type lectins 
regarding their structural and functional properties [42]. Siglecs are transmembrane proteins, 
constitute of multiple extracellular immunoglobulin (1 unusual V-set and 1 to 16 C2-set 
domains [124]) domains and one immunoglobulin constant (C-set) domain, as well as an inter-
membrane domain and for some siglecs also several tyrosine containing, cytoplasmic 
immunotyrosine-based inhibition motifs (ITIMs) [111,160,161]. Latter can be phosphorylated 
by specific kinases and lead to modulation of cell-signalling cascades. 
The three siglecs, sialoadhesin (Sn), CD22 (Siglec-2) and the myelin-associated 
glycoprotein (MAG) expressed on macrophages, B-cells and oligodendrocytes respectively, 
represented the first three family members, which were shown to specifically recognise 
terminal sialic acids of cell surface glycoconjugates, as target ligands in cell adhesion 
processes [160,162-164].  
In addition, CD22 was cloned and expressed as recombinant protein, C-terminal fused 
to the hinge region and constant Fc-part of human IgG [163]. Subsequently it was 
demonstrated that the first two extracellular Ig-like domains (V-set and C-set) of CD22 are 
involved in Sia recognition [165-167], whereas only the first (V-set) was required in case of Sn 
[163,168]. Furthermore, also sialic acid binding for the siglecs CD33 (expressed by different 
cell types of the immune system), human myelin-associated glycoprotein (MAG), expressed 
on oligodendrocytes, and its avian ortholog Schwann cell myelin protein (SMP) (grouped 
together as Siglec-4a and b), could be demonstrated [163,169]. Not surprisingly, the Sia 
binding-site of MAG was also determined to be located in the N-terminal V-set Ig domain 
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[170]. The fact that all the four siglecs mentioned above share a homologue V-set domain, 
which has been identified as Sia binding domain, in addition to their function as cell adhesion 
molecules, lead to the designation “Sialoadhesin family” or “Sialoadhesins” [171], which was 
changed to siglecs in the following years [124]. Furthermore, additional siglecs have been 
identified, characterised and termed CD33-related Siglecs, due to their high degree in 
structural relation to CD33 [161]. 
Interestingly, all siglecs are expressed in a highly cell type specific fashion [111], 
leading to the assumption that they are involved in a variety of different cell processes. 
Indeed, it was demonstrated that Sn (restricted to macrophages [164]) and CD33 are involved 
in regulation of myeloid cell interactions [169,172], MAG was shown to play a role in myelin 
maintenance and to inhibit axonal growth [163,173-175], whereas CD22 was demonstrated to 
be a negative regulator of B-cell activation, and plays a potential role in B-cell guidance to 
bone marrow [176-179]. The diverse expression profile of CD33-related siglecs in the 
hematopoietic and immune cells [161], together with the presence of cytosolic ITIM motifs, 
suggests a potential role as inhibitory receptors, down-regulating innate immune cell 
reactivity [111,161]. Recently, Jellusova and Nitschke demonstrated that CD22 and Siglec-10 
(CD33-related siglec) negatively modulate B-cell antigen receptor signalling [179]. Besides 
that, a potential involvement of CD33-related Siglec-5 in bacterial uptake has been reported 
[180]. All these functional related findings strongly suggest potential divergent Sia binding 
specificities of siglecs, which was approved in several studies. Remarkable different binding 
preferences were found for Sn, CD22 and MAG. In contrast to CD22, Sn and MAG 
preferably bind Neu5Ac [181,182], whereas former binds either Neu5Gc or Neu5Ac [183]. 
Regarding the Sia-linkage to the underlying Gal, CD22 is highly specific for α2,6-linked Sia 
[184], whereas Sn, MAG and CD33 exhibit binding specificities to α2,3-linked Sia with 
different affinities, respectively [111,163]. The presence of siglecs on different cell types of 
the immune and nervous system clearly demonstrates their fundamental importance in 
regulating both systems. However, with respect to the high structural diversity of Sia in nature 
as mentioned above, numerous unknown functions of siglecs may remain to be discovered. 
1.4 Trypanosomes and trypanosomiasis 
Plasmodium, Leishmania and Trypanosoma are all protozoan parasites, causing fatal 
diseases in humans as well as in domestic and wild animals [185]. Unicellular flagellate 
trypanosomes (Figure 3) are the major causative agent of Latin American Chagas’ disease 
[186] and African Trypanosomiasis, whereas latter is further divided into Human African 
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Trypanosomiasis (HAT, Sleeping sickness in human) [187] and Animal African Trypanoso-
miasis (AAT, Nagana, Sleeping sickness in animal) [188]. 
 Kinetoplastid parasites evolve in a variety of hosts and vectors, depending on their 
presence and natural habitats respectively. For example, the Latin American parasite 
Trypanosoma cruzi (T. cruzi) is transmitted by blood sucking triatomine bugs through their 
defecation. In contrast, African trypanosomes are mainly taken up and transmitted by tsetse 
flies, during their blood meal [189]. Both, African and Latin American parasites undergo 
different developmental stages during their life cycles, in which they change their 
morphology and biochemical composition. 
 
1.4.1 Chagas’ disease, HAT and Nagana 
Chagas’ disease, caused by T. cruzi, was first discovered in 1909 by the Brazilian 
Scientist Carlos Chagas, who is the eponym of this disease and reported primary data about 
parasites transmission cycle and clinical manifestations [190]. Chagas’ disease is categorised 
as one of the world’s 13 most tropical neglected diseases [191]. First symptoms of the acute 
phase of this disease are in some cases relatively mild [186] and therefore often neglected, 
also because for most of the infected patients experience a spontaneous decay of symptoms 
after a short time, leading to fatal misdiagnosis. Symptoms of the chronic phase are more 
Figure 3. Coloured electron microscopic image of Trypanosoma 
brucei (light blue) in the presence of erythrocytes (red) and 
lymphocytes (yellow). The image was downloaded from the 
Deutsches Elektronen-Synchrotron (DESY) homepage.  
http://www.desy.de/information__services/press/press_releases/
2012/pr_291112/index_eng.html. The original image was pro-
vided by Prof. Dr. Duszenko (permission was granted). 
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lethal and will be only observable 25-30 years after infection [192,193]. Besides this it should 
be mentioned here that paleoparasitologists isolated T. cruzi DNA from 9000 years old human 
mummies, indicating that people had already suffered from Chagas’ disease long ago [194]. 
Also Charles Darwin potentially suffered from this disease. In his records (The Voyage of the 
Beagle [195]), he mentioned that he got in contact with Triatomine bugs during his expedition 
to Latin America in 1835. As a possible consequence, he suffered from symptoms for the rest 
of his life, similar to that reported for patients infected with T. cruzi [196]. However it still 
remains unclear whether these symptoms are actually related to Trypanosomiasis, since 
Darwin died 1882 and Carlos Chagas (1879-1934) discovered the disease 27 years later. 
Recently, it was reported that Chagas’ disease is not only restricted to Latin America 
anymore, but has also spread to non-endemic regions such as North America, Canada, Europe 
and the western Pacific regions, most likely due to infections by blood transfusion, organ 
transplantation, directly from mother to infant or even orally through food contamination by 
vector’s feces [197-203].  
HAT is a fatal, tropical neglected disease (WHO) that is caused by two subspecies of 
the African Trypanosoma brucei (T. brucei), namely T. brucei gambiense and T. brucei 
rhodesiense [204]. In contrast, T. b. brucei, which is only infective for livestock [205], 
together with the related Trypanosoma congolense (T. congolense) and Trypanosoma vivax 
(T. vivax), represent the major causative agents of the wasting Animal African 
Trypanosomiasis (AAT), also termed Nagana in livestock and wild animals [188]. T. brucei 
spp. and T. congolense are transmitted by several tsetse fly sub-species (Glossina spp.), which 
are exclusively found in sub-Saharan Africa (tsetse belt, covering an area grater than the 
entire Australian continent), therefore also localising HAT and AAT in that region. 
Furthermore, two additional species have been reported, Trypanosoma evansi (T. evansi), 
causing surra [206], and the non-pathogenic Trypanosoma lewisi (T. lewisi), which are widely 
spread over more then three continents. This might be due to the wide distribution of their 
correlated vectors. In addition, further trypanosomal subspecies and some cases of atypical 
Human Trypanosomiasis (aHT) have been reported and were recently reviewed [207]. 
Without appropriate treatment, HAT is a fatal disease, estimated to affect 10-30 
thousand individuals every year, representing a recent decline compared to 2006 with about 
60 thousand new cases [208]. This drop is most likely related to several reasons, such as the 
cessation of civil wars, the increased engagement of different organisations (e.g. WHO), 
production and free supply of anti-trypanosomal drugs, efficient strategies for vector control 
and active surveillance of the population in endemic countries [209]. However, many cases 
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remain undiagnosed, due to a massive lack of clinical representation and surveillance in 
unstable areas. In addition, it has been reported that some tsetse fly subspecies have already 
adapted to areas with high population densities as in West Africa [210], thus possibly 
spreading this disease. 
Pathogenesis evolves in two distinct stages, including the haemolymphatic stage 
characterised by presence of parasites only in the blood and lymphatic system, followed by a 
more chronic phase, in which trypanosomes start invading the central nervous system and 
even cross the blood brain barrier into the brain and cerebrospinal fluid. Several stage specific 
clinical symptoms were observed. Finally, untreated sleeping sickness will lead to coma or 
death [187]. 
Nagana, the wasting disease in domestic and wild animals is not affecting humans 
directly, but indirectly by annual losses in agricultural productivity of about 4.5 billion USD. 
This is mainly due to death of about 3 million cattle, whereas 40 million are threatened, and 
the low productivity of those who survived but suffered from wasting effects of the disease 
[211]. Thus animal trypanosomiasis impedes agriculture development in tsetse fly afflicted 
regions. Common domestic animals suffering from AAT, besides cattle, include sheep, goats, 
pigs, horses and camels. Also Nagana is fatal without proper treatment, whereas typical 
symptoms comprise anemia, drastic weight loss, infertility and immunosuppression. 
1.4.2 Life cycle of African trypanosomes 
African trypanosomes are mainly transmitted by tsetse flies, and require both, 
mammalian host and tsetse vector for efficient development. During their life cycle T. brucei 
and T. congolense undergo complex developmental changes, immediately initiated after 
ingestion of an infectious blood meal by the tsetse fly [212-214]. A schematic illustration of 
the general life cycle of African trypanosomes is shown in Figure 4. Trypanosomal 
bloodstream forms (BSF) are taken up during blood meal and settle in the midgut of the tsetse 
fly, where they differentiate into the non-infectious, long procyclic trypomastigotes. One 
fundamental feature of this form is a drastically change in composition of their surface 
glycoproteins to evade flies digestive system, which comprises several antimicrobial peptides 
and lectins as defence system [215-217]. After cease dividing they become mesocyclic 
trypomastigotes and start migrating to proboscis lumen (T. congolense) or salivary glands (T. 
brucei ssp.) of the insect. By reaching the proboscis or salivary glands, parasites differentiate 
into epimastigotes, which are able to adhere to salivary gland epithelium cells (T. brucei ssp.) 
or fly’s proboscis and mouth-parts (T. congolense) via their flagellum. 
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In this stage, a second amplification occurs, after which they detach and differentiate 
into infective metacyclic trypomastigotes. The parasitic developmental cycle in the fly 
requires 2-5 weeks [218,219]. After injection of metacyclic trypomastigotes into the 
mammalian host during a blood meal, parasites keep multiplying at the site of injection for a 
few days, before they invade the lymphatic system followed by migration to the bloodstream, 
thus finally differentiating into BSF trypomastigotes and completing their life cycle [220]. 
1.4.3 Parasite’s strategies to evade immune response in host and vector 
In contrast to T. cruzi, which invades host cells to evade immune response [30], African 
trypanosomes are extracellular parasites, thus exhibiting different strategies to ensure its 
Figure 4. Schematic scheme showing the general life cycle of African trypanosomes.1) 
Infected tsetse fly taking a blood meal transmits infectious traypanosomes into mammalian 
host. 2) Injected metacyclic trypomastigotes transform into bloodstream trypomastigotes, 
multiply in blood and establish an infection. 3,4) Bloodstream trypomastigotes are taken up 
by the tsetse fly during blood meal on infected animals. 5) Ingested bloodstream 
trypomastigotes transform into procyclic trypomastigotes and proliferate in the tsetse midgut. 
6) Mesocylic trypomastigotes migrate towards proboscis (T. congolense) or salivary glands 
(T. brucei ssp). 7) Epimastigotes multiply and subsequent transform into infectious 
metacyclic trypomastigotes. Note that this is a general description of the trypanosomal life 
cycle and that slight differences between several species exist. The graphic is a modified 
version of the original downloaded from Centers for Disease Control and Prevention (CDC), 
(http://www.cdc.gov/para-sites/sleepingsickness/biology.html)(permission was granted). 
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survival in the mammalian host. BSF trypomastigotes are able to multiply by longitudinal 
binary fission at all sites in the mammalian host, in which a periodically fluctuating 
parasitaemia is observed, due to immune response. The reason for that is mainly related to the 
parasite surface, which consists of a various number of antigenic, but highly variable surface 
glycoproteins (VSG).  
Trypanolytic factors (TLF1 and TLF2 [221]) found in human serum are able to lyse 
trypanosomes upon entry [222], therefore serving as a natural host innate parasite defence 
mechanism (immunity) besides the innate complex immune system. However, trypanosomes 
evolved multiple strategies to evade these innate defence mechanisms, in order to insure their 
survival in host and establishment of chronic infection. Besides evolved resistance against 
TLF, it was recently found that specific trypanosomal adenylate cyclases inhibit TNF (Tumor 
necrosis factor) production of myeloid-cells and therefore block the early host immune 
response [223,224]. Nevertheless this parasite-host interaction has to be well regulated, since a 
parasitical overgrowth would lead to early host death and therefore counterproductive for the 
establishment of pathogenesis and a subsequent vector infection. One possibility to overcome 
a potential overgrowth involves the differentiation from the proliferating to a non-dividing 
form, which is pre-adapted for a effective subsequent vector infection [220]. However, 
another more efficient system to evade the immune system and ensure permanent 
parasitaemia in the mammalian host is termed antigenic variation, a strategy which is also 
observed for other pathogens [225,226]. 
The surface of T. brucei and T. congolense metacyclic and BSF trypomastigotes is 
densely covered with glycosylphosphatidylinositol (GPI)-membrane bound surface 
glycoproteins (VSG) [227]. Each trypanosome has the potential to express hundreds of 
different VSGs, encoded by a repertoire of more than 1000 distinct VSG genes, whereas only 
one is expressed at a time [228]. These immunogenic VSGs induce host immune responses, 
which initially set the parasite under permanent immune pressure. Before the first generation 
of parasites, expressing the same VSG, are killed completely by the host’s immune response, 
a second generation has evolved, presenting another type of VSG, which will not be 
recognised by currently generated antibodies [229]. These new antigenic distinct 
trypanosomes amplify and overgrow the first until they in turn are cleared by another set of 
antibodies. This process repeats multiple times, thus resulting in a periodically observable 
parasitaemia [230]. This efficient switching of the entire VSG coat occurs spontaneously, 
antibody independent and enables the parasite to continuously evade new antibody attacks 
and results in the development of a chronic infection in the host [230,231].  
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However, another scenario is observed in the fly vector. In contrast to the VSG coat of 
metacyclic trypomastigotes and BSF of T. brucei and T. congolense, both, their procyclic and 
epimastigote forms exhibit a more restricted composition of surface glycoproteins, termed 
procyclins [227,232]. After trypamosomes were taken up by tsetse fly during a blood meal and 
subsequent differentiation into procyclic trypomastigotes, parasites shed their VSG coats via 
involvement of GPI-phospholipase C as well as a metalloprotease [219], and express a new 
layer of procyclins. In T. brucei this layer consist of two related types of procyclins, 
comprising either multiple tandem repeats of glutamic acid and proline (EP, single-letter 
amino acid code) or protease-resistant pentapeptide repeats of the type GTEEP, respectively 
[218,233,234]. The appropriate analogues in T. congolense have also been identified, termed 
protease-resistant surface molecule (PRS), glutamic acid-alanine rich protein (GARP) [235] as 
well as T. congolense procyclin [236]. These surface glycoproteins exhibit a specific 
expression profile during development in tsetse fly. They are glycosylated with polymannose 
and galactose containing oligosaccharides [237], for which the exact composition still has 
remained unclear. Procyclins are membrane bound via a unique, modified GPI-anchor [238], 
consisting of an unusual lipid structure and a polydisperse carbohydrate unit comprising of a 
branched unique poly-N-acetyllactosamine side chain and a mannose core [236,238,239]. In 
addition, it has been demonstrated by Engstler and Schauer [240,241], as well as Schenkman 
and co-worker’s [242] that terminal galactose residues of this poly-N-acetyllactosamine side 
chains are substituted with α2,3-linked sialic acids. Interestingly trypanosomes are unable to 
synthesise Sia and utilise unusual enzymes termed trans-sialidases (TS), which appear to be 
unique to these parasites, to transfer terminal Sia residues from the environment to their own 
surface molecules, [241,243,244] (A more detailed description of these enzymes is provided in 
chapter 1.5). However, strong evidence suggested that polyanionic procyclins, in combination 
with the negatively charged Sia residues of their GPI-anchors, form a strong negatively 
charged glycocalyx, which protects the parasites against the fly’s digestive system [241,244]. 
Ruepp et al. demonstrated that the introduction of GARP into procyclin-knock out T. brucei 
recovered their ability to establish infection in the flies midgut, indicating their fundamental 
role in parasite survival and development [245]. Nevertheless, these suggestions were 
supported by findings, demonstrating the absence of procyclins or related structures in T. 
vivax, a trypanosomal species, which apparently develops exclusively in the flies proboscis, 
but seems to be unable to colonise the flies midgut [236] and therefore do not require a 
protection against digestive enzymes. 
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However, these strategies of antigenic variation, incorporating the expression of VSGs 
in mammalian host, as well as the expression of procyclins and their subsequent sialylation in 
the vector represent very effective defensive systems, which seem to be unique to 
trypanosomes, and ensures survival and development at all stages during their life cycles. 
1.4.4 Therapies and pharmaceuticals against trypanosomiasis 
In order to fight Chagas’ disease, HAT and Nagana, several vaccination strategies have 
been generated over the past years, but not yet resulted in a single promising therapy with a 
100 % sterile immunity against the disease or even found its way to a serious field application 
[246]. With respect to the antigenic variation strategy of the parasite to evade host immune 
system discussed above, it is obvious that a potential vaccination against VSG is impossible. 
Another major challenge is the ability of some trypanosomes to cross the blood-brain barrier 
(BBB) and invade the brain and central nervous system, because most pharmaceuticals cannot 
pass and therefore are ineffective. Thus, questionable chemotherapies were used to treat HAT 
infections, including the medicaments pentamidine and suramin for the early phase, as well as 
eflornithine, nifurtimox and melarsoprol against the chronic phase of the disease [247]. 
Besides an increasing resistance against these drugs, a series of adverse and even toxic effects 
were observed but endured due to the absence of more effective therapeutic alternatives [247]. 
In addition, increasing treatment failure rates for suramin (polyanionic naphthalene bearing 
compound with unknown mechanism of action) [248] and melarsoprol (highly toxic arsenical 
diamidine prodrug, which irreversibly and unspecifically inactivate enzymes) [249] have 
already been reported and represent a current, fundamental growing problem in Africa. 
However, the mechanisms of action for most of the trypanocidal-compounds (anti-
trypanosomiasis medicaments) remain still unclear. A recent publication regarding the 
identification of several trypanosomal factors involved in anti-trypanosomal drug interactions, 
revealed advances for a better understanding of drug efficacy and resistance and may provide 
a further step towards novel drug design and more efficient therapeutic applications [250]. 
1.5 Trypanosomal trans-sialidase 
The biological importance of Sia and its modifying enzymes, such as sialyl-transferases 
and sialidases (neuraminidases) have been discussed in the previous chapters (1.2). On one 
hand, these enzymes were found in several catabolic and regulatory processes in eukaryotic 
cells [251], as well as virulence factors in some bacteria and viruses, such as Vibiro cholerae 
(VC-neuraminidase) [252] and Influenza virus (IV-neuraminidase) [253], on the other hand. 
Introduction 
 24 
Biological functions related to these sialidases comprise unmasking and generation of 
receptor sites, enhancing affinities to host cells, protein degradation and the involvement in 
pathogenesis [123,254]. However, first reports concerning sialidase activities in trypanosomes 
were made by Esievo in 1979 and Pereira in 1983 who detected free Sia production by T. 
vivax and T. cruzi [255], respectively. Surprisingly, Sia (Neu5Ac and Neu5Gc) have also been 
detected in glycoconjugates of T. cruzi, which were not synthesised by the parasite itself due 
to a lack of the appropriate Sia processing machinery [256]. Only a few years later in 1987, it 
was observed that T. cruzi sialidase does not only exhibit hydrolysing activity, but 
surprisingly, was also capable of transferring terminal Sia form host glycoconjugates onto 
trypanosomal surface molecules, and was therefore termed trans-sialidase (TS) [30,257,258]. 
In addition, this novel TS was found to be involved in the generation of surface receptor 
molecules for mammalian cell invasion by T. cruzi, thus already indicating its essential role in 
parasite survival and pathogenesis in the host [30,259]. With respect to these fundamental 
findings, in the following years, enhanced attention was also paid to African trypanosomes 
regarding a possible TS occurrence. Not surprisingly, developmental regulated TS from 
procyclic T. brucei [241,258] and T. congolense [241,260] were detected and subsequently 
partial characterised.  
Trypanosomal TS were generally found to be located on the cell surface of the parasite 
attached to the plasma membrane via a GPI-anchor similar to those of procyclins described in 
the previous chapter (1.4.3). However, T. cruzi TS (TcruTS) not only acts on the cell surface 
but is also shed into the blood during host infection [261], whereas the same is assumed for T. 
congolense TS (TconTS). Interestingly, comparisons between TcruTS and the African 
trypanosomal TS, T. congolense TS (TconTS) and T. brucei TS (TbruTS) regarding structure, 
enzyme activity, substrate specificity and other properties, revealed significant similarities. 
For example both, T. congolense and T. cruzi express a number of different TS, encoded by 
several genes, exhibiting different sialyl-transferase and sialidase activities [260,262-267]. 
However, in addition only few active TS were found in T. brucei [268,269]. Interestingly a 
large TS gene family comprising over 1000 members were identified in T. cruzi, of which the 
majority encodes for inactive TcruTS [266,270]. A different situation exists in the African 
trypanosomes, where 4 TS genes were identified for T. vivax, 9 for T. brucei and 14 for T. 
congolense so far [267-269,271] including those described during the course of this thesis 
[272,273]. 
One unique feature of trypanosomal TS is the transfer of Sia to terminal galactose 
residues of oligosaccharides or glycoconjugates without the requirement of the activated 
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form, CMP-Sia, as donor substrate [274]. In the presence of suitable acceptor molecules, TS 
preferentially transfer Sia from one glycoconjugate to another, instead of hydrolysing the 
glycosidic bond [30]. For example, from a biological point of view, the enzymatic behaviour 
of TS, in the absence of suitable Sia acceptor molecules, is the same as that of common 
sialidases [275], determined by the release of free Sia from sialylated glycoconjugates. In 
addition, by the current state of knowledge regarding the catalytic mechanism of TS, the 
reaction would chemically rather be described as a transfer of Sia to a water molecule 
(detailed explanations are provided in following chapters). In this context, it should also be 
mentioned that trypanosomal TS share several structural homologies with common viral and 
bacterial sialidases [252,275], which will be discussed in the following chapters. Nevertheless, 
trypanosomes utilise TS to sialylate their own surface molecules, hence generating a 
negatively charged glycocalyx, which is known to play a fundamental role in several 
biological processes during the life cycle of trypanosomes in host and vector (chapter 1.4.2). 
In summary, TS modulate the presence, localisation and quantity of Sia on parasites’ surface 
molecules and their environment. Also an essential role for TS in parasite development was 
suggested, since its expression is stage specifically regulated in the mammalian and insect 
forms. This hypothesis has been subsequently confirmed by several following studies 
[267,276-279], clearly representing TS as a distinct virulence factor in Chagas’ disease and 
African Nagana not only in procyclic insect forms but also in BSF. For example Nok and 
Balogun demonstrated TconTS involvement in anaemia in animals, caused by the parasitical 
desialylation of erythrocytes [267,277].  
1.5.1 TS substrate specificities 
Trypanosomal TS catalyse the reversible transfer of preferentially α2,3-linked Sia to 
terminal βGal residues of glycoconjugates to specifically form a new α2,3 glycosidic linkage 
[30]. This enzymatic transfer activity is temperature, pH and acceptor substrate concentration 
dependent [280,281]. A variety of different donor and acceptor substrates have been tested 
with live trypanosomes and later with recombinant TS to further investigate substrate 
specificities [241,243,244,258,260]. Using T. brucei TS (TbruTS), Sia donor substrates, such as 
Neu5Ac-α(2,3)-lactose (3’SL), Neu5Ac-α(2,3)-lactitol, fetuin (sialo-glycoprotein), 
methylumbelliferone-Neu5Ac (MU-Neu5Ac), as well as human and bovine erythrocytes were 
found to be suitable donors for sialyl-transferase activity, whereas only negligible transfer 
rates have been observed for Neu5Ac-α(2,6)-lactose (6’SL) and Neu5Ac-α(2,8)-Neu5Ac, 
respectively [240,243]. In contrast, neither CMP-Neu5Ac, the well-known substrate for 
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eukaryotic and bacterial STs, nor the monosaccharide Neu5Ac were utilised as substrates 
[243]. Similar enzyme activities and substrate specificities have been observed for TconTS, 
for which Sia-transfer has additionally been detected using procyclic GARP or PARP as Sia 
acceptor substrates [241]. Interestingly, one exception regarding substrate specificity was 
observed by Tiralongo et al., who demonstrated the efficient Sia transfer using 6’SL as donor 
substrate, catalysed by two different isolated TS-forms from T. congolense procyclic 
trypomastigotes, respectively [260]. Furthermore, substrate specificities for several Sia 
acceptor molecules and consequent TS activities have been determined for both, TconTS and 
TbruTS. Although significant transfer activities were detected using galactose (weak 
acceptor), lactose, lactitol, lactobionic acid, β-methyl-galactopyranoside, asialofetuin and 
asialo-PARP [241,282]. Asialo-GARP has also been demonstrated to be a suitable acceptor 
substrate for TconTS [241]. In contrast, mannose, glucose, galactose, methylumbelliferone 
and α-methyl-galactopyranoside turned out to be non-suitable Sia acceptor substrates for 
TconTS and TbruTS, respectively [241,243]. In addition, Sia donor and acceptor specificities 
have been demonstrated for TcruTS, including for example the transfer of α2,3-linked 
Neu5Gc or even its O-acetylated derivate, but with less efficiency, besides Neu5Ac [242,283-
286]. Other suitable donor substrates comprise pNP(p-nitrophenole)-αNeu5Ac and Neu5Ac-
α(2-3)Galβ(1-4)GlcNAc (3’-sialyl-N-acetyllactosamin) [281,287]. Furthermore, several Sia 
acceptor substrates, such as N- and O-glycans of asialofetuin, some asialo-gangliosides and 
mucins were trans-sialylated by TcruTS [242,288]. On the other hand, Man, Gal, GalNAc and 
terminal α-linked Gal were identified as non-suitable acceptor substrates for the transfer of 
Sia by TcruTS [284]. These findings clearly demonstrated the general regio specific substrate 
preferences of trypanosomal TS towards α2,3-linked Sia donors and terminal βGal-containing 
oligosaccharides, glycoproteins and glycolipids as Sia acceptor substrates, as well as the close 
relation between the two African trypanosomal species T. brucei and T. congolense.  
Another interesting observation regarding TS-siglec interactions was made by 
Neubacher et al. [289]. They utilised recombinant T. cruzi TS to specifically synthesise a set 
of novel, unnatural sialyl-oligosaccharides, such as pNP-Neu5Ac and several other 
derivatives. These Neu5Ac analogues were used to study substrate specificity and binding 
affinity of MAG, since latter specifically recognises α2,3-linked Sia [163], the product of TS 
trans-sialylation. This also reflects the potential of trypanosomal TS to generate sialyl-
glycoconjugates in vivo, which may represent a set of suitable ligands for siglecs, 
preferentially recognising α2,3-linked Sia ligands. 
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Reasons for the region and stereo selectivity of TS to specific donor and acceptor 
substrates are determined by the defined architecture of the catalytic centre, which will be 
discussed in the following chapters.  
1.5.2 TS mediated interactions between parasite and siglecs from host cells 
TS mediated trans-sialylation to specifically generate terminal α2,3-linked Sia 
containing oligosaccharides on parasites surface, will not only enhance the repulsive 
electrochemical properties but also provides a set of structures which can serve as potential 
ligands for different host cell lectins. The myelin associated glycoprotein (MAG), which is a 
member of a superfamily of sialic acid binding proteins called siglecs [163], represents such 
an example. Several family members are expressed on the plasma membrane of different cell 
types of the immune and nervous system, which has been already discussed in previous 
chapter (1.3.1). Sialoadhesin (Siglec-1, Sn), a cell adhesion molecule expressed on the cell 
surface of macrophages, has been demonstrated to be involved in Sia mediated association of 
T. cruzi procyclic trypomastigotes [290,291]. The parasites’ association with macrophages 
observed was drastically reduced, when anti-Sn antibodies or desialylated macrophages were 
used [291], indicating a Sia-siglec mediated interaction, probably initiated by TcruTS. 
Another interesting finding comprises the interaction of T. cruzi with the inhibitory 
murine Siglec-E of dendritic cells. Erdmann et al. demonstrated that T. cruzi trypomastigotes 
suppressed the production of inflammatory cytokines and subsequent T-cell activation due to 
Sia mediated binding of the parasite to murine Siglec-E on host cell surface [292]. It was 
proposed that this effect might be induced by TS-dependent transfer of Sia from dendritic 
sialo-glycoconjugates, which serve as ligands for cis-interactions with Siglec-E to 
trypomastigote mucins, hence generating sialylated ligands on the parasite surface for trans-
interactions with Siglec-E. Such cis-interaction mimicry maintain inhibitory effects of Siglec-
E and therefore impair the immune response [291-295]. Thus, Siglec specific interactions with 
sialo-glycoconjugates of the parasite may represent the basic mechanism, which enables 
trypanosomes to sabotage and modulate host immune system. This weakening effect of TS 
was even more obvious, when transfecting TS into Leishmania major (transgenic), resulting 
in an significant increase in virulence, thus declaring TS as a kind of inflammatory cytokine 
mimicry, termed parasitokine [293]. 
In summary, these findings illustrate the importance of TS in Sia mediated association 
to siglec positive immune-competent host cells, as a potential target for trypanosomes in the 
early phase of infection, as well as the importance in establishment of chronic infection. 
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1.5.3 The structure of trypanosomal TS 
In the early 1990s genes encoding for several TcruTS enzymes haven been identified 
[30,296-299]. The appropriate amino acid sequence for enzymatic active TS proteins were 
predicted and indicate significant structural similarities with known viral and bacterial 
sialidases [30,296,300,301].  
Affranchino et al. reported about an antigen from T. cruzi trypomastigotes, which was 
shed into cell culture supernatant from cultured procyclic trypomastigotes and blood of 
infected patients and animals recently after infection, therefore being a major secreted antigen 
in the acute phase of the disease and termed Shed-Acute-Phase-Antigen (SAPA) [302]. SAPA 
was declared as a highly antigenic protein comprising a number of C-terminal repeats, as well 
as some N-terminal motifs, which were subsequently found to be conserved in bacterial and 
viral sialidases [297]. Only two years later, in 1991, Pereira et al. surprisingly investigated a 
high gene sequence homology of SAPA with T. cruzi sialidases [296]. Finally, in 1992 Parodi 
et al. identified SAPA not only as the major sialidase but also the major TS of T. cruzi, and 
suggested the hydrolytic as well as the sialyl-transferase activity to be located in the N-
terminal domain [299] of the two domain comprising enzyme [303]. This suggestion was 
subsequently confirmed, although it has been demonstrated that SAPA repeats in the C-
terminus were not required for enzymatic activity of TcruTS [304,305], but rather increase TS 
half-life in blood due to its highly antigenic feature [261,306]. Furthermore, it was observed 
that the N-terminal catalytic domain (CD) of TcruTS contains all the amino acid residues, 
which were known to interact with terminal Sia residues of glycoconjugates in the catalytic 
centre of sialidases from Vibrio cholera and Salmonella [307,308]. Primary structure 
alignments, revealed further insights into the potential tertiary structure of TcruTS, suggesting 
that CD is followed by a large domain of unknown function, exhibiting fibronectin type III 
(Fn3) similarities, the segment containing SAPA repeats and finally a GPI-anchor [296].  
To further characterise the region in TcruTS, which is required for sialyl-transferase 
activity, Smith and Eichinger expressed several chimeric recombinant proteins, containing 
amino acid segments of TcruTS and T. rangeli sialidase (TranSA), respectively [309]. In 
addition, they also performed point mutation experiments to identify amino acids essential for 
Sia transferase activity. Impressively, without the employment of any structural resolving 
methods, such as nuclear magnetic resonance (NMR)-spectroscopy or X-ray crystallography, 
they were able to relative precisely predict a couple of essential tertiary structure elements. 
Besides several others, one interesting finding was that the C-terminal Fn3-like domain does 
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not induce sialyl-transferase activity to TranSA, since latter also exhibit this domain and its 
exchange from TcruTS to TranSA did not add Sia transfer activity to the TranSA [309].  
In addition to that, however, the Fn3-like domain was demonstrated to be required for 
the expression of enzymatically active recombinant TcruTS and TranSA, respectively 
[305,310]. This suggests a crucial role of the Fn3-like domain in enzyme folding or indicates 
other, so far, unknown functions. 
The breakthrough regarding tertiary structure and catalytic mechanism of TcruTS, 
succeeded with the resolved crystal structure of TcruTS [311], as well as TranSA [312] 
reported by Buschiazzo et al. in 2002 and 2000, respectively. Both, TcruTS and TranSA 
exhibit a similar overall structure. Although, the predicted six-bladed β-propeller topology at 
the N-terminus, as seen for microbial sialidases [300], was confirmed. The architecture of the 
catalytic centre exhibits a similar arrangement and orientation of amino acids, which were 
suggested to be involved in catalysis. Amino acids of the TcruTS hydrophobic Sia binding 
pocket comprise an essential arginine triad (R35, R245 and R314), which stabilise the 
carboxyl group of Sia, a glutamic acid (E357) residue, which in turn stabilise the R35, a 
tyrosine (Y342) and another glutamic acid (E230) residue, which are involved in the 
formation of the covalent transition state, and finally an aspartic acid (D59), which catalysis 
the cleavage and subsequent formation of the Sia-Gal glycosidic linkage [311,313] (Figure 5).  
Most of these and other residues of the catalytic centre are well conserved among the 
trypanosomal TS family [260,267,269,313]. One major finding includes the natural occurring 
mutation of Y342 to histidine (Y342H), observed for inactive TS [270]. This consequently 
indicates the essential role of Y342 in enzyme activity and confirms it as a main factor to 
differentiate between active and inactive TS. 
Furthermore, the C-terminal Fn3-like domain, following the CD, exhibit a high 
structural similarity to the carbohydrate recognition domain (CRD) of common plant lectins, 
typically characterised by a conserved β-barrel topology [314-317]. Hence suggesting that the 
C-terminal domain may provide a potential carbohydrate-binding-site and consequently 
termed “lectin-like” domain (LD) due to its structural homology to plant lectins [312]. 
TcruTS CD is approximately 371 and LD 237 amino acids long, whereas both domains 
are connected via a 22 amino acid long α-helix (generating a 70 kDa globular core). These 
defined arrangements result in a relatively close contact between the two domains (Figure 5). 
Interestingly, the surface area of this extended interface of TcruTS CD and LD was found to 
be significantly larger compared to that of other microbial sialidases, such as Vibrio cholera  
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or Macrobdella decora neuraminidase [301,318], thus illustrating a structural topology distinct 
from those of classical sialidases, but comprising similar structural elements. 
So far no crystal structures of any African trypanosomal TS or sialidases are available. 
However, several in silico data, including amino acid alignments and homology modelling of 
TbruTS and TconTS revealed high overall structure homology to TcruTS and TranSA 
[260,263,267,268,319] (Further data are part of this thesis). Another structural element shared 
by all trypanosomal TS comprise a single disulfide bridge (formed between C396 and C410 in 
TcruTS), which is located right after the connecting α-helix and constricts a small hairpin 
loop, which includes a short non-conserved amino acid sequence (Figure 5). This loop has 
remained unresolved in the crystal structures of both, TcruTS and TranSA [311,312], 
Figure 5. Crystal structure of TcruTS (PDB code: 1S0I) [311]. A) Overall structure, 
comprising the six-bladed β-propeller topology of the catalytic domain (CD) on the left, the 
fibronectin type III (Fn3) topology of the lectin-like domain (LD) on the right and the α-helix 
connecting both domains. B) Catalytic center of CD in complex with α-2,3-sialyllactose. 
Critical amino acids are shown and labelled with their respective numbers. C) Rear view of 
LD relative to A. The well-conserved disulfide-bridge (C396-C410), as well as the functional 
relevant salt-bridge (R610-E616) are illustrated. Purple spheres indicate the non-resolved 
loop of TcruTS crystal structure. 
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indicating its relatively high steric flexibility. Besides the α-helix connecting CD and LD, a 
second α-helix was observed from both crystal structures, located at the end of the C-terminal 
LD, sterically close to the first α-helix and the following unresolved loop (Figure 5). 
Interestingly, point mutation experiments on TcruTS, carried out by Smith et al., 
suggested the relevance of a specific salt-bridge, formed by arginine (R642) and glutamine 
(E648) side chains [309] (Figure 5). They demonstrated that its disruption by site-directed 
mutagenesis of any of the two amino acids involved resulted in increased TcruTS Sia transfer 
activity [309]. Surprisingly, this crucial structural element, which is well conserved in the 
trypanosomal TS family, is located far away from the catalytic centre and therefore, not likely 
to be directly involved in Sia transfer [320]. So far, there are still no explanations available for 
this functional effect. However, these findings clearly suggest a potential role for TS LD in 
enzymatic activity, although its mechanism still remains unclear. Therefore, biochemical 
characterisation of TconTS-LD, including its carbohydrate recognition potential and ligand 
specificity, has represented an integral part of this thesis. 
1.5.4 Catalytic mechanism 
Several approaches have clearly demonstrated the fundamental role of trypanosomal TS 
in the survival and development of the parasite in host and vector, as well as in pathogenesis 
(detailed discussed in the previous chapters 1.4 – 1.5). With respect to this, it seems more than 
obvious to elucidate the highly stereo and region specific mechanism of TS Sia transfer 
activities, in order to achieve enhanced insight into this unique class of enzymes.  
The general catalytic mechanism, by which common glycosidases hydrolyse the glycosidic 
bond of oligosaccharides, has been extensively studied and revealed the presence of both, 
inverting (chiral inversion of the anomeric carbon) as well as retaining (retain configuration at 
the anomeric carbon) glycosidases [321]. In contrast to that, it was found that trypanosomal 
TS exclusively act as retaining enzymes [241,243,260,283], similar as classical exo-sialidases, 
suggesting an analogues overall mechanism. 
However, compared to glycosidases, which utilize a pair of carboxylic acids in the 
catalytic centre, acting as proton donor (acid-catalysed hydrolysis) and nucleophile to form an 
oxoniumion-like transition state, sialidases do not contain such negatively charged groups as 
their central catalyst, most likely due to appearance of potential repulsive interactions with the 
carboxyl group of Sia. Hence a different catalytic mechanism exists for sialidases, proposed 
by several studies [251,322,323], involving a distinct set of amino acid residues in the active 
centre, catalysing the reaction. 
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The crystal structures of TcruTS and TranSA, representing the most intensive studied 
TSs, resolved by Buschiazzo et al. revealed several highly conserved amino acid residues in 
the catalytic centre of TS and SA (as mentioned in the previous chapter 1.5.3), which were 
also found in other microbial and human sialidases and known to be involved in catalytic 
activity. This new structural data together with subsequent mutagenesis results on selected 
amino acid residues of the active centre [312], has provided evidence for a potential catalytic 
mechanism analogue to that for common exo-sialidases [275,322] as follows: 1: Effective 
binding of the Sia donor substrate to the active site (Michaelis complex) is mainly stabilised 
by three arginine residues (arginine triad), forming several hydrogen bonds to the carboxyl 
group at C-1, as well as to the C-8 hydroxyl group of the glycerol side chain of Sia, which is 
accompanied by conformational change from a chair (2C5) into a boat (2,5B) configuration 
[313]; 2: An aspartate residue, located close to the glycosidic linkage between Sia and the 
underling oligosaccharide, directly acts as an acid/base catalyst and leads to the cleavage of 
the glycosidic bond, subsequently releasing the reducing end glycan structure; 3: The 
resulting Sia oxocarbonium-intermediate is then stabilised by a nucleophilic tyrosine residue, 
which is in turn formed by deprotonation via a neighbouring glutamate residue; 4: The same 
aspartate residue, which catalysed the cleavage of the initial glycosidic bond, deprotonates the 
C-3 hydroxyl group of the terminal βGal moiety of the acceptor substrate (or a water 
molecule in terms of hydrolysis), which is followed by a nucleophilic attacking at the C-2 of 
Sia, finally forming a new α2,3-glycosidic linkage accompanied by a conformational change 
of Sia back into 2C5 configuration; 5: The formed sialo-glycoconjugate is then released from 
the active centre [312]. 
This proposed conventional double-displacement or “ping-pong” mechanism is typical 
for common retaining sialidases and generally characterised by a long-lived reaction 
intermediate [259,280,312]. In contrast, from a chemical point of view, such oxocarbonium 
ion-like transition states, as proposed for TcruTS, are energetically unfavourable and in order 
to that relatively unstable and very short-lived, hence suggesting a different mechanism for 
trans-sialylation. Indeed, Watts et al. demonstrated that trans-sialylation catalysed by TcruTS 
proceeds via a covalent sialyl-enzyme-intermediate [324]. Using deoxy-2,3-difluorosialic acid 
as substrate, they were able to trap this covalent intermediate, as it has been reported for other 
glycosidases [325]. Furthermore, they could identify tyrosine 342 (Y342) as the respective 
nucleophile of TcruTS forming a covalent bond between the oxygen of Y342 side chain and 
the anomeric C-2 of Sia, before its transfer to an appropriate acceptor substrate occurs. 
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Interestingly, such a covalent aryl-sialyl-intermediate is unique for trypanosomal TS in 
respect to retaining sialidases reported so far. In respect to these findings, Amaya et al. 
proposed an adapted catalytic mechanism for TcruTS (Figure 6), also considering the 
glutamate residue 230 (E230) as the corresponding acid/base catalyst responsible for 
deprotonation of Y342 [313]. In principle, the mechanism follows the same scheme as 
described above, although difference comprise the formation of the covalent intermediate 
before a suitable acceptor substrate is bound, which is accompanied by an electrophilic 
migration of the C-2 towards the nucleophile via sugar ring relaxation of Sia to its 2C5 
conformation [313] (Figure 6). Acceptor substrate binding to the active centre of TcruTS 
(Michaelis complex) and the nucleophilic attack of the βGal C-3 hydroxyl group at the 
anomeric carbon of Sia occur in a reverse process as mentioned above.  
However, since the catalytic centre of trypanosomal TS is structurally very closely 
related to that of viral sialidases and also TranSA, the question still remains why 
trypanosomal TS act so efficiently in transferring compared to just hydrolysing the glycosidic 
bond with subsequent release of free Sia. Investigations regarding the comparison of kinetic 
reaction parameters and substrate binding properties of trypanosomal and viral enzymes 
revealed similar turnover rates but significant different ligand interactions [276,307], 
Figure 6. Proposed catalytic mechanism for trypanosomal TS. The Mechaelis complex is 
formed upon Sia donor substrate binding to the catalytic centre of TcruTS. The formation of 
the covalent sialyl-enzyme intermediate (shown in brackets) and the release of the aglycon 
moiety are catalysed by aspartate (acid/base catalyst), glutamate and tyrosine (nucleophile) 
residues of the catalytic centre. After binding of the galactosyl-substrate to the acceptor 
binding-site, Sia is transferred (or hydrolysis) to the terminal galactose residue, followed by 
the release of the new sialoside (or Neu5Ac) from the binding pocket of TcruTS. The figure 
was generated based on the catalytic mechanism proposed by Amaya et al. [313]. 
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suggesting a potential rearrangement of TS active centre and/or additional substrate 
interactions. Although the presence of distinct acceptor and donor substrate binding-sites in 
TS would provide a potential ternary complex mechanism contributing to a preferred Sia 
transfer activity. 
One primary observation was made in correlation with the crystal structure of TcruTS, 
identifying several hydrophobic residues at the active binding groove, which significantly 
contribute to an overall hydrophobic character and therefore suggested to contribute to 
exclude water molecules from the catalytic centre [311]. Furthermore, two of these 
hydrophobic amino acids, a tyrosine (Y119) and a tryptophan (W312) of TcruTS, which are 
located at opposite positions close to the active site cleft (Figure 5), were suggested to play a 
crucial role in enzyme activity by generating stacking interactions (π-π*) with cyclohexane 
rings of the donor and acceptor substrate, respectively [311-313]. Interestingly, Y119 is 
substituted by a serine residue in TranSA (S141), whereas the W312 is present in both 
enzymes (Figure 7). Key mutagenesis experiments on these two amino acids in TcruTS, 
carried out by Paris et al., clearly demonstrated their direct involvement in substrate binding 
[326]. When mutating the W312 to alanine, a complete loss of Sia transfer activity for TcruTS 
was observed, independent of the donor substrate used, although the sialidase activity was 
also significantly decreased [326]. These finding demonstrated the involvement of W312 in 
donor substrate binding. Interestingly, this conserved tryptophan residue was found in a 
completely different orientation in TranSA (W334, Figure 7), due to a adjacent glutamine 
residue Q305 (P283 in TcruTS), which sterically hinders W334 to occupy the same 
configuration as in TcruTS [326]. Substitution of P283 to glutamine in TcruTS revealed 
mutants with abolished Sia transfer as well as sialidase activities, clearly demonstrating the 
requirement of an accurate orientation of W312 for efficient substrate binding and transfer 
activities. 
In addition, site directed mutagenesis of Y119 to serine in TcruTS, drastically reduced 
Sia transfer but almost retained sialidase activities [326], indicating the crucial role of Y119 in 
acceptor substrate binding, potentially being a part of the acceptor binding-site [312], and 
obviously representing an essential, characteristic feature of trypanosomal TS. These 
suggestions were further supported by a mutant TranSA, in which Sia transfer activities has 
been induced by five different point mutations, also including those residues discussed above 
[327]. Furthermore, it has been proposed that the lactose moiety of the ligand is bound 
between W312 and Y119 [312,326]. Numerous subsequent molecular dynamics simulations 
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on TcruTS in complex with several ligands revealed another striking feature of the catalytic 
mechanism, which has not been observed from crystallographic data. 
Demir et al. demonstrated a high plasticity of the catalytic grove of TcruTS as a 
potential consequence for the different catalytic behaviour of TcruTS and TranSA, 
respectively [328]. They showed that the high flexibility of the W312 comprising loop in the 
apo (without ligand bound)-enzyme (open form), and its motion upon donor substrate binding 
(holo-enzyme), leads to a more closed conformation of the catalytic centre with significantly 
decreased solvent exposure, probably enhancing sialyl-enzyme intermediate maintenance and 
facilitating subsequent acceptor substrate binding [328]. In addition, also the flexibility of 
Y119 provides its motion to a more outward position relative to the catalytic centre, which 
allows stacking interactions with the acceptor ligand, and an inward conformation proposed to 
be essential for blocking the Sia binding-site [313,328,329]. In addition, the orientation of 
Y119 was found to be correlated with the W312 loop motion [328]. In contrast to TcruTS, 
TranSA generally exhibits a more open conformation of the catalytic grove before and upon 
substrate binding [328], representing a possible explanation for the different catalytic 
behaviour of both enzymes. Recent in silico free-energy calculations of the sialyl-enzyme 
intermediate of TcruTS and TranSA, revealed a significant higher stability for that of TranSA 
Figure 7. Structural comparison of 
T. cruzi TS (TcruTS) and T. rangeli 
SA (TranSA). The superimposed 
catalytic centres of TcruTS (PDB 
code: 1S0I) and TranSA (PDB 
code: 1N1S) in complex with 3’-
sialyllactose are illustrated. Con-
served tryptophan residues W312 
in TcruTS (yellow) and W334 in 
TranSA (red) of the flexible loop, 
which defines the open and closed 
form of the catalytic pocket, exhibit 
distinct orientations, respectively. 
Together with the tyrosine 119 
(yellow), W312 stabilise the ligand 
via stacking interactions with the 
cyclohexane ring of the lactose 
moiety. Due to the substitution of Y 
to S141 in TranSA together with the 
altered orientation of W334, in 
contrast to that of TcruTS, a lack of 
interactions to the lactose moiety 
can be observed. Van der Waals 
surfaces of the illustrated residues 
and 3’-sialyllactose are shown in 
transparent spheres, respectively. 
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compared to TcruTS, therefore indicating a subsequent Sia-transfer to a suitable donor 
substrate as rather unfavourable [330]. 
In summary, these highly dynamic structural regulatory processes, controlling the 
substrate entry and binding, represent a much more complex situation for trypanosomal TS 
activity as it was previously assumed and might be also responsible for the preferred Sia 
transfer activities compared to sialidases. A recent study has demonstrated the experimental 
existence of an acceptor substrate binding-site in TcruTS, which is generated upon donor 
substrate binding, accompanied by subsequent conformational changes and clearly distinct 
from that reported for the donor substrate [331]. From their novel experimental and in silico 
data, they concluded that the Sia transfer mechanism catalysed by trypanosomal TS cannot 
simply be described as a classical sequential or conventional double-displacement (ping-
pong) mechanism, but rather as a hybrid of both systems characterised by the formation of a 
ternary complex after the sialyl-enzyme intermediate is formed [331]. In conclusion, this new 
insights into the catalytic mechanism of trypanosomal TS provide a better understanding of 
this unique Sia transfer and opens new strategies for synthetic anti-TS drug development. 
1.5.5 TS inhibitors, a strategy to fight trypanosomiasis 
As discussed in previous chapters, trypanosomes provide several strategies to evade 
host immune response and vectors digestive system to ensure their survival and development 
during their life cycles. However, potential strategies against the parasite in controlling the 
vector have been used effectively but also implicate several striking challenges [187,191,332]. 
Furthermore, the fact that eradication of the entire trypanosomal reservoir is obviously 
impossible, another more logical strategy in controlling the parasite includes anti-
trypanosome vaccination. Although, a major problem constitutes the surface coat of the 
parasite during host infection, which is made of densely packed VSGs and permanently 
changed due to parasites antigenic variation strategy. Thus representing vaccination against 
these targets as totally ineffective (see previous chapter 1.4.3). Besides some established 
drugs, such as pentamidine, nifurtimox and melarsoprol currently used against 
trypanosomiasis with only moderate success (see previous chapter 1.4.4), the interest in 
identifying new potential targets and developing novel strategies towards more efficient anti-
trypanosomal drug-design has significantly increased over the past decade [333]. One 
promising drug target against trypanosomiasis comprise the family of TS, since they have 
been demonstrated to play a key role for parasite survival and pathogenesis (see previous 
chapters 1.5), they are expressed in the different life stages of the parasite during its 
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development in both, vector and host and do not occur naturally in either of them. Several 
different potential inhibitors have been tested, but unfortunately with only minor inhibitory 
efficiency as expected [334,335]. Generally they can be differentiated in two major classes of 
synthetic structures, the Sia mimicking derivatives, also comprising the Sia donor substrates, 
and the acceptor substrate analogue compounds [334]. One example constitutes 2,3-
didehydro-2-deoxy-N-acetylneuraminic acid (DANA), the well-studied and potent inhibitor of 
the influenza virus neuraminidase [253,336]. However, this effective sialidase inhibitor and 
even other derivatives with further modifications at several positions in the cyclohexane ring 
as well as additional functional groups, revealed only extremely weak inhibition potential for 
TcruTS in the higher mM range [288,327,337,338]. In addition also deoxy-2,3-difluorosialic 
acid, which has been used to trap and characterise the sialyl-TS intermediate (discussed in the 
previous chapter 1.5.5), only exhibits reasonable inhibitory effects at relatively high mM 
concentrations [339]. 
On the other hand, acceptor substrate analogous, such as lactitol, lactobionic acid or 
galactosyl-arabinose have been also identified as only very weak TcruTS inhibitors [282,340]. 
Nevertheless, a modified derivate of the ganglioside GM3 (A membrane-bound 
glycosphingolipid with the general composition Neu5Ac-Gal-Glc-ceramide) has been 
identified as one of the most potent TcruTS inhibitors known so far (IC50 value in the lower 
µM range) [283], most likely due to its ability to bind both, donor and acceptor substrate 
binding-sites in TcruTS. Using this potent TcruTS inhibitor as a model structure and new 
strategy towards more efficient derivatives, novel potentially inhibitory compounds have been 
synthesised, also in respect to maintain their multivalent interaction to both binding-sites in 
TS [338]. Surprisingly, these new class of inhibitors turned out to be only efficient at low mM 
concentrations just as some other compounds mentioned above. Nevertheless, following the 
strategy to develop trypanosomal TS inhibitors targeting both, acceptor and donor binding-
sites but with additional substitutions to improve binding affinities, several other compounds 
could be generated during the past years. 
Utilizing the “click chemistry” [341] approach, Carvalho et al. recently synthesised a 
library of triazole-substituted galactosides, a group that has been explored as potent inhibitors 
for different glycosyl-transferases [342], glycosidases [343,344] and influenza neuraminidase 
[345,346], as novel potent TcruTS inhibitors, bearing additional substitutions at C-1 and C-6, 
such as aryls, azoles, aliphatic alcohols and others [347]. Certainly, also these compounds 
were proven to be moderate to weak TcruTS inhibitors (low mM range) in vitro, but 
surprisingly showed significant trypanocidal activity against cultured T. cruzi trypomastigotes 
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[347]. On that basis a set of further differential modified 1,2,3-triazole sialyl-mimetic 
neoglycoconjugates have been recently synthesised by Campo et al. and verified to inhibit 
TcruTS even more effectively (around 1 mM) compared to previously reported synthetic 
compounds [348]. However, even if these compounds do not exhibit a desirable inhibitory 
activity in the low µM to nM range, a clear improvement towards more effective multivalent 
substances has been observed. Currently, a series of different relatively potent TcruTS 
inhibitors exist, comprising modified gangliosides [283], sulfonamide chalcones [349], 
modified octyl-galactosides [350], flavonoids (Myricetin) and anthraquinones [351], but no 
100 % specific and sufficient effective trypanosomal TS inhibitor has been established so far, 
possibly due to the fact that trypanosomal TS have still not been fully characterised and 
understood well enough in detail. Therefore, further characterisation of these unique enzymes 
represents a fundamental necessity for the synthesis of more effective TS inhibitors to 
efficiently fight trypanosomiasis in Latin America, Africa and all the other threatened 
countries around the planet. 
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2 Objectives 
Trans-sialidases are unique enzymes, expressed on trypanosomal cell surfaces during 
the entire life cycle, and utilised to protect the parasite from immune response, as well as to 
generate receptor molecules for host cell interactions. Due to its essential role in pathogenesis 
and parasite survival in mammalian host and insect vector, research on trypanosomal TS has 
increased over the past decades, mainly focusing on TcruTS from the Latin American parasite 
T. cruzi. However, only little is known about the orthologous TS from the African parasite T. 
congolense. 
The main aim of this study was to identify and biochemically characterise trans-
sialidases from T. congolense to get further insights into i) enzymatic activity, ii) structure-
function relationships, iii) synthetic and natural substrate affinity and specificity, iv) as well 
as its biological function also in comparison to other already well-described trypanosomal TS. 
Furthermore, additional biochemical data of TconTS should provide new strategies for the 
synthesis of novel specific and highly potent trypanosomal TS inhibitors. The specific 
objectives in these four sections were: 
i. Enzymatic activity of TconTS: To study enzyme activities in detail, it is necessary to 
express the proteins encoded by different TS-like genes from T. congolense genome 
available at the Welcome Trust Sanger Institute database. For this, all variants were 
cloned and expressed as recombinant proteins in fibroblasts. Using well-established 
standard reaction conditions and fetuin as highly sialylated donor substrate, reaction 
product analysis employing a carbohydrate optimised HPLC-based method, was used 
to provide comparable data on enzymatic activities. In addition, a strategy to swap and 
recombine catalytic (CDs) and lectin-like domains (LDs) from different TconTS was 
established and chimeric recombinant enzymes were expressed by fibroblasts and 
bacteria to investigate the influence of LD on enzymatic activities. 
ii. Structure-function relations: Since there is no crystal structure or NMR resolved 
structure of TconTS available so far, homology modelling using the published crystal 
structure of TcruTS as template was used to generate TconTS structure models based 
on amino acid sequence alignment of all enzymes. Together with the data obtained on 
TconTS enzyme activities these models should not only provide further insights into 
structure-function relations and enhance understanding of TS function, but also be 
helpful in respect to future TconTS applications as catalysts for sialylation reactions. 
iii. Substrate affinity and specificity: Besides the selected sialyl-donor substrates 3’SL 
and fetuin for TS reactions also more natural substrates available in the mammalian 
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host as well as the parasites’ midgut environment, such as serum glycoproteins, have 
been chosen to investigate enzymatic activities of the different TconTS variants, 
mimicking a more native system. On the other hand, TconTS activities were also be 
investigated under conditions related to tsetse vector environment. Since T. 
congolense migrates through different tissues with different environmental conditions 
during its developmental life cycle in tsetse vector, which is e.g. characterised by a pH 
shift, it was important to investigate TconTS pH dependency. Results should provide 
new insight into enzyme catalysis and support synthesis of more effective, stage 
specific inhibitors and/or the establishment of other anti-trypanosomal therapeutic 
strategies. 
iv. Biological function: Many studies have been focused on the structural topology of the 
catalytic domain (CD) and the active centre of TS and sialidase, in respect to 
biological function and catalytic mechanism. However, only very little is known about 
TS lectin-like domains (LD), for which no functional data and/or biological relevance 
have been described so far. Therefore, it was of fundamental interest to biochemically 
characterise TconTS-LD function by cloning and expressing recombinant proteins as 
model structures. In cooperation with Dr. Joe Tiralongo and Dr. Thomas Haselhorst 
(Institute for Glycomics, Griffith University, Goldcoast Australia) carbohydrate 
binding affinities and specificities of several TconTS-LDs were determined, utilising a 
number of techniques specific to investigate protein-ligand interactions, such as SPR, 
glycan array and STD NMR. Additionally, establishment of a microtitre-based 
TconTS-LD binding/inhibition assay, as well as other TS activity studies regarding the 
influence of LD on enzyme activity provided further essential data in respect to the 
biological function of these unusual enzymes. 
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variants from Trypanosoma congolense
Hendrik Koliwer-Brandl, Thaddeus T Gbem, Mario Waespy, Olga Reichert, Philipp Mandel, Eric Drebitz, Frank Dietz
and Sørge Kelm*
Abstract
Background: Animal African trypanosomiasis, sleeping sickness in humans and Nagana in cattle, is a resurgent
disease in Africa caused by Trypanosoma parasites. Trans-sialidases expressed by trypanosomes play an important
role in the infection cycle of insects and mammals. Whereas trans-sialidases of other trypanosomes like the
American T. cruzi are well investigated, relatively little research has been done on these enzymes of T. congolense.
Results: Based on a partial sequence and an open reading frame in the WTSI database, DNA sequences encoding
for eleven T. congolense trans-sialidase 1 variants with 96.3% overall amino acid identity were amplified. Trans-
sialidase 1 variants were expressed as recombinant proteins, isolated and assayed for trans-sialylation activity. The
purified proteins produced a2,3-sialyllactose from lactose by desialylating fetuin, clearly demonstrating their trans-
sialidase activity. Using an HPLC-based assay, substrate specificities and kinetic parameters of two variants were
characterized in detail indicating differences in substrate specificities for lactose, fetuin and synthetic substrates.
Both enzymes were able to sialylate asialofetuin to an extent, which was sufficient to reconstitute binding sites for
Siglec-4. A mass spectrometric analysis of the sialylation pattern of glycopeptides from fetuin revealed clear but
generally similar changes in the sialylation pattern of the N-glycans on fetuin catalyzed by the trans-sialidases
investigated.
Conclusions: The identification and characterization of a trans-sialidase gene family of the African parasite T.
congolense has opened new perspectives for investigating the biological role of these enzymes in Nagana and
sleeping sickness. Based on this study it will be interesting to address the expression pattern of these genes and
their activities in the different stages of the parasite in its infection cycle. Furthermore, these trans-sialidases have
the biotechnological potential to be used for enzymatic modification of sialylated glycoconjugates.
Background
Animal African trypanosomiasis, called sleeping sickness
in humans and Nagana in cattle, is a resurgent disease
in Africa. Nagana is caused by Trypanosoma congolense
(T. congolense), Trypanosoma vivax (T. vivax) and Try-
panosoma brucei (T. brucei) subspecies. Most research
on African trypanosomes has focused on T. brucei,
whereas only few studies have been done with other
African trypanosomes including T. congolense. In wild
animals, these parasites cause relatively mild infections
while in domestic animals they cause a severe, often
fatal disease. Because of Nagana, stock farming is very
difficult within the tsetse belt of Africa [1].
Although of crucial importance for their survival,
cyclical transmission and hence pathogenicity of trypa-
nosomes, trypanosomes lack the biochemical metabolic
machinery synthesizing sialic acids (Sia), but use a
unique enzyme, trans-sialidase (TS) to transfer Sia onto
the parasites surface molecules from the environment.
Structurally TS belong to the family of sialidases (SA).
In contrast to the usual sialyltransferases, TS does not
utilize CMP-activated Sia as monosaccharide donors,
but catalyzes the transfer of carbohydrate-linked Sia to
another glycan forming a new a2,3-glycosidic linkage to
galactose or N-acetylgalactosamine.
Whereas more detailed studies exist on the role of TS
in the pathogenicity of T. cruzi, the etiologic agent of
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Chagas diseases in South America, where TS was first
discovered [2], the current knowledge about the corre-
sponding enzymes in the African trypanosomes is very
limited. Of all the African trypanosomes, only T. brucei
full length TS genes have been cloned and studied [3].
Sialylation of parasite surfaces is believed to protect the
parasites from the action of glycolytic enzymes as well
as from immunocompetent substances present in the
tsetse gut and blood meal respectively, as well as influ-
encing the interaction of parasites with the gut epithelial
cells [4-6]. In the African trypanosomes where TS is
thought to be expressed only in the procyclic insect
stages [5,7], TS has been shown to increase the survival,
maturation and hence establishment of the parasites in
the vector midgut [8].
Two TS forms, named TS-form 1 and TS-form 2,
have been purified from procyclic T. congolense cultures
[6]. Interestingly, glutamic acid and alanine-rich protein
(GARP) was co-purified with TS-form 1, suggesting that
GARP may be a natural substrate for TS-form 1. Inter-
estingly, TS-form 1 had significantly less SA activity and
higher TS activity, whereas SA activity was predomi-
nately found in preparations of TS-form 2. An anti-T.
congolense TS antibody (mAb 7/23) was developed using
TS form 1 as antigen. This antibody is specific for T.
congolense TS recognizing TS-form 1 and TS-form 2,
but does not bind to T. brucei TS. Peptides micro
sequencing revealed the amino acid sequence
VVDPTVVAK in TS-form 1. Subsequently, fragments of
two TS genes (TS1 and TS2) were sequenced, sharing
about 50% sequence identity [9]. TS1 encoded this pep-
tide sequence, whereas in TS2 this sequence ended in
VVK. These data strongly suggested that the gene pro-
duct of TS1 has been present in TS-form 1. Neverthe-
less, it has remained unclear whether only TS1 and/or
TS2 gene products were present in TS-form 1 and TS-
form 2 preparations. Due to the fact that the monoclo-
nal antibody mAb 7/23 bound both TS preparations, it
is quite possible that TS-form 2 contained at least some
amounts of TS1 gene product, which might have been
responsible for the TS activity of this preparation.
Here, we report the cloning of eleven trans-sialidase
TS1 variants from T. congolense and their recombinant
expression in CHOLec1 cells. Furthermore, the enzymatic
properties of two of these recombinant TS1 variants
were compared with TS from T. cruzi.
Results
Diversity of TS1 genes and structural model
Based on the partial sequence of TS1 [GenBank:
AJ535487.1] [9], an open reading frame in the Welcome
Trust Sanger Institute (WTSI) database was identified.
The full-length translation product consists of 750
amino acids extending the partial sequence of TS1 by
153 amino acids at the N-terminus and by 84 amino
acids at the C-terminus. It contains a 16 amino acids N-
terminal signal peptide and a catalytic domain (residues
17-467), which is connected through a long a helix
(residues 468-491) to a lectin domain (residues 492-732)
followed by a potential C-terminal GPI-anchor attach-
ment site (residues 733-750, identified by big-PI predic-
tor [10]). Furthermore, nine potential N-glycosylation
sites were identified (Figure 1).
T. congolense TS1 shares about 57% sequence identity
with T. brucei TS [EMBL: AAG32055.1] and 48% with
T. cruzi TS [EMBL: BAA09334.1] (Figure 2). The T.
brucei TS has a prolonged N-terminus of approx. 90
amino acids, which is conserved in T. congolense TS1
sharing 50% amino acids, but is absent in T. cruzi TS.
The catalytic domain of both African proteins has 60%
and the lectin domain 43% sequence similarities. T. con-
golense TS1, like T. brucei TS and T. rangeli SA, has no
C-terminal SAPA domain typical for T. cruzi TS [11].
Almost all amino acid residues reported to be required
for TS activity are identical in TS1 with the exception of
A325 (corresponding to P231 in T. cruzi TS) [11], R127,
G344-Q346 and Y408 (corresponding to Y248 and
W312, respectively in T. cruzi TS) [12] (Figure 2).
To produce recombinant protein for enzyme charac-
terization, the DNA encoding amino acids 17-732 was
amplified using genomic T. congolense DNA as a tem-
plate and inserted into a mammalian expression vector
as described in Methods. 13 clones were picked from
two independent cloning experiments and sequenced.
Interestingly, not all the 13 clones had identical
sequences and eleven different sequences were obtained
(TS1a through TS1j), exhibiting an overall amino acid
identity of 96.3%. A more detailed search of the WTSI
database using these sequences as queries confirmed the
presence of these TS1 genes in the T. congolense gen-
ome database. As shown in Figure 3, changes are not
evenly distributed over the protein sequences. Eight
were found in the lectin domain and 17 in the catalytic
domain, some close to the predicted active site as
shown in Figure 4A.
For a better understanding of how these differences
may affect TS function, we calculated a model structure
(Figure 4) for TS1 e-1 by homology modeling based on
the crystal structure of T. cruzi TS [12], which was com-
plexed with the Sia derivative 3-fluoro-5-N-acetyl-9-ben-
zamido-2,9-dideoxy-neuraminic acid. The superimposed
structures of T. cruzi TS and the T. congolense TS1 e-1
model had a root mean square deviation (RMSD) of
0.685 Å over 594 aligned residues.
In Figure 4A, amino acids of the active site are high-
lighted. Most of the amino acids reported to be relevant
for TS activity are identical in all T. congolense TS1 var-
iants (white labels). However, differences to T. cruzi TS
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were identified at three positions (yellow labels in Figure
4A). (I) At position 325 all T. congolense TS1 variants
have an alanine, like in T. brucei TS, replacing a proline
occurring in T. cruzi TS (P231); (II) Y408 of all T. con-
golense TS1 variants corresponds to a tryptophan in T.
cruzi TS (W321) and T. brucei TS; (III) the group of
G342, G343 and Q344 replaces a tyrosine (Y248) in T.
cruzi TS. In addition, near the catalytic site at position
407 (red label) in T. congolense TS1 variants, a serine or
valine occurs instead of arginine (R311) in T. cruzi TS.
Interestingly, similar differences occur also in T. brucei
TS (Figure 2). Since these amino acids are close to the
active site, they could influence the acceptor binding
specificity. The arginine at position 144 (blue label) is
conserved in all TS, with the exception of T. congolense
TS1g, where it is a cysteine.
In Figure 4B the amino acid positions are highlighted,
which have different side chains in TS1a-TS1j (Figure
3). It should be noted that these are all on the same
side of the protein as the catalytic site. Striking is a clus-
ter of amino acid variations in the lectin domain (posi-
tion 599 to 602 and 643) suggesting that these changes
may influence substrate binding of larger substrate
molecules, such as glycoproteins.
Characterization of T. congolense TS1 enzyme activity
All eleven TS1 gene products (TS1a-TS1j) were
expressed as recombinant proteins and were recognized
by the anti- T. congolense TS antibody (mAb 7/23) [6]
(data not shown). For all TS1 variants similar robust TS
activity could be determined, except for TS1g. This var-
iant, which carries cysteine instead of arginine at posi-
tion 144, had only very low TS activity. However, in
contrast to the other variants, TS1g released free Sia
from fetuin at about 50% of the transfer to lactose. Two
of the T. congolense TS1 variants, TS1b and TS1 e-1,
were further characterized. They differ in eleven of the
total 25 positions with amino acid variations listed in
Figure 3, three in the catalytic domain and eight in the
lectin domain.
The donor substrates fetuin 3’SL or pNP-Neu5Ac and
the acceptor substrates lactose, galactose or Gal-MU
were employed to determine sialidase and trans-sialidase
activities. For this purpose, a new assay was established
ATGTGG CCGGT GAAT T GT T ACGCGCTGCT GGCGCT T GT T GT GGCGGGT CAGT GCTGCGA CCACATGCATGCCACTGCCGCTGTGGGAACGA CGCACCAGGCGCTGCTATGGGG CTCCAAATGGGCT CT GAGGA
ACAAGACGACCCCGAAAGATGG CGAGGTGTGGT GGA GCAA CCCCCAGCCGGG CTGGAAGGA GGT GTACGA CGATGAGTGGGA GGAGTGGT T T ATGGA GCAGGA GGGA CCAA CGGGT GTGAATGGT GT GCGGGG
T GAGTGGT ACCGT CGCATGAAGGA TGGGT AT AT ACTCGT T GGCGGA CCGAAG CTGAACT CACCCGACAT GAA CAGCACCGGCACGA CGATGCGGA CTGTGCACT CGTACCGCAT ACCCT CAATT GT TGAGGT T
GG CGGT GTGCTAATGTGTGTGGGGGA T GCGCGCTACAT CACGT CGA CGGA T T AT T TCTT CACGGA CACCGT T GCCGCATACAG CACTGA CGGT GGGA GAACGTGGAAGAGGGA GGT T ATAAT CCCGAATGGT C
GTGTGGA T GCCCACT ACTCCCGCGT CGTTGATCCCACT GT T GT T GCGAAGGGT AATAA CAT T T AT GT TCTCGT TGGG CGGT ACAAT GT CACGCGGGG CTACTGGCACAATAAGAA CAACAGGGCT GGCGTAG C
CGAT TGGGAGCCCT TCGT GT ACAAGGG CACGGT GAACGTGGG CACGAAGGA CAATGCCACTGAT GTGT CGAT CAG CTGGGA GAGGACT GCACTGAAGT CGCT GTACAACT TCCCGGT T TCGGGAAG CCCT GGC
ACGCAGT TCCT TGGT GGGG CTGGGGGT GGT GT T GT AACAT CCAA CGGGACGAT T GT GCTGCCAGTGCAGGCAAGGA ACAAAG CCAA CCGTGT T GT GAG CAT GATCCT GT ACTCGGCT GACGATGGAAAGT CAT
GG CACT T T GGGAAGGGT GAGG CCGGT GTAGGCACGT CCGAGG CTGCCCTCACTGAGTGGGA CGGCAAGCT GCTGAT T AGTGCACGAT CCGATGGT GGA CAGGG CTACCGT AT GATATT CGAATCGAGT GACCT
TGGT GCGA CGTGGAAAGAGATGCT CAA CAGCAT CTCCCGCGTGAT T GGCAA CTCTCCGGGT CGCAGTGGT CCT GGCAG CTCGAGTGGCT TCAT CACGGT GA CAGTGGA GGGT GTGCCTGTGATGCTT CT CACC
CAT CCGAAGAA CCT TAAGGG CTCGT AT TAT CGT GAT CGCCT GCAGATGTGGA T GACGGA CGGCAATCGT AT GT GGCATGT CGGG CAGGT CTCTGAGGG CGACGACAACAGT GCCT ACAGCT CCCTGCT GT ACA
CTCCGGA CGGGGT CCT GT ACTGCT T GCAT GAG CAGAACAT T GATGAGGT GT ACAGCCTCCACCT T GT GCGCCT T GTGGA CGAG CTGAAAAG CAT TAAAT CAACGG CTCTGGT GTGGAAGGCACAGGA CGAG CT
T CT CCTGGGCAA CTGCCTCCCGGG CGATAAATATGATCCCGGGT GTGA CGGCAT CCCCACCGCTGGGCT T GCCGGG CTGCTGGT AGGA CCCCT GACGGA GAAGACGTGG CCCGA CGCGT AT CGGT GCGT GAA C
GCT GCAACCAGCGG CGCTGTGAGCACT GCTGAAGGCGTGCGG CTCGACGTGGGT GG CGGT GG CCATGT T GT GT GGCCCGTGAGTGAGCAGGGG CAGGA CCAG CGGTAT T ACT T T ACCAA CAGCGAGTT CACGC
T CGCCGT CACGGT GCGGT T T GACGAGATGCCACAGGGGGA GCTCCCGT T GCTGGGG T T T GT GAA CCGCGAAGGG AAGGT GAAGAAGAT ACTGAAGGT GT CGCTGAGCGGGGT GGA GTGG CTCCT GGCATACGG
GAATGAGTACAA CAGCACAG CCGCT GAGCCGCTGGA CGT GAA CGAGAG CCACCAGGT GGT GCT AGCGCT TCACGACGGGA T CGT CTCCCT GCACGT T GACGGGGGTAA CACGACGG CGACT GTGAG CGTGCGC
GTGG CGAG CCCTGCGGA GCT GCTGAACATT CAT CAT CT CT TCGT TGGCACCCCAGT T GATGGA GG CGCCAAGGA GCACGCCAACAT CACAGTGAGCAATGT CCTGGT GTACAAT CGACCGCTGCGTGGCGTGG
AG CTGCT T G GGCTATT CGCGAACAGGGGACGGA T TCGT GT GCCTGGGAG CGACAA CGGT GT CCT CAGT GGCGGGT GT CTGT CCCT CT GT T AT CT CCTGCT GCTCGT GCAT GT GCTGAT GT T T
M W P V N C Y A L L A L V V A G Q C C D H M H A T A A V G T T H Q A L L W G S K W A L R
N K T T P K D G E V W W S N P Q P G W K E V Y D D E W E E W F M E Q E G P T G V N G V R G
E W Y R R M K D G Y I L V G G P K L N S P D M N S T G T T M R T V H S Y R I P S I V E V
G G V L M C V G D A R Y I T S T D Y F F T D T V A A Y S T D G G R T W K R E V I I P N G
R V D A H Y S R V V D P T V V A K G N N I Y V L V G R Y N V T R G Y W H N K N N R A G V A
D W E P F V Y K G T V N V G T K D N A T D V S I S W E R T A L K S L Y N F P V S G S P G
T Q F L G G A G G G V V T S N G T I V L P V Q A R N K A N R V V S M I L Y S A D D G K S
W H F G K G E A G V G T S E A A L T E W D G K L L I S A R S D G G Q G Y R M I F E S S D L
G A T W K E M L N S I S R V I G N S P G R S G P G S S S G F I T V T V E G V P V M L L T
H P K N L K G S Y Y R D R L Q M W M T D G N R M W H V G Q V S E G D D N S A Y S S L L Y
T P D G V L Y C L H E Q N I D E V Y S L H L V R L V D E L K S I K S T A L V W K A Q D E L
L L G N C L P G D K Y D P G C D G I P T A G L A G L L V G P L T E K T W P D A Y R C V N
A A T S G A V S T A E G V R L D V G G G G H V V W P V S E Q G Q D Q R Y Y F T N S E F T
L A V T V R F D E M P Q G E L P L L G F V N R E G K V K K I L K V S L S G V E W L L A Y G
N E Y N S T A A E P L D V N E S H Q V V L A L H D G I V S L H V D G G N T T A T V S V R
V A S P A E L L N I H H L F V G T P V D G G A K E H A N I T V S N V L V Y N R P L R G V
E L L G L F A N R G R I R V P G S D N G V L S G G C L S L C Y L L L L V H V L M F
1 10 20 30 40 50 60 70 80 90 100 110 120 130
140 150 160 170 180 190 200 210 220 230 240 250 260
270 280 290 300 310 320 330 340 350 360 370 380 390
400 410 420 430 440 450 460 470 480 490 500 510 520 530
540 550 560 570 580 590 600 610 620 630 640 650 660
670 680 690 700 710 720 730 740 750 760 770 780 790
800 810 820 830 840 850 860 870 880 890 900 910 920 930
940 950 960 970 980 990 1,000 1,010 1,020 1,030 1,040 1,050 1,060
1,070 1,080 1,090 1,100 1,110 1,120 1,130 1,140 1,150 1,160 1,170 1,180 1,190
1,200 1,210 1,220 1,230 1,240 1,250 1,260 1,270 1,280 1,290 1,300 1,310 1,320 1,330
1,340 1,350 1,360 1,370 1,380 1,390 1,400 1,410 1,420 1,430 1,440 1,450 1,460
1,470 1,480 1,490 1,500 1,510 1,520 1,530 1,540 1,550 1,560 1,570 1,580 1,590
1,600 1,610 1,620 1,630 1,640 1,650 1,660 1,670 1,680 1,690 1,700 1,710 1,720
1,730 1,740 1,750 1,760 1,770 1,780 1,790 1,800 1,810 1,820 1,830 1,840 1,850 1,860
1,870 1,880 1,890 1,900 1,910 1,920 1,930 1,940 1,950 1,960 1,970 1,980 1,990
2,000 2,010 2,020 2,030 2,040 2,050 2,060 2,070 2,080 2,090 2,100 2,110 2,120
2,130 2,140 2,150 2,160 2,170 2,180 2,190 2,200 2,210 2,220 2,230 2,240 2,250
Figure 1 Primary sequence of TS1a. The full length coding domain sequence [EMBL: HE583283] with corresponding amino acid translations is
shown. The recombinant protein was generated without the N-terminal signal peptide and without the C-terminal region predicted to be
replaced by a GPI anchor in the native protein (framed boxes). Predicted N-glycosylation sites are highlighted by light grey boxes.
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                             1       10        20        30        40        50
                          60        70        80        90        100       110
                          120       130       140       150       160       170
T. congolense TS1e   --------MWPVNCYALLALVVAGQCCDHMHATAAVGTTHQALLWGSKWALRNKTTPKDG
       T. cruzi TS   ------------------------------------------------------------
      T. brucei TS   -MEELHQQMHMPISRLLLIFTAVCHCCALTSKAAGKGTTREAFLSGGSWALRKKLSEKDG
     T. rangeli SA   ------------------------------------------------------------
T. congolense TS1e   EVWWSNPQPGWKEVYDDEWEEWFMEQEGPTGVNGVRGEWYRRMTDGYILVGGPKLNSPDM
       T. cruzi TS   ---------------------------ASLAPGSSRVELFKRQSSKVPFEK---------
      T. brucei TS   EVWWWQDGPNWKDKYDKEWERWFKEEKGPWGGSEKRSEWFARMTGGYITLGKTKILSSAI
     T. rangeli SA   ----------------------------MLAPGSSRVELFKRQSSKVPFEK---------
T. congolense TS1e   NSTGTTMRTVHSYRIPSIVEVGGVLMCVGDARYITSTDYFFTDTVAAYSTDGGRTWKREV
       T. cruzi TS   -DGKVTERVVHSFRLPALVNVDGVMVAIADARYETSFDNSLIDTVAKYSVDDGETWETQI
      T. brucei TS   EGSDKVERTVHSFRIPSFVEVDGVLMGIGDARYLTSTDYFFTDTVAKYSADGGKTWKTEA
     T. rangeli SA   -DGKVTERVVHSFRLPALVNVDGVMVAIADARYETSNDNSLIDTVAKYSVDDGETWETQI
T. congolense TS1e   IIPNGRVDAHYSRVVDPTVVAKGNNIYVLVGRYNVTRGYWHNKNNRAGVADWEPFVYKGT
       T. cruzi TS   AIKNSRA-SSVSRVVDPTVIVKGNKLYVLVGSYNSSRSYWT---SHGDARDWDILLAVGE
      T. brucei TS   IIENGRVDPTYSRVVDPTVVAKADSVFVLVARYNVTKGYWHNENNAAGIADWEPFVYKGV
     T. rangeli SA   AIKNSRA-SSVSRVVDPTVIVKGNKLYVLVGSYNSSRSYWT---SHGDARDWDILLAVGE
T. congolense TS1e   VNVGTKDNATDVSISW-ERTALKSLYNFPVSGSPGTQFLGGAGGGVVTSNGTIVLPVQAR
       T. cruzi TS   VTKSTAGGKITASIKWGSPVSLKEFFPAEMEGMHTNQFLGGAGVAIVASNGNLVYPVQVT
      T. brucei TS   VTKGADGKTSDVRISW-TKTPLKPLYDFTVAGSKGTQFIGGAGNGVVTLNGTILFPVQAR
     T. rangeli SA   VTKSTAGGKITASIKWGSPVSLKEFFPAEMEGMHTNQFLGGAGVAIVASNGNLVYPVQVT
T. congolense TS1e   NKANRVVSMILYSADDGKSWHFGKGEAGVGTSEAALTEWDGKLLISARSDGG-----QGY
       T. cruzi TS   NKKKQVFSKIFYSEDEGKTWKFGKGRSAFGCSEPVALEWEGKLIINTRVD-------YRR
      T. brucei TS   NEDNAVVSMVMYSVDDGVSWHFARGETALLTSEASLTEWNGKLLMSARTDTSGVNVEGGF
     T. rangeli SA   NKKKQVFSKIFYSEDEGKTWKFGKGRSAFGCSEPVALEWEGKLIINTRVD-------YRR
T. congolense TS1e   RMIFESSDLGATWKEMLNSISRVIGNSPGRSGP-------GSSSGFITVTVEGVPVMLLT
       T. cruzi TS   RLVYESSDMGNTWLEAVGTLSRVWGPSPKSNQP-------GSQSSFTAVTIEGMRVMLFT
      T. brucei TS   RKVLESSNLGATWEESLGTISRVIGNSPDRTKPSPTANYPGSSGALITVTLGDVPVMLIT
     T. rangeli SA   RLVYESSDMGNSWLEAVGTLSRVWG-------PSPKSNQPGSQSSFTAVTIEGMRVMLFT
T. congolense TS1e   HPKNFKGSYYRDRLQMWMTDGNRMWHVGQVSEGDDNSAYSSLLYTPDGVLYCLHEQNIDE
       T. cruzi TS   HPLNFKGRWLRDRLNLWLTDNQRIYNVGQVSIGDENSAYSSVLYK-DDKLYCLHEINSNE
      T. brucei TS   HPKNTKGAWSRDRLQLWMTDGNRMWLVGQISEGDDNSAYSSLLLARDGLLYCLHEQNIDE
     T. rangeli SA   HPLNFKGRWLRDRLNLWLTDNQRIYNVGQVSIGDENSAYSSVLYK-DDKLYCLHEINSNE
T. congolense TS1e   VYSLHLVRLVDELKSIKSTALVWKAQDELLLGNCLPGD----KYDPGC-DGIPTAGLAGL
       T. cruzi TS   VYSLVFARLVGELRIIKSVLQSWKNWDSHLSSICTPADPAASSSERGCGPAVTTVGLVGF
      T. brucei TS   VYSLHLVHLVDELEKVNATVRKWKAQDALLAGLCSSSR---KKNDPTCS-GVPTDGLVGL
     T. rangeli SA   VYSLVFARLVGELRIIKSVLQSWKNWDSHLSSICTPADPAASSSERGCGPAVTTVGLVGF
T. congolense TS1e   LVGPLTEKTWPDAYRCVNAATSGAVSTAEGVRLDVGGGGHVVWPVSEQGQDQRYYFTNSE
       T. cruzi TS   LSHSATKTEWEDAYRCVNASTANAERVPNGLKF-AGVGGGALWPVSQQGQNQRYHFANHA
      T. brucei TS   LAGPVGASVWADVYDCVNASISDGVKVSEGVQLGGKRNSPLLWPVSEQGQDQRYYFANTH
     T. rangeli SA   LSHSATKTEWEDAYRCVNASTANAERVPNGLKFA-GVGGGALWPVSQQGQNQRYRFANHA
T. congolense TS1e   FTLAVTVRFDEMPHGELPLLGFVNRKDQVKKILKVSLSG-VEWLLAYGNEYNSTAAEPLN
       T. cruzi TS   FTLVASVTIHEVPKGASPLLGASLDSSGGKKLLGLSYDKRHQWQPIYGSTPVTPT-GSWE
      T. brucei TS   FTLLATVRFAGEPKAEAPLMGFSNAEGKTSETLSLTVGGK-KWVLTYGSVRKEGPTTSMD
     T. rangeli SA   FTVVASVTIHEVPSVASPLLGASLDSSGGKKLLGLSYDERHQWQPIYGSTPVTPTGSWE-
T. congolense TS1e   VNESHQVVLTLHDGIVSLHVDGGNMTATVSVRVASPAELLNIHHLFVGTPVDGGAKEHAN
       T. cruzi TS   MGKRYHVVLTMANKIGSVYIDGEPLEGSGQ-TVVPDERTPDISHFYVGGYKRSGMPTDSR
      T. brucei TS   WNQTHQIALTLRDGKVDAHANGELIIKEVSVGASESSAHLHLSHFFIGAPVNDSGEGGNN
     T. rangeli SA   MGKRYHVVLTMANKIGSEYIDGEPLEGSGQ-TVVPDERTPDISHFYVGGYKRSDMPTISH
T. congolense TS1e   ITVSNVLVYNRPLRGVELLGLFANRGRIRVPGSDNSVLSGGCLSLCYLLLLVHVLMF-
       T. cruzi TS   VTVNNVLLYNRQLNAEEIRTLFLSQDLIGTEAHMD-----------------------
      T. brucei TS   VIVRNVLLYNRKLDEDELQVLYSNREKIQPVVSAVGIPEGMSAPRLCCLLILMYVLAI
     T. rangeli SA   VTVNNVLLYNRQLNAEEIRTLFLSQDLIGTEAHMDSSSDTSA----------------
                          180       190       200       210       220       230
                          240       250       260       270       280       290
  400       410       420       430        440      450
  460       470       480       490           500        510
  520       530       540       550       560       570
  580       590       600       610        620       630
  640       650       660       670       680       690
  700       710       720       730       740       750 
                          300       310       320       330       340
350       360       370              380       390
Figure 2 Primary sequence alignment of trypanosomal trans-sialidases. The amino acid sequence of T. congolense [EMBL: HE583287] TS1 e-
1 was aligned with T. cruzi TS [EMBL: BAA09334.1, PDB: 3B69], T. brucei TS [EMBL: AAG32055.1] and T. rangeli SA [EMBL: AAC95493.1] based on a
structural alignment of T. congolense TS1 e-1 with T. cruzi TS generated with Yasara during homology modeling. Amino acids, which have been
proposed to be relevant for enzymatic activity are marked with black frames if conserved or with black frames and light grey background if not
conserved. Positions with variations occurring in T. congolense TS1 or T. brucei TS [3] are highlighted by dark grey boxes.
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as described under Methods, using HPAEC-PAD to
quantify sialylated oligosaccharide products with the
detection limit of 20 pmol 3’SL corresponding to 0.5
μM in the reaction mixture. In standard assays, 50 μL
TS reactions were set up with 50 ng TS1b or TS1 e-1,
100 μg fetuin (approx. 600 μM bound Sia) as donor sub-
strate and 100 nmol acceptor substrate (2 mM e. g. lac-
tose or galactose). Under these conditions, linear
product formation was obtained for up to 2500 pmol
corresponding to 50 μM 3’SL (Figure 5).
If lactose is used as a donor substrate under standard
conditions, 3’SL concentration increases linearly for
about 30 minutes before the reaction velocity started to
decrease (Figure 5A). It should be noted that lactose
was sialylated almost twice as fast by TS1b than by TS1
e-1. In contrast to lactose, galactose was sialylated at the
same rate by both enzymes, but at about 20-fold lower
velocity than lactose.
Different specific activities were obtained for T. congo-
lense TS1b, TS1 e-1 and T. cruzi TS (Figure 6). The
reaction velocity was linearly dependent on the amount
of TS as long as the concentration of the product 3’SL
was below 50 μM. Under standard conditions 50 μM
3’SL was produced in 30 minutes with 50 ng TS. If 200
ng TS or more were used, product formation was inde-
pendent of the amount of TS, probably due to the
increased use of 3’SL as a donor substrate in the reverse
reaction, finally leading to an equilibrium between lac-
tose, 3’SL, sialylated and desialylated glycans on fetuin.
This equilibrium apparently was reached in 30 minutes
with 500 ng TS (266 ± 4 μM 3’SL for T. cruzi TS, 194
± 6 μM 3’SL for TS1b and 165 ± 7 μM 3’SL for TS1 e-
1). After 20 h incubation, 50 ng TS was sufficient to
reach the equilibrium. Independent of the amount of
enzyme used, for all three TS applied similar final con-
centrations of 3’SL were obtained after 20 h incubation
(Table 1).
The HPAEC-PAD method used allowed not only
determining the TS, but also SA activity, since free Sia
and 3’ SL could be quantified from the same chromato-
gram. In standard reactions (50 ng TS, 30 min incuba-
tion time) no SA activity could be detected, both in the
presence or absence of lactose as an acceptor substrate.
This suggests that these TS1 variants usually need an
acceptor substrate like lactose to cleave Sia from a
donor substrate. However, after 20 h incubation, free Sia
was detected. The quantity of Sia released was depen-
dent on the amount of TS used (Table 1). Besides stan-
dard TS reactions with fetuin as donor and lactose as
acceptor substrate, TS reactions with 2 mM 3’SL as
donor and 2 mg/mL ASF as acceptor substrate were
performed. In these reactions, free Sia was detected after
short reaction times and after incubation for 24 h, 0.5-1
mM free Sia were produced (data not shown).
position TS1a TS1b TS1c TS1d TS1e TS1e' TS1f TS1g TS1h TS1i TS1j
79 E K E E E E E E E E E
89 G T G G G G G G A G G
96 K K T T T T K K K K T
144 R R R R R R R C R R R
170 R R R S R R S R R R R
215 K K R Q K K Q K K Q Q
217 N N D D N N D N N D D
218 R R K E R R E R R E E
220 G G A G G G A G G G G
221 V V I V V V I V V V V
293 K K K K K K K K K K N
338 A A A A A A T A A A A
375 G G K G G G P K K K S
377 S S N S S S S N N N S
404 L L L L F L L L L L L
407 S S S V S S S S S S S
409 Y Y Y S Y Y Y Y Y Y Y
588 Q Q Q Q H H H Q R R R
599 R R R R R R R H H R R
600 E E E E K K K K K K K
601 G G G G D D D G G G G
602 K K K K Q Q Q K K K K
633 D D D D N N N N L D D
643 A A A A T T T T A A A
658 T T T T M M M T T M T
Catalytic domain
Lectin domain
Figure 3 Amino acid variations found in T. congolense TS1a-
TS1j. TS1a [EMBL: HE583283], TS1b [EMBL: HE583284], TS1c [EMBL:
HE583285], TS1d [EMBL: HE583286], TS1 e-1 [EMBL: HE583287] , TS1
e-2 [EMBL: HE583288], TS1f [EMBL: HE583289], TS1g [EMBL:
HE583290], TS1h [EMBL: HE583291], TS1i [EMBL: HE583292], TS1j
[EMBL: HE583293]. Differences in amino acids are highlighted (light
grey: conservative; dark grey: modest; black: drastic change).
Figure 4 Homology model of T. congolense TS1. The crystal
structure of T. cruzi TS [12] in complex with 3-fluoro-5-N-acetyl-9-
benzamido-2,9-dideoxy-neuraminic acid was used as template to
calculate a model structure for T. congolense TS1 e-1. Only the
Neu5Ac part (orange) of the ligand in the binding site of the
complex is illustrated. (A) Conserved amino acids of the active site
are labeled in white. Amino acids at positions reported to be
important for ligand binding in T. cruzi TS [12], which are not
conserved in T. congolense are labeled in yellow. The red labeled
position 407 is a serine or valine in T. congolense TS1 forms. R144,
which is exchanged to a cysteine in TS1g, is labeled in blue. (B)
Green clouds mark positions at which different amino acids occur in
other T. congolense TS1 forms.
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For kinetic experiments, assays were incubated for 30
minutes using 50 ng TS, since under these conditions
3’SL production was linear for all three TS. To deter-
mine the kinetic parameters for the acceptor substrates
lactose (Figure 7A) or Gal-MU (Figure 7C), 100 μg
fetuin (600 μM bound Sia) was used as donor substrate.
The lowest KM for lactose was found for T. cruzi TS
with 327 μM compared to 1683 μM for TS1b and 727
μM for TS1 e-1 (Table 2). Furthermore, T. cruzi TS was
able to produce twice more 3’SL than TS1b and fourfold
more than TS1 e-1 under these conditions.
To determine the kinetic parameters for the donor
substrate fetuin (Figure 7B), 2 mM lactose was used as
acceptor substrate. Both T. congolense TS1 had similar
vmax-values, whereas the vmax for T. cruzi TS was about
fivefold higher. Different to the KM of lactose, the lowest
KM for fetuin was exhibited by TS1b with 359 μM,
which is about fivefold lower compared to TS1 e-1 with
1617 μM and about 12-fold lower compared to T. cruzi
TS with 4124 μM.
Kinetic studies with TS were also performed for the
acceptor substrate Gal-MU (Table 2) and the donor
substrate pNP-Neu5Ac. Almost similar KM and vmax-
values were found for both T. congolense TS1. The sub-
strate pNP-Neu5Ac was only weakly used as a donor
substrate by all three TS species. Therefore, no reliable
kinetic parameters could be determined.
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Figure 5 Time dependence of TS reactions. Reactions of 100 μg fetuin with 100 nmol lactose (A) or 100 nmol galactose (B) were started with
50 ng TS in 50 μL and incubated at 37°C. The amount of 3’SL produced was determined by HPAEC-PAD as described under Methods. Data
points are means ± standard deviations of three replicates.
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Figure 6 Concentration dependence of TS reactions. Reactions
of 100 μg fetuin with 100 nmol lactose were started with varying
amounts of TS in overall 50 μL 10 mM phosphate buffer, pH 7.4
and incubated at 37°C for 30 min. The amount of 3’SL produced
was determined by HPAEC-PAD as described under Methods. Data
points are means ± standard deviations of three determinations.
Table 1 Free Sia and 3’SL production at equilibrium of
the reaction
Neu5Ac [pmol] 3’SL [pmol]
0 ng TS 262 ± 46 0
50 ng T. cruzi TS 580 ± 8 12597 ± 115
250 ng T. cruzi TS 1820 ± 13 11199 ± 288
50 ng TS1b 415 ± 7 15378 ± 117
250 ng TS1b 1095 ± 129 14435 ± 2226
50 ng TS1 e-1 348 ± 83 12719 ± 3057
250 ng TS1 e-1 1186 ± 9 13655 ± 491
only fetuin 116 ± 8 0
Neu5Ac and 3’SL produced by TS after 20 h incubation under standard
conditions were determined as described under Material and Methods. Data
points are means ± standard deviations of three replicates.
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Sialylation pattern of glycopeptides
Structural differences between TS1 variants may influ-
ence the enzymes preference for glycans on glycopro-
teins, such as fetuin. This could possibly result in
different sialylation patterns on glycoproteins after incu-
bation with TS. Fetuin contains 3 N-glycosylation sites
and 3 O-glycans, which all can serve as Sia donors in
TS reactions [13]. To investigate the specificity of TS
towards different N-glycans on fetuin, we used MALDI-
TOF-MS to determine the sialylation pattern of glyco-
peptides (GPs) from trypsin-digested fetuin after incuba-
tion with TS and lactose (Figure 8).
The sialylation patterns of three glycopeptides, GP
127-141 (dibranched or tribranched), and GP 54-85
(tribranched) were determined. All 14 potential sialyla-
tion variants of these glycopeptides could be identified
unambiguously and quantified from the MALDI-TOF-
MS spectra. In untreated fetuin most branches on the
three N-glycans investigated were sialylated, whereas
upon treatment with TS and lactose after 30 minutes a
clear shift towards incompletely sialylated glycans was
observed. After 24 h TS incubation the relative
amounts of unsialylated glycans was further increased
and monosialylated glycans represented the most pro-
minent species on both, di- and tribranched glycans
(Figure 9).
Sialylation of glycoproteins
As described above, T. congolense TS1b and TS1 e-1
readily used fetuin as donor substrate for the production
of 3’SL. However, long-term TS reactions or experi-
ments with higher amounts of TS had suggested that
the reverse reaction also takes place. Therefore, we
investigated whether T. congolense TS1b and TS1 e-1
can restore sialylated glycans on Vibrio cholerae siali-
dase-treated fetuin (ASF) as model glycoprotein. Resialy-
lation experiments were performed with 100 μg ASF as
acceptor and 100 nmol 3’SL as donor substrate as well
as 50 ng TS1 in 50 μL to start the TS reaction and were
incubated up to 24 h. This resialylation partially
reversed the shift in electrophoretic mobility in SDS-
PAGE observed for sialidase-treated fetuin (Figure 10).
Also by MALDI-MS of glycopeptides, the sialylation of
unsialylated glycans was confirmed (data not shown).
Furthermore, we addressed the question of whether
through this reaction recognition sites for siglecs can be
restored. For this purpose, TS-treated ASF was immobi-
lized to a microtitre plate and used as target for Siglec-
4, which preferentially binds a2,3-linked Sia. Under
these conditions robust Siglec-4 binding was observed
of ASF that had been treated with TS for 4 h. A pro-
longed (up to 24 h) TS reaction only led to little further
increase reaching 40% of binding levels observed with
native fetuin (Figure 11).
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Figure 7 Michaelis-Menten kinetics of TS reactions. All reactions
were started with 50 ng TS in a final volume of 50 μL and
incubated for 30 min at 37°C. (A) 600 μM fetuin-bound Sia was
used as donor substrate with varying concentrations of lactose as
acceptor substrate. (B) Varying concentrations of fetuin-bound Sia
were used as donor substrate with 2 mM lactose as acceptor
substrate. (C) Varying amounts Gal-MU were used as acceptor
substrate and 50 nmol 3’SL as donor substrate. The amount of 3’SL
(in the case of (A) and (B)) or 3’Sia-Gal-MU (in the case of (C))
produced was determined by HPAEC-PAD as described under
Methods. Data points are means ± standard deviations of three
replicates.
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Discussion
In 2003 Tiralongo et al. published a partial sequence for
T. congolense TS1 [9]. Our approach to obtain the full
length sequence of TS1 led to the discovery of 11 var-
iants of this gene with an overall sequence identity of
96.3% in the genome of this parasite. The previously
published partial TS1 sequence, which had been
assembled from 47 independent PCR reactions, turned
out to represent a mixture of fragments from the 11
TS1 forms identified in this study. Therefore, it is likely
that that sequence doesn’t exist in nature.
Similar TS-like gene families occur also in other trypa-
nosomes. In T. brucei the situation appears to be less
complex, since only 8 TS closely related genes have
been identified [3] and these differences lead to 6 amino
acid mutations. The largest TS gene family has been
found in T. cruzi. Its 140 members fall into three differ-
ent groups [14]. Blood stream trypomastigotes express
two of these groups, one with TS activity and the other
only with lectin activity. A third group has TS activity
and is expressed by epimastigotes. At present it is
unknown whether the expression of the different TS
genes in African trypanosomes is also stage-dependent.
T. congolense TS1 shares about 57% identical amino
acids with T. brucei TS and 48% sequence identity with
T. cruzi TS. By comparison, the American T. rangeli SA
and T. cruzi TS are more closely related with approxi-
mately 70% sequence identity [15].
The homology model for T. congolense TS1 based on
crystal structures from T.cruzi TS and T. rangeli SA
provided (I) insight in differences in the active site and
its surrounding between TS from these parasites and
(II) revealed the spatial distribution of the amino acid
differences between the TS1 variants.
Compared to T. cruzi TS only three amino acids are
changed in TS1 (A325, S407 and Y408). At position 325
a proline at the corresponding position of T. cruzi TS
appears to be relevant for full TS activity [11]. However,
in both, T. brucei TS and in T. congolense TS1, position
325 is an alanine. Tiralongo et al., (2003) postulated
A325 might be common to African trypanosomes and
does not seem to have an effect on enzymatic activity
[9]. Our data have demonstrated that an alanine at this
position is well compatible with TS activity, since all
active TS1 variants have A325. The exchanges at 407
and 408 may be relevant for the different substrate
Table 2 Kinetic parameters of T. cruzi TS, T. congolense TS1b and TS1 e-1
Acceptor substrates Donor substrates
Lactose Gal-MU Fetuin-bound Siax
vmax
(μmol/(min × mg TS))
KM
(μM)
vmax
(μmol/(min × mg TS))
KM
(μM)
vmax
(μmol/(min × mg TS))
KM
(μM)
TS1b 4.3 ± 0.1 1683 ± 101 0.77 ± 0.03 57 ± 14 7.9 ± 0.3 359 ± 45
TS1 e-1 2.1 ± 0.1 727 ± 48 0.72 ± 0.03 74 ± 17 7.6 ± 0.5 1617 ± 223
T. cruzi TS 8.4 ± 0.3 327 ± 31 n.d. n.d. 37.9 ± 6.0 4124 ± 985
KM and vmax were calculated from Michaelis-Menten kinetics (Figure 7) by SigmaPlot. Data points are means ± standard deviations of three replicates. ×
Approximately 30 nmol Sia per 100 μg fetuin. Abbr.: n.d.: not determined.
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Figure 8 MALDI-TOF-MS of glycopeptide 127-141 sialylation variants. 100 μg fetuin were treated with trypsin and analyzed by MALDI-TOF-
MS as described under Methods. The symbols code for the monosaccharide units is according to the nomenclature of the Consortium for
Functional Glycomics (http://www.functionalglycomics.org): GlcNAc (blue squares), Man (green circles, Gal (yellow circles), Neu5Ac (purple
diamonds).
Koliwer-Brandl et al. BMC Biochemistry 2011, 12:39
http://www.biomedcentral.com/1471-2091/12/39
Page 8 of 16
Results 3.1  
 73 
 
specificities of TS species, since this area possibly parti-
cipates in the interaction with the underlying galactose.
With the full length coding sequence of TS1 available,
the enzymes were expressed and characterized as
recombinant proteins to address the question of
whether TS1 accounts for the TS activity in the two
preparations (TS-form 1 and TS-form 2) from procyclic
parasite cultures [6]. The amino acid sequences of the
eleven TS1 variants described here contain the peptide
VVDPTVVAK present in TS-form 1. Furthermore, all
recombinant TS1 variants reacted with the anti-T. con-
golense TS antibody (mAb 7/23) [6]. Based on this
information, it is now clear that TS1 was present in
both, TS-form1 and TS-form 2. However, two
observations made with recombinant TS1 suggest that
the native enzyme preparations of TS-form 1 and even
more for TS-form 2 contained additional TS1-like pro-
teins. (I) The reaction velocities with the synthetic sub-
strates pNP-Neu5Ac (as donor) and Gal-MU (as
acceptor) were much lower than with fetuin and lactose
for all three TS. Tiralongo et al., 2003 [6] determined a
KM of 500 μM for Gal-MU, which is approximately 10-
fold higher than for TS1b (57 μM) and TS1 e-1 (74
μM). These differences could be due to the presence of
other TS1-like enzymes in the preparations of TS-form
1 and TS-form 2. (II) Using the substrate Neu5Ac-MU
no SA or TS activity could be detected for the T. congo-
lense TS1 variants investigated here, whereas cleavage of
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Figure 9 Relative changes of the sialylation pattern of fetuin N-glycans. Shown are the sialylation patterns of the glycopeptides GP 127-141
with dibranched (GP 127-141 di) or tribranched (GP 127-141 tri) glycans and of the glycopeptide GP 54-85 with tribranched glycans (GP 54-85
tri) relative to the non-sialylated GP 1 -32. 100 μg fetuin was incubated with 50 ng TS1b, TS1 e-1 or T. cruzi TS and 100 nmol lactose for the
times indicated, trypsinized and glycopeptides analyzed by MALDI-MS as described under Methods. Data points are averages ± standard
deviations of three to ten replicates.
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this substrate indicated SA activity in preparations of
TS-form 1 and TS-form 2 [6], as well as TS activity in
procyclic parasites [16]. Also this apparent discrepancy
can easily be explained by the presence of other TS1-
like enzymes accepting Neu5Ac-MU as TS or SA
substrate.
Ten of the eleven recombinant TS1 variants revealed
TS activity, which is in agreement with the TS-form 1
purified by Tiralongo et al. [6]. Only TS1g, which carries
a cysteine at position 144 instead of an arginine, showed
very low TS but clear SA activity. This suggests that
R144 is important but not essential for the transfer reac-
tion and hinders SA activity in T. congolense TS1. In a
previous study on T. rangeli SA [17] R144 has been pos-
tulated to form a hydrogen bond to the O4 of Sia. How-
ever, it remains unclear how this could relate to TS
activity. Furthermore, the homology model of TS1 does
not provide evidence for such a hydrogen bond for the
binding site of T. congolense TS1.
The TS1 homology model (Figure 4B) displays also
the position of amino acid exchanges in the eleven
TS1 forms identified. It could be speculated that
these positions are relevant determinants of antigenic
sites and that these variations help to escape recogni-
tion by the immune system. However, if TS1 is
expressed in the procyclic form in the insect vector,
this is unlikely to be relevant. Interestingly, these
exchanges are located on the same side of the protein
where substrate binding occurs, which opens the pos-
sibility that these changes influence the binding speci-
ficities. The cluster of changes from position 599 to
602 and 643 could be involved in recognition of lar-
ger substrate molecules, such as glycoproteins. Posi-
tions, 407 and 408 (Figure 4B), as well as positions
375, 377 and 404 (Figure 4A) are closer to the active
site in the catalytic domain, possibly contributing to
interactions with substrates. It should be noted that
the six amino acid differences occurring in T. brucei
TS are not found in clusters like in T. congolense
TS1, and furthermore, they are not even on the same
side of the protein.
For a more detailed characterization of their differ-
ences in activity, we choose two TS1 variants, TS1b and
TS1 e-1. The two amino acid sequences of TS1b and
TS1 e-1 differ mainly in the lectin domain (Figure 4),
whereby the exchange from E600 in TS1b to K600 in
TS1 e-1 represents the most drastic change.
The observation that lactose is a much better acceptor
substrate than Gal is in agreement with previously
reported relative transfer activity data for the prepara-
tions TS-form 1 and TS-form 2 [9]. Interestingly, with
fetuin as donor substrate T. cruzi TS, T. congolense
TS1b and TS1 e-1 produced different amounts of 3’SL
in 30 minutes under identical conditions. It is likely that
these differences are due to distinct substrate specifici-
ties for the sialoglycans of fetuin. However, after 20 h,
equilibriums for the reactions were attained and the
three TS applied produced almost the same amounts of
3’SL. Most likely this reflects a similar equilibrium for
these three TS.
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Figure 10 SDS-PAGE of resialylated fetuin. ASF (45 to 58 kDa):
Vibrio cholera sialidase-treated fetuin (58 to 65 kDa). For resialylation
ASF was treated with TS1 e-1 and 3’SL for 24 h. 2 μg protein per
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Figure 11 Binding of Siglec-4 to resialylated fetuin . Vibrio
cholera sialidase-treated fetuin (ASF) was treated with TS1 e-1 and
3’-SL for the times indicated as described under Material and
Methods. Siglec-4 binding relative to untreated fetuin is shown.
Data points are means ± standard deviations of three independent
determinations.
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Clear differences were found in the kinetic parameters
of TS1b and TS1 e-1 for lactose and fetuin. Reliable
kinetic parameter for 3’SL as donor substrate could not
be determined, because of the inaccurate quantification
of the high concentrations of 3’SL as donor substrate.
Whereas TS1b has a slightly higher KM (1683 μM) for
lactose compared to TS1 e-1 (727 μM), the opposite
and more pronounced difference was observed for
fetuin-bound Sia, where TS1 e-1 has approximately five-
fold higher KM (81 μM) compared to TS1b (17 μM). In
combination, this implies that the ratio of KM for lac-
tose/KM for fetuin-bound Sia is approximately 100 for
TS1b, whereas it is only 10 for TS1 e-1. By comparison,
for T. cruzi TS the KM for both substrates is quite simi-
lar (326 over 206 μM) and its vmax was fourfold higher
than for the TS1 isoforms. The differences in the kinetic
parameters for fetuin observed for TS1b and TS1 e-1
are possibly related to altered affinities resulting from
amino acid divergences in the lectin domain of TS1b
and TS1 e-1. This would suggest a mechanism linking
the lectin domain to the enzymatic properties of TS.
No release of free Sia could be detected after 30 min-
utes of TS reactions with fetuin as donor and lactose as
acceptor substrates, demonstrating the absence of SA
activity. However, after 20 h incubation, free Sia was
detected clearly indicating SA activity. This activity cor-
related with the TS amount present, implying SA activ-
ity to be a side reaction observable only in extended
reactions. Interestingly, in the reverse TS reactions with
3’SL as donor substrate for sialylation of galactose resi-
dues of ASF, free Sia is detected very early in the reac-
tion (data not shown). This suggests that the free Sia
detected in extended TS reactions times with fetuin as
donor substrate is mainly the product of a SA side activ-
ity of the reaction using 3’SL as substrate. Therefore, the
amount of free Sia could provide indirect information
on the velocity of the reverse reaction. This assumption
is further supported by the fact that lower amounts of
TS can led to the same amount of final 3’SL but pro-
duce less free Sia as side product (Table 1). In this con-
text it should be noted, that TS from T. cruzi clearly
produced more free Sia than T. congolense TS1b or TS1
e-1. The structural basis for this phenomenon is unclear
but may be related to the kinetics of the reaction. TS
have been reported to follow ping-pong bi bi kinetics
[12,18,19]. It will be interesting to investigate the struc-
ture-function relationship of this phenomenon and
whether this is related to the SA activity of TS1g.
The TS substrate specificities for the glycans of the
donor substrate fetuin were investigated by a MALDI-
TOF analysis of TS treated glycopeptides from trypsin
digested fetuin, since the glycosylation of fetuin is well
established [13,20-23]. Three glycopeptides coming from
two of the three N-glycosylation sites (di- and
tribranched GP 127-141, and tribranched GP 54-85)
could be analyzed reliably. The predicted masses of GP
142-169 di could not be identified in any spectra. GP
54-85 di and GP 142-169 tri differed only in one Da,
which were not resolved by the equipment available and
were excluded from the analysis. The peptide containing
the three O-glycosylation sites could not be detected
due to its high mass. But it is important to note, that
TS1 clearly utilizes sialylated O-glycans as donor sub-
strates as indicated by a rapid unmasking of peanut
agglutinin recognition sites (data not shown).
Only minor differences in the sialylation pattern of
fetuin GPs were observed using the different TS species.
In summary, these were too small to draw a conclusion
that these TS differ in their substrate specificities for
fetuin glycans. In general, the TS applied cleaved Sia
from N-glycans of glycopeptides investigated, but also
transferred Sia back to these N-glycans. N-glycans that
carried three and four Sia molecules in the case of the
tribranched N-glycans as well as N-glycans that carried
two Sia molecules in the case of dibranched N-glycans
before TS incubation, were reduced to predominantly 0-
2 Sia molecules in the case of tribranched and 0-1 Sia
molecule in the case of dibranched N-glycans after 24 h
TS incubation.
Whereas in the reactions discussed above Sia was
transferred from fetuin to synthesize 3’SL, we could also
show that T. congolense TS1 as well as T. cruzi TS
transfer Sia in the reverse direction from 3’SL to glyco-
proteins. Furthermore, the TS reaction restores binding
of Sia-binding proteins, such as Siglec-4. Due to the
reversibility of the reaction, a complete resialylation of
an acceptor substrate applying TS cannot be expected
under these conditions. Nevertheless, differences in the
kinetic parameters as shown for two of the eleven T.
congolense TS1 variants could be used in kinetically con-
trolled reactions to optimize the TS reaction to one or
the other product, making the TS1 variants interesting
tools for biotechnological applications. Thus, TS1 can
be utilized to transfer Sia in a2,3-linkage on biologically
relevant glycoproteins containing terminal galactose as
Sia acceptor.
Conclusions
For the first time, full length TS from the African para-
site T. congolense has been cloned and sequenced, open-
ing new perspectives for investigations on the biological
role of these enzymes in the pursuit of a cure for
Nagana and sleeping sickness. Eleven T. congolense TS1
variants were identified and expressed as recombinant
proteins. The eleven TS1 differ in 25 of 702 amino acid
positions and a structural model revealed that these var-
iations occur in three clusters on the side of the protein
that is open to substrate binding. Ten of these TS1
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variants share predominantly TS and little SA activity.
Only one, TS1g, has much lower TS but increased SA
activity, probably due to an exchange of an arginine to
a cysteine at position 144. Interestingly, the kinetic
parameters of two characterized TS1 variants reveal
subtle differences in substrate specificities. However,
these did not lead to major differences in the sialylation
pattern of N-glycans on fetuin after treatment with dif-
ferent TS variants. Finally a proof of principle has been
provided that these TS can be used to sialylate glyco-
conjugates to create binding sites for Sia-binding pro-
teins like Siglec-4.
It will be interesting to investigate the expression pat-
terns of TS1 variants in the parasite’s life cycle in future
investigations addressing their importance for the mani-
festation of midgut colonization and maturation in the
tsetse vector with possible implications for the transmis-
sion to the mammalian host.
Methods
Materials
Complete Mini, EDTA free protease-inhibitor tablets
and Vibrio cholerae sialidase were purchased from
Roche Diagnostics, Mannheim, Germany. Pfu DNA
polymerase and restriction enzymes BamHI and SpeI,
isopropyl b-D-1-thiogalacto-pyranoside (IPTG), Page-
Blue and molecular weight marker (PageRuler) were
from Fermentas, St. Leon-Rot, Germany. Trypsin was
from Promega, Mannheim, Germany, 2,5-Dihydroxyben-
zoic acid from Bruker Daltonics, Billerica, USA. Ultrafil-
tration units Vivaspin6 and VivaCell250 were from
Sartorius, Göttingen, Germany. BCA Protein Assay Kit
was purchased from Thermo Scientific Pierce, Rockford,
USA. Anti-SNAP-tag rabbit polyclonal antibody was
from GenScript, Piscataway, USA. Anti-Strep-tag rabbit
polyclonal antibody, StrepTactin beads and buffers were
purchased from IBA, Göttingen, Germany and hygromy-
cin from PAA, Pasching, Austria. 2’-(4-Methylumbelli-
feryl)-a-D-N-acetylneuraminic acid sodium salt hydrate
(MU-Neu5Ac), 4-methylumbelliferyl ß-D-galactoside
(MU-Gal), 4-methylumbelliferone (MU), glucoronic
acid, Ex-cell® CD CHO media, fetuin and PEI transfec-
tion reagent were purchased from Sigma-Aldrich,
Munich, Germany. X-ray film, enhanced chemilumines-
cence system, Ni-NTA and Q-Sepharose FF were pur-
chased from GE Healthcare, Munich, polyvinylidene
difluoride membranes and ZipTips from Millipore,
Schwalbach, Germany.
Cloning and expression of recombinant TS1
The published partial sequences of Trypanosoma congo-
lense TS1 [Genebank: AJ535487.1] [6,9] was used as
starting query for searching the T. congolense genomic
database for pathogen genomics at the WTSI (http://
www.sanger.ac.uk/). Based on the obtained sequence
fragments, an open reading frame encoding TS1 was
assembled. Based on this, primers were designed to
amplify TS1 from T. congolense (strain STIB 249) geno-
mic DNA [9] using Pfu DNA polymerase in a nested
PCR reaction leaving out the N-terminal signal peptide
sequence and the C-terminal GPI anchor attachment
site. Both outside primers (forward ATG CGG CCG
GTG AAT TGT TAN and reverse CAT CAG CAC
ATG CAC GAG CAN) were degenerate at the 3’ end,
whereas the internal primers (forward CGA CTA GTC
AGT GCT GCG ACC ACA TGC AN and reverse CGG
GAT CCG TCG CTC CCA GGC ACA CGA AN) were
designed to introduce Spe1 and BamHI restriction sites,
respectively. These restriction sites were used to ligate
the PCR-products in frame into a modified pDEF [24]
vector (pDEF-T3C/SNAPstrep) providing in frame a
Transin cleavable signal peptide [25], a 3C-protease
cleavage site [26] followed by SNAP (Covalys, Witters-
wil, Switzerland) and Strep (IBA, Göttingen, Germany)
tags. The pDEF-T3C/SNAPstrep was obtained as fol-
lows: The coding sequence for the Transin signal pep-
tide has been introduced into pcDNA 3 Amp Strep-tag
[27] using the HindIII/BamHI-digested linker obtained
by hybridization of the following oligonucleotides: sense
5’-CGAAGCTTATGAAAGGGCTCCCAGTCCTGC
TGTGGCTGTGTACGGCTGTGTGCTC
ATCCTACCCATTGCATGGCAGTGAAGAAGAT
GCTGGCATGGAGACTAGTGGATCCCG
and antisense primer 5’-
CGGGATCCACTAGTCTCCATGCCAGCATCTT
CTTCACTGCCATGCAATGGGTAGG
ATGAGCACACACAGCCGTACACAGCCACAGCA
GGACTGGGAGCCCTTTCATAAGCTTCG.
This Transin linker introduced a unique SpeI restric-
tion site. The coding sequence of the hAGT protein
(SNAP) was amplified using the pSNAP-tag® (T7) vec-
tor (NEB, Ipswich, MA, USA) as a template and sub-
cloned in frame into BamHI/EcoRI digested pcDNA3
Amp Transin Strep-tag providing pcDNA3-T3C/SNAP-
strep. The primers used for amplification were: sense 5’-
CGGGATCCCTGGAGGTGCTGTTCCAGGGCCC-
CATGGACAAAGACTGCGAAATGAAGCG-3’ includ-
ing the coding sequence for the 3C protease recognition
site of the human rhinovirus HRV 3C (LEVLFQGP,
underlined) and antisense 5’- CGGAATTCACCCAGC
CCAGGCTTGCCCAGA.
CHOLec1 cells were used for TS1 expression due to
their ability to express only high-mannose glycans, since
these cells are lacking N-acetyl glucosaminyltransferase I
[28]. Transfection of CHOLec1 cells grown in aMEM
supplemented with 10% fetal calf serum at 37°C, 5%
CO2 was accomplished with polyethylenimine (PEI)
transfection reagent following the manufacturer’s
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instructions. 24 h after transfection, cells were passaged
into 96-well plates in a selection media of aMEM con-
taining varying amounts of hygromycin, ranging from
400 μg/mL to 1000 μg/mL. Expression of recombinant
TS1 (120 kDa including SNAP and Strep tags) was
tested by analyzing cell culture supernatant using Wes-
tern blots with anti TS1 monoclonal antibody (mAb 7/
23) as primary antibody [9]. The presence of SNAP and
Strep tags was confirmed using anti-SNAP-tag rabbit
polyclonal antibody and anti-Strep-tag rabbit polyclonal
antibody respectively in Western blots analysis. Selected
cells were then adapted to Ex-cell® CD CHO media
supplemented with 8 mM L-glutamine.
Purification of Trypanosoma congolense trans-sialidase
The harvested tissue culture supernatant was supple-
mented with 10 mM Tris/HCl, pH 7.5, 1 mM EDTA, 1
mM DTT and 0.02% sodium azide (all final concentra-
tions) and centrifuged at 125,000 × g for 1 h. The
cleared supernatant was then concentrated 100-fold by
ultrafiltration (100 kDa cut off). Buffer was exchanged
twice using 250 mL 100 mM Tris-Cl, pH 8.0, 150 mM
NaCl, 1 mM EDTA (buffer A) in the same ultrafiltration
unit and concentrated to a total volume of 10 mL for 1
L tissue culture supernatant. This was further clarified
by centrifugation at 21,000 × g for 30 minutes before
applying on a column of 1 mL StrepTactin® beads equi-
librated with buffer A. After loading the column was
washed with 5 column volumes wash buffer (100 mM
Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA) and TS1
was eluted with 3 column volumes of elution buffer
(100 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA,
2.5 mM desthiobiotin) in fractions of 0.5 mL. The affi-
nity purified TS1 was dialyzed (10 kDa cut off) against
10 mM phosphate, pH 7.4. Purification products were
analyzed by SDS-PAGE and quantified by BCA assay
with bovine serum albumin as standard.
Expression and purification of Trypanosoma cruzi trans-
sialidase
Recombinant T. cruzi TS was produced in E. coli M15
(pREP4) according to Agusti et al., 2004 and Neubacher
et al., 2005 [29,30]. In brief, cells were grown in 1 L
“terrific broth” medium overnight at 18°C. Protein
expression was initiated with 0.5 mM IPTG. The cells
were dissolved in 40 mL lysis buffer (50 mM phosphate,
300 mM NaCl, pH 8.0 and 0.05% Lubrol), 1 tablet pro-
tease-inhibitor (Complete Mini, EDTA free) and 1 spa-
tula tip of lysozyme were before incubation of 30
minutes at 4°C. The cells were disrupted by 5 cycles of
sonification on ice. Cells debris was removed by centri-
fugation at 40,000 × g for 60 minutes at 4°C and the
supernatant was filtered using a 0.2 μm pore size filter.
20 mM imidazol was added before application on 0.5
mL Ni-NTA beads. Target proteins were eluted in the
same buffer and 250 mM imidazole. The eluted protein
was dialyzed against 20 mM Tris, 30 mM NaCl, pH 8.0
and further purified using a Q-Sepharose FF column in
the same buffer with a linear gradient up to 1 M NaCl.
The activity of the purified protein was tested by a siali-
dase activity assay using MU-Neu5Ac as donor substrate
and lactose as acceptor substrate as described below.
Vibrio cholerae sialidase treatment of fetuin
Asialofetuin (ASF) was prepared from fetuin by Vibrio
cholerae sialidase (VCS) treatment as described [31]. In
brief, fetuin was digested with VCS in 50 mM sodium
acetate, 9 mM CaCl2, pH 5.5 overnight at 37°C in a dia-
lysis bag against the same buffer and afterwards against
distilled water. Sialylated fetuin and sialidase was sepa-
rated from ASF by anion exchange chromatography
using Q-Sepharose. The proteins were eluted by a linear
gradient from 0 to 1 M NaCl in 10 mM Tris, pH 7.4.
Collected fractions were assayed for protein at 280 nm
and for SA activity with MU-Neu5Ac acid as substrate
as described below. The fractions containing ASF but
no SA activity were pooled and the buffer was
exchanged against 10 mM phosphate, pH 7.4 using
VivaSpin6 ultrafiltration units (10 kDa cut off).
Sialidase activity assay
Sialidase activity (+/- lactose) was determined by apply-
ing a microtitre plate assay detecting free 4-methylum-
belliferone (MU) released from Neu5Ac-MU [6]. In
brief, 50 μL sample were incubated with 1 mM
Neu5Ac-MU (final concentration) in a black 96-well
microtitre plate. To determine T. cruzi TS 1 mM lactose
was added as acceptor substrate. The plate was centri-
fuged for 1 minute at 1,000 × g and incubated for 30
minutes at room temperature in the dark. The reactions
were stopped with 200 μL 100 mM glycine, pH 10 and
the fluorescence intensities were measured at 355 nm
excitation and 460 nm emission using a fluorimeter
(Ascent Fluoroscan).
Trans-sialidase reactions
The principle of this assay is based on the quantification
of sialylated oligosaccharides by high performance
anion-exchange chromatography with pulsed ampero-
metric detection (HPAEC-PAD) as described below. In
these reactions either fetuin is used as donor substrate,
e.g. lactose as acceptor or 3’-sialyllactose (3’SL) is used
as donor substrate with ASF as acceptor. A final volume
of 50 μL 10 mM phosphate buffer were used for all TS
reactions. Stock solutions of donor and acceptor sub-
strate were mixed in 40 μL buffer (10 mM Tris/HCl, pH
7.5) and the reactions were started with 10 μL TS (50
ng in standard reactions) and incubated at 37°C. The
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reactions were stopped with 200 μL ice-cold acetone
containing 28 μM glucuronic acid and incubated over-
night at -20°C. After centrifugation for 15 minutes at
20,000 × g and 4°C, 225 μL supernatant were removed
and both, protein pellets and supernatants were
lyophilized.
The dried supernatant of the acetone precipitation was
dissolved in 125 μL H2O for HPAEC-PAD, which was
carried out by using a DX600 system (Dionex, Sunny-
vale, CA, USA) with an electrochemical detector (ED50),
a gradient pump (GP50) and an autosampler (AS50).
Carbohydrates were separated by HPAEC on a Carbo-
PAC PA1 (4 × 250 mm) analytical column (Dionex)
together with a guard column (4 × 50 mm) using a con-
stant flow rate of 1 mL/min. Sample volumes of 25 μL
were injected and the chromatography was performed
as follows: 100 mM NaOH for 2 min, followed by 100
mM NaOH/100 mM NaOAc for 22 min. The column
was regenerated by washing for 5 min with 100 mM
NaOH/500 mM NaOAc, followed by 5 min with 100
mM NaOH. For PAD the typical quadruple waveform
was used as described previously [32]. The Dionex soft-
ware Chromeleon 6.40 SP8 was used for data acquisition
and data evaluation.
Calculation of kinetic parameters
Vmax and KM were calculated using the curve fit module
of SigmaPlot 11 employing the Michaelis-Menten equa-
tion v = vmax ×cs/(cs + KM).
Siglec-4 binding assay
Murine Siglec-4d1-3-Fc was purified by protein-A affinity
chromatography from tissue culture supernatants of sta-
bly transfected CHO Lec3.2.8.1 as described before [33].
The protein solution was dialyzed against 10 mM phos-
phate buffer pH 7.4, sterile filtered and stored at 4°C.
Binding assays with Siglec-4 were performed as
described previously [33]. In brief, 4 μg/mL fetuin, ASF
or TS-treated fetuin were immobilized in microtitre
plates and binding of serially diluted Siglec-4d1-3-Fc (8
dilutions starting with 16 μg/mL) was determined using
alkaline phosphatase-labeled anti-Fc antibodies. The
concentrations sufficient for 50% binding (relative to
Siglec-4d1-3-Fc binding to fetuin) were determined from
corresponding binding curves. At least three indepen-
dent titrations were performed.
SDS-PAGE and Western Blot analysis
Samples were separated by SDS-PAGE (MiniProtean III;
Bio-Rad, München, Germany) according to Laemmli
[34] and stained with PageBlue.
For Western blot analysis, samples were transferred onto
polyvinylidene difluoride membranes after SDS-PAGE.
The membranes were blocked with 5% BSA in Tris-
buffered saline (TBS) buffer containing 0.15% Tween20
(TBS-T) for 1 h. Washing of the membrane was done five
times for 5 minutes each using TBS-T. Immunodetection
was performed by incubating membranes with a primary
antibody diluted in blocking buffer overnight at 4°C. The
following antibodies were used: anti-T. congolense TS
mAb 7/23 (1:1000) and rabbit anti-Strep-tag (1:1000). Fol-
lowing four washes with TBS-T of 10 minutes each, the
membranes were incubated with a secondary antibody
conjugated to horseradish peroxidase for 2 h at room tem-
perature. After washing four times with TBS-T, blots were
developed with the enhanced chemiluminescence system
using X-ray film.
Matrix-assisted laser desorption ionisation-time of flight
mass spectrometry (MALDI-TOF-MS)
TS reactions were carried out with 50 ng TS, 100 nmol
lactose and 100 μg fetuin as described above. The dried
protein pellets after TS reaction were dissolved in 200 μL
50 mM ammonium hydrogen carbonate, pH 7.8 and 1.6
μL 45 mM DTT were added. After 30 minutes incubation
at 50°C, 1.6 μL 100 mM IAA were added and further incu-
bated for 30 minutes at 37°C. The tryptic digestion was
started with 2 μg trypsin dissolved in 1 μL 50 mM acetic
acid and incubated overnight at 37°C and stored at -20°C.
5 μL of the tryptic digest were mixed with 5 μL H2O
and 1 μL 1% trifluoroacetic acid and were directly
mixed with matrix and 1 μL was applied to the MALDI-
TOF-MS target plate. The remaining 9 μL were desalted
using C18-reversed phase pipette tips (ZipTip). Peptides
were eluted with 3 × 100 μL 12% and 30% acetonitrile
in H2O and lyophilized. 2,5-Dihydroxybenzoic acid in
0.1% trifluoroacetic acid was used as MALDI matrix.
The dried peptides were directly dissolved in 10 μL
DHB solution and 1 μL of the mixture were spotted to
the target plate for crystallization.
The mass spectrometry was performed using a Voya-
ger DE Pro MALDI-TOF N2-Laser with a wavelength of
337 nm (Applied Biosystems, Foster City, USA). All
spectra were measured in the linear detector mode.
Laser intensities and the number of records per spec-
trum were varied manually.
Voyager software was used for data acquisition and
peak detection. For quantification the peak intensity of
each peptide was determined relative to the non-sialy-
lated glycopeptide 1-32 (3459.66 Da) as internal stan-
dard. This peptide is detected in all spectra of the
sialylation variants of the glycopeptides and is not chan-
ged by TS reaction (Figure 8). All measurements were
repeated for at least three times.
Homology Modeling
A homology model of T. congolense TS1 e-1 was calcu-
lated using the software Yasara 10.11.8 [35-40]. The
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crystal structure of T. cruzi TS (UniProt: Q26964; PDB
entry: 3B69), previously reported by Buschiazzo et al.,
2002 [12] was used as the template structure. A benzoy-
lated N-acetylneuraminic acid derivative used as a ligand
for T. cruzi TS in the template structure was kept in the
binding site during the calculation of the homology
model.
The following parameters of the Yasara homology
modeling module were modified manually from the
default settings of the program: Modeling speed: slow,
PsiBLASTs: 6, EValue Max: 0.5, Templates total: 1,
Templates SameSeq: 1, OligoState: 4, alignments: 10,
LoopSamples: 50, TermExtension:10.
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Biochemical Diversity in the Trypanosoma congolense
Trans-sialidase Family
Thaddeus T. Gbem1, Mario Waespy1, Bettina Hesse1, Frank Dietz1, Joel Smith1, Gloria D. Chechet2,
Jonathan A. Nok2, Sørge Kelm1*
1Centre for Biomolecular Interactions Bremen, Faculty for Biology and Chemistry, University Bremen, Bremen, Germany, 2Department of Biochemistry, Ahmadu Bello
University, Zaria, Nigeria
Abstract
Trans-sialidases are key enzymes in the life cycle of African trypanosomes in both, mammalian host and insect vector and
have been associated with the disease trypanosomiasis, namely sleeping sickness and nagana. Besides the previously
reported TconTS1, we have identified three additional active trans-sialidases, TconTS2, TconTS3 and TconTS4, and three
trans-sialidase like genes in Trypanosoma congolense. At least TconTS1, TconTS2 and TconTS4 are found in the bloodstream
of infected animals. We have characterised the enzymatic properties of recombinant proteins expressed in eukaryotic
fibroblasts using fetuin as model blood glycoprotein donor substrate. One of the recombinant trans-sialidases, TconTS2, had
the highest specific activity reported thus far with very low sialidase activity. The active trans-sialidases share all the amino
acids critical for the catalytic reaction with few variations in the predicted binding site for the leaving or acceptor glycan.
However, these differences cannot explain the orders of magnitudes between their transfer activities, which must be due to
other unidentified structural features of the proteins or substrates selectivity. Interestingly, the phylogenetic relationships
between the lectin domains correlate with their specific trans-sialylation activities. This raises the question whether and how
the lectin domains regulate the trans-sialidase reaction. The identification and enzymatic characterisation of the trans-
sialidase family in T. congolense will contribute significantly towards the understanding of the roles of these enzymes in the
pathogenesis of Animal African Trypanosomiasis.
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Introduction
Trypanosoma congolense (subgenus: Nannomonas) is a major causative
agent of the Animal African Trypanosomiasis (AAT) otherwise
known as nagana. Other parasites implicated in nagana include T.
vivax (subgenus: Duttonella) and T. brucei brucei (subgenus: Trypano-
zoon). These protozoan parasites are transmitted by several species
of hematophagous biting flies of the genus Glossina. Nagana
exhibits a severe negative impact on stock farming, milk and meat
production [1]. The impact of the disease is thought to be
underestimated as most affected areas are remote, limiting access
and hence accurate data acquisition. The need for an alternative
arsenal against AAT is heightened as existing drugs are either toxic
or rapidly becoming ineffective due to drug resistance [2].
The role of TS in Chaga’s disease caused by the South American
T. cruzi has been extensively studied [3]. On the other hand, studies
on the trans-sialidases from African trypanosomes responsible for the
Human African Trypanosomiasis (HAT) as well as AAT are scanty.
In T. brucei, TS has been implicated in the cyclical survival of the
parasite as evidence supports enhanced survival of parasite in
midgut of the insect host [4]. No data exist on T. congolense in this
regard. Though scanty, the role of blood stream TS and sialidase in
anaemia in animals suffering trypanosomiasis caused by T. congolense
[5] [6] and T. vivax [7] has been established.
Multiple copies of TS-like genes exist in Trypanosoma genomes.
The highest number occurs in T. cruzi, but most of the over 1000
genes encod enzymatically inactive proteins [8]. In African
trypanosomes, the TS-like gene families are much smaller. For
example, 9 members have been identified in T. brucei [9] [10] [11].
In T. congolense, at least 17 TS-like genes have been identified [12]
[13] [14] [6]. Eleven of these, forming the TconTS1 family, are
closely related and share over 95% sequence identity [14]. The key
element mediating the functions of TS has been ascribed to the N-
terminal catalytic domain (CD) harbouring the active site with
characteristic conserved amino acids [15] [16] [17] [9] [18],
whereas hardly anything is known about possible functions of the
lectin-like domain (LD) at the C-terminus of these enzymes.
Here we report that besides TconTS1, three additional
members of the T. congolense TS gene family transfer sialic acids
between glycoconjugates, but have much lower sialidase activities.
The identification and biochemical characterisation of T. congolense
TS genes will enable new studies investigating the role of these
genes in nagana disease.
Methods
Unless where stated, all chemicals and reagents used were cell
culture and analytical grade. Vibrio cholerae sialidase was purchased
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from Roche Diagnostics (Mannheim, Germany). Pfu DNA
polymerase, HindIII, XbaI, SpeI, EcoRI and DpnI, PageBlue,
molecular weight marker (PageRuler), BCA assay protein kit were
all purchased from Thermo Scientific (St. Leon-Rot, Germany).
VivaSpin 6 and VivaCell250 ultracentrifugation units were from
Sartorius (Go¨ttingen, Germany). Anti-SNAP-tag rabbit polyclonal
antibody was from GeneScript (Piscataway, USA) while anti-Strep-
tag rabbit polyclonal antibody, Strep-Tactin resin beads and buffers
were from IBA (Go¨ttingen, Germany). Hygromycin and Genta-
mycin were purchased from PAA, (Pasching, Austria). Polyethy-
lenimin transfection reagent, glucuronic acid, N-acetyl-neuraminic
acid (Neu5Ac), 3’sialyllactose (3’SL) and lactose were purchased
from Sigma-Aldrich (Steinheim, Germany). Ex-cell CD CHO
media from SAFC, USA, X-ray film, Enhanced Chemilumines-
cence system, and recProtein-A Sepharose Fast Flow were
purchased from GE Healthcare (Uppsala, Sweden). Polyvinylidene
difluoride membrane was from Millipore (Schwabach, Germany).
Cloning, sequencing, expression and purification of
trans-sialidase genes
The Basic Local Alignment Search Tool (BLAST) was used to
search the shot-gun sequences of T. congolense at the WSTI (http://
www.sanger.ac.uk). Using the BLASTN algorithm, the ‘‘T.
congolense reads’’ were queried with the partial nucleotide sequences
(Genbank Accession numbers TS1: AJ535487 and TS2:
AJ535488) previously described [13]. Perfect BLAST hits (smallest
sum probability P(N),10-10) were arranged into contiguous
sequences using Contig Express (Invitrogen, Carlsbad, USA). By
searching the database with ends of the contiguous sequences, the
assembled contigs were expanded until open reading frames
(ORF) were obtained. On the basis of the obtained ORFs, primers
(Supporting Information, Table S1) were designed to amplify by
nested PCR the ORF including flanking regions encoding for
TconTS2, TconTS3 and TconTS4 using genomic DNA of T.
congolense strain STIB249 [13]. The resulting products were cloned
into the pBlueScript KS- vector (Stratagene, Santa Clara, Ca,
USA) via SpeI and BamHI (TconTS2) or via EcoRI and SmaI
(TconTS4) or into the mammalian expression vector pcDNAIII
Amp (Invitrogen, Carlsbad, USA) via HindIII and XbaI (TconTS3)
and sequenced (Supporting Information, Table S2).
Cloning and sequencing of T. brucei TS genes followed a similar
strategy as described for T. congolense above except that genes were
cloned in pJET1.2/blunt vector (Thermo Scientific) following
instructions of the manufacturer (for primers see Supporting
Information, Table S1).
For the expression of secreted TconTS proteins in mammalian
fibroblasts, corresponding DNA sequences without those encoding
the signal peptides and GPI anchors were subcloned into a
modified pDEF vector providing a 3C protease recognition site,
SNAP and Strep tags using SpeI and BamHI restriction sites [14].
For this purpose, the BamHI site in TconTS3 as well as the SpeI
and BamHI sites in TconTS4 were removed by site directed
mutagenesis without changing the amino acid sequence encoded
(for primers see Supporting Information, Table S1). All sequences
and mutations were confirmed by Sanger dideoxy DNA sequenc-
ing at the Max Planck Institute for Marine Microbiology, Bremen,
Germany.
Recombinant TconTS proteins were purified as described [14].
Briefly, CHOLec1 cells (ATCC CRL-1735) were transfected with
polyethylenimine, transfection reagent (Sigma, Steinheim, Ger-
many) and stably expressing cell lines selected with hygromycin.
Expression of recombinant protein was tested from cell culture
supernatant by SDS-PAGE and Western blots methods using
rabbit anti-Strep and anti-SNAP antibodies. CHOLec1 cells
producing TconTS proteins were subsequently adapted to
chemically defined Excel CD CHO media.
Purification of anti-TS1 monoclonal antibody
The 7/23 hybridoma cells [12] were grown for 3 days in RPMI
media supplemented with IgG depleted 10% FCS. The tissue
culture supernatant was cleared by ultracentrifugation at 1056g
for 60 min and anti-TconTS antibody was purified using
recProtein-A Sepharose Fast Flow and eluted with 0.1 M
glycine/HCl pH 3.0. Antibody containing fractions were neutral-
ised with 1M Tris pH 8.0 and dialysed against 10 mM phosphate
buffer. Purified antibodies were used in the detection of TconTS
proteins in SDS-PAGE and Western Blot analysis as described
[14].
Trans-sialidase and sialidase reactions
Purified recombinant proteins were assayed for sialidase and TS
activities using Neu5Ac-MU and fetuin as sialic acid donor
substrates and lactose as acceptor substrate as described before
[14]. In brief, reactions of 50 mL containing substrates and
enzymes were incubated at 37uC for the times indicated. Sialidase
activity was determined as free sialic acids released from Neu5Ac-
MU, 3’SL or fetuin in the absence and/or presence of an acceptor
substrate. TS activity on the other hand was determined as 3’SL
produced in the presence of lactose. Both, free Neu5Ac and 3’SL
were quantified using high performance anion exchange chroma-
tography with pulsed amperometric detection (HPAEC-PAD)
using the Dionex system, DX600 (Dionex Sunnyvale, CA, USA)
[14]. The curve fit module of SigmapPlot 11 was used to calculate
vmax and KM employing the Michaelis-Menten equation v=
vmax6Cs/(Cs+KM).
Phylogenetic analysis
For the phylogenetic analysis TconTS1b, TconTS2, TconTS3
and TconTS4 were aligned with TS and sialidase sequences from
T. brucei, T. vivax, T. cruzi and T. rangeli. As outgroup the sialidase
from Vibrio cholerae was used (genes listed in Supporting Informa-
tion Table S2). Full length protein sequences were first aligned
using ClustalW in Geneious and then truncated at the N-terminus.
CDs started from the FRIP region to the N-terminus of the
conserved a-helix (HL) linking the CD to the LD. The LDs were
taken immediately after the a-helix linkage to the C-terminus
Author Summary
Trypanosomiasis is a disease also known as sleeping
sickness in humans (Human African Trypanosomiasis) and
nagana in animals (Animal African Trypanosomiasis). This
disease is caused by protozoan parasites of the genus
Trypanosoma. Tsetse flies are responsible for the transmis-
sion of these parasites. Trypanosoma congolense is the
main causative agent of nagana in cattle. The clinical signs
of the disease have been linked to the presence of an
enzyme called trans-sialidase. Interestingly, the enzyme
alternates in different forms in the mammalian and the
insect vector. Previous knowledge had shown that the
parasite requires the enzyme for survival in the fly vector.
Our current work has revealed other forms of the enzyme
that could be essential for the persistence of the disease in
mammalian and vector hosts. These enzymes, though
similar in structural architecture, show differences in their
activities that could be key in delineating their individual
roles in the pathophysiology of the disease.
Diversity of T. congolense Trans-sialidases
PLOS Neglected Tropical Diseases | www.plosntds.org 2 December 2013 | Volume 7 | Issue 12 | e2549
  Results 3.2  
 85 
 
without the stop codon. DNA sequences encoding either full
length proteins, the CDs or the LDs were aligned based on the
alignment obtained for the amino acid sequences by T-Coffee
algorithm in RevTrans, version 2.0 (http://www.cbs.dtu.dk/
services/RevTrans-2.0/web/). DNA sequences used in the
phylogenetic calculations are shown in Supporting Information
Files S1, S2 and S3. Best parameters (HKY substitution model
with 6 gamma rate categories) for phylogenetic constructions were
determined using MEGA5 and applied in the phylogenetic
calculations using the ‘‘MrBayes’’ plug-in of Geneious.
Results
T. congolense sialidase/trans-sialidase genes
Partial coding sequences of TconTS1 and TconTS2 genes had
been described [13]. From ‘‘reads’’ of the WTSI T. congolense
genome sequencing project (http://www.sanger.ac.uk), we assem-
bled the full length sequences coding TconTS1 and TconTS2.
Further BLAST hits with smallest sum probabilities (P(N),1–10)
were identified and arranged into contiguous sequences leading to
further five genes with sequence similarities. Two of the putative
gene products shared over 40% sequence identity with TconTS1
and TconTS2 and contained all the conserved amino acids
required for transfer reactions [17] [18] [10]. Consistent with the
naming of TconTS1 and TconTS2 [13], we refer to them as
TconTS3 and TconTS4. The other three genes were distantly
related with 20–30% amino acid identity (Table 1) and lack several
of the conserved amino acid residues. We assume that these set of
genes are likely without sialidase or TS activity and were named
TconTS-Like1, TconTS-Like2, and TconTS-Like3.
In order to compare sequence similarities between TconTS
genes, we cloned and sequenced full lengths TconTS2, TconTS3
and TconTS4. In an earlier study, we amplified eleven highly
similar (about 96% identical amino acids) but clearly different
sequences of TconTS1 from T. congolense genomic DNA [14].
Sequencing several clones of TconTS2, TconTS3 and TconTS4
provided no evidence for such heterogeneity of these genes. The
alignment of these genes is given in Figure 1.
Amaya et al. [18] identified amino acids in T. cruzi TS involved
in the catalytic and substrate binding. Whereas these amino acids
are not conserved in the three TconTS-like gene products, they
are almost completely conserved in TconTS1, TconTS2,
TconTS3 and TconTS4 (Table 2). Most of these are conservative
changes, with the exception of position 293 (numbering in the
consensus sequence), where a Tyr is replaced by Pro in TconTS2.
Furthermore, based on mutagenesis experiments [19] [17] with
T. cruzi TS, two proline residues corresponding to positions 411
and 465 appear to be required for full TS activity. Whereas at
position 465 Pro is conserved across the TconTS, it is not found
in the TconTS-like gene products (Table 2). However, at position
411 the Pro is not conserved in TconTS, but replaced by Ala or
Ser.
TS orthologues occur in T. congolense and T. brucei but
not in T. vivax
To decipher the phylogenetic relationship between TS and TS-
like genes of African trypanosomes, we compared the four
TconTS and three TconTS-Like sequences together with seven
sequences from T. brucei and five from T. vivax (Supporting
Information Table S2) using the alignment of DNA sequences
reverse transcribed from the protein alignment (see Supporting
Information Files S1, S2 and S3 for DNA sequences used). As
shown in Figure 2A, for each TconTS and TconTS-Like gene a
corresponding orthologue was identified in T. brucei, whereas T.
vivax gene products cluster separately from TS of the other African
trypanosomes. TconTS-Like2 and TconTS-Like3 form a branch
together with their T. brucei orthologues separate from all South
American TS genes. In contrast, TconTS-Like1 and its T. brucei
orthologue appear to be more closely related with the more distant
South American branch than the African genes.
Trypanosomal TS contain an N-terminal CD followed by a C-
terminal LD. Besides the phylogenetic analysis with the entire
ORFs, analysis were performed using sequences coding for each
domain separately. The phylogenetic tree obtained for the CDs
resembles that for complete ORFs (not shown). Surprisingly, a
different situation was observed for the LDs of TconTS1,
TconTS2, TconTS3 and TconTS4 and the T. brucei TS genes
(Figure 2B). First, within the TconTS genes, the LD of TconTS2 is
most closely related to that of TconTS1, whereas the CD of
TconTS3 is more closely related to TconTS2. Second, it should be
noted that not the same T. congolense and T. brucei genes group as
orthologous pairs, if LDs are compared. Amplification and
sequencing ORF of T. brucei TS genes confirmed that the
combination of the CDs and LDs were as predicted from the
contigs in the databases.
Monclonal anti-TS1 antibody cross-reacts with TconTS2,
recognising an epitope on the lectin domain
To biochemically characterise TconTS genes, recombinant
proteins were made for TconTS2, TconTS3 and TconTS4 as
previously described for TconTS1 [14]. Recombinant TconTS
proteins were expressed in CHOLec1 [20] and purified by affinity
chromatography to obtain pure protein from eukaryotic cells with
high mannose-type N-glycans. The apparent molecular masses of
the recombinant TconTS proteins including the SNAP and Strep
tags are between 110 and 125 kDA as resolved on SDS-PAGE.
The generic Strep tag fused to the proteins is recognised by anti-
Strep polyclonal Ab in all the recombinant TconTS proteins as
shown in Figure 3 (upper panel). Surprisingly, the monoclonal
anti-TS antibody [12] reacted with both TconTS1 and TconTS2,
Table 1. Trypanosoma congolense trans-sialidase sequence similarities expressed as percentage of identical amino acids in pair-
wise alignments.
Trans-sialidase TconTS2 TconTS3 TconTS4 TconTS-Like1 TconTS-Like2 TconTS-Like3
TconTS1 42.2% 43.6% 46.2% 21.1% 26.3% 29.8%
TconTS2 - 48.3% 42.8% 20.8% 26.2% 29.3%
TconTS3 - 48.9% 21.1% 25.1% 29.9%
TconTS4 - 21.3% 27.8% 29.8%
Tcon= Trypanosoma congolense
doi:10.1371/journal.pntd.0002549.t001
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but not TconTS3 and TconTS4 (Figure 3; lower panel). This
result points to a similar epitope being present in both TconTS1
and TconTS2. Further experiments provided evidence that the
epitope is located in the LDs.
TconTS2, TconTS3 and TconTS4 are trans-sialidases
In order to investigate the enzymatic activities we used the
glycoprotein fetuin as donor and lactose as acceptor substrates.
Free sialic acid (the product of sialidase activity) and 3’SL (the
product of TS activity) could be quantified simultaneously from
HPAEC-PAD chromatograms of the reactions. Under standard
conditions 25 ng TconTS2 produced about 330 pmol/min 3’SL
leading to 200 mM 3’SL in the reaction mix within 30 minutes
(Figure 4A). Product formation by TconTS2 was linear for up to
50 ng enzyme under these conditions. The reaction catalysed by
TconTS3 was slower than that of TconTS2, since 500 ng of
enzyme generated only 4.2 pmol/min 3’SL corresponding to
10 mM 3’SL after 4 h (Figure 4B). 3’SL formation by TconTS3
was almost linear for 4 h. TS activity was also detected for
TconTS4. However, the activity was even lower than that of
TconTS3 and 500 ng of TconTS4 produced less than 0.1 pmol/
min 3’SL (Figure 4C). Therefore, 24 h incubations were routinely
used to determine TconTS4 activity.
To determine kinetic parameters (Table 3) reactions were
conducted under standard conditions for 30, 120 and 1440 min-
utes for TconTS2, TconTS3 and TconTS4, respectively.
TconTS2 exhibited the lowest KM for fetuin (299 mM), similar
to that reported for TconTS1b (395 mM) [14], whereas those
determined for Tcon TS3 (6090 mM) and TconTS4 (949 mM)
were higher. The lowest KM for lactose was found for TconTS2
(602 mM), followed by TconTS3 (1104 mM) and TS4 (1806 mM).
Comparing the results with those obtained for two variants of
TconTS1 [14], TconTS2 has a KM value for lactose similar to
TconTS1e-1 but about 3-fold less than TconTS1b. For both
substrates, TconTS2 showed about 2-, 200- and 2000-fold
higher vmax values than TconTS1, TconTS3 and TconTS4,
respectively.
Sialidase activities
Sialidase activity has been shown for TconTS purified from
T.congolense axenic culture [12] and for T. congolense infected
animals [5] [7]. Therefore, we investigated the sialidase activities
of TconTS using fetuin as a model glycoprotein. Whereas no
release of free Neu5Ac was observed for TconTS1, TconTS2 and
TconTS3 under standard conditions of TS assays, TconTS4
clearly showed sialidase activity producing 0.76 pmol/min
Neu5Ac up to 48 h (Figure 5A). Indeed, the sialidase activity of
TconTS4 is relatively stable and retained a residual sialidase
activity of 40% even after incubation at 37oC for 120 days.
We also investigated the effect of lactose on TconTS4 sialidase
activity. At lactose concentrations above 3 mM, release of Neu5Ac
dropped to undetectable levels (Figure 5B). This result indicates
the existence of a competition between lactose and water for the
cleaved Neu5Ac from the donor fetuin. This is confirmed by the
increased amount of 3’SL produced with increasing lactose
concentration.
When we incubated TconTS2 or TconTS3 with fetuin and
lactose for extended periods, it was observed that increasing
amounts of Neu5Ac were released, similar to TconTS1 [14].
Interestingly, free Neu5Ac appeared only after 3’SL has
accumulated as a product of transialylation. For example, in
TconTS2 reactions, Neu5Ac was detectable (0.68 mM, 27 pmol)
when the 3’SL concentration had reached almost 600 mM, the
maximum 3’SL concentration reached. Whereas further incuba-
tion did not result in higher 3’SL concentrations, the amount of
free Neu5Ac continuously increased. This observation suggests
that TconTS2releases free Neu5Ac from 3’SL but not from
fetuin. Similar observations were made for TconTS1, but the
highest 3’SL concentration reached was about 300 mM. These
data indicated that for TconTS1 and TconTS2 at 300 mM and
600 mM 3’SL, respectively, the transfer of Neu5Ac between fetuin
and 3’SL has reached an equilibrium. For TconTS3, we could
not reach such equilibrium; probably since the maximum 3’SL
concentration obtained was 50 mM due to the low specific activity
of this enzyme. Nevertheless, small amounts of free Neu5Ac were
detected in prolonged TconTS3 reactions leading to 50 mM 3’SL.
Also in this case, Sia appears to be released from 3’SL only, since
in the absence of lactose no release of free Neu5Ac could be
observed.
These observations suggest that TconTS1, TconTS2 and
TconTS3 can release free Neu5Ac from glycoconjugates, but the
level of product released is too low to be detected under standard
TS assay conditions. To address this, higher amounts (500 ng) of
TconTS1, TconTS2, TconTS3 and TconTS4 were incubated
with 600 mM fetuin-bound Neu5Ac without lactose for 2 h. Under
these conditions sialidase activities could also be detected for
TconTS1 and TconTS2, but not for TconTS3 (Table 4).
However, compared to the corresponding TS activities, the
sialidase activities were very low.
Discussion
The enzymatic properties of four TconTS were compared using
fetuin as a model for a blood glycoprotein donor substrate. Two of
these enzymes, TconTS1 and TconTS2, exhibit about 100- or
1000-fold higher specific TS activities than TconTS3 and
TconTS4, respectively. The KM values for lactose were around
1 mM (0.6 to 1.8 mM) for all four TconTS and did not correlate
with their specific activities. The KM values for the donor fetuin
were more different ranging from 0.4 to 6 mM glycoprotein
bound sialic acids. The KM for fetuin also did not correlate with
the specific activity, since the highest KM was determined for
TconTS3, one of the enzymes with low activity, and TconTS4 has
a similar KM as TconTS1, but is 1000-fold less active. Since the
KM values are lower than the substrate concentrations used,
especially for TconTS4, the specific activities given in Table 3 are
lower than those to be expected, if the acceptor substrate lactose
would be at saturating concentrations.
Figure 1. Primary amino acid sequence alignment of TconTS and TconTS-Like genes. Amino acid sequences of TconTS1b
(EMBL:HE583284), TconTS2, TconTS3 and TconTS4 were obtained by sequencing of cloned genes. Those of TconTS-Like 1, TconTS-Like 2 and
TconTS-Like 3 were obtained from the WSTI database. CluwstalW alignment plugin of the Geneious software was used employing BLOSUM12 with
gap openings and extension penalties of 10 and 0.1, respectively. Increasing darkness of background indicates increasing numbers of identical amino
acids at each position. The numbers on top of the sequences indicate the positions in the consensus sequence. Amino acid residues postulated to be
critical for catalysis, substrate binding and structure as given in Table 2 are boxed.
doi:10.1371/journal.pntd.0002549.g001
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Table 2. Amino acids in the catalytic domains of TS and TS-Like genes from T. congolense involved in enzymatic activities*.
Consensus Tcon TS1 Tcon TS2 Tcon TS3 Tcon TS4 Tcon TS-Like1 Tcon TS-Like2 Tcon TS-Like3
catalysis
212 D150 D135 D142 D207 D110 E85 K86
410 E324 E309 E316 E381 N291 Y257 S262
532 Y438 Y423 Y430 Y493 F404 L375 H382
substrate binding
188 R126 R111 R118 R183 E86 H61 R62
425 R339 R324 R331 R396 A306 Q272 S277
496 R410 R395 R402 R465 N375 L339 D346
206 R144 R129 R136 R201 R104 R79 W80
270 D188 D173 D180 D245 G160 L122 P132
293 Y211 P196 Y203 Y268 A183 G145 S155
294 W212 W197 W204 W269 L184 T146 L156
374 Q289 Q274 Q281 Q364 V255 E222 V227
494 Y408 W393 W400 Y463 A373 E337 D344
structure
411 A325 A310 S317 A382 P292 C258 S263
465 P379 P364 P371 P434 V344 G308 G315
*The indicated amino acids have been selected based on structural [18] and mutation [19] [23] studies with T. cruzi TS and on the sequence alignment of TconTS1b with
T. cruzi [14]. Amino acid positions have been numbered based on the consensus of alignment (Figure 1) or starting methionine of each ORF.
doi:10.1371/journal.pntd.0002549.t002
Figure 2. Phylogenetic analysis TS genes. Phylogenetic analyses of DNA sequences were performed as described under Methods using
‘‘MrBayes’’ plug-in of Geneious. Trees are midpoint rooted and nodes supported by posterior probability values and non-parametric bootstraps
generated by maximum likelihood analysis in ‘‘MrBayes’’ as described under Methods. TS genes from T. congolense and T. brucei are marked by blue
frames, TS genes from T. vivax by red frames. A: Phylogenetic tree for full ORFs, the ‘‘African TS-branch’’ is marked by a grey frame; B: Phylogenetic
tree for LDs, the most active TconTS and their orthologues from T. brucei are highlighted by a grey box.
doi:10.1371/journal.pntd.0002549.g002
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Tiralongo et al. [12] purified two TconTS forms with different
TS/sialidase activity ratios from procyclic T. congolense cultures.
Peptide sequences from these preparations have demonstrated that
they contained at least TconTS1 [12] [14]. Recombinant
TconTS1 variants expressed in eukaryotic cells had lower specific
activities for synthetic substrates than described for the purified
enzyme [12] suggesting that these TconTS preparations also
contained other enzymes and/or factors influencing the TS/
sialidase activities [14]. For example, in those preparations,
Glutamic Acid-Rich Protein, GARP, a natural substrate for
TconTS was co-purified with one of the TS forms [12]. Although
it is unclear what role GARP might have played, its presence, as
well as other TS enzymes, might have been responsible for the
reported higher specific activities of these TS preparations for
synthetic substrates. In summary, it appears that TconTS1 and
TconTS2 are responsible for most of the TS activity of T.
congolense. However, it may well be that TconTS3 and TconTS4
are more active on other donor substrates, such as glycoproteins
and/or glycolipids from blood components, the natural substrates
for trypanosomal TS.
It has been established that procyclic forms of African
trypanosomes express TS [21] and emerging evidences point to
expression also in the blood stream forms [6] [7]. So far, no
information is available on which TS genes are expressed at what
stage of the parasite’s life cycle. Recently, we have identified
mRNAs for TconTS1, TconTS2 and TconTS4 in the blood of
infected goats (data not shown). Also the stability and persistence
of shed enzymes in the blood stream has to be taken into account.
In vitro TconTS1 and TconTS3 are the most stable of the four
enzymes investigated, retaining full TS activities even after four
months at 37uC. Under these conditions TconTS2 lost its activity
completely, while TconTS4 retained 40% residual sialidase but no
transfer activity (data not shown). It would be interesting to
investigate whether this long-term stability correlates with a
sustained persistence of enzyme activity in the blood stream.
Lactose was found to suppress the sialidase activity of TconTS4.
In vitro, lactose appears to be a better acceptor than water
(Figure 5B). Therefore, in presence of lactose, the transfer activity
of TconTS4 is more efficient than its hydrolytic activity. Anaemia
in animals suffering African Trypanosoma infections has been
attributed to the effects of sialidases [22] [5] [7]. Desialylation of
erythrocytes by sialidases exposes underlying galactose residues
and their subsequent degradation. The presence of lactose in
mammalian blood would lead to lowered efficiency of parasites
sialylation and eventual clearance by the immune system.
However, desialylation of parasites is equally possible in presence
of lactose due to the action of TS. Along this line it is interesting to
note that infusion of lactose in the blood of sheep suffering
experimental anaemia from T. congolense suppressed anaemia
(unpublished observation).
All amino acid residues shown to be involved in the catalytic
reaction or interaction with the substrate for T. cruzi TS are
conserved in the TconTS enzymes (Table 2). Only the two
residues interacting with the methylumbelliferyl aglycon or the
lactose part of 3’SL in the T. cruzi TS [18], positions 293 and 494
in consensus sequence (Figure 1), are different in the two most
active TconTS1 and TconTS2. This could explain why these
enzymes do not use Neu5Ac-MU as substrate (data not shown).
Furthermore, these changes could lead to a weaker interaction
with the leaving groups and thus facilitate their release during
catalysis. In this context it is interesting to note that the most
drastic change, Tyr to Pro at position 293, occurs as P196 in
TconTS2, the most active enzyme with the highest TS/sialidase
ratio (Table 4). Certainly, this modification will reduce the
interaction with hydrophobic aglycons or the leaving galactose
residue of the donor substrate.
Amaya et al. [18] also provided evidence that in T. cruzi TS
Y119 (position 293 in the consensus sequence) also contributes to
hydrogen bonding with O9 of the covalently bound Sia following a
conformational change induced by the reaction. Such an
interaction would not be possible in TconTS2, but could be
compensated by hydrogen bonding with the conserved side chains
W197 and Q274 of TconTS2 corresponding to W120 and Q195
in T. cruzi TS, two amino acids contributing to the hydrogen
bonding network of O9 in the covalently bound Sia [18].
Similarly, although to a lesser degree, the replacement of a Trp
at position 494 (corresponding to W312 in T. cruzi TS) with a Tyr,
as found in TconTS1, is expected to reduce the hydrophobicity of
this site leading to a reduced affinity for the leaving group. In T.
cruzi TS substitution of this Trp (W312) by Ala basically abolished
Neu5Ac transfer but only slightly decreased hydrolytic activity for
3’SL [23]. Interestingly, in contrast to the wild type T. cruzi TS,
this mutant was not able to hydrolyse Neu5Ac-MU, similar to
TconTS1, which also does not accept Neu5Ac-MU as a substrate
[14].
It appears that TS activity depends on well controlled
conformational changes [17] influenced by specific proline
residues. This is supported by the potential of the T. rangeli
sialidase to acquire transfer ability due to a change of Gln to Pro at
position 284 [24] and the loss of enzymatic activity in T. cruzi TS
by the reverse mutation [16]. At the corresponding position 465
Pro is found in all active TconTS (Table 2). The relevance of
conformational changes in the enzyme rather than a direct specific
interaction of the amino acid were also indicated by mutation of
Pro231 to Ala in T. cruzi TS [19], corresponding to position 411 in
the consensus sequence. Although this mutation led to a significant
decrease in T. cruzi TS activity, all active TconTS have an Ala or
Ser at this position. It would be interesting to see, if higher TS
activities can be obtained by introducing a Pro at this position,
particularly in TconTS3 or TconTS4, the two enzymes with low
TS activities.
Besides these critical amino acids listed in Table 2, other
structural features obviously control the ratio of TS versus sialidase
activities, since TconTS2 and TconTS4 share identical amino
acids at all these positions. Yet, TconTS4 has the highest sialidase
to TS ratio amongst the TconTS enzymes, whereas TconTS2 has
the lowest ratio (Table 4). Koliwer-Brandl et al. [14] observed for
TconTS1 that a natural mutation that replaced R144 (206 in
Figure 3. Recognition of TconTS proteins by antibodies. 100 ng
of affinity purified TconTS proteins were analysed by Western blot as
described under Methods. Blots were probed either with polyclonal
rabbit anti-Strep (upper pane) or with monoclonal mouse anti-TS1
antibody, which shows cross reactivity with TconTS2 (lower pane).
doi:10.1371/journal.pntd.0002549.g003
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consensus) sequence with Cys in the variants TconTS1g (EMBL:
HE582290) did not terminate but only reduced TS activity, while
increasing relative hydrolytic activity. It can be assumed that a
weaker interaction with the hydroxyl group at C4 of sialic acid is
responsible for the catalytic properties of TS1g, since the Arg (R53
in T. cruzi TS) is in close contact with the bound sialic acid and
probably supports the stabilisation of the enzyme-substrate
complex [18].
Conservation and/or substitution of amino acids in the active
centre of the catalytic domain did not give clear indications of
activity differences between the TconTS enzymes. In this context,
an interesting aspect is how the different specific activities of
TconTS enzymes correlate with those of related gene products
from other African trypanosomes. Phylogenetic analyses have
allowed the clear assignment of orthologues for T. brucei, but not
for T. vivax, where TS genes clustered exclusively together and
away from the TS genes of T. congolense and T. brucei (Figure 2) [7]
[25]. A direct comparison of the TS activities between T.
congolense and T. brucei is difficult, since limited comparable data
for enzymatic activities is available. In T. brucei TbTS and TbSA
C2 have been identified as active TS [9] [10] [11]. This is
consistent with the observation that their orthologues (TconTS1
and TconTS2, respectively) are the most active TS in T.
congolense. RNAi based experiments provided evidence that in T.
brucei TS and sialidase activities are encoded by different genes,
TbTS and TbSA C [10], whereas assays with purified
recombinant proteins demonstrated both enzyme activities for
TbTS and TbSA C2 [11]. Noticeably, the diversity of TS-related
genes in T. vivax is lower than what was obtained for T. congolense
and T. brucei. Equally, T. vivax is distinctively different from T.
congolense and T. brucei in terms of development in the insect host.
While the later two develop in the insect midgut and proboscis or
salivary glands respectively, T. vivax develops exclusively in
mouthparts of the tsetse. Moloo and Gray [26] showed that T.
vivax ingested with blood meal to the midgut is disintegrated. TS-
like genes from T. vivax share all but two (consensus sequence
positions 411 and 494) of the conserved amino acids listed in
Table 2 with the active TconTS. Recently Guegan et al. [7]
reported that TvivTS2 has TS activity. Furthermore, they
obtained evidence for the presence of at least TvivTS1, TvivTS3
and TvivTS5 in the bloodstream form and none in epimastigotes
and the possible involvement of these proteins in anaemia in
infected mice. In summary, it may be possible that T. vivax is
missing a suitable TS to survive and colonise the fly vector
midgut. To this end, it would be interesting to see the survival
ability of transgenic T. vivax expressing a TS, which is expressed
by T. congolense in the midgut of tsetse flies.
The presence of multiple highly similar TS genes, as described
for TconTS1 [14], suggests that these genes undergo active
rearrangements, which could lead to strain specific differences. For
example, Coustou et al. [6] referred to two highly related TconTS3
genes in the IL3000 strain identified in GeneDB and TrytrypDB
databases. However, we could not find evidence for their existence
in the STIB294 strain used in this study. Similarly, closely related
genes with over 80% sequence identity have been identified for
TbSA B and TbSA C in T. brucei [11].
TS and sialidase genes of African trypanosomes are organised in
two major domains; the CD and the LD. The LDs of TconTS are
more varied (40% pairwise identity) when compared with the CDs
(58% pairwise identity). Surprisingly, the phylogenetic relation-
ships between the TS are clearly different, if only the LDs are
included in the analysis (Figure 2). Furthermore, the LDs of the
two most active enzymes TconTS1 and TconTS2 are more closely
related than the CDs, where TconTS2 is most closely related to
TconTS3. Interestingly, the monoclonal anti-TS1 antibody also
binds TconTS2, recognising an epitope in the LD. First
preliminary experiments obtained with recombinant proteins, in
which the LDs have been swapped between TconTS, provided
supporting evidence that the LD influences TS and sialidase
activities of the enzymes (data not shown). However, the specific
activities of these proteins expressed in bacteria is much lower than
those of the proteins expressed in fibroblasts described here,
Figure 4. Concentration dependency of TS activity. The indicated amounts of recombinant TconTS proteins were incubated with 100 mg fetuin
(600 mM bound Sia) and 2 mM lactose for 30 (TconTS2), 240 (TconTS3), or 1440 (TconTS4) minutes. 3’SL produced was determined by HPAEC-PAD as
described under Methods. Data points are means 6 standard deviations of three independent experiments, each as triplicates. A: TconTS2, B:
TconTS3, C: TconTS4.
doi:10.1371/journal.pntd.0002549.g004
Table 3. Kinetic parameters of TconTS.
Donor substrate (fetuin-bound Sia)* Acceptor (lactose)**
vmax*** (mmol/(min6mg TS)) KM*** (mM) vmax*** (mmol/(min6mg TS)) KM*** (mM)
TS1b**** 7.960.3 359645 4.360.1 16836101
TS1e-1**** 7.660.5 16176223 2.160.1 727648
TconTS2 17.6260.13 299.0067.0 17.8560.13 602616
TconTS3 0.1760.02 6090.0061267 0.056760.0014 1104679
TconTS4 0.006760.0002 949650 0.007560.0002 18066112
*Approximately 30 nmol Sia per 100 mg fetuin; 2 mM lactose was used as acceptor substrate.
**600 mM fetuin-bound Sia was used as donor substrate.
***KM and vmax were calculated from Michaelis-Menten kinetics (see Supplementary Information, Figure S1) by SigmaPlot. Data points are mean 6 standard deviations
of three independent experiments, each replicated thrice.
****values from Koliwer-Brandl et al. [14].
doi:10.1371/journal.pntd.0002549.t003
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suggesting that for conclusive interpretation the domain swapped
TconTS have to be expressed in eukaryotic cells and that further
studies are necessary to optimise the fusion of the two domains. In
summary, these data indicate a more significant role for the LD for
the TS activities of TS1 and TS2 and thus possibly in the
pathogenesis of African trypanosomiasis.
Figure 5. Sialidase activity of TconTS4. A: Recombinant TconTS4 was incubated with 100 mg fetuin (600 mM bound Sia) for the times indicated
(see insert for long term reactions) and free Sia determined by HPAEC-PAD as described under Methods. Data points are means 6 standard
deviations of 3 independent reactions each triplicated. B: Recombinant TconTS4 was incubated for 1440 min with 100 mg fetuin (600 mM bound Sia)
in the presence of the lactose concentrations indicated and free Sia determined by HPAEC-PAD as described under Methods. Data points are means
6 standard deviations of 3 independent reactions each as triplicates.
doi:10.1371/journal.pntd.0002549.g005
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Supporting Information
Figure S1 Trans-sialidase reaction velocities depending
on substrate concentrations. Product (39-sialyl-lactose)
amounts were determined as described under Methods. vmax and
KM for lactose shown in Table 3 were calculated from these data.
Data points are mean 6 standard deviations of three independent
experiments, each replicated thrice. A) TconTS2 with different
donor substrate concentrations. 50 ng TconTS2 were
incubated for 30 minutes with 2 mM lactose and the indicated
concentrations of fetuin-bound Sia. B) TconTS2 with different
acceptor substrate concentrations. 50 ng TconTS2 were
incubated for 30 minutes with 600 mM fetuin-bound Sia and the
indicated lactose concentrations. C) TconTS3 with different
donor substrate concentrations. 250 ng TconTS3 were
incubated for 120 minutes with 2 mM lactose and the indicated
concentrations of fetuin-bound Sia. D) TconTS3 with different
acceptor substrate concentrations. 500 ng TconTS3 were
incubated for 120 minutes with 600 mM fetuin-bound Sia and the
indicated lactose concentrations. E) TconTS4 with different
donor substrate concentrations. 500 ng TconTS4 were
incubated for 1440 minutes with 2 mM lactose and the indicated
concentrations of fetuin-bound Sia. F) TconTS4 with different
acceptor substrate concentrations. 500 ng TconTS4 were
incubated for 1440 minutes with 600 mM fetuin-bound Sia and the
indicated lactose concentrations.
(PDF)
File S1 Nucleotide sequences of the sialidase and trans-
sialidase genes used in the phylogenetic comparison of
‘‘full length open reading frames’’ (catalytic plus lectin
domains). The gaps inserted for the alignment as described
under Methods are indicated by dashes. The file is a text file in
FASTA format with the gene names (see Table S2) in the first line
for each gene.
(TXT)
File S2 Nucleotide sequences of the sialidase and trans-
sialidase genes used in the phylogenetic comparison of
‘‘catalytic domains’’. The gaps inserted for the alignment as
described under Methods are indicated by dashes. The file is a text
file in FASTA format with the gene names (see Table S2) in the
first line for each gene.
(TXT)
File S3 Nucleotide sequences of the sialidase and trans-
sialidase genes used in the phylogenetic comparison of
‘‘lectin domains’’. The gaps inserted for the alignment as
described under Methods are indicated by dashes. The file is a text
file in FASTA format with the gene names (see Table S2) in the
first line for each gene.
(TXT)
Table S1 List of primers used for cloning and muta-
genesis. Listed are the primers used in this study for cloning,
expression plasmids and mutagenesis as described under Methods.
(PDF)
Table S2 Trans-sialidase and sialidase genes used for
phylogenetic analysis. Listed are accession numbers and
literature references for the genes used in the phylogenetic analysis
in this study.
(PDF)
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Abstract
Nagana,  the  animal  form  of  trypanosomiasis,  caused  by  Trypanosoma species  is  a  serious
livestock production problem in Africa. Trans-sialidases (TS) play a key role in the pathology of
nagana. Active TS genes from  T. congolense,  TconTS1, TconTS2, TconTS3 and TconTS4 are
expressed in both the tsetse vector and the bloodstream of infected animals. We studied the pH
optima and activities of these diverse gene products on blood glycoconjugates and fetuin. TconTS2
was found to be active at pH 9, corresponding to the pH of the tsetse midgut, an unusual pH for
sialidases. Though they all transfer sialic acids (Sia) in presence of acceptor molecules, two of
them,  TconTS1  and  TconTS2  exhibit  highest  specific  activities  for  transfer  on  serum
glycoconjugates. Sialidase activities of TconTS1, TconTS2 and TconTS4 were higher on serum
glycoconjugates  than  on  the  single  substrate,  fetuin.  TconTS3  formed  two  products  peaks
differentially  favoured at  different  serum-Sia concentrations.  Serum presents  varied targets  for
TconTS2 than any other TconTS indicated by changes in several peak areas in reactions involving
this enzyme.  The diversity and different pH optima of TconTS may be a direct response of the
parasite to the changing environments during the life cycle. 
Author Summary
Trans-sialidases (TS), a multigene family of enzymes have been established as virulent factors in
the Animal African Trypanosomiasis (AAT).  The disease caused by protozoan parasites of  the
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genus  Trypanosoma are  transmitted  by  tsetse  flies,  exposing  the  parasites  to  different 
environments. It has been established that T. brucei require TS to establish infections in the tsetse 
vector  midgut  for  subsequent  transmission  to  the  mammalian  host.  Both  T.  brucei  and T.  
congolense share several common aspects of life cycle. The pH in tsetse midgut is different from 
that obtained in the mammalian host. In the mammal, T. congolense requires sialic acids (Sia) for 
survival. There are several Sia types and linkages in the blood and serum of mammalian hosts. We 
studied  the  pH  optima  for  the  active  TconTS genes  as  well  as  enzyme  activities.  Our  study 
revealed that different pH optima as well the diverse nature of TS genes are a direct response to 
changing environments during the life cycle of the parasite as it seeks to survive in the two host  
systems.
Introduction
Trypanosoma congolense (subgenus:  Nannomonas)  is  a  major  causative  agent  of  the  Animal 
African  Trypanosomiasis  (AAT)  otherwise  known  as  nagana.  Nagana  has  profound  negative 
impact  on  stock  farming,  milk  and  meat  production  on  the  African  continent  [1].  Other 
Trypanosoma species  implicated  in  nagana  include  but  not  limited  to  T.  vivax (subgenus: 
Duttonella)  and  T.  brucei  brucei (subgenus:  Trypanozoon),  which  are  transmitted  by  bites  of 
Glossina spp.  Apart  from the bites  of  Glossina,  another  Trypanosoma pathogen implicated  in 
nagana,  T. evansi could also be transmitted mechanically by other bitting flies. Trypanosomes 
harbour a multigene family expressing unique sets of enzymes, the trans-sialidases (TS). Their 
role in establishing infection in tsetse midgut has been established for T. brucei [2]. While no such 
information is available for  T. congolense,  TS genes are likely  to play a similar role,  since  T. 
congolense and  T.  brucei exhibit  several  common  aspects  of  life  style,  for  e.g.  establishing 
infection first in the tsetse midgut. Both  T. brucei,T. congolense [3,4] and  T. evansi [5] share TS 
orthologues that are distinctively absent in  T. vivax [3,6]. The pH in the midgut of tsetse ranges 
between 9 and 10 [7]. This is rather an unusual pH for known sialidases as sialidases have rather 
acid pH optima and are inactive at pH between 9 and 10 [8]. Therefore, for any TS/sialidase to be 
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active in the tsetse midgut, such an enzyme must have evolved to accommodate prevailing pH
conditions found therein.
In the mammalian host, TS/sialidase are shed in the serum and blood plasma of infected animals
[9,10] and have been identified as virulent factors in trypanosomiasis caused by T. congolense [11]
and T. vivax [6]. A significant level of sialidase activities of T. congolense [10] as well as sialidase
and TS of T. vivax [6] in the blood of infected mice have been reported. Similarly, the mechanism of
anaemia induction that directly implicates TS/sialidases has been established. It has been shown
that removal of Sia from erythrocytes' major surface sialoglycoproteins, the glycophorins leads to
erythrophagocytosis in the course of T. congolense [11] and T. vivax [6] infections. 
Serum  contains  a  wide  range  of  glycoproteins  and  glycolipids  that  are  heavily  sialylated.  A
comprehensive list of serum components has been compiled [12] and can be assessed at SMDB:
http://www.serummetablome.ca/http://www.serummetablome.ca.  Sia  occur  on  these  glycocon-
jugates linked as ?2,3, ?2,6 or ?2,8 to a variety of  glycan structures and further diversity comes
from  the  different  naturally  occurring  Sia  modifications  [13].  About  96%  of  Sia  on  human
erythrocytes are glycoprotein-associated comprising 9 types beside the predominant Neu5Ac [14].
Indeed, the constant interplay between host and pathogens is said to be the driving force behind
the rapid evolution of  Sia leading to Sia diversification on the one hand, and the evolution of
attributes by the parasites to be able to overcome such a rapid Sia modification on the other hand
[15]. Pathogens can alter the chemical and physiological composition of serum and blood plasma.
For example, the intracellular  Trypanosoma parasite  T. cruzi is poorly sialylated when released
from cells but becomes densely sialylated upon contact with serum  [16]. While a proportion is
transferred to the parasites, as described for T. cruzi [16,17], a certain proportion is lost becoming
free Sia in the serum. The desialylated blood glycoconjugates products are rapidly cleared via
galactose specific mechanisms [13], a process which is most likely an important reason for several
pathological effects of nagana, such as anaemia and impaired immune response. 
Both the procyclic [18,19] and blood stream forms, BSF [3,11] of T. congolense express several TS
isoforms  but  the  biological  relevance  of  this  diversity  has  not  been  addressed.  This  study
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investigated pH optima and enzyme activities of single recombinant TconTS and concludes that the 
diversity of TconTS genes is tied to the complexity of the changing environments during the life 
cycle of the parasite.
Methods
All  chemicals  and reagents  used  were  cell  culture  and analytical  grade.  Anti-SNAP-tag  rabbit 
polyclonal antibody was from GeneScript (Piscataway, USA) while anti-Strep tag rabbit polyclonal 
antibody,  Strep-tactin  resin  beads and buffers  were from IBA (Göttingen,  Germany).  Pfu DNA 
polymerase, HindIII, XbaI, SpeI, EcoRI and DpnI, PageBlue, molecular weight marker (PageRuler), 
BCA assay protein kit were all purchased from Thermo Scientific (St. Leon-Rot, Germany). X-ray 
film and Enhanced Chemiluminescence system were purchased from GE Healthcare (Uppsala, 
Sweden).  Polyvinylidene  difluoride  membrane  was  from  Millipore  (Schwabach,  Germany). 
VivaSpin 6® and VivaCell250® ultracentrifugation units were from Sartorius (Göttingen, Germany). 
Hygromycin  and  gentamycin  were  purchased  from  PAA,  (Pasching,  Austria).  Polyethylenimin 
transfection  reagent,  glucoronic  acid,  N-acetyl-neuraminic  acid (Neu5Ac),  3'sialyllactose (3'SL), 
lactose, HCl and orcinol were purchased from Sigma-Aldrich (Steinheim, Germany). Excell  CD 
CHO media from SAFC, USA, and 96-well plates were from Sarstedt (Hamburg, Germany).
Recombinant trans-sialidases
Cell  lines derived from CHOLec  1 cells  [20] expressing recombinant TconTS1 through TconTS4, 
fused with both SNAP and Strep tags and the purification of these proteins have been described  
[3,21].
Serum preparations and serum Sia quantification
To obtain serum, human blood was collected without anticoagulant and allowed to clot at room 
temperature  for  at  least  30  minutes.  The  clotted  components  were  separated from serum by  
centrifugation at 1500 min-1 for 10 minutes at 4°C. To quantify Sia content, serum was serially 
diluted in 40 µL amounts per well and total sialic acid determined using the resorcinol/Fe3+ reagent 
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as described [22].
Trans-sialidase and sialidase reactions
Enzymes used in control assays were heat inactivated. All reactions were incubated at 37°C in 10 
mM phosphate buffer, pH 7.4. Fetuin and human serum served as Sia donor substrates while 
lactose served as the acceptor substrate. Except for the experiments involving determination of pH 
optima, all other tests were carried out as previously described [3,21]. For pH optima experiments, 
pH was adjusted to the required pH of 6, 7, 8, 9 and 10, while reactions in which pH 7.4 was  
maintained served as control. Quantification of Neu5Ac, 3'SL, lactose and glucoronic acid (internal 
standard) were carried out using the HPAEC-PAD system as previously described [3,21].
In order to establish kinetic parameters, the ligand binding (single site saturation) curve fit module 
of SigmapPlot 11 was used to calculate vmax and KM employing the Michaelis-Menten equation v = 
vmax Cs/(Cs+ KM).
Results
TconTS enzymes exhibit different pH optima
The pH in the midgut of the tsetse vector is between 9 and 10 [7]. In the mammal, the parasite 
encounters a pH of  about 7.  pH optimum may give a  likely  indication  of  which TconTS gene 
product operates at the optimum in the different host systems. Using fetuin as a model donor blood  
glycoprotein and lactose as acceptor substrates, we measured enzyme activities at different pH 
(Figure  1  A-D).  Extended  incubation  periods  were  required  to  asses  hydrolytic  activities  for 
TconTS1 and TconTS2 given their poor sialidase activities compared to the high TS activities [3]. 
Therefore while  TS activities were  run for  30 minutes, using 50 ng enzyme for  TconTS1 and 
TconTS2, transfer activity experiments for both TconTS3 and TconTS4 were incubated for 24 h with 
250 ng of each enzyme. For sialidase activities, 250 ng of each enzyme (TconTS1, TconTS2, 
TconTS3 and TconTS4) were incubated with 600 µM fetuin-bound Sia for 24 h without the acceptor 
lactose.
Transfer  activities  for  TconTS1,  TconTS3  and  TconTS4  had  pH  optima  at  pH  7  with  low  TS 
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activities between pH 8 and 10 (Figure 1 A, C and D). TS activity of TconTS2 was highest at pH 9, 
producing about 370 µM 3'SL as compared to 320 µM 3'SL at pH 7.4 (Figure 1 B). Sia released for  
TconTS1  and  TconTS2  did  not  vary  significantly  at  different  pH  points,  with  both  enzymes 
producing about 100 µM Sia (Figure 1 A and B). Sialidase activities of TconTS3 and TconTS4 in 
the presence of lactose showed pH optima at pH 6 with progressive reduction in sialidase activity 
as pH increased (Figure 1 C and D). Interestingly, sialidase activity increased for both TconTS3 
and TconTS4 in absence of lactose. However, the increment was more pronounced for TconTS4, 
attending a pH optima at pH 9 at which 35 µM compared to 15 µM Sia for TconTS3. 
Enzyme activities of TconTS on serum glycoconjugates 
Sia transfer was determined from 3'SL production in reactions containing serum and lactose as 
donor and acceptor substrates, respectively. Sialidase activity was monitored by Neu5Ac release 
from serum either in the absence or presence of lactose. A summary of these results is presented  
in Table 1. 200 ng TconTS1 produced 42 pmol 3'SL/ min during the first 2 h (Figure 2 A). At longer  
incubation times, the reaction velocity decreased until a maximum of 6 nmol 3'SL was reached. 
This did not appear to be due to donor substrate depletion, since this amount corresponds to 120 
µM 3'SL, which is only 20 % of the 600 µM serum-bound Sia available in the reaction. Even at 
prolonged incubations for up to 24 h with up to 1000 ng TconTS1 no significant increase of 3'SL 
was obtained (Figure 2 B). This suggests that at 120 µM 3'SL, equilibrium has been attained or the 
residual serum-bound Sia is not available for transfer by TconTS1, for example due to sialidase 
activity. However, free Sia could only be detected after longer incubations or with high amounts of  
TconTS1, whereas the maximum Sia released was 1.5 nmol after 24 h with 1000 ng enzyme 
(Figure  2  B),  representing  less than 3 % of  total  serum-bound Sia  added.  In  the  absence of  
lactose, higher sialidase activity was detected and 200 ng TconTS1 released about 8 pmol Sia/ min 
for up to 4 h, after which the velocity started to decrease, attaining 5 nmol free Sia after 24 h  
(Figure 2 A). Even 1000 ng TconTS1 released only slightly more Sia (6.5 nmol). Interestingly, this 
is similar to the 6 nmol 3'SL formed by the same amount of enzyme.
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A similar pattern of 3'SL formation was observed for TconTS2. 200 ng TconTS2 produced 75 pmol 
3'SL/ min for the first 2 h (Figure 2 C). Reaction velocity decreased at longer incubation times until  
a maximum of 8 nmol 3'SL was reached. Increasing the amount of enzyme up to 1000 ng TconTS2 
did  not  lead  to  higher  amounts  of  3'SL (Figure  2  D)  corresponding  to  160  µM 3'SL,  which 
represents 27 % of the total serum-bound Sia available in the reaction. In the presence of 2 mM 
lactose, free Sia could only be detected after longer incubation times and reached a maximum of  
0.25 nmol free Sia, less than 1 % total serum-bound Sia available in the reaction (Figure 2 C and 2 
D). Higher sialidase activities were observed in the absence of lactose, where 200 ng TconTS2 
released 13 pmol free Sia/ min in the first 2 h (Figure 2 C). Reaction velocity decreased at longer  
incubation times. The maximum amount of free Sia obtained was 5 nmol and did not increase, 
even when 1000 ng TconTS2 was used for incubation for 24 h.
Sia transfer from serum donor substrate by TconTS3 was almost two orders of magnitude slower  
relative to TconTS2, since 250 ng TconTS3 produced 0.83 pmol 3'SL/ min. This reaction velocity 
was linear during the first 8 h (Figure 2 E) before it decreased and a total of 0.65 nmol 3'SL was 
reached after 24 h. Increasing the enzyme to 1000 ng TconTS3, 1 nmol 3'SL could be obtained 
(Figure 2 F). This corresponds to 20 µM representing 3 % of the total 600 µM serum-bound Sia 
available in the reaction. Under these conditions, free Sia was not detected in TconTS3 reactions 
containing the acceptor lactose, even at longer incubation times and higher enzyme amounts. In  
absence of lactose however, sialidase activity was detected and 1000 ng enzyme released 0.3 
nmol free Sia in 24 h (Figure 2 F).
TconTS4  showed  faster  Sia  transfer  from  serum  donor  than  TconTS3  with  250  ng  enzyme 
producing 4  pmol  3'SL/  min  in  1  h  (Figure  2  G).  Reaction  velocity  decreased over  extended 
incubation times leading to 0.8 nmol 3'SL in 24 h.  Incubation with 1000 ng TconTS4 for 24 h 
produced 1.1 nmol (Figure 2 H). In the presence of lactose, 1000 ng TconTS4 released 0.21 nmol 
free Sia in 24 h and the amount increased to 4.5 nmol in absence of lactose (Figure 2 H).
Kinetic  parameters of  serum-bound Sia as substrate for sialidase and trans-sialidase activities 
were determined in the presence of 2 mM lactose as acceptor substrate for Sia transfer activity  
(Table 1, Figure S1 A-D). Similarly, KM and vmax values of lactose as acceptor substrate for trans-
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sialidase was determined in the presence of 600 µM serum-bound Sia (Table 1, Figure S2 A-D). In 
summary,  TconTS1 and  TconTS2  have  higher  specific  activities  than  TconTS3 and  TconTS4. 
TconTS1 and TconTS2 have lower KM values for the acceptor substrate lactose, whereas TconTS3 
and TconTS4 have lower KM for serum-bound Sia.
Kinetic parameters were also established for sialidase activities on serum-bound Sia by incubating 
under standard conditions without lactose (Table 2, Figure S3a-c). Since 250 ng TconTS3 did not 
exhibit sialidase activity within a 24 h incubation, no further reaction was set up for this enzyme. 
TconTS1 had the lowest KM (0.16 mM) followed by TconTS2 (0.41 mM). TconTS4 had the highest 
KM (1.28 mM) but lowest free Sia release from serum-bound Sia. Free Sia release by TconTS4 is  
about 50- and 80-fold less than that released by TconTS1 and TconTS2, respectively.
TconTS3  supports  an  extra  product  peak  in  chromatograms  while  TconTS2  accesses 
several other Sia types and/ or linkages on donor serum glycoconjugates 
It  was earlier  established  that  among the TconTS enzymes,  TconTS1 and  TconTS2 have the 
highest specific activities on the donor blood glycoprotein fetuin using lactose as acceptor when 
compared  to  TconTS3  and  TconTS4  [3].  It  was  speculated  on  the  basis  of  that  finding,  the 
possibility  of  substrate  selectivity  being  responsible  for  differences  in  the  specific  activities  of 
TconTS enzymes; for example, TconTS3 and TconTS4 exhibiting enhanced specific activities on 
other donor and acceptor substrates, possibly blood glycoproteins and/or glycolipids.
Utilising HPAEC-PAD analysis for quantification of TconTS reaction products described previously 
[21], it was possible to detect and differentiate sialyl- as well  as asialo-analyte peaks from the 
resulting chromatograms of the same reaction. When TconTS3 was incubated with human serum 
as donor substrate, an additional product peak was observed besides the one for 3'SL, Neu5Ac 
and lactose. This peak eluted after 3'SL, with a retention time, tR of 8 mins under the conditions 
used. So far, we could not identify this peak and without suitable standards therefore, quantification 
could only be done using peak areas. Quantification of the unknown product revealed higher peak 
areas when compared with the 3'SL peak (Figure 3 A). Like the known 3'SL, the peak areas of the  
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unknown  product  increased  with  increasing  lactose  concentrations.  Interestingly,  varying  the 
concentration of  serum-bound Sia while keeping constant that of  lactose (2 mM) favoured the 
formation of the unknown product at low serum-Sia concentrations. The unknown peak attained a 
maximum peak area at 600 µM serum-bound Sia. Above this Sia concentration, the peak area 
decreased and at serum-Sia concentration of 1200 µM, the unknown peak area became lower 
than those of  3'SL even though at  this  point,  3'SL formation  has already attained  equilibrium 
(Figure 3 B).
Control  serum  samples  usually  contained  inherent  analyte  peaks  that  were  detected  by  the 
HPAEC-PAD method used. We observed that when TconTS2 was used, at  least two of  these 
inherent  peaks labelled a  and b (Figure  4 A) had reduced peak areas over consecutive time 
counts.  No  changes  in  peak  areas  were  observed  in  the  control  serum  samples  and  those 
incubated with TconTS1 (Figure 4 B) as well as with TconTS3 and TconTS4 (not shown). Yet there 
was 3'SL formation in all the TconTS incubated samples but none in the controls. Equally, the peak 
areas of the internal standard, glucuronic acid remained unchanged over time (Figure 4 A and B), 
ruling out the possibility of losses. This indicates the ability of TconTS2 to use either different Sia 
sources or access different types/linkages.
Sialidase activities on fetuin
Sialidase activities of TconTS have been implicated in anaemia in animals suffering Trypanosoma 
infections [6,10,11] due to desialylation of erythrocytes by Trypanosoma TS enzymes. This leads to 
their clearance from the host circulatory system [13]. Serum is a complex substrate with different 
sialylated glycolipids, and glycoproteins.  As a comparative basis,  a  single substrate, the blood 
glycoprotein fetuin was used for the following reasons; (i) it is comparatively less complex allowing 
easy  comparison  and  inferences,  (ii)  it  has  been  extensively  employed  to  biochemically 
characterise the Sia transfer activities of TconTS [3,21] and (iii) though found only in foetal serum 
and may be less relevant in this respect, likely substrates like acute-phase proteins (APPs) e.g. the 
Alpha-1-acid glycoprotein (AGP) present in serum are highly sialylated and thought to play a role in 
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modulating immune and inflammatory responses [23].
Gbem et al. reported that TconTS enzymes exhibited low sialidase activities with TconTS4 showing 
the highest  activity  when fetuin was used as donor  in  TS reactions  [3].  Sialidase activities of 
TconTS1, TconTS2 and TconTS3 became detectable only when 3'SL accumulated in the reaction. 
This indicated the release of free Sia from 3'SL but not from the initial  donor substrate fetuin.  
Similarly, in the absence of lactose, except for TconTS4, sialidase activities were observed for 
TconTS1 and TconTS2 when 500ng enzyme (10-fold more than standard conditions used  [21]) 
were incubated with fetuin for 2 h.  TconTS3 did not show sialidase activity  even under these 
conditions. However, the study did not reveal vmax and KM values for sialidase activities of these 
enzymes. Equally, enzyme amounts higher than 50 ng were not incubated with fetuin for longer 
times and therefore, no definite statement could be made as to whether or not lower enzyme 
amounts could also exhibit sialidase activities.
In the present study, sialidase reactions contained approximately 600 µM fetuin-bound Sia without 
an acceptor substrate. Reaction velocities were measured at indicated time points (Figure 5 A, 
Table 3). 200 ng TconTS1 released 16,4 µM Sia in 8 h (1.7 pmol/ min). Incubations over extended 
periods up to 24 h revealed 40 µM Sia, showing reduced reaction velocity. TconTS2 showed a 
similar pattern but higher Sia release. 200 ng TconTS2 released 20 µM Sia in 8 h (2.2 pmol/ min) 
with the velocity of free Sia release decreasing with a total of 50 µM free Sia within 24 h. 250 ng 
TconTS3 released 2.8 µM Sia in 4 h (0.75 pmol/ min). Velocity decreased as prolonged incubations 
revealed a total of 12 µM Sia after 24 h. 250 ng TconTS4 released 3 µM Sia in 2 h (1.25 pmol/ 
min). At prolonged incubations up to 24 h, reactions velocities decreased until a total of 22 µM Sia 
(22 µM). Since fetuin contained 600 µM Sia, the amount of Sia available could not be responsible 
for the decrease in the velocity of Sia release. However, in typical bacteria sialidases, free Sia has 
been shown to inhibit sialidase activity [24]. Varied enzyme amounts up to 1000 ng were incubated 
for 24 h to monitor if Sia release from fetuin depended on the amount of enzyme (Figure 5 B).  
Under  these  conditions,  Sia  release  from fetuin  by  TconTS1 and  TconTS2 was  concentration 
dependent. 500 ng enzyme released 120 µM Sia (4.2 pmol/ min) and 1000 ng released 240 µM 
Sia (8.3 pmol/ min) for both TconTS1 and TconTS2. At below 500 ng enzyme amounts, differences 
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exist in the amount of Sia released by the two TconTS enzymes. At 200 ng enzyme amounts,  
TconTS1 released 2 pmol Sia/ min while TconTS2 released 2.4 pmol Sia/ min, indicating faster Sia 
release by TconTS2. The amount of Sia released by TconTS3 followed a similar pattern with those 
of TconTS1 and TconTS2 but with lower Sia amounts produced as 500 ng released 42 µM while 
1000 ng released 84 µM Sia after 24 h.  Increased Sia release was observed with increasing 
TconTS amounts. 500 ng TconTS4 enzyme released 90 µM while 1000 ng released 130 µM Sia in 
24 h.
Kinetics parameters were determined for sialidase activities of TconTS enzymes on fetuin (Tables 
1, Figure S1 A-D). To achieve this, we used 200 ng each for TconTS1 and TconTS2, and 250 ng 
each for TconTS3 and TconTS4 and incubated with 600 µM fetuin-bound Sia for 2 h for both 
TconTS1 and TconTS2, and 24h for both TconTS3 and TconTS4. TconTS1 and TconTS2 exhibited 
similar magnitudes of specific activity on fetuin (about 0.1 µmol/(min x mg TS)). This is 13- and 33-
fold higher than that exhibited by TconTS4 and TconTS3 respectively on the same substrate. KM 
values were also similar for TconTS1 (20 µM) and TconTS2 (30 µM). The KM values for TconTS3 
(137 µM) and TconTS4 (441 µM) were higher than those of TconTS1 and TconTS2.
Discussion
Trypanosoma are digenetic parasites with a life cycle that alternate between two different host 
systems; the tsetse vector and the mammalian host. Profound differences exist between these two 
systems, not least the pH. Sialidases have rather acid pH optima and are inactive at pH between 9 
and 10 [8].  The pH at which each enzyme showed highest activities was established for TconTS 
enzymes. Sialidase activities of TconTS3 and TconTS4 in absence of lactose have a pH optimum 
of 9. This is in contrast to Sia transfer activities for both enzymes with pH optima at pH 7, even  
though  the  amount  produced  is  comparatively  lower  than  those  produced  by  TconTS1  and 
TconTS2  under  similar  conditions.  Sialidase  activity  on  serum glycoconjugates  in  absence  of 
lactose for all enzymes is higher than when lactose is present (Figure 2 A-D, Table 5). Biologically, 
it is difficult to envisage a situation warranting a lack of acceptors in host systems hence sialidase 
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activities in presence of lactose are biologically more relevant. In this light, except for TconTS3 
which did not  show sialidase activity in presence of  lactose (Figure 2 F),  the remaining three 
enzymes  are  the  most  likely  candidates  responsible  for  the  release  of  free  Sia  as  has  been 
observed [10,11] in the blood of animals suffering T. congolense infections.
Considering the pH optimum for TconTS enzymes, the TS activity of TconTS2 can be expected to 
function optimally in the fly midgut. On the other hand, the sialidase activities of TconTS3 and 
TconTS4 would function optimally in the fly midgut. However, the magnitude of these activities 
differs by at least 8-folds in favour of the TconTS2 Sia transfer activity. It would be interesting to  
see the impact of a TconTS2 knockout or whose activity has been genetically modified to act as a  
sialidase in the gut of tsetse carrying Trpanosoma parasites.
In previous studies [3,21], the enzymatic activities of four TconTS gene products using fetuin as a 
model blood glycoprotein donor substrate were compared. While the use of fetuin as a substrate 
provided important insight into the biochemical diversity of these enzymes, a natural medium in 
which these enzymes operate, such as serum is ideal. Specific activity patterns were similar for 
both fetuin [3] and serum glycoconjugates in presence of lactose as common acceptor. TconTS2 
showed the highest specific activity, followed by TconTS1>TconTS3 >TconTS4 in that order (Table 
2, Figure S1 and S2). Except for TconTS4, 3'SL production for the other three TconTS enzymes is  
at least 10-fold higher in reactions involving fetuin-bound Sia  [3,21] than those in which serum 
glycoconjugates is the donor substrate. Engstler  et al. observed poor Sia transfer activity of TS 
from T. brucei  on equine serum glycoconjugates compared with other donor substrates [25]. Put 
together,  Trypanosoma trans-sialidases are poor at  transferring Sia in  a complex systems like 
mammalian  host  fluids.  In  alternative,  it  could  be  that  a  complex  pattern  of  sialylation  and 
desialylation from the diverse sources of Sia donors and acceptors respectively operates in the 
complex mammalian host environment. TconTS2 generates analyte peaks, proposed to be due to 
sialylated glycan structures (Figure 4 A) that were not observed for TconTS1 (Figure 4 B) as well 
as for TconTS3 and TconTS4 (not shown), yet there is 3'SL formation in TconTS1 (Figure 4 B), 
TconTS3 and TconTS4 (not shown). This would mean that these other enzymes utilise Sia sources 
other than the ones used by TconTS2. Interestingly, no free Sia was detected in the TconTS2 
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reaction medium up to 8 h (Figure 2 C) indicating an efficient Sia transfer to lactose and other 
acceptors present in serum. Expressing more than one TS could increase the efficiency of transfer  
onto the parasites body surface in presence of other competing acceptors. The vmax obtained for 
TconTS1 and TconTS2 from assays with varying lactose concentrations are lower than the specific 
activities  determined  by  varying  the  donor  substrate,  since  for  technical  reasons  the  donor 
substrate concentration was non-saturating (0.3- and 0.8-fold of the KM values for the serum-bound 
Sia for TconTS1 and TconTS2, respectively).
TconTS1 and TconTS2 have the highest specific activities of the TconTS variants on both fetuin [3] 
and  serum glycoconjugates.  This  however  does  not  preclude  the  possibility  of  TconTS3  and 
TconTS4 being more active on other substrates.  TconTS3 showed an additional  product peak, 
which we were unable to identify with methods used (Figure 3 A), in addition to the 3'SL peak. The 
formation of this additional product, eluting at 8 minutes, 2 minutes after 3'SL under conditions 
used, was favoured. This collaborates our earlier postulations on activities differing on the basis of 
substrates  [3]. Further, the differential formation of these unidentified product peaks at different  
serum-Sia concentrations (Figure 3 B) indicates the possibility of Sia transfer to different acceptors 
under differing Sia concentrations or the use of different Sia types and/or linkages by TconTS3. It is 
not  implausible to  envisage such a  scenario  employed by  the  parasites at  different  stages of 
infection in the mammalian life stage.
Recently, the amino acid composition in the catalytic pocket of active TconTS enzymes; TconTS2, 
TconTS3 and TconTS4 was reported [3]. When TconTS ORFs were aligned with the reference T. 
cruzi TS [26], two residues at consensus positions 293 and 494 were found substituted in the most 
active  TconTS1  and  TconTS2  but  conserved  in  the  less  active  TconTS3  and  TconTS4  [3]. 
Structural and catalysis studies [26] showed the residues in question to be essential in interacting 
with the methylumbelliferyl aglycon or the lactose-part of 3'SL. However, due to the huge variability 
in serum composition [12] it is more than likely that other suitable donor and acceptor entities exist 
in  serum that  would  present  better  side  chains  that  are  readily  utilised  by  TS enzymes.  The 
variability in serum composition is compounded across mammalian species. For example, while 
Neu5Gc is widely distributed in the animal kingdom, it is absent in the normal tissues of humans 
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[15,27,28].
Recently,  it  was  suggested that  the  lectin  domain  of  trans-sialidases  play  a  likely  role  in  the 
pathogenesis of nagana  [3,29,30]. Put together, the diverse pattern of expression, differences in 
the critical amino acids at the catalytic domain, different pH optima of TconTS gene products as 
well as structural differences in the TS enzyme structures could contribute in enhancing survival 
and establishment of infection of the parasites in the different hosts environments.
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Figure legends
Figure 1. pH optima for TconTS enzymes. Reactions to determine pH optima were carried out at 
indicated pH points as described under Methods using 100 µg fetuin (600 µM fetuin-bound Sia) in 
presence  and  absence  of  lactose.  A-B:  50  ng TconTS1 and  TconTS2 were  incubated for  30 
minutes to measure Sia transfer activities indicated by 3'SL formation, while 250 ng TconTS1 and 
TconTS2 were incubated with 600 µM fetuin-bound Sia in absence of lactose for 24 h. C-D: 250 ng 
TconTS3 and TconTS4 were incubated in presence and absence of lactose for 24 h. All  other 
experimental  conditions  are  as  stated  in  Methods.  Neu5Ac  and  3'SL  were  measured  using 
HPAEC-PAD as described under  Methods.  Data  points  are means ±  standard deviations of  3 
independent experiments, each performed in triplicates.
Figure  2.  Concentration  and  time  dependency  of  TconTS  enzymes  on  human  serum 
glycoconjugates. In concentration dependency experiments, indicated amounts of recombinant 
TconTS proteins were incubated with 600 µM serum-bound Sia in presence and absence of 2 mM 
lactose for 24 h. In the time dependency studies, 200 ng each of TconTS1 and TconTS2, and 250  
ng each of TconTS3 and TconTS4 were incubated at 37°C for the indicated times. Detection of 
3'SL represents Sia transfer activity while the presence of Neu5Ac represents sialidase activity. 
Both were determined using HPAEC-PAD analysis described under Methods. A-D: TconTS1 and 
TconTS2. E-H: TconTS3 and TconTS4. Data points are means ± standard deviations of at least 3  
independent experiments, each performed in triplicates.
Figure 3. Additional product peak observed in TconTS3 reactions. An additional product peak 
was formed by TconTS3 in addition to that of 3'SL when incubated with serum-bound Sia in the 
presence of lactose. 250 ng recombinant TconTS3 was used against a fixed concentration of one 
substrate and reactions were incubated for 12 h.  A:  Lactose variation against  600 µM serum-
bound Sia.  B: Serum-bound Sia variation against 2 mM lactose. In all cases, HPAEC-PAD was 
employed to  detect  and  quantify  reaction  products  as  described  in  Methods.  Data  points  are 
??
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means ± standard deviations of at least 3 independent experiments, each performed in triplicates.
Figure  4.  Effects  of  TconTS2  on  human  serum  glycoconjugates. 200  ng  TconTS1  and 
TconTS2 were incubated with 600 µM serum-bound in presence of 2 mM lactose for 24 h. Letters 
a, b, c and d represent unidentified glycoconjugate peaks while GlcAc represent glucuronic acid, 
used as internal  standard. A:  TconTS2 showing desialylated peaks.  B:  TconTS1 showing 3'SL 
formation without desialylation of peaks. Colours represent different incubation times: black, blue, 
pink, brown and green indicate chromatograms of products obtained after 0, 4, 8, 12, 16 and 24 h 
of incubation, respectively.
Figure 5. Concentration and time dependency of Sia release from fetuin. TconTS enzymes 
were incubated at 37oC with 600 µM fetuin-bound Sia in absence of lactose. Formation of Neu5Ac, 
indicating sialidase activity, was determined by HPAEC-PAD analysis as described under Methods. 
A: 200 ng enzyme was used for both TconTS1 and TconTS2 while 250 ng enzymes were used for 
TconTS3 and TconTS4 and incubated at 37oC over indicated times and values for 24 h incubation 
are given in Table 2.  B: Varying amounts of TconTS enzymes incubated for 24 h. In all cases, 
values are means ± standard deviations of at least 3 independent experiments replicated trice.
Supporting Information
Figure  S1.  Trans-sialidase  reaction  velocities  depending  on  serum  glycoconjugates 
concentrations. 3'SL amounts were determined as described in Methods. vmax and KM as shown in 
Table 1 were calculated from these set of data. A: 200 ng TconTS1 incubated with 2 mM lactose 
and  varying serum-bound glycoconjugates  for  2  h.  B:  200  ng  TconTS2 incubated with  2  mM 
lactose and varying serum-bound glycoconjugates for 1 h.  C. 250 ng TconTS3 incubated with 2 
mM lactose and varying serum-bound glycoconjugates for 12 h. D: 250 ng TconTS4 incubated with 
2  mM lactose  and  varying  serum-bound  glycoconjugates  for  24  h.  Data  points  are  means  ±  
1?
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standard deviations of 3 independent experiments, each as triplicates.
Figure S2. Trans-sialidase reaction velocities depending on lactose concentrations.  3'SL 
amounts were determined employing HPAEC-PAD analysis as described in Methods. vmax and KM 
as shown in Table 1 were calculated from these set of data using the software SigmaPlot11 as 
described under Methods. A: 200ng TconTS1 was incubated with 600 µM serum glycoconjugates 
and varying amounts of lactose as indicated for 2 h. B: 200 ng TconTS2 was incubated with 600 
µM serum glycoconjugates and varying concentrations of lactose as indicated for 1 h. C: 250 ng 
TconTS3 was incubated with 600 µM serum glycoconjugates and varying concentrations of lactose 
as indicated for 12 h. D: 250 ng TconTS4 was incubated with 600 µM serum glycoconjugates and 
varying  concentrations  of  lactose  as  indicated  for  24  h.  Data  points  are  means  ±  standard 
deviations of at least 3 independent experiments, each as triplicates.
Figure S3. Sialidase reaction velocities depending on serum glycoconjugates concentra-
tions.  Neu5Ac  amounts  were  determined  employing  HPAEC-PAD  analysis  as  described  in 
Methods. vmax and KM shown in Table 2 were calculated from these set of data. A: 200 ng TconTS1 
and  B:  200ng  TconTS2,  both  incubated  for  1  and  2  h  respectively,  with  varied  serum 
glycoconjugates concentration without the acceptor lactose. C: 250 ng TconTS4 incubated for 24 h 
with varied concentrations of serum-bound Sia. Data points are means ± standard deviations of 3 
independent experiments, each as triplicates.
Figure  S4.  Sialidase  reaction  velocities  depending  on  fetuin-bound  Sia  concentration. 
Neu5Ac amounts were determined employing HPAEC-PAD analysis as described in Methods. vmax 
and KM shown in Table 2 are calculated from these set of data. A: 200 ng TconTS1 and B: 200ng 
TconTS2, both incubated for 2 h with varied amounts of fetuin-bound Sia.  C: 250 ng TconTS3 
incubated for 12 h with varied amounts of fetuin-bound Sia. D: 500ng TconTS4 incubated for 24 h 
with  varied  amounts  of  fetuin-bound  Sia.  Data  points  are  means  ±  standard  deviations  of  3 
independent experiments, each as triplicates.
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Table 1. Kinetic parameters of TconTS on sialic acid transfer from serum-bound Sia
Transfer
TconTS Acceptor (lactose)* Donor substrate (serum-bound Sia)**
vmax***
(nmol/(min x mg TS))
KM***
(µM)
vmax***
(nmol/(min x mg TS))
KM***
(µM)
TconTS1f 181 ± 1.5 203 ± 16 315 ± 16 669 ± 83
TconTS2 486 ± 9.3 79 ± 7.1 1005 ± 60 750 ± 104
TconTS3 4.2 ± 1.0 1165 ± 91 5.1 ± 0.1 339 ± 25
TconTS4 2.2 ± 0.1 1321 ± 156 3.2 ± 0.1 259 ± 26
* 600 µM serum-bound Sia was used as donor substrate.
**2 mM lactose was used as acceptor substrate.
***KM and vmax were calculated from Michaelis-Menten kinetics (Figure S2 and S3) using SigmaPlot 11. Data  
points are mean ± standard deviations of three independent experiments, each as triplicates.
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Table 2. Kinetic parameters for sialidase activities of TconTS enzymes on fetuin- and serum-
bound Sia
TconTS Fetuin-bound Sia* Serum-bound Sia*
v
max
**
(µmol/(min x mg TS))
K
M 
**
(µM)
v
max
**
(µmol/(min x mg TS))
K
M 
**
(µM)
TconTS1f 85 ± 1.6 20 ± 1.5 63 ± 0.6 155 ± 7.1
TconTS2 99 ± 1.7 30 ± 1.7 105 ± 3.5 412 ± 40
TconTS3 3.2 ± 0.6 137 ± 7.5 - -
TconTS4 8.1 ± 0.3 441 ± 16 1.3 ± 0.0 1281 ± 146
* 600µM was used as substrate for both fetuin-bound Sia and serum-bound Sia.
**K
M
 and vmax were calculated from Michaelis-Menten kinetics (Figure S1 and S4) by SigmaPlot11. Data  
points are mean ± standard deviations of three independent experiments, each replicated thrice
- = no hydrolytic activity on serum
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Table 5. Relationship between sialidase and trans-sialidase activities of TconTS enzymes on 
serum glycoconjugates
TconTS Trans-sialidase* activity
(nmol/(min x mg TS)
Sialidase activity
(nmol/(min x mg TS)
TS/sialidase
- lactose** + lactose*** - lactose**** + lactose
TconTS1f 315 ± 16 63 ± 0.6 1.04 ± 0.001 5 303
TconTS2 1005 ± 60 105 ± 3.5 0.17 ± 0.0 10 5912
TconTS3 5.1 ± 0.1 n.d.***** n.d.***** >5 >5
TconTS4 3.2 ± 0.1 1.3 ± 0.0 0.31 ± 0.0001 2,5 10
* TS activity values are given in Table 1
** Sialidase activity values in absence of lactose are given in Table 1 
*** Sialidase activities in presence of 2 mM lactose were determined by incubating 1000 ng of indicated  
TconTS enzymes for 24 h with 600 µM serum-bound Sia. Data points are mean ± standard deviations of 3  
independent reactions, each in 3 replicates.
**** sialidase activity values in absence of lactose acceptor.
*****n.d. not determined, below 0.1 nmol Sia
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Abstract 
Fourteen different active Trypanosoma congolense trans-sialidases (TconTS), 11 variants of 
TconTS1 besides TconTS2, TconTS3 and TconTS4, have been described. Notably, the specific 
transfer and sialidase activities of these TconTS differ by orders of magnitude. Surprisingly, 
phylogenetic analysis of the catalytic domains (CD) grouped each of the highly active TconTS 
together with the less active enzymes. In contrast, when aligning lectin-like domains (LD), the 
highly active TconTS grouped together, leading to the hypothesis that the LD of TconTS modulates 
its enzymatic activity. So far little is known about the function and ligand specificity of these LDs. 
To explore their carbohydrate-binding potential, glycan array analysis were performed on the LD of 
TconTS1, TconTS2, TconTS3 and TconTS4. In addition, Saturation Transfer Difference (STD) 
NMR experiments were done on TconTS2-LD for a more detailed analysis of its lectin activity. 
Several mannose-containing oligosaccharides, such as mannobiose, mannotriose and higher 
mannosylated glycans, as well as Gal, GalNAc and LacNAc containing oligosaccharides were 
confirmed as binding partners of TconTS1-LD and TconTS2-LD. Interestingly, terminal mannose 
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residues are not acceptor substrates for TconTS activity. This indicates a different, yet unknown 
biological function for TconTS-LD, including specific interactions with oligomannose-containing 
glycans on glycoproteins and GPI anchors found on the surface of the parasite, including the 
TconTS itself. Experimental evidence for such a scenario is presented. 
 
Author Summary 
In this study we demonstrated the binding of TconTS lectin domains (TconTS-LD) to high-mannose 
N-glycans and provide evidence for a biological function for this interaction.  
TconTS1 and TconTS2 lectin domain bind to galactosyl as well as mannosyl glycans with different 
affinities as shown by glycan array analysis. Along this line, we have also demonstrated binding of 
TconTS-LD to high-mannose N-glycans on glycoproteins, which is competitively inhibited by the 
corresponding free high-mannose N-glycans, underlining the TconTS-LD substrate specificities. 
TconTS1 dimerisation is mediated by TconTS-LD binding to its N-glycans and enzymatic N-
deglycosylation of TconTS leads to an increase of monomers. STD NMR results obtained indicate 
that oligo-mannosylated glycans bind to TconTS-LD to a different site than lactose. In summary, 
this is good evidence that the lectin domains of TconTS1 and TconTS2 play relevant roles 
modulating the biological functions of these and possibly other trans-sialidases. Further detailed 
analysis on TconTS-LD and its role in enzyme activity will lead to a better understanding and 
possibly to new strategies against Nagana in livestock. 
 
Introduction 
The protozoan parasite Trypanosoma congolense is the most prevalent cause of animal African 
Trypanosomiasis (AAT), also called Nagana in cattle and other livestock, causing death to millions 
of animals resulting in huge economic losses [1-3]. During the parasite’s life cycle in the 
mammalian host and the tsetse fly vector T. congolense undergoes different developmental stages 
utilising various strategies to escape the defence systems of both host and vector. For instance, 
trypanosomes are unable to synthesise sialic acid (Sia) [4], instead T. congolense, like several 
other trypanosomatids, expresses an unusual glycosyl-transferase called trans-sialidase (TS) that 
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transfers Sia from host cell glycoconjugates to its own surface structures [5,6]. 
TS are found in both the African and South American trypanosomes [7-10]. However, their roles in 
parasite development and pathogenesis appear to be species dependent, as the relevance of TS 
or sialidase activities has been shown for nagana caused by T. congolense [9], but not for sleeping 
sickness caused by T. brucei ssp. The TS from Trypanosoma cruzi (TcTS), the causative agent of 
Chagas' disease in humans [11], is the best characterised [12-18] with the mechanism of sialic 
acid transfer and catalytic activity being described in detail. It has been suggested that the catalytic 
domain (CD) of TconTS is located at the N-terminus and folds into a ?-propeller structure, similar 
to that of known bacterial and viral sialidases [19-21]. The CD of trypanosomal TS is presumed to 
be linked via a well-conserved, relatively long ?-helix (22 to 25 amino acids) to a C-terminal 
domain, whose function has remained unclear. The crystal structure of TcTS [14] revealed that the 
C-terminal domain folds into a ?-barrel topology similar to that of known plant lectins such as GS4 
(Griffonia simplicifolia lectin 4) [22], GNA (Galantus nivalis agglutinin, Snowdrop lectin) [23], LOL 
(Lathyrus ochrus lectin) [24] and WGA (Wheat germ agglutinin) [25]. This structural similarity 
suggests that the C-terminal domain may be a potential carbohydrate-binding site or “lectin-like” 
domain (LD). In contrast to TcTS, only a few studies have investigated the enzymatic activities of 
T. brucei TS (TbTS) [26-29] and TconTS [6,30,31]. However, given the overall high primary 
sequence similarity of all TS at the catalytic site it can be assumed that the molecular mechanisms 
of the African TS are similar to those described for TcTS. 
In addition to several other TS-like genes, T. congolense possesses eleven TS1 (TconTS1) genes 
encoding variants with 96.3% overall amino acid identity [30]. Recombinant TconTS1 variants are 
able to desialylate fetuin in the presence of lactose to generate ?2,3-sialyllactose (3‘SL), 
demonstrating not only their TS activity but also their sialidase activity, reflecting their ability to 
hydrolyse terminal sialic acids [30]. Three additional T. congolense TS family members, TconTS2, 
TconTS3 and TconTS4, have recently been described, sharing more then 40% amino acid identity 
[31]. Furthermore, kinetic data show that all TconTS investigated so far have different affinities for 
glycoprotein and oligosaccharide substrates [30,31].  
Previous research on trypanosomal TS has been focussed on investigating the TS CD with respect 
to substrate specificities, mechanisms of sialic acid transfer and sialidase activities [6,12,14,27,30-
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34]. However, apart from sequence and structural data, limited information regarding the LD of the 
trypanosomal TS is available, with the actual function of the LD in TS remaining unknown. Due to 
structural similarities with known lectins, it had been proposed [13,35] that TS LD binds 
carbohydrates and may play a role in mediating cell adhesion. Recently, Ammar et al. suggested 
that TconTS lectin like domain binds sialic acids and is involved in endothelial cell activation [36]. 
However, to the best of our knowledge no direct evidence for carbohydrate-binding specificities of 
TS LD has been described. 
Interestingly, a detailed phylogenetic analysis comparing TS domains revealed that the TconTS-
CDs grouped the highly active TconTS together with the less active enzymes. In contrast, when 
aligning TconTS-LDs, the highly active TconTS grouped together [31], indicating a potential role of 
TconTS-LD in modulating enzyme activities.  
Here we report on the biochemical characterisation of four recombinant TconTS-LD (TconTS1-4) 
employing glycan array, STD NMR and binding/inhibition assays that identified TconTS-LD as a 
carbohydrate recognition domain (CRD), with several oligosaccharides identified as TconTS-LD 
binding partners. Interestingly, prominent ligands involved were oligosaccharides with terminal 
mannose, which are not substrates for trypanosomal TS activity, suggesting previously not 
reported biological functions. In addition, we provide strong evidence for a second binding site for 
oligosaccharides with terminal galactose moieties. 
 
Results 
Expression of recombinant TS-LD 
To characterise the LDs of TconTS the gene sequences encoding the TconTS1-LD, TconTS2-LD, 
TconTS3-LD and TconTS4-LD were subcloned into a modified pET28a bacterial expression vector 
as described under Methods. All proteins comprise a N-terminal poly histidine tag (His-tag) directly 
attached to maltose binding protein (MBP) as well as C-terminal SNAP- and Strep-tags. In these 
proteins, the tags flanking TconTS-LD can be enzymatically cleaved using the tobacco etch virus 
(TEV) and human rhinovirus 3C (HRV 3C) proteases (Fig. 1 A).  
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Fig. 1. Generated TconTS-LD proteins. A: Schematic presentation of recombinant TconTS-LD 
fusion proteins expressed in bacteria. Fusion tags flanking TconTS-LD are: His: poly histidine tag, 
MBP: maltose binding protein tag, TEV: tobacco etch virus protease cleavage site, 3C: human 
rhinovirus 3C protease cleavage site, SNAP: SNAP-tag, Strep: Strep-tag. B: Homology model of 
TconTS2-LD comprising the ?-helix calculated using TconTS2 amino acid sequence and crystal 
structure of Trypanosoma cruzi TS (PDB code: 3b69) as template employing the software Yasara. 
C: The molecular electrostatic surface of the homology model (B) was calculated using the 
ESPPME method of Yasara structure. Red colour indicates a positive potential, blue a negative 
and grey a neutral. A yellow ellipse indicates the groove encompassing the proposed binding site. 
D: SDS-PAGE of purified TconTS-LD proteins. After expression in E. coli Rosetta pLacI, 1-2 ?g 
double affinity purified recombinant TconTS-LD, containing and lacking the ?-helix, were loaded in 
each lane of an 10 % SDS polyacrylamide gel as indicated. After electrophorese, the gel was 
stained using Coomassie Brilliant Blue. 
 
Recombinant protein comprising only His-MBP-SNAP-Strep, but no TconTS-LD was used in 
control experiments. For TconTS-LD interaction studies, based on homology models (Fig. 1 B and 
C) two sets of constructs were generated with or without the ?-helix connecting CD to the LD 
(Table 1), to investigate its potential influence on binding activity. Expression conditions were 
optimised for efficient production of soluble TconTS-LD in amounts ranging from 0.5 – 2 mg/L 
bacterial culture as described under Methods. After tandem affinity chromatography employing Ni-
NTA and Strep-tag consecutively, protein purity was confirmed by gel electrophoresis and Western 
blot analysis (Fig. 1 D). All TconTS-LD were obtained as pure proteins clearly showing a migration 
shift due to the presence or absence of the N-terminal ?-helix.  
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Table 1. Bacterial and eukaryotic expressed recombinant TconTS constructs.  
        
  
Expression system  Domains 
  
 
Nr. TconTS E. coli CHO-Lec1  CD ?Hel LD Length* (AA) 
MW 
(kDa) Abbreviation 
1 1 + -  - + + 258 27.5 TconTS1-?Hel-LD 
2 1 + -  - - + 236 25.1 TconTS1-LD 
3 2 + -  - + + 263 29.3 TconTS2-?Hel-LD 
4 2 + -  - - + 238 26.5 TconTS2-LD 
5 3 + -  - + + 250 27.2 TconTS3-?Hel-LD 
6 3 + -  - - + 225 24.3 TconTS3-LD 
7 4 + -  - + + 261 28.1 TconTS4-?Hel-LD 
8 4 + -  - - + 236 25.3 TconTS4-LD 
9 1 - +  + + + 711 77.5 TconTS1 
10 2 - +  + + + 694 77.0 TconTS2 
11 3 - +  + + + 682 74.7 TconTS3 
12 4 - +  + + + 747 82.7 TconTS4 
* Length of the proteins are given in number of amino acids (AA) for the TconTS part excluding the 
N- and C-terminal tags. 
 
Screening and identification of glycans as potential TconTS-LD ligands 
Glycan array analysis was performed to identify potential TconTS-LD oligosaccharides binding 
partners. Recombinant TconTS-LD containing His and MBP fusion tags (Table 1, Fig. 1 A) were 
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pre-complexed with anti His mouse polyclonal antibody, anti mouse-IgG-TexasRed conjugated 
rabbit polyclonal antibody and anti rabbit-IgG-TexasRed conjugated donkey polyclonal antibody. 
These were then applied to glycan arrays printed onto SuperEpoxy2 glass slides comprising 367 
diverse biologically relevant glycan structures (Fig. S2). The major subset of glycans bound by 
TconTS-LD are summarised in Fig. 2 (full binding data provided in Fig. S2, Table S1). As 
expected, initial glycan array experiments revealed signals associated with maltose, maltotriose, 
isomaltotriose, maltotretraose, isomaltotetraose and related glycans due to the binding of MBP 
(Fig. S1 A). Therefore, 10 mM maltose was added as a competitor during binding and washing 
steps to inhibit the MBP interaction with maltose and related structures present on the arrays. 
Under these conditions the majority of maltose related signals disappeared. Only some signals for 
maltotriose, maltotetraose and other maltodextrins remained. Given that maltotriose has a more 
than 6-fold higher affinity for MBP (Kd: 0.16 ?M) compared to maltose (Kd: 1 ?M) [37], 10 mM 
maltotriose instead of maltose was used during binding and 1 mM in all wash steps. Under these 
conditions, binding of MBP to all remaining maltose related structures was successfully inhibited 
(Fig. S1 B). Another option that could have been used to prevent MBP associated binding to our 
glycan array would have been a proteolytic cleavage using the TEV protease cleavage site of the 
recombinant TconTS-LD protein (Fig. 1 A). However, the removal of the MBP-tag and subsequent 
purification of TconTS-LD leads to low yield of pure TconTS-LD, since often the protease digest is 
not complete. Therefore, we choose to inhibit MBP binding to maltose-related structures on the 
glycan arrays with maltotriose in the analyses of all eight TconTS-LD constructs. Glycan array 
analysis of TconTS2-?Hel-LD and TconTS2-LD showed clear binding to several different 
galactobiose and lactose containing oligosaccharides, as well as to some of their N-actetylamine 
derivatives listed in Fig. 2. Also several fucosylated, and two sialylated glycans were bound, 
although the binding to these structures was less pronounced compared to unsubstituted N-
acetyllactosamine. Whereas binding to potential TS substrates containing galactose was not 
unexpected, surprisingly, we also observed binding to ?1-6-mannobiose and ?1-3,?1-6-
mannotriose, which was similar for TconTS2-LD with and without the ?-helix. No obvious 
preference of TconTS2-LD for any of the oligomannose isomers present on the array was 
identified. The number of glycan structures bound by TconTS1-LD was lower than that observed 
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for TconTS2-LD, and no binding to any glycan structures was observed for either TconTS3-LD or 
TconTS4-LD under the conditions used.  
 
Fig. 2. Summary of TconTS-LDs binding to glycans as determined by glycan array analysis. 
TconTS-LDs binding to the glycan arrays was determined as described under Methods. Black bars 
indicate glycans bound by the TconTS-LDs. The presence and absence of the ?-helix in TconTS-
LD constructs is indicated with “+” and “-“, respectively. Further binding data (Fig. S2) and all 
glycans on the arrays (Table S1) are available as Supporting Information.  
 
STD NMR studies provide evidence for a secondary binding site in TconTS-LD 
TconTS2-LD showed the highest lectin activity on glycan arrays. Therefore, in further experiments 
we focused on TconTS2-LD to more fully characterise and confirm the binding of TconTS-LD to 
both galactose and mannose containing oligosaccharides observed on the glycan array. Several 
NMR-based methods have been employed to investigate protein carbohydrate interactions on a 
structural level. For example, line broadening and peak shifts of 1H-NMR signals from amino acid 
side chains provide information on the type of amino acids involved as well as the occupation of 
the binding site and thus equilibrium kinetic data, as has been shown for Siglec-1 [38]. Saturation 
transfer difference (STD) NMR experiments provide important information on the binding epitope of 
the complexed carbohydrate ligand, since the relative signal intensities of the difference spectra 
provide direct information on the proximity of the affected protons to the protein [39]. Protein 
signals are selectively saturated at -1.00 ppm (on-resonance) and subtracted from an off-
resonance spectrum (30 ppm) resulting in the final STD NMR spectrum revealing only protons and 
functional groups of a binding ligand that are in close proximity to the protein surface. Therefore, 
STD NMR has been widely used to analyse the binding of lectins to their specific carbohydrate 
ligands. Lactose and ?1-3,?1-6-mannotriose were used as ligands for TconTS2-LD as described 
under Methods. Fig. 3 A shows the 1H NMR (off resonance) and STD NMR spectra of ?1-3,?1-6-
mannotriose. The relative signal intensities of the STD spectrum (red line) are almost identical to 
those of the oligosaccharide 1H NMR spectrum (black line). Binding of lactose to TconTS2-LD was 
also clearly observed (Fig. 3 B). It is important to note that relatively strong STD NMR signals at 
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3.36 ppm (?-GlcH2) and at 3.92 ppm (GalH4) provide good evidence that both monosaccharide 
units of lactose are in close contact with the protein. 
Taken together, the STD NMR data confirmed binding of both lactose and ?1-3,?1-6-mannotriose 
to TconTS2-LD, which were initially identified by glycan array analysis, and raises the question as 
to whether both oligosaccharides bind to the same or distinct sites on TconTS2-LD. To try and 
address this question, an additional STD NMR competition experiment was performed, where an 
equal quantity of lactose was added to the TconTS2-LD/?1-3,?1-6-mannotriose complex. If lactose 
was able to bind to the same site as ?1-3,?1-6-mannotriose, the two oligosaccharide ligands would 
compete, which then would lead to a reduction in the STD NMR signals for one or both ligands, 
depending on their relative affinities for this site [40]. However, no such reduction was observed for 
either lactose or ?1-3,?1-6-mannotriose (Figs. 3 C and D) suggesting that both ligands are likely to 
bind simultaneously to different binding sites on TconTS2-LD.  
 
Fig. 3. STD NMR experiments of TconTS2-LD. STD NMR experiments with 5.5 µM TconTS2-LD 
were performed as described under Methods. Off-resonance (black lines) and STD NMR (red 
lines) spectra are shown. A: In the presence of 1.73 mM for 3?,6?-mannotriose; B: In the presence 
of 3.45 mM lactose; C: In the presence of 1.73 mM 3?,6?-mannotriose and 1.73 mM lactose. D: 
STD NMR effects for the signals indicated were determined as ratios between the intensities at the 
indicated ppm in the off-resonance spectra and corresponding STD NMR spectra using the 
software TopSpin 3.2. M1, M2, M3 and M4 stand for the NMR signals of 3?,6?-mannotriose, and 
L1, L2, L3 and L4 for those of lactose, for which the STD NMR effects are shown either for the 
single ligands (spectra shown in A and B) or for the mixture (spectra shown in C). n.d.: not 
determined, since in the ligands mixture the STD effect for M3 could not be determined from the 
spectra. 
 
Binding of TconTS-LD to mannosylated glycoproteins 
We established microtitre plate based binding and inhibition assays to further characterise 
TconTS-LD binding affinity and specificity. Our glycan array and STD NMR experiments revealed 
TconTS-LD binding to oligo-mannose oligosaccharides. To further investigate how this specificity 
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mediates interactions of TconTS-LD with glycoproteins, recombinant human Siglec 2 (huS2-Fc, 
described under Methods) expressed in Chinese hamster ovary Lec1 (CHO-Lec1) cells was used 
as a model glycoprotein. Due to the lack of N-acetylglucosaminyltransferase 1 (GnT1) CHO-Lec1 
cells are unable to synthesise complex and hybrid N-glycan structures. Therefore, these proteins 
contain only high-mannose glycans of the type Man5GlcNAc2-Asn [41]. Purified huS2-Fc 
immobilised in microtitre plate wells was incubated with different concentrations of TconTS2-LD 
and binding was detected as described under Methods. TconTS1-catalytic domain (TconTS1-CD) 
was used as a control for binding specificity. As shown in Fig. 4 A, concentration-dependent 
binding of TconTS2-LD to immobilised huS2-Fc was clearly observed, reaching a maximum 
intensity at approximately 2 ?g/mL TconTS2LD due to saturation of the binding sites. Wells without 
immobilised huS2-Fc were used as a control. No detectable binding to immobilised huS2-Fc was 
observed for TconTS1-CD at 4 ?g/mL (Fig. 4 A), confirming the specificity of this assay. 
To investigate whether the binding of TconTS2-LD to huS2-Fc was mediated by its high-mannose 
N-glycans, huS2-Fc was treated with Endoglycosidase H (EndoHf), a recombinant glycosidase, 
which specifically cleaves high-mannose and some hybrid oligosaccharides from N-linked 
glycoproteins [42]. Released N-glycans were then isolated and used in a 1:2 serial dilution as 
potential competitive inhibitors of TconTS2-LD binding. Fig. 4 B shows the concentration-
dependent inhibition of TconTS2-LD by the EndoHf released N-glycans. Importantly the undiluted 
purified N-glycans inhibited binding completely, demonstrating that the interaction of TconTS2-LD 
with huS2-Fc is exclusively mediated by binding to N-glycans. 
 
Fig. 4. Binding specificity of TconTS2-LD. A: TconTS2-LD concentration dependent binding to 
immobilised huS2-Fc (5?g/mL). B: Competitive inhibition of TconTS2-LD binding to huS2-Fc in the 
presents of serially diluted high-mannose N-glycans. Undiluted inhibitor solution was set to 1.0. 
The maximum increase in relative fluorescence units (RFU) over time was determined as 
described under Methods. Data points are means ± standard deviation of triplicates. 
 
Oligomerisation of TconTS 
The enzymatic activities of TconTSs were previously characterised [30,31] using recombinant 
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proteins expressed in CHO-Lec1 cells that therefore contain N-glycans of the high-mannose-type, 
similar to the recombinant huS2-Fc used here in binding/inhibition assays. N-glycosylation site 
prediction analysis revealed 8-9 potential sites in TconTSs, and none for the attached SNAP-tag 
(Fig. S3). In view of the interaction of TconTS-LD with huS2-Fc, we addressed the question of 
whether TconTS could oligomerise through binding of N-glycans. First, the presence of 
mannosylated glycans on TconTS1 and TconTS2 expressed in CHO-Lec1 cells was confirmed by 
lectin blot analysis using concanavalin A (ConA) (Fig. 5). To analyse TconTS oligomerisation we 
used gel permeation chromatography of TconTS expressed in fibroblasts. These proteins contain 
CD and LD followed by SNAP- and Strep-tags, but no His-MBP at the N-terminus. Fig. 6 A shows 
the chromatograms of recombinant TconTS1 and TconTS2 under identical conditions. A double 
peak of similar intensities was observed for TconTS1, whereas TconTS2 showed a clear single 
peak with a small shoulder in front of it. The molecular weight (MW) of the TS1 peak eluting at 13 
mL (peak 2) was 293 kDa and for that at 16.9 mL (peak 3) was 119 kDa (Fig. 6 A). This is 
consistent with peak 3 representing TconTS1 monomers and peak 2 dimers. Furthermore, a 
molecular mass of 603 kDa calculated for peak 1 eluting at 10 ml is consistent with tetramers of 
TconTS1. The deviation from the expected monomer (101 kDa without glycosylation) from the 
calculated MW (119 kDa) can be explained by increased hydrodynamic volumes (Stokes radii) of 
the oligomeric TconTS1, which is well-known to influence the elution behaviour of a molecule in 
size-exclusion chromatography [43]. Additionally, glycosylation also influences the protein elution 
behaviour. For the prominent peak of TconTS2 in Fig. 6 A eluting at 17 mL (peak 2) a MW of about 
113 kDa was calculated, which is consistent with the TconTS2 monomer (100 kDa without 
glycosylation). The small shoulder at 13.3 mL (peak 1) that represents a MW of about 260 kDa is 
consistent with the dimeric form of TconTS2 (200 kDa without glycosylation). These findings 
strongly suggest that both TconTS1 and TconTS2 exist as monomers as well as oligomers in 
solution, however at different ratios. TconTS1 showed an approximate 1:1 ratio of monomer to 
dimer, whereas TconTS2 mainly migrates as monomer under the conditions used. To address 
whether oligomerisation is mediated by N-linked glycans, TconTS1 was enzymatically 
deglycosylated using EndoHf, and the resulting oligomeric state assessed by size-exclusion 
chromatography. As shown in Fig. 5 a clear molecular weight shift as well as a reduction in signal 
Results 3.4  
 144 
  12 
intensity for ConA binding was observed, strongly indicating the release of mannose containing 
glycans from TconTS1. Subsequent gel permeation chromatography of the deglycosylated 
TconTS1 resulted in a changed elution profile (Fig. 6 B, dashed line) compared to the untreated 
protein (Fig. 6 B, solid line). Calculating the molecular weight, peak 2 of the deglycosylated protein 
in Fig. 6 B is determined as the dimeric form with 260 kDa (elution volume: 13.3 mL) and peak 3 as 
the monomer with 109 kDa (elution volume: 17.2 mL). The small differences in MW can again be 
explained by the reduced glycosylation effect on the Stokes radius after EndoHf treatment. 
Comparing the MW of monomer and dimer from the EndoHf treated sample (peak 2: 260 kDa; 3: 
109 kDa, dashed line) to those from the untreated (2: 293 kDa; 3: 119 kDa, solid line), it can be 
seen that both are decreased due to the loss of high-mannose N-glycans released by EndoHf. 
Interestingly, it was also observed that EndoHf treatment of TconTS1 reduced the abundance of 
dimers indicated by the smaller peak 1 (dashed line) in chromatogram B compared to untreated 
TconTS1 (Fig. 6 B, solid line). In summary, these results provide strong evidence for 
oligomerisation of TconTS1 by binding to its N-glycans. Similar, but less pronounced is the 
oligomerisation of TconTS2. 
 
Fig. 5. Cleavage of N-glycans from TconTS1 and TconTS2. 100 ?g TconTS1 and TconTS2 
expressed in CHO-Lec1 cells were incubated without (-) or with (+) 4000 units EndoHf glycosidase 
under native (-) or denaturing (+) conditions as described under Methods. A: 10 % SDS 
polyacrylamide gel with subsequent Coomassie Brilliant Blue staining. B: Western blot of 
deglycosylated TconTS, detected using anti-Strep-tag mAb. C: Concanavalin A (ConA) lectin blot 
using 2 ?g/mL biotinylated ConA and an peroxidase conjugated avidin-biotin system (ABC-Kit, 
VECTASTAIN) for detection. 50 ng TconTS sample were used for ConA and Wester blot analysis 
and 800 ng for SDS-PAGE. 
 
Fig. 6. Oligomerisation of TconTS. Size exclusion chromatography on Superdex200 column and 
detection at E280nm was used, MWs of different peaks were determined and assigned to oligomeric 
(1), dimeric (2) and monomeric (3) TconTS1 as described under Methods. A: Oligomerisation 
pattern of TconTS1 (solid line) or TconTS2 (dashed line), 300 ?g protein was loaded. B: Effect of 
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TconTS1 deglycosylation on enzyme oligomerisation. 100 ?g TconTS1 were deglycosylated using 
4000 units EndoHf glycosidase in phosphate buffer pH 7.4 for 4 hours and directly applied to the 
column (dashed line). As control 100 ?g TconTS1 was treated correspondingly without the addition 
of enzyme was loaded (solid line). 
 
Discussion 
Lectin domains (LD) of the four TconTS1-4 were expressed and characterised with respect to their 
ability and specificity to bind carbohydrate structures. Structural comparison to other known 
bacterial (Salmonella typhimurium LT2) [44] and viral (Vibrio cholerae neuraminidase) [45] 
sialidases, as well as to plant lectins (Griffonia simplicifolia lectin 4, GS4; Lathyrus ochrus lectin, 
LOL) [22,46] provided structural evidence for potential carbohydrate-binding of TconTS-LD. 
Besides typical structural elements seen for several lectins, such as the ?-barrel topology, each 
TconTS-LD also comprises a cluster of histidine, phenylalanine and arginine residues in its 
potential binding site, a rather shallow indentations (Fig. 1 C). These could presumably be involved 
in carbohydrate recognition via aromatic side-chain and sugar ring interaction as well as hydrogen 
bonding, as described for other lectins [47]. Furthermore, it is noticeable that this potential TconTS-
LD carbohydrate-binding site is oriented in the same direction as the TconTS-CD catalytic site, 
similar to T. cruzi TS, T. rangeli SA and leech IT-sialidase [14,35,48]. This structural organisation 
of TconTS-CD and LD appears to be stabilised by a relatively extended close contact site between 
both domains comprising a network of hydrogen bonds and complementary hydrophobic patches 
(Fig. 7). 
 
Fig. 7. Contact site between TconTS-CD and LD. Homology model of TconTS1 was calculated 
using the crystal structure of TcTS (PDB: 3b69) as template and the software Yasara. Molecular 
surface of TconTS1 was calculated using the surface module of Yasara Structure. Illustrated are 
the parts of TconTS-CD (yellow) and LD (orange), which are in close contact to each other. The ?-
helix connecting both domains is shown in blue. 
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We have identified TconTS-LD as a carbohydrate-binding domain. Employing glycan arrays, 
TconTS2-LD showed binding to a variety of oligosaccharides (Fig. 2), whereas only a few of the 
glycans presented on the arrays were bound by TconTS1-LD, and none by TconTS3-LD or 
TconTS4-LD. It remains unclear, why only TconTS1-LD containing the ?-helix at its N-terminus 
showed binding activity in the glycan array experiments. One explanation could be that folding or 
the accessibility of the binding site is compromised for TconTS1-LD without the ?-helix serving as 
a spacer to the N-terminal MBP tag. It appears unlikely, that the ?-helix is directly involved in 
binding activity, since the binding pattern and signal intensities for TconTS2-LD were not 
influenced by the presence of the ?-helix. Furthermore, our binding assay data (Fig. 3 A) have 
provided evidence that TconTS1-LD also binds high-mannose glycans, which were not available 
on the glycan arrays, besides 1N and 4D. In addition, EndoH treatment reduced oligomerisation of 
TconTS1. Finally, it should also be pointed out that most of the differences in amino acid sequence 
among the 11 TconTS1 gene variants occur in the LD and are clustered close to the postulated 
binding site [30]. Therefore, it may well be possible that the other TconTS1-LD variants, besides 
the TconTS1a-LD used in this study, have different carbohydrate-binding specificities. Interestingly, 
variants that differ only in this cluster (TconTS1b and TconTS1e) have different kinetic properties 
for the trans-sialylation reaction, which further supports the hypothesis that TconTS-LD modulates 
also the enzymatic activities. This may also explain the low enzymatic activity of TconTS3 and 
TconTS4, since no carbohydrate-binding activity was observed for TconTS3-LD and TconTS4-LD. 
However, as discussed above for TconTS1-LD, TconTS3-LD and TconTS4-LD may bind to 
carbohydrate structures not present on the glycan arrays. In this context it should be kept in mind 
that the amino acid sequence diversity of TconTS-LDs (Table S2) is high enough to allow different 
binding activities. Furthermore, the structures of spacers used to immobilise the glycans may have 
prevented binding of TconTS3-LD and TconTS4-LD, since these affect lectin binding to glycan 
arrays [49,50]. However, given the diverse spacer structures and lengths utilised here, it appears 
less likely that binding would have escaped detection. Finally, we cannot exclude the possibility 
that insufficient folding of TconTS-LDs in the bacteria during expression is the reason for 
undetected lectin activity. 
According to a phylogenetic analysis comparing separately TconTS-LDs and TconTS-CDs [31] 
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TconTS1-LD and TconTS2-LD are more closely related with each other than TconTS3-LD and 
TconTS4-LD. However, when comparing CDs, TconTS2-CD is more closely related to TconTS3-
CD and TconTS4-CD, but least to TconTS1-CD. Interestingly, the highest enzyme activities of 
TconTS were found with TconTS1 and TconTS2, whereas TconTS3 and TconTS4 were 100- or 
1000-fold less active [31]. Together with the carbohydrate-binding activities of TconTS1-LD and 
TconTS2-LD described in this study, it can be postulated that LDs may directly influence enzyme 
activities. In agreement with this hypothesis is the observation that disrupting a salt bridge between 
R642 and E648 in the LD of T. cruzi TS enhanced trans-sialidase relative to sialidase activity 
[35,51]. Along this line it could be postulated that binding of oligosaccharide substrates to TconTS 
via oligomannose clusters may lead to an improved presentation of the terminal acceptor 
galactose residues towards the active centre of the CD and therefore lead to an enhanced catalytic 
efficiency.  
Ammar et al. recently demonstrated that TconTS can induce activation of endothelial cells [36] and 
assumed that the TconTS-LD may be involved in this process. In this context, they prepared a 
mutant (Y438H) of TconTS1 (TcoTS-A1 according to their nomenclature) to prevent transfer 
activity. Since this mutant competed with Mal (Maackia amurensis lectin) binding to ?2,3-linked Sia 
of the surface of endothelial cells, they concluded that lectin binding to cell surface carbohydrates 
play the key role in endothelial cell activation. Based on our data regarding the carbohydrate-
binding specificities of TconTS-LD, it appears unlikely that the LD mediates the activation of 
endothelial cells. However, their findings are in agreement with an involvement of the CD. 
TconTS2-LD binds structures containing mannose, such as ?1-6-mannobiose and ?1-3,?1-6-
mannotriose (Fig. 2) and several galactose and lactose containing oligosaccharides. Given that the 
few fucosylated and sialylated glycans recognised by TconTS2-LD all possess core galactose, 
lactose or N-acetyl-lactoseamine units, it can be assumed that fucosylation and/or sialylation at 
least in some positions does not interfere with binding. For example, when fucose is linked to 
positions of the glycan, which is more solvent exposed, it will not disturb ligand binding.  
Binding of TconTS-LD to galactosyl, lactosyl and potentially also sialyl glycans was not completely 
unexpected, since they also serve as substrates for TconTS [6,30,31] and lectin-like binding to 
sialidase substrates is not uncommon. For example, the lectin-like domain of Vibrio cholerae 
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sialidase (VCS) binds N-acetylneuraminic acid in a similar manner compared to the catalytic 
domain but without hydrolytic activity [52].  
Engstler et al. 1995 investigated procyclic TconTS substrate specificity using a selection of 
sialylated donor substrates and galactosylated acceptor substrate oligosaccharides, including the 
monosaccharide mannose, as substrates for TS [5]. Whereas transfer of Sia to terminal galactose 
oligosaccharides and even the monosaccharide galactose was observed, mannose did not appear 
to be a suitable acceptor for sialic acid transfer. Thus, our discovery that TconTS-LD binds to 
mannosylated oligosaccharides suggests a yet unknown function of the LD, distinct from that of the 
CD. The overall ligand specificities of TconTS-LD, binding to both mannosylated as well as 
galactosylated glycans, but not to glucose containing oligosaccharides (Fig. 2, Fig. S2), differs from 
that of other mannose-specific lectins, such as concanavalin A (ConA, Canavalia ensiformis) 
[53,54], LOL (Lathyrus ochrus lectin) [24] or GNA (Galantus nivalis agglutinin, Snowdrop lectin) 
[23]. In contrast to mannose and glucose, which both show equatorial orientation of the C4-OH 
group, in Gal the orientation of C4-OH is axial, which does not support binding to ConA or LOL, 
since C4-OH is involved in carbohydrate recognition by these lectins. Similarly, GNA specifically 
binds Man via an essential hydrogen bond to its C4-OH group. Considering these ligand selection 
mechanisms, it appears more likely that two structurally independent binding sites provide 
TconTS2-LD binding to both mannose- and galactose-containing oligosaccharides. This 
hypothesis is supported by our STD NMR data that clearly indicate that lactose and ?1-3,?1-6-
mannotriose do not compete for the same site on TconTS2-LD. According to published STD NMR 
data for lactose [55] and ?1-3,?1-6-mannotriose [56], it could be concluded that both moieties of 
lactose interact with TconTS2-LD, at least partially. For example, this is indicated by the ?Glc-H2 
and ?Gal-H4 protons of lactose (Fig. 3 B). All signals observed in the off-resonance spectrum of 
?1-3,?1-6-mannotriose could also be identified in the STD NMR spectra, showing no clear 
preference for any proton. This indicates specific binding and that all three mannose units appear 
to be in close contact with the protein. A similar binding epitope of ?1-3,?1-6-mannotriose has 
recently been described for the antibiotic Pradimicin S [56]. The binding epitope for lactose is less 
uniform, suggesting that not all protons of the disaccharide are in the same close contact with the 
protein. The exception constitutes the ?Glc-H2-proton, for which a two-fold higher STD signal 
Results 3.4  
 149 
  17 
intensity was observed compared to several other protons with similar STD effects than most of the 
protons of ?1-3,?1-6-mannotriose (Fig. 3 D). This finding might be explained by selective 
interaction of the ?Glc configuration of lactose with TconTS2-LD. An important result was that the 
STD NMR effects of both oligosaccharides were independent of the presence of the other ligand, 
since they were identical, if TconTS2-LD was incubated with an equimolar mixture, to those 
obtained for the individual compounds. If they did compete for the same site, reduced STD NMR 
signals would have occurred for either both ligands, if they bind with similar affinities, or at least for 
that ligand, which binds with much lower affinity, if they bind with different affinities [40]. It can be 
excluded that the STD NMR signals of lactose or ?1-3,?1-6-mannotriose reflect interactions with 
the MBP tag, since no binding of MBP to these structures have been observed in our glycan array 
experiments, which is in agreement with previous studies on MBP specificity applying diverse 
methods [57,58] including STD NMR [59]. In conclusion, our findings suggest that two distinct 
binding sites exist on TconTS2-LD, similar to the lectins WGA [60] and GNA [23]. 
Interestingly, in a previous STD NMR study TcTS binding to lactose was only observed in the 
presence of Neu5Ac [16]. Apparently, TcTS and TconTS2-LD have different carbohydrate-binding 
activities, since TconTS2-LD clearly binds to lactose and ?1-3,?1-6-mannotriose in the absence of 
Sia. Furthermore, the binding epitope for lactose in complex with TconTS2-LD is distinct from that 
observed for TcTS [16], most pronounced is this difference for the STD NMR signal of ?Glc-H2, 
which was not observed for TcTS. This further underlines that the binding site for lactose on 
TconTS2-LD is distinct from the acceptor-binding site of the CD described for TcTS. 
The crystal structure of TcTS [14] revealed that the binding pocket of the catalytic domain is 
located at the same side as carved ?-barrel groove of the lectin domain, in which conserved 
histidine and tyrosine residues were identified, known to be involved in carbohydrate recognition of 
other lectins [47]. Therefore, we assume this position to be the potential carbohydrate-binding site 
on TconTS-LDs. Furthermore this hypothesis is in agreement with our data assuming TconTS-LD 
interacts simultaneously with more then just one monosaccharide, suggesting an extended binding 
site, also termed sub-site multivalency [61]. However, detailed structural studies, such as X-ray 
crystallography of TconTS2-LD with these oligosaccharide ligands are required to locate and 
investigate these binding sites precisely.  
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For several lectins it has been reported that oligomerisation enhances binding due to interactions 
of multivalent glycoconjugate ligands to multiple binding sites of oligomeric lectins [47,62,63]. Also 
for TconTS1-LD and TconTS2-LD multivalent interactions in larger complexes strengthen binding 
to the target glycoprotein, since in our binding/inhibition assays pre-complexing of TconTS-LD with 
the anti His-tag mAb and the corresponding secondary antibodies used for detection lead to 
stronger signals compared to applying every component in consecutive steps (Fig. S4 A and B). 
By large, this binding is mediated by the high-mannose N-glycans of huS2-Fc, since it could be 
inhibited with N-linked oligosaccharides, enzymatically released from recombinant huS2-Fc, as 
competitive inhibitors. Interestingly, for the monosaccharide ?-methyl-mannopyranoside, which is a 
well-known inhibitor for ConA [64], only slight inhibition of TconTS-LD binding could be observed at 
50 mM (Fig. S4 C). This evidence for binding towards complex oligosaccharide ligands was 
already reported earlier for several other lectins, including the lectin GS4 (Griffonia simplicifolia 
lectin IV), which shows high affinity to poly- but not to monosaccharides [47,65]. This mechanism, 
providing poor affinities for lectins to monosaccharides, prevents unspecific interference from 
competing, structurally similar molecules and enhances ligand selectivity. In addition, recombinant 
TconTS enzymes expressed in CHO-Lec1 cell lines contain these N-linked high-mannose-type 
oligosaccharides. Eight to nine potential N-linked glycosylation sites are found in recombinant 
TconTS, distributed over CD and LD. As expected, lectin blot analysis using ConA, for detection of 
mannose oligosaccharides, clearly confirmed the presence of N-linked mannosylated glycans on 
recombinant TconTS expressed in CHO-Lec1 cells (Fig. 5). Recombinant TconTS exhibit much 
higher enzyme activity, if expressed in these fibroblasts compared to those expressed in bacteria 
(Fig. S4 D). This is possibly related to the absence of N-glycosylation in bacteria, which may have 
an indirect effect on enzyme activity by influencing proper enzyme folding or even directly by 
glycan mediated TconTS oligomerisation. In agreement with the latter scenario, binding to N-linked 
mannosyl oligosaccharides of recombinant TconTS expressed in CHO-Lec1 cells leads to 
oligomerisation. This conclusion is supported by (1) the observation that TconTS1 elutes in about 
equal amounts as monomer and as dimer in size exclusion chromatography (Fig. 6 A) and (2) that 
the removal of N-linked glycans with EndoHf glycosidase leads to a clear shift from the dimer 
towards the monomeric form of TconTS1 (Fig. 6 B). The remaining dimers are likely to be due to 
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inefficient deglycosylation, as suggested by ConA lectin blot analysis (Fig. 5) or due to other 
carbohydrate-independent protein-protein interactions. It remains unclear as to why TconTS1 
oligomerises to a larger extent than TconTS2. One possible explanation may be differences in the 
glycosylation pattern of the two recombinant enzymes. That is, potential N-glycosylation sites are 
distributed differently in both enzymes with nine potential sites for TconTS1, eight for TconTS2, 
only one site being conserved. Finally, it should be mentioned that it is also unclear, which of the 
predicted N-glycosylation sites of recombinant TconTS utilised in this work are actually 
glycosylated. In addition, it should be noted that the glycosylation pattern of the native TconTS is 
unknown as well. 
Based on the finding that TconTS-LD binds to high-mannose-type N-glycans we assumed that 
glycoconjugates containing high mannosylated structures might be preferred natural acceptor 
substrates for TconTS. Interestingly, such high-mannose-type glycans have been identified on the 
surface of T. congolense in both, bloodstream (mammalian host) and procyclic (tsetse vector) 
forms, either linked to amino acids or as part of the GPI anchors [66-69]. The African parasites 
express two major stage specific, glycosylphosphatidylinositol (GPI)-anchored glycoproteins on 
their surfaces, the variant surface glycoprotein (VSG) of the bloodstream form and procyclins of the 
procyclic form. During development of the bloodstream form (BSF) in the mammalian host, the 
parasites express a surface coat composed of hundreds of immunologically distinct VSG 
molecules (antigenic variation) to evade host immune response. These VSGs share relatively little 
primary sequence homology [70] but are structurally related to each other [71]. It has been 
demonstrated that VSGs from T. congolense and T. brucei BSF are highly glycosylated, exhibiting 
glycan structures similar to those of higher eukaryotic N-linked oligosaccharides. Interestingly, they 
are composed of N-linked high-mannose-type oligosaccharides (Man5-9) and N-acetyllactosamine 
oligosaccharides, as well as branched poly-N-acetyllactosamine oligosaccharides with a Man3-4 
core (GalGlcNAc)3Man3GlcNAc, which were also found to be sialylated in T. congolense [72-74]. 
The fact that terminal Sia were found on VSGs indicate that these are substrates for TS present on 
the cell surface. In this context, it is plausible, that TconTS-LD contributes to the binding of T. 
congolense VSG to TconTS via oligomannose oligosaccharides present on these glycoproteins. 
When parasites are taken up by tsetse fly through a blood meal, VSGs are replaced by procyclic 
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stage specific, membrane bound, major surface proteins known as procyclins or procyclic acidic 
repetitive proteins (PARP) [75,76] in T. brucei and glutamic acid/alanine-rich protein (GARP) in T. 
congolense [66-68,77]. Interestingly, compared to the highly N-glycosylated T. brucei BSF VSGs, 
procyclins only contain a single N-glycosylation site, substituted with oligomannose 
oligosaccharide Man5GlcNAc2, which is unusual and rare, but not unique [78]. The primary 
sequence of T. congolense procyclic GARP does not contain a single potential N-glycosylation 
site, which was also experimentally confirmed, as well as the absence of conventional O-linked 
glycans [77]. However, two large Man and Gal-rich oligosaccharides of the type Man11Gal6-7 linked 
via phosphodiester bonds to two threonine residues were found [77]. Considering these findings, 
GARP may also be a potential binding partner for TconTS-LD. Indeed, TconTS-mediated 
sialylation of GARP has been demonstrated and even procyclin was equally efficiently sialylated by 
the same enzyme, indicating their functional similarities at least as substrates for TS [5]. However, 
sialylation of procyclin occurs at the glycan moiety of its GPI anchor [26], which has been 
structurally characterised [79-81]. They share the common core structure of GPI anchor EtNH2-
HPO4-6Man(?1–2)Man(?1–6)Man(?1–4)GlcNH2(?1-6)-PI, but with an additional glycosylation at 
the Man3-core, which is unique for African trypanosomes [80,81]. It comprises oligolactosamine 
oligosaccharides (Gal-GlcNAc)9 for T. brucei procyclin GPI anchors and oligogalactosyl 
oligosaccharides Gal5-7 for T. congolense, which both represent substrates for trans-sialylation 
[77,80]. In this context it is important to note that GARP was co-purified and co-immunoprecipitated 
with TS-form 1 from procyclic cultures of T. congolense [6], indicating a relatively strong interaction 
between these two surface proteins. It is in complete agreement with the data of this study that this 
interaction is mediated by TconTS-LD binding to the GPI anchor Man3-core of GARP, since 
binding to similar oligomannose oligosaccharides like Man(?1–3)Man and Man(?1–6)Man was 
observed by glycan array and STD NMR analysis. Homology models of TconTS1-4 revealed, that 
the distance between the catalytic tyrosine residue in the active centre of TconTS-CD and a 
conserved phenylalanine residue in the predicted TconTS-LD carbohydrate-binding site, ranges 
from 40.5 to 42.6 Å. With an average diameter of 7 Å for a single hexose unit, an oligosaccharide 
of minimum 6 monosaccharide units from the Man3-core is needed to reach the catalytic centre of 
TconTS-CD, depending on the glycosidic linkage of the oligosaccharide. Consistent with this, the 
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oligosaccharide Gal5-7 of the GARP GPI-anchor has the appropriate size to reach the catalytic 
centre when TconTS-LD is bound to the Man3-core. In this case both TconTS domains could 
interact simultaneously with different sections of the same oligosaccharide, whereby the binding 
affinities of each domain contribute to the overall TconTS binding affinity, which is then clearly 
enhanced, consistent with the observed co-purification of TS-form 1 with GARP from T. 
congolense cultures [6]. This would be somewhat similar to the situation reported for the Vibrio 
cholerae sialidase, where Neu5Ac binds to a lectin domain without hydrolytic activity, leading to an 
increased affinity of the enzyme for highly sialylated regions [52]. In addition, the apparent 
organisation of the two native TS-forms isolated by Tiralongo et al. [6], who observed TS-form 2 as 
dimers and TS-form 1 as oligomers is in very good agreement with the oligomannosyl 
oligosaccharide-mediated interaction of recombinant, high-mannosylated TconTS1 and TconTS2. 
It should be noted that these are not identical to purified TS-forms 1 and 2 described by Tiralongo 
et al. [6]. Furthermore, T. brucei TS has been previously purified by ConA affinity chromatography 
from procyclic trypanosomes, suggesting that also this TS is highly mannosylated in its native state 
on the parasite [27]. 
In summary, we identified TconTS1-LD and TconTS2-LD as a carbohydrate recognition domain 
(CRD), exhibiting different binding affinities to several oligogalactosyl, oligolactosamine and 
oligomannosyl glycans, via two independent binding sites. Functionally, the interaction with specific 
oligomannosyl structures appears to be required to facilitate TconTS oligomerisation, and binding 
to oligogalactosyl and oligolactosamine oligosaccharides may represent the recognition event 
associated with TS acceptor substrate binding. Since the LD from T. congolense, T. brucei, T. cruzi 
and potentially other trypanosomes are structurally related, this may be a general function of TS-
LD and may open new avenues for the design of novel inhibitors for therapeutic applications 
controlling trypanosomiasis in Africa and Latin America. 
 
Methods 
Materials 
All chemicals and reagents used in this study were analytical grade. Recombinant EndoHf 
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glycosidase (EndoHf) was from New England Biolabs, UK. Pfu and Taq DNA polymerase, HindIII, 
NcoI, NotI, SalI Fast Digest restriction enzymes, T4-DNA ligase, isopropyl-?-D-1-
thiogalactopyranoside (IPTG), Dithiothreitol (DTT), Coomassie Brilliant Blue (Page Blue), protein 
molecular weight marker (PageRuler), GeneJET DNA Gel Extraction Kit, BCA Protein Assay Kit, 
enhanced chemiluminescence system (ECL-Kit), fluorescein diphosphate tetraammonium salt 
(FDP), Luria Broth (LB) microbial growth medium, anti His-tag mouse polyclonal antibody, anti 
mouse-IgG-alkaline phosphatase-conjugated donkey polyclonal antibody (serum purified) were 
from Thermo Scientific, Germany. Biozym LE Agarose was from Biozyme Scientific, Germany. 
StrepTactin Sepharose, purification buffers and anti Strep-tag rabbit polyclonal antibody were from 
IBA, Germany. Anti mouse-IgG-TexasRed conjugated rabbit polyclonal antibody, anti rabbit-IgG-
TexasRed conjugated donkey polyclonal antibody were purchased from Life Technologies. ?-D-
galactosyl-(1-4)-?-D-glucose (4?-lactose), ?-D-galactosyl-(1-4)-?-D-N-acetylglucosamine (4?-N-
acetyllactosamine), 4-?-D-maltose, ?-D-glucopyranosyl-(1-4)-?-D-glucose (4?-maltose), ?-D-
glucopyranosyl-(1-4)-?-D-glucopyranosyl-(1-4)-?-D-glucose (4?-maltotriose), ?-methyl-D-mannose, 
?-D-mannosyl-(1-2)-D-mannose (2?-mannobiose), ?-D-mannosyl-(1-3)-D-mannose (3?-
mannobiose), ?-D-mannosyl-(1-4)-D-mannose (4?-mannobiose), ?-D-mannosyl-(1-6)-D-mannose 
(6?-mannobiose), ?-D-mannosyl-(1-3)-[?-D-mannosyl-(1-6)]-D-mannose (3?,6?-mannotriose), 
polyethylene glycol sorbitan monolaurate (TWEEN 20), Gel Filtration Markers Kit for protein 
molecular weights between 29,000-700,000 Da were from Sigma-Aldrich, Germany. Concanavalin 
A (ConA), Sepharose and biotinylated recombinant ConA were purchased from Galab, Germany. 
VECTASTAIN ABC detection system was from Vector laboratories, UK. Ultrafiltration units Vivacell 
and Vivaspin6 were from Sartorius, Germany. X-ray film was purchased from GE Healthcare, 
Sweden. Protino Ni-NTA Agarose and NucleoBond Midi Plasmid DNA Purification Kit were from 
Macherey-Nagel, Germany. Polyvinylidenedifluoride (PVDF) membranes were from Millipore, 
Germany. 96-well transparent microtitre plates were from Sarstedt, Germany. High binding 384-
well black microtitre plate were purchased from Corning, USA. 6 mL gravity flow columns were 
from Biorad, Germany. 
 
Cloning and expression of recombinant TconTS-LD 
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To obtain non-glycosylated TconTS-LD as recombinant proteins in sufficient amounts, a bacterial 
expression system based on a modified pET28a+ expression vector was established. 
Modifications made comprised an N-terminal poly-histidine-tag (His-tag) followed by maltose 
binding protein (MBP) and a tobacco etch virus (TEV) protease cleavage site [82]. MBP was used 
to enhance expression and solubility of TconTS-LD in E. coli. SNAP- Strep- and His-tags were 
employed for affinity purification, detection and immobilisation of recombinant protein as previously 
described [30,31] The DNA sequence encoding the His-MBP part was amplified form pETM-41 
(EMBL, Germany) using Pfu DNA polymerase and the appropriate primers (Table S3). The purified 
PCR products were ligated into the NcoI and SalI digested pET28a (Novagene, USA) bacterial 
expression vector and transformed into chemical competent E. coli BL21 (DE3)(BD Bioscience, 
Clonetech, USA). Sequence identity was confirmed by commercial sequencing at the Max Planck 
Institute for Marine Biology (MPI) Bremen and results were evaluated using the Geneious 
Software.  
The modified eukaryotic expression pDEF-based vectors coding for TconTS1, TconTS2, TconTS3 
and TconTS4 [30,31] were used as template to amplify TconTS1-LD, TconTS2-LD, TconTS3-LD 
and TconTS4-LD containing C-terminal SNAP and Strep tags. Two sets of sense primers were 
designed for each TconTS variant (Table S3). The same reverse primer including a NotI restriction 
site (underlined) was used for all TconTS-LD constructs, since all TconTS-LD constructs contain 
C-terminal Strep-tag. Purified PCR-products were ligated in frame into the HindIII and NotI 
digested, modified pET28aMBP vector and transformed into E. coli Rosetta (DE3) pLacI (BD 
Bioscience, Clonetech, USA). Plasmid preparations of pET28aMBP/TconTS-LD were prepared 
and characterised as described above. 
E. coli Rosetta (DE3) pLacI colonies freshly transformed with pET28aMBP/TconTS-LD were 
inoculated in 20 mL of 50 ?g/mL kanamycin containing Luria Broth (LB) medium and incubated 
overnight at 37°C and 240 rpm shaking. 2 mL of these overnight cultures were transferred into 1 L 
of 50 ?g/mL kanamycin containing LB medium and grown at 37°C and 240 rpm until an optical 
density at 600 nm of 0.5 was reached. Recombinant protein expression was then induced by the 
addition of isopropyl-?-D-thiogalactopyranoside (IPTG), with a final concentration of 0.1 mM and 
cells were incubated for additional 120 min at 37°C and 240 rpm. Cells were harvested by 
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centrifugation for 15 min at 1500 x g, 4°C and the pellet was resuspended in 20 mL lysis buffer 50 
mM NaH2PO4, pH 8.0, 300 mM NaCl. Lysis was done by ultrasonication on ice applying 9 pulses of 
20 sec each (50 Watts) with 10 sec pauses between pulses. The bacterial lysates were centrifuged 
for 30 min at 15000 x g, 4°C. Clear supernatants were transferred to 4 mL of equilibrated Ni-NTA 
beads and incubated on a rotation wheel (6 rpm) at 4°C for 120 min. The suspensions were 
transferred to 6 mL gravity flow columns in portions, until all beads were settled in the column. 
Beads were washed with 40 mL wash buffer containing 50 mM NaH2PO4, pH 8.0, 150 mM NaCl, 
20 mM imidazole. Recombinant TconTS-LD was eluted using 250 mM imidazole in 50 mM 
NaH2PO4, pH 8.0, 150 mM NaCl and directly applied to a new gravity flow column containing 1.6 
mL StrepTactin beads equilibrated with wash buffer (100 mM Tris-Cl, pH 8.0, 150 mM NaCl and 1 
mM EDTA) and beads were washed with 5 column volumes of wash buffer. Recombinant proteins 
were eluted with wash buffer containing 2.5 mM desthiobiotin and dialysed against 10 mM 
phosphate buffer, pH 7.4 using a Vivaspin6 filtration unit with a 100 kDa cut off. Purified TconTS-
LD was characterised by SDS-PAGE and Western blot analysis and quantified by BCA assay 
using bovine serum albumin (BSA) as standard. 
T. congolense recombinant TconTS1 and TconTS2 containing catalytic (CD) and lectin domain 
(LD) expressed by CHO-Lec1 cells were prepared from culture supernatants and characterised 
using SDS-PAGE, Western Blot and BCA assay analysis as described [30]. 
 
Glycan Array 
Glycan arrays consisting of 367 diverse glycans with and without the presence of one of three 
spacers (sp2, sp3 or sp4 [49]) were prepared from two previously described glycan libraries 
[83,84]. Amine containing glycans with spacer’s sp2, sp3 or sp4 were synthesised as previously 
described [49] and glycans without spacers were amine functionalised as previously published 
[85]. All glycans were suspended in 1:1 DMF:DMSO at a concentration of 500 mM and were 
printed onto SuperEpoxy 2 glass slides (ArrayIt, Sunnyvale, CA) using a ArrayIt SpotBot Extreme 
array spotter in a six pin subarray print per glass slide format. All glycans were printed in replicates 
of four, including four FITC control spots as well as additional position controls (Fig. S1), per 
subarray using SMP4 pins and a contact time of 1 second at 60% relative humidity, with pins being 
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reloaded after every 12 spots. 
Prior to performing glycan array experiments, slides were scanned using a ProScanArray 
Microarray 4-laser scanner (Perkin Elmer, Waltham, MA) using the blue argon 488 laser set to the 
FITC settings (492 nm excitation and 517 nm emission). Array slides were blocked with 0.1 % BSA 
in 50 mM phosphate buffered saline (PBS), pH 7.4 for 5 min at 22°C. After washing with PBS, 
each slide was dried by placing them in an empty 50 mL tube and centrifuging for 5 min at 200 x g 
(900 rpm). Recombinant TconTS-LD (2 ?g) was incubated at a molar ratio of 1:2:3 with anti His-tag 
mouse polyclonal antibody (10 mg/mL, Cell Signalling Technology), anti mouse-IgG-Alexa555 
conjugated rabbit polyclonal antibody (2 mg/mL, Life Technologies) and anti rabbit-IgG-Alexa555 
conjugated goat polyclonal antibody (2 mg/mL, Life Technologies) in 50 mM PBS, pH 7.4 
containing 0.1 % BSA and 10 mM maltotriose for 15 min on ice protected from light. All subarrays 
on the slide were isolated using a Gene Frame (1.5 x 1.6 cm, 65 ?L, Abgene, Epsom, UK) prior to 
the addition of the TconTS-LD-antibody mix to the array. A coverslip was applied to the 
GeneFrame and array slides incubated for 30 min at 22°C in the dark. The GeneFrame and 
coverslip were subsequently removed and the slide gently washed twice with 50 mM PBS, pH 7.4 
containing 0.01 % TWEEN 20 and 10 mM maltose, and once with 50 mM PBS, pH 7.4 containing 
10 mM maltose. Slides were dried by centrifugation for 5 min at 200 x g (900 rpm), allowed to air 
dried for a further 5 min, and the fluorescence associated with the array spots detected using the 
microarray scanner settings outlined above. Image analysis and spot visualisation was performed 
using the ProScanArray software, ScanArray Express (Perkin Elmer). The resulting images were 
visually examined. Fluorescence signals were judged as being positive, if all four replicates for a 
glycan were clearly detectable (Fig. S1). 
 
STD NMR 
TconTS2-LD was several times buffer exchanged to 10 mM deuterated phosphate buffer, pD 7.4 
using a Microcon centrifugal ultrafiltration device (cut off 10 kDa). 200 ?L of a solution containing 
5.5 ?M TconTS2-LD was prepared for each experiment. 1024 Scans per STD NMR experiment 
were acquired as described before [40]. In separate experiments, lactose and 3?,6?-mannotriose 
were added to the TconTS2-LD solution resulting in 3.45 mM (for lactose) or 1.73 mM (for 3?,6?-
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mannotriose or in the mixture of both oligosaccharides) final concentrations. The STD NMR 
spectra were obtained by subtracting the on- from the off-resonance spectra. As controls, STD 
NMR spectra for only TconTS2-LD or ligand were recorded under identical conditions used. Data 
acquisition and evaluation was performed using NMR software TopSpin 3.2 (Bruker Daltonics, 
Germany). 
 
TS-LD binding/inhibition assay 
Microtitre plate based binding and inhibition assays, used for characterising protein binding to 
sialylated glycoproteins, has been described for siglecs [86]. In this study a modified version of 
these assays was established to investigate TconTS-LD binding to mannosylated glycoproteins. 
Recombinant huS2-Fc expressed and purified as previously described [87] was used as binding 
partner for TconTS-LD, since it contains high-mannose N-glycans due to expression in CHO-Lec1 
cells. 5 µL of 5 µg/ mL huS2-Fc in 50 mM NaHCO3, pH 9.6, were immobilised on a high binding 
384-well microtitre plate (Corning, USA) overnight at 4°C. The plate was washed five times with 20 
?L 10 mM Tris-Cl, pH 7.5, 150 mM NaCl containing 0.05% Tween20 (TBS-T) per well. A 1:2 serial 
dilution of TconTS2-LD ranging from 4 - 0.125 ?g/ mL in 10 mM TBS-T was prepared. 0.2 ?g/ mL 
anti His-tag mouse polyclonal antibody and 0.2 ?g/ mL anti mouse-IgG alkaline phosphatase(AP)-
conjugated donkey polyclonal antibody was added to each dilution step and incubated on ice for 
30 min. 5 ?L of each sample were transferred in triplicates onto the washed microtitre plate and 
centrifuged for 1 min at 600 x g. The plate was covered with parafilm and incubated at 4°C for 
additional 3.5 hours. After washing the plate 4 times with 10 mM TBS-T and twice with 10 mM 
TBS, 20 ?L of freshly prepared fluorescein diphosphate (FDP) substrate solution (50 mM Tris-Cl, 
pH 8.5, 10 mM MgCl2, 20 ?M FDP) was added to each well and the kinetic fluorescence 
measurement was immediately started employing a Tecan Infinite F200 Pro microtitre plate reader 
(Tecan, Germany). As controls, wells containing and lacking immobilised huS2-Fc were incubated 
with both antibodies but in the absence of TconTS2-LD. For comparison, 4 ?g/ mL recombinant 
catalytic domain (CD) of TconTS2 was used instead of TconTS2-LD under the same conditions 
used. 
Inhibiton assays were performed following the same procedure as for the binding assay, but free 
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oligomannose N-glycans were added as potential competitive inhibitors during the incubation with 
TconTS2-LD. Oligomannose N-glycans were released by endoglycosidase H (EndoHf) treatment 
of 10 ?g huS2-Fc in 50 mM sodium citrate, pH 5.5 at 37°C for 4 hours. Proteins were acetone 
precipitated at -20°C overnight [30]. Following centrifugation the supernatant was transferred into a 
fresh reaction tube and solvent was removed using SpedVac evaporator for 1 hour at 30°C, 100 
mbar. Glycans were resuspended in 10 mM TBS and used in inhibition assay as 1:2 dilution series. 
Data acquisition was done using the software Magellan 7.2. Binding and inhibition curves were 
generated using SigmaPlot 11. 
 
Deglycosylation of TconTS 
TconTS1 and TconTS2 were enzymatically deglycosylated using recombinant EndoHf cleaving the 
chitobiose core (GlcNAc(1-4)-?-GlcNAc) of high-mannose N-glycans from glycoconjugates [88]. In 
brief, 500 ?L 10 mM phosphate buffer, pH 7.4 containing 100 ?g TconTS and 4000 units EndoHf 
were incubated for 4 hours at 37°C. For deglycosylation of TconTS under denaturing conditions, 
100 ?g TconTS were incubated in 20 ?L denaturing buffer containing 40 mM dithiothreitol (DTT) 
and 0.5% sodium dodecyl sulfate (SDS) for 10 min at 95°C. After the addition of sodium citrate, 50 
mM final concentration, pH 5.5 and 4000 units EndoHf, reaction mix was incubated for additional 
60 min at 37°C. N-deglycosylation efficiency was determined by ConA lectin blot analysis. 
 
Gel permeation chromatography 
Oligomerisation of TconTS was analysed employing a fast protein liquid chromatography (FPLC) 
system (Amersham Pharmacia, USA) using Superdex 200 10/300 GL (GE Healthcare, Sweden) 
size exclusion column and photometric detection at 280 nm. Chromatographic analysis were done 
at 4°C. In brief, column was equilibrated with 10 mM phosphate buffer pH 7.4 and calibrated using 
a gel filtration marker kit for protein molecular weights between 29,000-700,000 Da (Sigma-Aldrich, 
Germany) according to manufactures instructions. 100 to 300 ?g TconTS in 500 ?L sample volume 
were injected and separated at a flow rate of 0.5 mL/min. Absorbance at 280 nm was continuously 
recorded through an analog writer and subsequently transformed to digital chromatograms using 
the software SigmaPlot 11. EndoHf treated samples were analysed in the same manner. 
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Western Blot and Con A lectin blot analysis 
Protein samples were separated employing SDS-PAGE as described previously [89] using a 
MiniProtean III electrophorese Unit (Bio-Rad, Germany) and stained with Coomassie Brilliant Blue. 
Western blot analysis were performed as previously described [30], using primary anti Strep-tag 
rabbit antibody (1:1000) and secondary anti rabbit-IgG donkey horseradish peroxidase(HRP)-
conjugated antibody (1:40000). Membranes were developed using enhanced chemiluminescence 
system (ECL-Kit, Thermo Scientific, Germany) and X-ray film (GE Healthcare, Sweden). 
ConA lectin blots were performed similar to the procedure for Western blotting. Instead of applying 
primary antibody, 2 ?g/mL solution of biotinylated recombinant ConA in 10 mM phosphate buffer, 
pH 7.4 was added to the membrane and incubated overnight at 4°C. Avidin-biotin HRP conjugated 
system (VECTASTAIN ABC-Kit, Vector Labs, UK) was used for detection according to 
manufactures instructions. 
 
Homology Modelling 
Homology models of TconTS-LD containing or lacking the ?-helix were calculated employing the 
molecular modelling software Yasara 13.3.26 [90-95] as previously described [30]. In brief, crystal 
structure of Trypanosoma cruzi TS (PDB: 3b69) [14] was used as a template structure for 
calculating the models. Yasara homology modelling module were modified manually from the 
default settings of the program as follows: Modelling speed: slow, PsiBLASTs: 6, EValue Max: 0.5, 
Templates total: 1, Templates SameSeq: 1, OligoState: 4, alignments: 15, LoopSamples: 50, 
TermExtension:10. The molecular and electrostatic potential surfaces were calculated using the 
ESPPME (Electrostatic Potential by Particle Mesh Ewald) method of Yasara Structure with the 
following parameters: Force field: AMBER96, Algorithm used to calculate molecular surface: 
numeric, Radius of water probe: 1.4 Å, Grid solution: 3, Maximum ESP: 300 kJ/mol. Red colour 
indicates a positive potential, blue a negative and grey a neutral. 
 
Acknowledgments 
M.W., T. T. G. and S.K. thank Petra Berger and Nazila Isakovic for expert technical assistance as 
well as Dr. Frank Dietz and Judith Weber for fruitful discussions. 
 
Results 3.4  
 161 
  ?? 
References 
1. Kamuanga M. Socio-economic and cultural factors in the research and control of trypanosomiasis. 
PAAT Technical and Scientific series. 2003 Sep 17;(4):1–67.  
2. WHO. Research priorities for ?hagas disease, ?uman ?frican trypanosomiasis and leishmaniasis. 
Technical Report Series. 2012 Feb 17;975:1–116.  
3. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG. The ?uman ?frican trypanosomiasis 
control and surveillance programs of the World Health Organization 2000–2009: The Way Forward. 
Aksoy S, editor. PLoS Negl Trop Dis. 2011 Feb 22;5(2):e1007–7.  
4. Schauer R, Kamerling JP. The chemistry and biology of trypanosomal trans-sialidases: virulence 
factors in Chagas disease and sleeping sickness. Chembiochem. WILEY-VCH Verlag; 2011 Oct 
17;12(15):2246–64.  
5. Engstler M, Schauer R, Brun R. Distribution of developmentally regulated trans-sialidases in the 
Kinetoplastida and characterization of a shed trans-sialidase activity from procyclic Trypanosoma 
congolense. Acta Tropica. 1995 May;59(2):117–29.  
6. Tiralongo E, Schrader S, Lange H, Lemke H, Tiralongo J, Schauer R. Two trans-sialidase forms with 
different sialic acid transfer and sialidase activities from Trypanosoma congolense. J Biol Chem. 2003 
Jun 27;278(26):23301–10.  
7. Schenkman S, Eichinger D. Trypanosoma cruzi trans-sialidase and cell invasion. Parasitol Today 
(Regul Ed). 1993 Jun;9(6):218–22.  
8. Engstler M, Schauer R. Sialidases from African trypanosomes. Parasitol Today (Regul Ed). 1993 
Jun;9(6):222–5.  
9. Nok AJ, Balogun EO. A bloodstream Trypanosoma congolense sialidase could be involved in anemia 
during experimental trypanosomiasis. J Biochem. 2003 Jun;133(6):725–30.  
10. Coustou V, Plazolles N, Guegan F, Baltz T. Sialidases play a key role in infection and anaemia in 
Trypanosoma congolense animal trypanosomiasis. Cellular Microbiology. 2012 Feb 13;14(3):431–45.  
11. Clayton J. Chagas disease 101. Nature. 2010 Jun 24;465(7301):S4–5.  
12. Cremona ML, Sánchez DO, Frasch AC, Campetella O. A single tyrosine differentiates active and 
inactive Trypanosoma cruzi trans-sialidases. Gene. 1995 Jul 4;160(1):123–8.  
13. Buschiazzo A, Tavares GA, Campetella O, Spinelli S, Cremona ML, París G, et al. Structural basis of 
sialyltransferase activity in trypanosomal sialidases. EMBO J. 2000 Jan 4;19(1):16–24.  
14. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM. The crystal structure and mode of 
action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell. 2002 
Oct;10(4):757–68.  
15. París G, Cremona ML, Amaya MF, Buschiazzo A, Giambiagi S, Frasch AC, et al. Probing molecular 
function of trypanosomal sialidases: single point mutations can change substrate specificity and 
increase hydrolytic activity. Glycobiology. 2001 Apr;11(4):305–11.  
16. Haselhorst T. NMR spectroscopic and molecular modeling investigations of the trans-sialidase from 
Trypanosoma cruzi. Glycobiology. 2004 May 26;14(10):895–907.  
17. Demir O, Roitberg AE. Modulation of catalytic function by differential plasticity of the active site: case 
study of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli sialidase. Biochemistry. 2009 
Apr 21;48(15):3398–406.  
18. Oliveira IA, Goncalves AS, Neves JL, Itzstein von M, Todeschini AR. Evidence of ternary complex 
formation in Trypanosoma cruzi trans-Sialidase catalysis. Journal of Biological Chemistry. 2014 Jan 
Results 3.4  
 162 
  3? 
3;289(1):423–36.  
19. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen 
neuraminidase at 2.9 Å resolution. Nature. 1983 May;303(5912):35–40.  
20. Taylor G. Sialidases: structures, biological significance and therapeutic potential. Curr Opin Struct 
Biol. 1996 Dec;6(6):830–7.  
21. Taylor NR, Itzstein von M. A structural and energetics analysis of the binding of a series of N-
acetylneuraminic-acid-based inhibitors to influenza virus sialidase. J Comput Aided Mol Des. 1996 
Jun;10(3):233–46.  
22. Delbaere LT, Vandonselaar M, Prasad L, Quail JW, Wilson KS, Dauter Z. Structures of the lectin IV of 
Griffonia simplicifolia and its complex with the Lewis b human blood group determinant at 2.0 Å 
resolution. Journal of Molecular Biology. 1993 Apr 5;230(3):950–65.  
23. Hester G, Kaku H, Goldstein IJ, Wright CS. Structure of mannose-specific snowdrop (Galanthus 
nivalis) lectin is representative of a new plant lectin family. Nat Struct Biol. 1995 Jun;2(6):472–9.  
24. Bourne Y, Roussel A, Frey M, Rougé P, Fontecilla-Camps JC, Cambillau C. Three-dimensional 
structures of complexes of Lathyrus ochrus isolectin I with glucose and mannose: fine specificity of 
the monosaccharide-binding site. Proteins. 1990;8(4):365–76.  
25. Wright CS. 2.2 Å resolution structure analysis of two refined N-acetylneuraminyl-lactose-wheat germ 
agglutinin isolectin complexes. Journal of Molecular Biology. 1990 Oct 20;215(4):635–51.  
26. Engstler M, Reuter G, Schauer R. The developmentally regulated trans-sialidase from Trypanosoma 
brucei sialylates the procyclic acidic repetitive protein. Mol Biochem Parasitol. 1993 Sep;61(1):1–13.  
27. Pontes de Carvalho LC, Tomlinson S, Vandekerckhove F, Bienen EJ, Clarkson AB, Jiang MS, et al. 
Characterization of a novel trans-sialidase of Trypanosoma brucei procyclic trypomastigotes and 
identification of procyclin as the main sialic acid acceptor. J Exp Med. 1993 Feb 1;177(2):465–74.  
28. Nakatani F, Morita YS, Ashida H, Nagamune K, Maeda Y, Kinoshita T. Identification of a second 
catalytically active trans-sialidase in Trypanosoma brucei. Biochemical and Biophysical Research 
Communications. Elsevier Inc; 2011 Nov 18;415(2):421–5.  
29. Montagna GN, Donelson JE, Frasch ACC. Procyclic Trypanosoma brucei expresses separate 
sialidase and trans-sialidase enzymes on its surface membrane. Journal of Biological Chemistry. 
2006 Nov 3;281(45):33949–58.  
30. Koliwer-Brandl H, Gbem TT, Waespy M, Reichert O, Mandel P, Drebitz E, et al. Biochemical 
characterization of trans-sialidase TS1 variants from Trypanosoma congolense. BMC Biochem. 
2011;12(1):39.  
31. Gbem TT, Waespy M, Hesse B, Dietz F, Smith J, Chechet GD, et al. Biochemical diversity in the 
Trypanosoma congolense trans-sialidase family. PLoS Negl Trop Dis. 2013;7(12):e2549.  
32. Schenkman S, Jiang MS, Hart GW, Nussenzweig V. A novel cell surface trans-sialidase of 
Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell. 
1991 Jun 28;65(7):1117–25.  
33. Cremona ML, Campetella O, Sánchez DO, Frasch AC. Enzymically inactive members of the trans-
sialidase family from Trypanosoma cruzi display ?-galactose binding activity. Glycobiology. 1999 
Jun;9(6):581–7.  
34. Tiralongo E, Martensen I, Grötzinger J, Tiralongo J, Schauer R. Trans-sialidase-like sequences from 
Trypanosoma congolense conserve most of the critical active site residues found in other trans-
sialidases. Biol Chem. 2003 Aug;384(8):1203–13.  
35. Amaya MF, Buschiazzo A, Nguyen T, Alzari PM. The high resolution structures of free and inhibitor-
bound Trypanosoma rangeli sialidase and its comparison with T.cruzi trans-sialidase. Journal of 
Results 3.4  
 163 
  3? 
Molecular Biology. 2003 Jan;325(4):773–84.  
36. Ammar Z, Plazolles N, Baltz T, Coustou V. Identification of trans-sialidases as a common mediator of 
endothelial cell activation by African trypanosomes. Beverley SM, editor. PLoS Pathog. 
2013;9(10):e1003710.  
37. Schwartz M, Kellermann O, Szmelcman S, Hazelbauer GL. Further studies on the binding of maltose 
to the maltose-binding protein of Escherichia coli. Eur J Biochem. 1976 Dec;71(1):167–70.  
38. Crocker PR, Vinson M, Kelm S, Drickamer K. Molecular analysis of sialoside binding to sialoadhesin 
by NMR and site-directed mutagenesis. Biochem J. Portland Press Ltd; 1999 Jul 15;341 ( Pt 2)(Pt 
2):355–61.  
39. Meyer B, Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to 
protein receptors. Angew Chem Int Ed Engl. 2003 Feb 24;42(8):864–90.  
40. Kelm S, Madge P, Islam T, Bennett R, Koliwer-Brandl H, Waespy M, et al. C-4 modified sialosides 
enhance binding to Siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy. Angew 
Chem Int Ed Engl. 2013 Mar 25;52(13):3616–20.  
41. Robertson MA, Etchison JR, Robertson JS, Summers DF, Stanley P. Specific changes in the 
oligosaccharide moieties of VSV grown in different lectin-resistant CHO cells. Cell. 1978 
Mar;13(3):515–26.  
42. Tarentino AL, Maley F. Purification and properties of an endo-?-N-acetylglucosaminidase from 
Streptomyces griseus. J Biol Chem. 1974 Feb 10;249(3):811–7.  
43. Batas B, Jones HR, Chaudhuri JB. Studies of the hydrodynamic volume changes that occur during 
refolding of lysozyme using size-exclusion chromatography. Journal of Chromatography A. 1997 Apr 
4;766(1-2):109–19.  
44. Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL. Crystal structure of a bacterial sialidase 
(from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. Proc 
Natl Acad Sci USA. 1993 Nov 1;90(21):9852–6.  
45. Crennell S, Garman E, Laver G, Vimr E, Taylor G. Crystal structure of Vibrio cholerae neuraminidase 
reveals dual lectin-like domains in addition to the catalytic domain. Structure. 1994 Jun 15;2(6):535–
44.  
46. Bourne Y, Rougé P, Cambillau C. X-ray structure of a (?-Man(1-3)?-Man(1-4)GlcNAc)-lectin complex 
at 2.1-Å resolution. The role of water in sugar-lectin interaction. J Biol Chem. 1990 Oct 
25;265(30):18161–5.  
47. Weis WI, Drickamer K. Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem. 
1996;65:441–73.  
48. Luo Y, Li SC, Li YT, Luo M. The 1.8 Å structures of leech intramolecular trans-sialidase complexes: 
evidence of its enzymatic mechanism. Journal of Molecular Biology. 1999 Jan 8;285(1):323–32.  
49. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, et al. Printed covalent glycan array for 
ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 2004 Dec 
7;101(49):17033–8.  
50. Grant OC, Smith HM, Firsova D, Fadda E, Woods RJ. Presentation, presentation, presentation! 
Molecular-level insight into linker effects on glycan array screening data. Glycobiology. 2013 Dec 
6;24(1):17–25.  
51. Smith LE, Eichinger D. Directed mutagenesis of the Trypanosoma cruzi trans-sialidase enzyme 
identifies two domains involved in its sialyltransferase activity. Glycobiology. 1997 Apr;7(3):445–51.  
52. Moustafa I. Sialic acid recognition by Vibrio cholerae neuraminidase. Journal of Biological Chemistry. 
2004 May 28;279(39):40819–26.  
Results 3.4  
 164 
  3? 
53. Kalb AJ, Levitzki A. Metal-binding sites of concanavalin A and their role in the binding of ?-methyl-D-
glucopyranoside. Biochem J. 1968 Oct;109(4):669–72.  
54. Derewenda Z, Yariv J, Helliwell JR, Kalb AJ, Dodson EJ, Papiz MZ, et al. The structure of the 
saccharide-binding site of concanavalin A. EMBO J. 1989 Aug;8(8):2189–93.  
55. Bubb WA. NMR spectroscopy in the study of carbohydrates: Characterizing the structural complexity. 
Concepts Magn Reson. Wiley Subscription Services, Inc., A Wiley Company; 2003 Aug 26;19A(1):1–
19.  
56. Shahzad-ul-Hussan S, Ghirlando R, Dogo-Isonagie CI, Igarashi Y, Balzarini J, Bewley CA. 
Characterization and carbohydrate specificity of Pradimicin S. J Am Chem Soc. 2012 
Aug;134(30):12346–9.  
57. Merino G, Shuman HA. Unliganded maltose-binding protein triggers lactose transport in an 
Escherichia coli mutant with an alteration in the maltose transport system. J Bacteriol. 1997 
Dec;179(24):7687–94.  
58. Oldham ML, Chen S, Chen J. Structural basis for substrate specificity in the Escherichia coli maltose 
transport system. Proc Natl Acad Sci USA. National Acad Sciences; 2013 Nov 5;110(45):18132–7.  
59. Albohy A, Richards MR, Cairo CW. Mapping substrate interactions of the human membrane-
associated neuraminidase, NEU3, using STD NMR. Glycobiology. Oxford University Press; 2015 
Mar;25(3):284–93.  
60. Wright CS. Structural comparison of the two distinct sugar binding sites in wheat germ agglutinin 
isolectin II. Journal of Molecular Biology. 1984 Sep 5;178(1):91–104.  
61. Rini JM. Lectin structure. Annu Rev Biophys Biomol Struct. Annual Reviews 4139 El Camino Way, 
P.O. Box 10139, Palo Alto, CA 94303-0139, USA; 1995;24(1):551–77.  
62. Weis WI, Drickamer K, Hendrickson WA. Structure of a C-type mannose-binding protein complexed 
with an oligosaccharide. Nature. Nature Publishing Group; 1992 Nov 12;360(6400):127–34.  
63. Weis WI, Drickamer K. Trimeric structure of a C-type mannose-binding protein. Structure. 1994 Dec 
15;2(12):1227–40.  
64. Dani M, Manca F, Rialdi G. Calorimetric study of concanavalin A binding to saccharides. Biochim 
Biophys Acta. 1981 Jan 30;667(1):108–17.  
65. Shibata S, Goldstein IJ, Baker DA. Isolation and characterization of a Lewis b-active lectin from 
Griffonia simplicifolia seeds. J Biol Chem. 1982 Aug 25;257(16):9324–9.  
66. Beecroft RP, Roditi I, Pearson TW. Identification and characterization of an acidic major surface 
glycoprotein from procyclic stage Trypanosoma congolense. Mol Biochem Parasitol. 1993 
Oct;61(2):285–94.  
67. Bayne RA, Kilbride EA, Lainson FA, Tetley L, Barry JD. A major surface antigen of procyclic stage 
Trypanosoma congolense. Mol Biochem Parasitol. 1993 Oct;61(2):295–310.  
68. Bütikofer P, Vassella E, Boschung M, Renggli CK, Brun R, Pearson TW, et al. 
Glycosylphosphatidylinositol-anchored surface molecules of Trypanosoma congolense insect forms 
are developmentally regulated in the tsetse fly. Mol Biochem Parasitol. 2002 Jan;119(1):7–16.  
69. Utz S, Roditi I, Kunz Renggli C, Almeida IC, Acosta-Serrano A, Bütikofer P. Trypanosoma 
congolense procyclins: unmasking cryptic major surface glycoproteins in procyclic forms. Eukaryotic 
Cell. 2006 Aug;5(8):1430–40.  
70. Carrington M, Miller N, Blum M, Roditi I, Wiley D, Turner M. Variant specific glycoprotein of 
Trypanosoma brucei consists of two domains each having an independently conserved pattern of 
cysteine residues. Journal of Molecular Biology. 1991 Oct 5;221(3):823–35.  
Results 3.4  
 165 
  3? 
71. Blum ML, Down JA, Gurnett AM, Carrington M, Turner MJ, Wiley DC. A structural motif in the variant 
surface glycoproteins of Trypanosoma brucei. Nature. Nature Publishing Group; 1993 Apr 
15;362(6421):603–9.  
72. Savage A, Geyer R, Stirm S, Reinwald E, Risse HJ. Structural studies on the major oligosaccharides 
in a variant surface glycoprotein of Trypanosoma congolense. Mol Biochem Parasitol. 1984 
Apr;11:309–28.  
73. Zamze SE, Wooten EW, Ashford DA, Ferguson MA, Dwek RA, Rademacher TW. Characterisation of 
the asparagine-linked oligosaccharides from Trypanosoma brucei type-I variant surface 
glycoproteins. Eur J Biochem. 1990 Feb 14;187(3):657–63.  
74. Zamze SE, Ashford DA, Wooten EW, Rademacher TW, Dwek RA. Structural characterization of the 
asparagine-linked oligosaccharides from Trypanosoma brucei type II and type III variant surface 
glycoproteins. J Biol Chem. 1991 Oct 25;266(30):20244–61.  
75. Mowatt MR, Clayton CE. Developmental regulation of a novel repetitive protein of Trypanosoma 
brucei. Mol Cell Biol. 1987 Aug;7(8):2838–44.  
76. Clayton CE, Mowatt MR. The procyclic acidic repetitive proteins of Trypanosoma brucei. Purification 
and post-translational modification. J Biol Chem. 1989 Sep 5;264(25):15088–93.  
77. Thomson LM, Lamont DJ, Mehlert A, Barry JD, Ferguson MAJ. Partial structure of glutamic acid and 
alanine-rich protein, a major surface glycoprotein of the insect stages of Trypanosoma congolense. J 
Biol Chem. 2002 Dec 13;277(50):48899–904.  
78. Treumann A, Zitzmann N, Hülsmeier A, Prescott AR, Almond A, Sheehan J, et al. Structural 
characterisation of two forms of procyclic acidic repetitive protein expressed by procyclic forms of 
Trypanosoma brucei. Journal of Molecular Biology. 1997 Jun 20;269(4):529–47.  
79. Ferguson MA, Homans SW, Dwek RA, Rademacher TW. Glycosyl-phosphatidylinositol moiety that 
anchors Trypanosoma brucei variant surface glycoprotein to the membrane. Ullstein Mosby. 1988 
Feb 12;239(4841 Pt 1):753–9.  
80. McConville MJ, Ferguson MA. The structure, biosynthesis and function of glycosylated 
phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem J. 1993 Sep 1;294 ( Pt 
2):305–24.  
81. Mehlert A, Richardson JM, Ferguson MA. Structure of the glycosylphosphatidylinositol membrane 
anchor glycan of a class-2 variant surface glycoprotein from Trypanosoma brucei. Journal of 
Molecular Biology. 1998 Mar 27;277(2):379–92.  
82. Miladi B, Marjou El A, Boeuf G, Bouallagui H, Dufour F, Di Martino P, et al. Oriented immobilization of 
the tobacco etch virus protease for the cleavage of fusion proteins. Journal of Biotechnology. 2012 
Apr 15;158(3):97–103.  
83. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, et al. Anti-carbohydrate antibodies 
of normal sera: findings, surprises and challenges. Mol Immunol. 2009 Sep;46(15):3037–49.  
84. Arndt NX, Tiralongo J, Madge PD, Itzstein von M, Day CJ. Differential carbohydrate binding and cell 
surface glycosylation of human cancer cell lines. J Cell Biochem. 2011 Aug 18;112(9):2230–40.  
85. Day CJ, Tiralongo J, Hartnell RD, Logue C-A, Wilson JC, Itzstein von M, et al. Differential 
carbohydrate recognition by Campylobacter jejuni strain 11168: influences of temperature and growth 
conditions. Heimesaat MM, editor. PLoS ONE. 2009;4(3):e4927.  
86. Bock N, Kelm S. Binding and inhibition assays for Siglecs. Methods Mol Biol. 2006;347:359–75.  
87. Koliwer-Brandl H, Siegert N, Umnus K, Kelm A, Tolkach A, Kulozik U, et al. Lectin inhibition assays 
for the analysis of bioactive milk sialoglycoconjugates. International Dairy Journal. Elsevier Ltd; 2011 
Jun 1;21(6):413–20.  
Results 3.4  
 166 
  3? 
88. Maley F, Trimble RB, Tarentino AL, Plummer TH. Characterization of glycoproteins and their 
associated oligosaccharides through the use of endoglycosidases. Anal Biochem. 1989 Aug 
1;180(2):195–204.  
89. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature. 1970 Aug 15;227(5259):680–5.  
90. King RD, Sternberg MJ. Identification and application of the concepts important for accurate and 
reliable protein secondary structure prediction. Protein Sci. Cold Spring Harbor Laboratory Press; 
1996 Nov;5(11):2298–310.  
91. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. Journal 
of Molecular Biology. 1999 Sep 17;292(2):195–202.  
92. Mückstein U, Hofacker IL, Stadler PF. Stochastic pairwise alignments. Bioinformatics. 2002;18 Suppl 
2:S153–60.  
93. Canutescu AA, Shelenkov AA, Dunbrack RL. A graph-theory algorithm for rapid protein side-chain 
prediction. Protein Sci. 2003 Sep;12(9):2001–14.  
94. Qiu J, Elber R. SSALN: an alignment algorithm using structure-dependent substitution matrices and 
gap penalties learned from structurally aligned protein pairs. Proteins. Wiley Subscription Services, 
Inc., A Wiley Company; 2006 Mar 1;62(4):881–91.  
95. Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, et al. Improving physical realism, 
stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed 
well in CASP8. Proteins. 2009;77 Suppl 9:114–22.  
Results 3.4  
 167 
  3? 
Supporting Information 
Fig. S1. Identification of potential TconTS-LD oligosaccharide ligands. Purified TconTS-LDs 
(2 ?g) were pre-complexed with mouse anti-His, rabbit anti-mouse TexasRed, and donkey anti-
rabbit TexasRed and applied to glycan array slides in the presence and absence of 10 mM 
maltotriose. Following washing and drying array slides were scanned using the ProScanArray 
Microarray 4-laser scanner, with the images generated analysed using the ScanArray Express 
software. A: 2 ?g His-MBP. B: 2 ?g His-MBP in the presence of 10 mM maltotriose during 
incubation and subsequent washing. C: TconTS1-?Hel-LD in the absence of maltotriose. D: 
TconTS1-LD (10 mM maltoriose). E: TconTS2-?Hel-LD (10 mM maltoriose). F: TconTS2-LD (10 
mM maltoriose). G: TconTS3-?Hel-LD (10 mM maltoriose). H: TconTS3-LD (10 mM maltoriose). I: 
TconTS4-?Hel-LD (10 mM maltoriose). J: TconTS4-LD (10 mM maltoriose). K: Array slide before 
incubation with MBP in the absence of maltotriose. L: Array slide before incubation with TconTS2-
?Hel-LD in the absence of maltotriose. Inhibited MBP binding to oligomaltose oligosaccharides are 
cycled in red. Spots cycled in yellow represent internal print controls that are present on all glycan 
array slides. 
 
Fig. S2. Results from glycan array analysis. MBP and TconTS-LD binding to several glycans 
was determined in the presence (+) or absence (-) of 10 mM mannotriose. No binding was 
detected to non-listed glycans (see Table S1 for all glycans on arrays). 
 
Fig. S3. Amino acid sequence alignment and predicted N-glycosylation sites of TconTS. The 
primary sequences of TconTS1, TconTS2, TconTS3 and TconTS4 were aligned applying 
Geneious Alignment module of the software Geneious 5.5.5 using the following settings: gap open 
penalty: 12, Gap extension penalty: 3, Alignment type: Global alignment with free end gaps, Cost 
Matrix: Blosum62. The predicted N-glycosylation sites are illustrated in red triangles and distributed 
over the catalytic (light blue) and lectin (yellow) domains. No N-glycosylation sites have been found 
in SNAP (orange) and Strep (purple) tags attached to TconTS enzymes. 
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Fig. S4. Binding specificity of TconTS2-LD and enzymatic activity of bacterial and 
eukaryotic expressed TconTS1. A, B) Binding activities of TconTS2-LD to high-mannose N-
glycans of immobilised Siglec-2. TconTS2-LD and the antibodies used for detection were 
consecutively added (triangles) to the immobilised ligands as well as in form of a precomplexed 
mixture (squares). C) Competitive inhibition of TconTS2-LD specific binding to high-mannose N-
glycans of Siglec-2. High-mannose N-glycans to be used as competitive inhibitor were obtained by 
EndoH treatment of Siglec-2 (see Methods section for details). ?Man: ?-methyl-mannopyranoside, 
Glc: D-glucose. D) Comparison of the specific enzymatic activities of recombinant TconTS1a 
expressed in E.coli (bacterial) and CHO-Lec1 (eukaryotic) cells. Velocities shown represent the 
production of 3‘SL (3‘-sialyllactose) or free Neu5Ac (N-acetyl-neuraminic acid) under standard 
conditions: 100 ?g fetuin, 2 mM lactose, 37°C, 30 min. 
 
Table S1. Library of all glycan structures present on our glycan array 
 
Table S2. Sequence similarities of TconTS-LDs 
 
Table S3. Primers for amplification of cDNA fragments encoding TconTS-LDs 
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Figure 3 
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Figure 4 
 
 
  
Results 3.4  
 173 
Figure 5 
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Figure 6 
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Figure 7 
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Fig. S2
MBP only TconTS1-LD
TconTS2-
LD
TconTS3-
LD
TconTS4-
LD
?-helix - - - - + - + - + - +
10 mM Maltotriose - + - + + + + + + + +
ID Glycan name
1B N-Acetyllactosamine
1E ?-1-3 Galactosyl-N-acetylgalactosamine
1L Tn Antigen GalNAc?1-O-Ser
1M Galactosyl-TF Antigen
1N ?1-3 Galactobiose
1P Linear B-6 Trisaccharide
2A ?1-3,?1-4,?1-3Galactotetraose
2B Gal?1-6Gal
2D GalNAc?1-4Gal
2E Gal?1-4Gal?1-4GlcNAc
4D N,N',N'',N''',N'''',N'''''-Hexaacetyl chitohexaose
4E GlcNAc?1-4MurNAc
5F ?1-6-Mannobiose
5G ?1-3,?1-6-Mannobiose
7A Lacto-N-fucopentaose I
7B Lacto-N-fucopentaose II
7K Blood Group A trisaccharide
7L Lactodifucotetraose (LDFT)
7M Blood Group B Trisaccharide
7N Lewis y
7O Blood Group H Type IITrisaccharide
8A Sulpho Lewis a
8C Monofucosyl-para-Lacto-N-hexaose IV
8E Difucosyllacto-N-hexaose
8G Lacto-N-fucopentaose VI(LNFP VI)
14J Heparin sulfate
14L Chondroitin disaccharide?di-OS
110 Glc?1-4Glc? (maltose)
240 (Glc?1-4)3? (maltotriose)
241 (Glc?1-6)3? (Isomaltotriose)
8L Difucosyllacto-N-
1
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neohexaose I
8M Difucosyllacto-N-neohexaose II 
8P Blood Group ATetrasaccharide
10A Sialyl Lewis a
10C Sialyllacto-N-tetraose a
10D
Monosialyl,
monofucosyllacto-N
neohexose
10H Sialyllacto-N-fucopentaoseVI (SLNFPVI)
10K 3'-Sialyllactosamine
10O LS-Tetrasaccharide c
11D Biantennary 2,6-sialylated-N-glycan-Asn
12D Neocarrahexaose-41, 3, 5-tri-O-sulphate (Na+)
12I DUA-2S-GlucNS
12N DUA-GalNAc-4S
12O DUA-GalNAc-6S (Delta Di-6S)
12P DUA-GalNAc-4S,6S
13A DUA-2S-GalNAc-4S 
13B DUA-2S-GalNAc-6S (DeltaDi-disD)
13C DUA-2S-GalNAc-4S-6S
13F Hyaluronan fragment (4mer)
13G Hyaluronan fragment (8mer)
13H Hyaluronan fragment(10mer)
13I Hyaluronan fragment(12mer)
13J Heparin
13O HA - 6 10mM
13P HA - 8 9.7mM
14B HA -12 6.5mM
14C HA-14 5.6mM
14D HA-16 4.9mM
390 (Glc?1-4)4? (Maltotetraose)
391
(Glc?1-6)4?
(Isomaltotetraose)
2
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Fig. S3
TconTS1
TconTS2
TconTS3
TconTS4
MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGNPAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEGGLAVKEWLLAHEGHRLGKPGLGEFDIGTWSHPQFEK
SNAP-Strep
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A
Fig. S4
B
C
TconTS Specific activity 
[nmol/(min*mg TconTS)] 
 
3’SL Neu5Ac 
TconTS1a 
(E. coli)  5,22 ± 0,03 0,65 ± 0,07 
TconTS1a 
(CHO-Lec1) 2732,33 ± 1,38 88,08 ± 0,74 
 
D
consecutive addition precomplexed no Siglec-2
no inhibitor N-glycans ??????????? ??????????
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Table S1 Library of all glycan structures present on our glycan array
Number Structures Common name
Saccharide with additional spacer
Monosaccharides
1 Fuc?-sp3 L-?-Fuc
2 Gal?-sp3 ?-Gal
3 Gal?-sp3 ?-Gal
4 GalNAc?-sp0 TnSer
5 GalNAc?-sp3 Tn 
6 GalNAc?-sp3 ?-GalNAc
7 Glc?-sp3 ?-Glc
9 Glc?-sp3 ?-Glc
10 GlcNAc?-sp3 ?-GlcNAc
14 GlcN(Gc)?-sp4 ?-GlcN(Gc)
15 HOCH2(HOCH)4CH2NH2 aminoglucitol
16 Man?-sp3 ?-Man
18 Man?-sp4 ?-Man
19 ManNAc?-sp4 ?-ManAc
20 Rha?-sp3 L-?-Rha
22 GlcNAc?-sp4 ?-GlcNAc
37 3-O-Su-Gal?-sp3 3-O-Su-?-Gal
38 3-O-Su-GalNAc?-sp3 3-O-Su-?-GalNac
43 6-O-Su-GlcNAc?-sp3 6-O-Su-?-GlcNAc
44 GlcA?-sp3 ?-glucoronic acid
45 GlcA?-sp3 ?-glucoronic acid
46 6-H2PO3Glc?-sp4 ?-Glc6P
47 6-H2PO3Man?-sp3 ?-Man6P
48 Neu5Ac?-sp3 ?-Neu5Ac
49 Neu5Ac?-sp9 ?-Neu5AcBn
52 Neu5Gc?-sp3 ?-Neu5Gc
54 9-NAc-Neu5Ac?-sp3 9-Nac-?-Neu5Ac
55 3-O-Su-GlcNAc?-sp3 3-O-Su-?-GlcNAc
Disaccharides
71 Fuc?1-2Gal?-sp3 Hdi
72 Fuc?1-3GlcNAc?-sp3
73 Fuc?1-4GlcNAc?-sp3 Le
75 Gal?1-2Gal?-sp3
76 Gal?1-3Gal?-sp3 Bdi
77 Gal?1-3GalNAc?-sp3 T??
78 Gal?1-3GalNAc?-sp3 T??
80 Gal?1-3GlcNAc?-sp3
81 Gal?1-4GlcNAc?-sp3 ?-LacNAc
83 Gal?1-6Glc?-sp4 Melibiose
84 Gal?1-2Gal?-sp3
85 Gal?1-3GlcNaAc?-sp3 Lec
87 Gal?1-3Gal?-sp3
88 Gal?1-3GalNAc?-sp3 T??
89 Gal?1-3GalNAc?-sp3 TF
93 Gal?1-4Glc?-sp4 Lac
94 Gal?1-4Gal?-sp4
97 Gal?1-4GlcNAc?-sp3 LacNAc
100 Gal?1-6Gal?-sp4
101 GalNAc?1-3GalNAc?-sp3 Fs-2
102 GalNAc?1-3Gal?-sp3 Adi
103 GalNAc?1-3GalNAc?-sp3 core 5
104 GalNAc?1-3Gal?-sp3
106 GalNAc?1-4GlcNAc?-sp3 LacdiNAc
110 Glc?1-4Glc?-sp3 maltose
111 Glc?1-4Glc?-sp4 cellobiose
112 Glc?1-6Glc?-sp4 gentiobiose
113 GlcNAc?1-3GalNAc?-sp3 core 3
114 GlcNAc?1-3Man?-sp4
115 GlcNAc?1-4GlcNAc?-Asn chitobiose-Asn
117 GlcNAc?1-4GlcNAc?-sp4 chitobiose 
118 GlcNAc?1-6GalNAc?-sp3 core 6
119 Man?1-2Man?-sp4
120 Man?1-3Man?-sp4
121 Man?1-4Man?-sp4
122 Man?1-6Man?-sp4
123 Man?1-4GlcNAc?-sp4
124 Man?1-2Man?-sp4
145 Gal?1-3(6-O-Su)GlcNAc?-sp3 6-O-Su-Lec
146 Gal?1-4(6-O-Su)Glc?-sp2 6-O-Su-Lac
147 Gal?1-4(6-O-Su)GlcNAc?-sp3 6-O-Su-LacNAc
149 GlcNAc?1-4(6-O-Su)GlcNAc?-sp2 6-O-Su-chitobiose
150 3-O-Su-Gal?1-3GalNAc?-sp3 3`-O-Su-TF
151 6-O-Su-Gal?1-3GalNAc?-sp3 6`-O-Su-TF
152 3-O-Su-Gal?1-4Glc?-sp2 SM3
153 6-O-Su-Gal?1-4Glc?-sp2 6`-O-Su-Lac 
155 3-O-Su-Gal?1-3GlcNAc?-sp3 3`-O-Su-Lec
157 3-O-Su-Gal?1-4GlcNAc?-sp3 3`-O-Su-LacNAc
159 4-O-Su-Gal?1-4GlcNAc?-sp3 4`-O-Su-LacNAc
161 6-O-Su-Gal?1-3GlcNAc?-sp3 6`-O-Su-Lec
163 6-O-Su-Gal?1-4GlcNAc?-sp3 6`-O-Su-LacNAc
164 GlcA?1-3GlcNAc?-sp3
165 GlcA?1-3Gal?-sp3
166 GlcA?1-6Gal?-sp3
167 GlcNAc?1-4-[HOOC(CH3)CH]-3-O-GlcNAc?-sp4 GlcNAc-Mur
168 GlcNAc?1--[HOOC(CH3)CH]-3-O-GlcNAc?-L-alanyl-D-i-glutaminyl-L-lysine GMDP-Lys
169 Neu5Ac?2-3Gal?-sp3 GM4
170 Neu5Ac?2-6Gal?-sp3
171 Neu5Ac?2-3GalNAc?-sp3 3-SiaTn
172 Neu5Ac?2-6GalNAc?-sp3 SiaTn
174 Neu5Gc?2-6GalNAc?-sp3 NeuGc-Tn
176 3-O-Su-Gal?1-4(6-O-Su)Glc?-sp2 3`,6-di-O-Su-Lac
177 3-O-Su-Gal?1-4(6-O-Su)GlcNAc?-sp2 3`,6-di-O-Su-LacNAc
178 6-O-Su-Gal?1-4(6-O-Su)Glc?-sp2 6,6`-di-O-Su-Lac
179 6-O-Su-Gal?1-3(6-O-Su)GlcNAc?-sp2 6,6`-di-O-Su-Lec
180 6-O-Su-Gal?1-4(6-O-Su)GlcNAc?-sp2 6,6`-di-O-Su-LacNAc
181 3,4-O-Su2-Gal?1-4GlcNAc?-sp3 3`,4`-di-O-Su-LacNAc
182 3,6-O-Su2-Gal?1-4GlcNAc?-sp2 3`,6`-di-O-Su-LacNAc
183 4,6-O-Su2-Gal?1-4GlcNAc?-sp2 4`,6`-di-O-Su-LacNAc
184 4,6-O-Su2-Gal?1-4GlcNAc?-sp3 4`,6`-di-O-Su-LacNAc
186 Neu5Ac?2-8Neu5Ac?2-sp3 (Sia)2
189 3,6-O-Su2-Gal?1-4(6-O-Su)GlcNAc?-sp2 3`,6,6`-tri-O-Su-LacNAc
192 GalNAc?1-4(6-O-Su)GlcNAc?-sp3 6-O-Su-LacdiNAc
193 3-O-Su-GalNAc?1-4GlcNAc?-sp3 3`-O-Su-LacdiNAc
194 6-O-Su-GalNAc?1-4GlcNAc?-sp3 6`-O-Su-LacdiNAc
195 6-O-Su-GalNAc?1-4-(3-O-Su)GlcNAc?-sp3 6`-Su-3-O-Ac-LacdiNAc
196 3-O-Su-GalNAc?1-4(3-O-Su)-GlcNAc?-sp3 3,3`-O-Su2-LacdiNAc
Table S1: Library of all glycan structures present on our glycan array 
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197 3,6-O-Su2-GalNAc?1-4GlcNAc?-sp3 3`,6`-Su2-LacdiNAc
198 4,6-O-Su2-GalNAc?1-4GlcNAc?-sp3 4`,6`-Su2-LacdiNAc
199 4,6-O-Su2-GalNAc?1-4-(3-O-Ac)GlcNAc?-sp3 4`,6`-Su2-3-O-Ac-LacdiNAc
200 4-O-Su-GalNAc?1-4GlcNAc?-sp3 4`-O-Su-LacdiNAc
201 3,4-O-Su2-Gal?1-4GlcNAc?-sp3 3`,4`-Su2-LacdiNAc
202 6-O-Su-GalNAc?1-4(6-O-Su)GlcNAc?-sp3 6,6`-O-Su-LacdiNAc
203 Gal?1-4(6-O-Su)GlcNAc?-sp2 6-O-Su-LacNAc
204 4-O-Su-GalNAc?1-4GlcNAc?-sp2 4`-O-Su-LacdiNAc
205 Neu5Ac?2-6GalNAc?-sp3
206 Neu5Gc?2-3Gal-sp3 NeuGc?3Gal
Trisaccharides
215 Fuc?1-2Gal?1-3GlcNAc?-sp3 Led, H (type 1)
216 Fuc?1-2Gal?1-4GlcNAc?-sp3 H (type 2)
217 Fuc?1-2Gal?1-3GalNAc?-sp3 H (type 3)
219 Fuc?1-2Gal?1-4Glc?-sp4 H (type 6
220 Gal?1-3Gal?1-4Glc?-sp2
222 Gal?1-3Gal?1-4GlcNAc?-sp3 Galili (tri)
224 Gal?1-4Gal?1-4Glc?-sp3 Pk, Gb3, GbOse3
225 Gal?1-4Gal?1-4GlcNAc-sp2 P1
226 Fuc?1-2(Gal?1-3)Gal?-sp3 Btri
228 Gal?1-2Gal?1-4GlcNAc?-sp4
229 Gal?1-3Gal?1-4GlcNAc?-sp4
231 Gal?1-4GlcNAc?1-3GalNAc?-sp3
232 Gal?1-4GlcNAc?1-6GalNAc?-sp3
233 Gal?1-3(Fuc?1-4)GlcNAc?-sp3 Lea
234 Fuc?1-3(Gal?1-4)GlcNAc?-sp3 Lex
235 Fuc?1-2(GalNAc?1-3)Gal?-sp3 Atri
238 GalNAc?1-4Gal?1-4Glc?-sp3 GA2, GgOse3
240 (Glc?1-4)3?-sp4 maltotriose
241 (Glc?1-6)3?-sp4 isomaltotriose
246 GlcNAc?1-2Gal?1-3GalNAc?-sp3
247 GlcNAc?1-3Gal?1-3GalNAc?-sp3
248 GlcNAc?1-3Gal?1-4Glc?-sp2
250 GlcNAc?1-3Gal?1-4GlcNAc?-sp3
251 GlcNAc?1-4Gal?1-4GlcNAc?-sp2
252 GlcNAc?1-4GlcNAc?1-4GlcNAc?-sp4 chitotriose
253 GlcNAc?1-6Gal?1-4GlcNAc?-sp2
254 Gal?1-3(GlcNAc?1-6)GalNAc?-sp3 core 2
255 GlcNAc?1-3(GlcNAc?1-6)GalNAc?-sp3 core 4
258 Man?1-3(Man?1-6)Man?-sp4 Man3
262 Gal?1-3GalNAc?1-3Gal-sp4 T??-Gal
264 Gal?1-4Gal?1-4GlcNAc-sp3
287 3-O-Su-Gal?1-3(Fuc?1-4)GlcNAc?-sp3 Su-Lea
288 Fuc?1-3(3-O-Su-Gal?1-4)GlcNAc?-sp3 Su-Lex
289 Gal?1-3(Neu5Ac?2-6)GalNAc?-sp3 6-SiaTF
290 Gal?1-3(Neu5Ac?2-6) GalNAc?-sp3
292 Neu5Ac?2-3Gal?1-3GalNAc?-sp3 3`-Sia-TF
293 Neu5Ac?2-3Gal?1-4Glc?-sp3 3`SL
294 Neu5Ac?2-3Gal?1-4Glc?-sp4 3`SL
295 Neu5Ac?2-6Gal?1-4Glc?-sp2 6`SL 
298 Neu5Ac?2-3Gal?1-4GlcNAc?-sp3 3`SLN
299 Neu5Ac?2-3Gal?1-3GlcNAc?-sp3 3`-SiaLec
300 Neu5Ac?2-6Gal?1-4GlcNAc?-sp3 6`SLN
303 Neu5Gc?2-3Gal?1-4GlcNAc?-sp3 3`SLN (Gc)
304 Neu5Gc?2-6Gal?1-4GlcNAc?-sp3 6`SLN (Gc)
306 9-NAc-Neu5Ac?2-6Gal?1-4GlcNAc?-sp3
315 Neu5Ac?2-3Gal?1-4-(6-O-Su)GlcNAc?-sp3 6-Su-3`SLN
317 Neu5Ac?2-3Gal?1-3-(6-O-Su)GalNAc?-sp3 6-Su-3`SiaTF
318 Neu5Ac?2-6Gal?1-4-(6-O-Su)GlcNAc?-sp3 6-Su-6`SLN
319 Neu5Ac?2-3-(6-O-Su)Gal?1-4GlcNAc?-sp3 6`-Su-3`SLN
321 (Neu5Ac?2-8)3-sp3 (Sia)3
323 Neu5Ac?2-6Gal?1-3GlcNAc-sp3 6`-SiaLec
324 Neu5Ac?2-6Gal?1-3(6-O-Su)GlcNAc-sp3 6Su-6`-SiaLec
331 Neu5Gc?2-3Gal?1-3GlcNAc?-sp3 3`SiaLec  (Gc)
Tetrasaccharides
359 Fuc?1-2(Gal?1-3)Gal?1-3GlcNAc?-sp3 B (type 1)
360 Fuc?1-2(Gal?1-3)Gal?1-4GlcNAc?-sp3 B (type 2)
362 Fuc?1-2(Gal?1-3)Gal?1-3GalNAc?-sp3 B (type 3)
363 Fuc?1-2(Gal?1-3)Gal?1-3GalNAc?-sp3 B (type 4)
364 Fuc?1-3(Gal?1-3Gal?1-4)GlcNAc?-sp3 ?GalLex
366 Fuc?1-2(GalNAc?1-3)Gal?1-3GlcNAc?-sp3 A (type 1)
368 Fuc?1-2(GalNAc?1-3)Gal?1-4GlcNAc?-sp3 A (type 2)
371 Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc?-sp3 Leb
372 Fuc?1-3(Fuc?1-2Gal?1-4)GlcNAc?-sp3 Ley
373 Gal?1-3Gal?1-4GlcNAc?1-3Gal?-sp3 Galili (tetra)
375 Gal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp3
376 Gal?1-3GlcNAc?1-3Gal?1-4Glc?-sp4 LNT
377 Gal?1-3GlcNAc?1-3Gal?1-3GlcNAc?-sp2
378 Gal?1-3GlcNAc?1-3Gal?1-4GlcNAc?-sp3
379 Gal?1-3GlcNAc?1-3Gal?1-4GlcNAc?-sp3
380 Gal?1-3GlcNAc?1-6Gal?1-4GlcNAc?-sp2
381 Gal?1-3GlcNAc?1-6Gal?1-4GlcNAc?-sp2
382 Gal?1-3GalNAc?1-4Gal?1-4Glc?-sp3 Asialo-GM1
383 Gal?1-4GlcNAc?1-3Gal?1-4Glc?-sp2 LNnT
385 Gal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp3 i
387 Gal?1-4GlcNAc?1-6Gal?1-4GlcNAc?-sp2
388 Gal?1-3(Gal?1-4GlcNAc?1-6)GalNAc?-sp3
389 GalNac?1-3Gal?1-4Gal?1-4Glc?-sp3 Gb4, P
390 (Glc?1-4)4?-sp4 maltotetraose
391 (Glc?1-6)4?-sp4 isomaltotetraose
392 Fuc?1-2(GalNAc?1-6)Gal?1-3GalNAc?-sp3 A (type 3)
395  GlcNAc?1-3(GlcNAc?1-6)Gal?1-4GlcNAc?-sp3 Tk
401 Gal?1-3GlcNAc?1-3Gal?1-3GlcNAc?-sp3 Lec3Lec
419 3-O-SuGal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp3
420 4-O-SuGal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp3
421 Neu5Ac?2-3(GalNAc?1-4)Gal?1-4Glc?-sp2 GM2
422 Neu5Ac?2-3Gal?1-4GlcNAc?1-3Gal?-sp3
423 Fuc?1-3(Neu5Ac?2-3Gal?1-4)GlcNAc?-sp3 SiaLex
426 Neu5Ac?2-3Gal?1-3(Fuc?1-4)GlcNAc?-sp3 SiaLea
428 Fuc?1-3(Neu5Ac?2-3Gal?1-4)6-O-Su-GlcNAc?-sp3
429 Fuc?1-3(Neu5Ac?2-3(6-O-Su)Gal?1-4)GlcNAc?-sp3
433 Neu5Ac?2-3Gal?1-3(Neu5Ac?2-6)GalNAc?-sp3 Sia2-TF
434 Neu5Ac?2-8Neu5Ac?2-3Gal?1-4Glc?-sp4 GD3
Penta-Nona Saccharides
479 Fuc?1-2Gal?1-3GlcNAc?1-3Gal?1-4Glc?-sp4 LNFP-I
480 Fuc?1-2Gal?1-3GlcNAc?1-3Gal?1-4GlcNAc?-sp2 H (type1) penta
481 Gal?1-3Gal?1-4GlcNAc?1-3Gal?1-4Glc?-sp4 Galili (penta)
483 Fuc?1-3(Fuc?1-2 (Gal?1-3)Gal?1-4)GlcNAc?-sp3              Bley
488 Gal?1-4GlcNAc?1-3(Gal?1-4GlcNAc?1-6)GalNAc?-sp3
489 Gal?1-4GlcNAc?1-3(GlcNAc?1-6)Gal?1-4GlcNAc-sp2
490 GlcNAc?1-3(Gal?1-4GlcNAc?1-6)Gal?1-4GlcNAc?-sp2
492 (Glc?1-6)5?-sp4 isomaltopentaose
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493 (GlcNAc?1-4)5?-sp4 chitopentaose
495 Man?1-3(Man?1-3(Man?1-6)Man?1-6)Man?-sp4 Man5
496 Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc?1-3Gal?1-4Glc?-sp4 Leb-Lac
497 Fuc?1-3(Fuc?1-2Gal?1-4)GlcNAc?1-3Gal?1-4Glc?-sp4 Ley-Lac
498 (Gal?1-4GlcNAc?1-3)3-sp3 (LN)3
499 Gal?1-4GlcNAc?1-3(Gal?1-4GlcNAc?1-6)Gal?1-4GlcNAc-sp2 I
501 Gal?1-3GalNAc?1-3Gal?1-4Gal?1-4Glc?-sp4 Gb5
502 (Glc?1-6)6?-sp4 maltohexaose
503 (GlcNAc?1-4)6?-sp4 chitohexaose
504 (A-GN-M)2-3,6-M-GN-GN?-sp4 9-OS
505 (GN-M)2-3,6-M-GN-GN?-sp4 7-OS
527 Neu5Ac?2-3Gal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp2 3`SLN-LacNAc
528 Fuc?1-3(Neu5Ac?2-3 Gal?1-4)GlcNAc?1-3Gal?-sp3 SiaLex-3Gal
529 Neu5Ac?2-6(Gal?1-3)GlcNAc?1-3Gal?1-4Glc?-sp4 LSTb
531 GalNAc?1-4(Neu5Ac?2-8Neu5Ac?2-3)Gal?1-4Glc-sp2 GD2
532 Neu5Ac?2-8Neu5Ac?2-8Neu5Ac?2-3Gal?1-4Glc-sp2 GT3
533 (Neu5Ac?2-8)2Neu5Ac?2-3(GalNAc?1-4)Gal?1-4Glc-sp2 GT2
534 Neu5Ac?2-3Gal?1-4GlcNAc?1-3Gal?1-4GlcNAc?-sp3 6`SLN-LacNAc
536 Neu5Ac?2-3Gal?1-3GlcNAc?1-3Gal?1-4Glc?-sp4 LSTa
537 Neu5Ac?2-3Gal?1-4GlcNAc?1-3Gal?1-4Glc?-sp4 LSTd
538 Lex1-6'(Lec1-3')Lac-sp4 MFLNH III
539 LacNAc1-6'(Led1-3')Lac-sp4 MFLNH I 
540 Lex1-6'(6'SLN1-3')Lac-sp4 MSMFLNnH
541 Lex1-6'(Led1-3')Lac-sp4 DFLNH (a)
542 LecLex1-6'(Lec1-3')Lac-sp4 MF(1-3)iLNO
543 Lex1-6'(Leb1-3')Lac-sp4 TFLNH
Higher Oligosaccharides
625 (GlcA?1-4GlcNAc?1-3)8-NH2-ol hyaluroninc acid
627 (Sia2-6A-GN-M)2-3,6-M-GN-GN?-sp4 11-OS, YDS
              Terminal Galactose
1A Gal?1-3GlcNAc Lacto-N-Biose I
1B Gal?1-4GlcNAc N-Acetyllactosamine
1C Gal?1-4Gal b-1-4-galactosyl-galactose
1D Gal?1-6GlcNAc b-1-6 Galactosyl-N-acetyl glucosamine
1E Gal?1-3GalNAc b-1-3 Galactosyl-N-acetyl galactosamine
1F Gal?1-3GalNAc?1-4Gal?1-4Glc asialo GM1
1G Gal?1-3GlcNAc?1-3Gal?1-4Glc Lacto-N-tetraose
1H Gal?1-4GlcNAc?1-3Gal?1-4Glc Lacto-N-neotetraose
1I Gal?1-4GlcNAc?1-6(Gal?1-4GlcNAc?1-3)Gal?1-4Glc Lacto-N-neohexaose
1J Gal?1-4GlcNAc?1-6(Gal?1-3GlcNAc?1-3)Gal?1-4Glc Lacto-N-hexaose
1K Gala1-4Gal?1-4Glc Globotriose
1L GalNAca1-O-Ser Tn Antigen  GalNAca1-O-Ser
1M Galb1-3GalNAc?1-O-Ser Galactosyl-Tn Antigen
1N Gala1-3Gal a1-3 Galactobiose
1O Gala1-3Gal?1-4GlcNAc Linear B-2 Trisaccharide
1P Gala1-3Gal?1-4Glc Linear B-6 Trisaccharide
2A Gala1-3Gal?1-4Gal?1-3Gal a1-3, b1-4,a1-3 Galactotetraose
2B Gal?1-6Gal beta1-6galactobiose
2C GalNAc?1-3Gal terminal disaccharide of Globotriose
2D GalNAc?1-4Gal receptor for P.aureginosa
2E Gal?1-4Gal?1-4GlcNAc P1 antigen
2F GalNAc?1-3Gal?1-4Glc a-D-N-acetylgalactosamine 1-3Gal?1-4Glc
2G Gal?1-3GlcNAc?1-3Gal?1-4GlcNAc?1-6(Gal?1-3GlcNAc?1-3)Gal?1-4Glc iso-Lacto-N-octaose (iLNO)
2H Gal?1-3GlcNAc?1-3Gal?1-4GlcNAc?1-3Gal?1-4Glc para-Lacto-N-hexaose (pLNH)
18B Gal?1-3GalNAc?1-3Gal?1-4Gal?1-4Glc Globopentaose
18C Gal?1-3GalNAc?1-3Gal Core type 4/Gb5 triose structure
             Terminal GlcNAc
4A GlcNAc?1-4GlcNAc N,N'-Diacetyl chitobiose
4B GlcNAc?1-4GlcNAc?1-4GlcNAc N,N',N''-Triacetyl chitotriose
4C GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc N,N',N'',N'''-Tetraacetyl chitotetraose
4D GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc N,N',N'',N''',N'''',N'''''-Hexaacetyl chitohexaose
4E Bacterial cell wall muramyl discaccharide   GlcNAcb1-4MurNAc
4F GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc?1-4GlcNAc Pentacetyl chitopentaose
            Mannosyl containing glycans
5A GlcNAc?1-2Man b1-2 N-Acetylglucosamine-mannose
5B GlcNAc?1-2Man?1-6(GlcNAc?1-2Man?1-3)Man Bianntennary N-linked core pentasaccharide
5C Man?1-2Man a1-2-Mannobiose
5D Man?1-3Man a1-3-Mannobiose
5E Man?1-4Man a1-4-Mannobiose
5F Man?1-6Man a1-6-Mannobiose
5G Man?1-6(Man?1-3)Man a1-3,a1-6-Mannobiose
5H Man?1-6(Man?1-3)Man?1-6(Man?1-3)Man a1-3,a1-3,a1-6-Mannopentaose
             Fucosylated glycans
7A Fuc?1-2Gal?1-3GlcNAc?1-3Gal?1-4Glc Lacto-N-fucopentaose I
7B Gal?1-3(Fuca1-4)GlcNAc?1-3Gal?1-4Glc Lacto-N-fucopentaose II
7C Gal?1-4(Fuca1-3)GlcNAc?1-3Gal?1-4Glc Lacto-N-fucopentaose III
7D Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc?1-3Gal?1-4Glc Lacto-N-difucohexaose I
7E Gal?1-3(Fuc?1-4)GlcNAc?1-3Gal?1-4(Fuc?1-3)Glc Lacto-N-difucohexaose II
7F Fuc?1-2Gal H-disaccaride
7G Fuc?1-2Gal?1-4Glc 2'-Fucosyllactose
7H Gal?1-4(Fuc?1-3)Glc 3'-Fucosyllactose
7I Gal?1-4(Fuc?1-3)GlcNAc Lewisx
7J Gal?1-3(Fuc?1-4)GlcNAc Lewisa
7K GalNAc?1-3(Fuc?1-2)Gal Blood Group A trisaccharide
7L Fuc?1-2Gal?1-4(Fuc?1-3)Glc Lactodifucotetraose (LDFT)
7M Gal?1-3(Fuc?1-2)Gal Blood Group B Trisaccharide
7N Fuc?1-2Gal?1-4(Fuc?1-3)GlcNAc Lewisy
7O Fuc?1-2Gal?1-3GlcNAc Blood Group H Type II Trisaccharide
7P Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc Lewisb tetrasaccharide
8A SO3-3Gal?1-3(Fuc?1-4)GlcNAc Sulpho Lewisa
8B SO3-3Gal?1-4(Fuc?1-3)GlcNAc Sulpho Lewisx
8C Gal?1-3GlcNAc?1-3Gal?1-4(Fuc?1-3)GlcNAc?1-3Gal?1-4Glc Monofucosyl-para-Lacto-N-hexaose IV
8D Gal?1-4(Fuc?1-3)GlcNAc?1-6(Gal?1-3GlcNAc?1-3)Gal?1-4Glc Monofucosyllacto-N-hexaose III
8E Gal?1-4(Fuc?1-3)GlcNAc?1-6(Fuc?1-2Gal?1-3GlcNAc?1-3)Gal?1-4Glc Difucosyllacto-N-hexaose
8F Gal?1-4(Fuc?1-3)GlcNAc?1-6(Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc?1-3)Gal?1-4Glc Trifucosyllacto-N-hexaose
8G Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)Glc Lacto-N-fucopentaose VI (LNFP VI)
8H Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4Glc Lacto-N-neodifucohexaose I (LNnDFH I)
8I Fuca1-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)Glc Lacto-N-neodifucohexaose II (LNnDFH II)
8J Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3(Fuca1-2)Galb1-4Glc Trifucosyllacto-N-neoteraose I (TFLNnTI)
8K Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc Monofucosyllacto- N-neohexaose I (MFLNnH I)
8L Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-4(Fuca1-3)GlcNAcb1-3)Galb1-4Glc Difucosyllacto-N-neohexaose I (DFLNnH I)
8M Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc Difucosyllacto-N-neohexaose II (DFLNnH II)
8N Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc Monofucosyl(1-3)-iso-lacto-N-octaose (MFiLNO)
8O Fuca1-2Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc Trifucosyl(1-2,1-2,1-3)-iso-lacto-N-octaose (TFiLNO (1-2,1-2,1-3))
8P GalNAcb1-3(Fuca1-2)Galb1-4Glc Blood Group A Tetrasaccharide
9A Galb1-3(Fuca1-2)Galb1-4(Fuca1-3)Glc Blood Group B pentasaccharide
18D Gal?1-3(Fuc?1-2)Gal?1-4Glc blood group B antigen tetraose type 5
18E GalNAc?1-3(Fuc?1-2)Gal?1-4(Fuc?1-3)Glc blood group A pentasaccharide
19J Gal?1-4(Fuc?1-3)GlcNAc?1-3Gal Lewis X tetraose
19L Fuc?1-2Gal?1-4(Fuc?1-3)GlcNAc?1-3Gal lewis Y pentaose
19M Gal?1-3(Fuc?1-4)GlcNAc?1-3Gal lewis a tetraose
19N Fuc?1-2Gal?1-3(Fuc?1-4)GlcNAc?1-3Ga lewis b pentaose
           Sialylated glycans
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10A Neu5Ac?2-3Gal?1-3(Fuc?1-4)GlcNAc Sialyl Lewisa (S Lea)
10B Neu5Ac?2-3Gal?1-4(Fuc?1-3)GlcNAc Sialyl Lewisx (S Lex)
10C Neu5Ac?2-3Gal?1-3GlcNAc?1-3Gal?1-4Glc Sialyllacto-N-tetraose a
10D Gal?1-4(Fuc?1-3)GlcNAc?1-6(Neu5Ac?2-6Gal?1-4GlcNAc?1-3)Gal?1-4Glc Monosialyl, monofucosyllacto-N-neohexose
10K Neu5Ac?2-3Gal?1-4GlcNAc 3'-Sialyllactosamine
10L Neu5Ac?2-6Gal?1-4GlcNAc 6'-Sialyllactosamine
10M Neu5Ac?2-3Gal?1-3GlcNAc?1-3Gal?1-4Glc LS-Tetrasaccharide a (LSTa)
10N Gal?1-3(Neu5Ac?2-6)GlcNAc?1-3Gal?1-4Glc LS-Tetrasaccharide b (LSTb)
10O Neu5Ac?2-6Gal?1-4GlcNAc?1-3Gal?1-4Glc LS-Tetrasaccharide c (LSTc)
10P Neu5Ac?2-3Gal?1-3(Neu5Ac?2-6)GlcNAc?1-3Gal?1-4Glc Disialyllacto-N-tetraose
11A Neu5Ac?2-3Gal?1-4Glc 3'-Sialyllactose
11B Neu5Ac?2-6Gal?1-4Glc 6'-Sialyllactose
11C (Neu5Ac?2-8Neu5Ac)n (n<50) Colominic acid
18A Neu5Ac?2-3Gal?1-4GlcNAc?1-3Gal?1-4Glc LS-Tetrasaccharide d
19K Neu5Ac?2-3Gal?1-4(Fuc?1-3)GlcNAc?1-3Gal Sialyl lewis X pentaose
          Glycosaminoglycans - high and low molecular weight
12A Neocarratetraose-41, 3-di-O-sulphate (Na+) C24H36O-25S2Na2 (Mixed anomers. Tetrasaccharide of regular ? - carrageenan)
12B Neocarratetraose-41-O-sulphate (Na+) C24H37O22SNa (Mixed anomers. Derived from C1003 by removal of  the non-reducing terminal 4-sulphate)
12C Neocarrahexaose-24,41, 3, 5-tetra-O-sulphate (Na+) C36H52O40S4Na4 (Mix. anomers. A hybr. seq. compr. carrageenan disacch. in the order k-i-k, deriv. f. the carrageenan f. Chondrus crispus)
12D Neocarrahexaose-41, 3, 5-tri-O-sulphate (Na+) C36H53O37S3Na3 (Mixed anomers. Hexasaccharide of regular ?-carrageenan)
12E Neocarraoctaose-41, 3, 5, 7-tetra-O-sulphate (Na+) C48H70O49S4Na4 (Mixed anomers. Octasaccharide of regular ?-carrageenan)
12F Neocarradecaose-41, 3, 5, 7, 9-penta-O-sulphate (Na+) C60H87O61S5Na5 (Mixed anomers. Decasaccharide of regular ?- carrageenan)
12G ?UA-2S-GlcNS-6S C12H15NO19S3Na4 (Predominant disaccharide  produced from heparin by heparinase I and II)
12H ?UA-GlucNS-6S C12H16NO16S2Na3 (Produced from heparinase II digestion of heparin and heparin sulphate)
12I ?UA-2S-GlucNS C12H16NO16S2Na3 (Produced from heparin by digestion with heparinase I and II)
12J ?UA-2S-GlcNAc-6S C14H18NO17S2Na3 (Minor component produced from heparin by heparinase II)
12K ?UA-GlcNAc-6S C14H19NO14SNa2 (Product of the action of  heparinases II and III on heparin and heparan sulphate)
12L ?UA-2S-GlcNAc C14H19NO14SNa2 (Minor product of the action of heparinase II on heparin)
12M ?UA-GlcNAc C14H20NO11Na (Produced from heparin sulphate by digestion With heparinase III)
12N ?UA-GalNAc-4S (Delta Di-4S) C14H19NO14SNa2 (Produced from various chondroitin sulphates By the action of chondroitinases ABC, B and AC-1)
12O ?UA-GalNAc-6S (Delta Di-6S) C14H19NO14SNa2 (Produced from various chondroitin sulphates By the action of chondroitinases ABC, AC-1 and C)
12P ?UA-GalNAc-4S,6S (Delta Di-disE) C14H18NO17S2Na3 (Produced from various chondroitin sulphates By the action of chondroitinases ABC, B and AC-1)
13A ?UA-2S-GalNAc-4S (Delta Di-disB) C14H18NO17S2Na3 (Prod. f. var. chondroitin sulphates by action of c. ABC and/or B. Most typ. f. chondroitin sulphate B (dermatan sulphate))
13B ?UA-2S-GalNAc-6S (Delta Di-disD) C14H18NO17S2Na3 (Produced from various chondroitin sulphates by the action of chondroitinase ABC)
13C ?UA-2S-GalNAc-4S-6S (Delta Di-tisS) C14H17NO20S3Na4 (Produced as a minor component by the action of chondroitinase ABC on various chondroitin sulphates, particularly B)
13D ?UA-2S-GalNAc-6S (Delta Di-UA2S) C14H19NO14SNa2 (Produced as a minor component from various chondroitin sulphates by the action of chondroitinase ABC)
13E ?UA-GlcNAc (Delta Di-HA) C14H20NO11Na (The only unsaturated disaccharide produced from hyaluronic acid by the action of chondroitinase ABC or AC-1)
13F (GlcA?1-3GlcNAc?1-4)n (n=4) Hyaluronan fragments (4mer)    
13G (GlcA?1-3GlcNAc?1-4)n (n=8) Hyaluronan fragment (8mer)
13H (GlcA?1-3GlcNAc?1-4)n (n=10) Hyaluronan fragment (10mer)
13I (GlcA?1-3GlcNAc?1-4)n (n=12) Hyaluronan fragment (12mer)
13J (GlcA/IdoA?/?1-4GlcNAc?1-4)n (n=200) Heparin
13K (GlcA/IdoA?1-3(±4/6S)GalNAc?1-4)n (n<250) Chondroitin sulfate
13L ((±2S)GlcA/IdoA?/b1-3(±4S)GalNAc?1-4)n (n<250) Dermatan sulfate
13M (GlcA/IdoA?1-3(±6S)GalNAc?1-4)n (n<250) Chondroitin 6-sulfate
13 N HA - 4 10mM
130 HA - 6 10mM
13P HA - 8 9.7mM
14A HA 10 7.83mM
14B HA-12 6.5mM
14C HA-14 5.6mM
14D HA-16 4.9mM
14E HA 30000 da 2.5mg/ml
14F HA 107000 da 2.5mg/ml
14G HA 190000 da 2.5 mg/ml
14H HA 220000 da 2.5 mg/ml
14I HA 1600000 da 2.5 mg/ml
14J Heparin sulfate 5 mg/ml
14K ?1-3Glucan
14L Chondroitin disaccharide ?di-OS, sodium salt C14H20NNaO11 (produced from various chondriotin sulfates by the action of chondriotinases ABC, AC-1 and C)
Ganglioside oligosaccharides
17A GalNAc?1-4Gal?1-4Gl asialo GM2
17B Gal?1-3GalNAc?1-4Gal?1-4Glc asialo GM1
17C Gal?1-3GalNAc?1-4(Neu5Ac?2-8Neu5Ac?2-8 Neu5Ac?2-3)Gal?1-4Glc GT1c ganglioside sugar
17D Neu5Ac?2-8Neu5Ac?2-3Gal?1-3GalNAc?1-4(Neu5Ac?2-3)Gal?1-4Glc GT1a ganglioside sugar
17E Gal?1-3GalNAc?1-4(Neu5Ac?2-8Neu5Ac?2-3)Gal?1-4Glc GD1b ganglioside sugar
17F Neu5Ac?2-3Gal?1-3GalNAc?1-4(Neu5Ac?2-3)Gal?1-4Glc GD1a Ganglioside sugar
17G Neu5Ac?2-3Gal?1-3GalNAc?1-4Gal?1-4Glc GM1b ganglioside sugar
17H Gal?1-3GalNAc?1-4(Neu5Ac?2-3)Gal?1-4Glc GM1a ganglioside sugar
17I Fuc?1-2Gal?1-3GalNAc?1-4(Neu5Ac?2-3)Gal?1-4Glc fucosyl GM1 ganglioside sugar
17J GalNAc?1-4(Neu5Ac?2-8Neu5Ac?2-8Neu5Ac?2-3)Gal?1-4Glc GT2 ganglioside sugar
17K GalNAc?1-4(Neu5Ac?2-8Neu5Ac?2-3)Gal?1-4Glc GD2 gangliosifde sugar
17L GalNAc?1-4(Neu5Ac?2-3)Gal?1-4Glc GM2 ganglioside sugar
17M Neu5Ac?2-8Neu5Ac?2-8Neu5Ac?2-3Gal?1-4Glc GT3 ganglioside sugar
17N Neu5Ac?2-8Neu5Ac?2-3Gal?1-4Gl GD3 ganglioside sugar
17O Neu5Ac?2-3Gal?1-4Glc GM3 ganglioside sugar
Complex type N-glycans
19A Gal?1-4GlcNAc?1-2Man?1-3(Gal?1-4GlcNAc?1-2Man?1-6Man)?1-4GlcNAc?1-4(Fuc?1-6)GlcNAc Asialo galactosylated, fucosylated biantennary
19B
Gal?1-4GlcNAc?1-2(Gal?1-4GlcNAc?1-4)Man?1-3(Gal?1-4GlcNAc?1-2(Gal?1-4GlcNAc?1-6)Man?1-
6Man)?1-4GlcNAc?1-4GlcNAc Asialo, galactosylated, tetranatennary, N-linked glycan
19C Neu5Ac?2-6Gal?1-4GlcNAc?1-2Man?1-3(Gal?1-4GlcNAc?1-2Man?1-6)Man?1-4GlcNAc?1-4GlcNAc Monosialo(2,6), biantennary (A1)
19D
Neu5Ac?2-6Gal?1-4GlcNAc?1-2Man?1-3(Neu5Ac?2-6Gal?1-4GlcNAc?1-2Man?1-6)Man?1-4GlcNAc?1-
4GlcNAc Disialo (2,6) biantennary (A2)
19E Gal?1-4GlcNAc?1-2Man?1-3(Gal?1-4GlcNAc?1-2Man?1-6)Man?1-4GlcNAc?1-4GlcNAc Asialo, galactoyslated, biantennary (NA2)
19F
Neu5Ac?2-6Gal?1-4GlcNAc?1-2Man?1-3(Neu5Ac?2-6Gal?1-4GlcNAc?1-2Man?1-6)Man?1-4GlcNAc?1-
4(Fuc?1-6)GlcNAc Disialo, galactosylated, fucosylated, biantennary (A2F)
19G
Neu5Ac?2-6Gal?1-4GlcNAc?1-2(Neu5Ac?2-6Gal?1-4GlcNAc?1-4)Man?1-3(Neu5Ac?2-6Gal?1-
4GlcNAc?1-2Man?1-6)Man?1-4GlcNAc?1-4GlcNAc Trisialylated, galactosylated, triantennary (A3)
19H GlcNAc?1-2(GlcNAc?1-4)Man?1-3(GlcNAc?1-2Man?1-6)GlcNAc?1-4Man?1-4GlcNAc?1-4GlcNAc Asialo, agalacto, bisected triannary (NGA3B)
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Table S2: Sequence similarities between TconTS-LDs
TconTS1-LD TconTS2-LD TconTS3-LD TconTS4-LD
TconTS1-LD - 42.3% (54.6%) 41.0% (57.7%) 40.7% (51.8%)
TconTS2-LD 42.3% (54.6%) - 39.9% (54.4%) 37.4% (55.1%)
TconTS3-LD 41.0% (57.7%) 39.9% (54.4%) - 45.4% (61.7%)
TconTS4-LD 40.7% (51.8%) 37.4% (55.1%) 45.4% (61.7%) -
The amino acid sequences of TconTS-LD were pairwise aligned using the Blosum62
matrix with a gap opening penalty of 12 and a gap extension penalty of 5. Shown are the
percent of positions with identical or similar (giving a positive value in the Blosum62 matrix;
in brackets) amino acids.
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Table S?. Primers for amplification of cDNA fragments encoding TconTS-LDs  
Coding Sequence Sense primer 5'-3') 
His-MBP-TEV GCCCATGGGCCATCACCATCACCATCAC (NcoI) 
TconTS1-LD GC AAG CTT AAC TGC CTC CCG GGC (HindIII) 
TconTS1-?Hel-LD GC AAG CTT GAC GAG CTG AAA AGC (HindIII) 
TconTS2-LD GC AAG CTT TGT CAA CTG AAC AAA AAG CG (HindIII) 
TconTS2-?Hel-LD GC AAG CTT CTG GAG GAT GAG ATG GAG G (HindIII) 
TconTS3-LD GC AAG CTT TGT TCC TCA CCG GAT GGT G (HindIII)  
TconTS3-?Hel-LD GC AAG CTT CTA GAA GAC GAG CTG GAA AGC(HindIII) 
TconTS4-LD GC AAG CTT TGC TCT GCA ACT ACC G (HindIII) 
TconTS4-?Hel-LD GC AAG CTT CTC GCT GAC GAA CTG AAG (HindIII) 
Sense primers used in combination with reverse primers (A) 
GCGTCGACGCCCTGAAAATAAAGATTCTC (SalI) for His-MBP-TEV; or (B) GC GCG GCC 
GCT TAT TTT TCG AAC TGC GG (NotI) for the TconTS-LD fragments. The restriction sites 
used are underlined. 
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Abstract
Trans-sialidases (TS) are unusual enzymes that catalyse the transfer of terminal sialic acids from
sialoglycoconjuagtes to terminal galactose or  N-acetylgalactosamine of oligosaccharides without
the  requirement  of  CMP-Neu5Ac,  the  activated  Sia  used  by  sialyltransferases.  Most  work  on
trypanosomal TS has been done on enzymatic activities of TS from T. cruzi the causative agent of
Chagas disease in Latin America, T. brucei, causing sleeping sickness in humans, and TS from T.
congolense (TconTS),  the  causative  agent  of  Nagana in  livestock.  Recently  we demonstrated
TconTS-LD  binding  activities  to  several  carbohydrates,  such  as  oligosaccharides  containing
mannose or terminal galactose.
To investigate the influence of TconTS-LD on enzyme activities we established a novel strategy
swapping  LDs  and  CDs  from  different  TconTS  and  expressing  these  recombinant  TconTS
constructs in bacteria and eukaryotic cells. Domain swapped, chimeric trans-sialidases showed
clear sialidase and sialic acid (Sia) transfer activities, when using fetuin and lactose as Sia donor
and acceptor substrates, but their specific and relative activities differed drastically from that of wild
type TconTS, indicating an influence of the lectin domain on enzyme activities and possibly also
substrate specificities. Besides that, we could demonstrate that the presence of 1,4-?-mannotriose
during  TS reactions,  modulates  enzyme activities,  namely  increasing the  ratio  between trans-
sialylation and hydrolysis.
Author's summary
Here we reported a strategy to swap catalytic (CD) and lectin domains (LD) of trans-sialidases (TS)
from Trypanosoma congolense (TconTS) and provide evidence for a potential influence of LD on
1
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enzymatic activities.
Using  the  crystal  structure  of  T.  cruzi  TS (TcruTS)  homology  models  for  TconTS1,  TconTS2,
TconTS3 and TconTS4 were calculated. This structure models together with amino acid sequence
alignments of TconTS were used to locate a suitable region for the insertion of a unique restriction
site  utilised  to  exchange  and  recombine  LDs  from  different  enzymes.  Domain  swapped
recombinant TconTS, comprising CD from a highly active and LD from a less active TconTS were
expressed by bacteria  (E. coli  Rosetta pLacI) as well as fibroblasts (CHO-Lec1). Enzymes were
purified and analysed for their specific catalytic activities using fetuin and lactose as sialic acid
(Sia)  donor  and  acceptor  substrates.  TS reaction  products  3'SL and  Neu5Ac  were  quantified
employing  a  HPLC-based  method  (HPAEC-PAD)  specific  for  carbohydrate  analysis.  Obtained
results clearly demonstrated Sia transfer and sialidase activities for domain swapped enzymes,
although  activities  determined,  drastically  differed  from  that  observed  for  wild  type  TconTS,
therefore potentially indicating a modulating function for LD on enzymatic activities. Interestingly,
TconTS  mutated  to  comprise  the  inserted  unique  restriction  site  but  have  not  been  domain
swapped also showed significant changes in enzyme activities compared to wild type TconTS.
Additional western blot analysis of these modified TconTS enzymes using an anti TS monoclonal
antibody provided evidence that changes in enzymatic activities observed are possibly  N-glycan
dependent.
In  summary,  the  strategy  to  exchange  and  recombine  CDs  and  LDs  from  different  TconTS,
presented in this study, was successfully used to generate chimeric active enzymes expressed and
isolated from bacteria and fibroblasts exhibiting Sia transfer and sialidase activities different from
that of wild type TconTS. Furthermore, results also provided evidence that TconTS-LDs potentially
play  relevant  roles  in  modulating  the  biological  functions  of  these  and  possibly  other  trans-
sialidases.
Introduction
Trypanosomes are protozoan parasites causing trypanosomiasis in Latin America (T. cruzi), also
known as  Chagas'  disease  [1,2],  Human African  trypanosomiasis  (HAT,  T.  brucei  brucei)  and
2
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Animal African trypanosomiasis (AAT, also called Nagana) in livestock (T. congolense)  in Sub-
Sahara Africa [3-5], bringing death to multiple-thousands humans and millions of cattle every year
[6-8]. To evade mammalian host immune response and insect vectors digestive system, parasites
stage specifically  express  an  unusual  enzyme called  trans-sialidase (TS)  on their  surfaces  to
transfer terminal sialic acids (Sia) from host glycoconjugates to terminal galactose residues on their
own surface glycoproteins [9-12]. Several studies have shown that trypanosomal TS play important
roles in the pathology of the disease in mammalian hosts and are necessary for survival of the
parasite also in the insect vector  [9,13-15].  Structurally,  TS contain two domains, a N-terminal
catalytic (CD) and a C-terminal lectin-like domain (LD), which are connected via a 23 to 25 amino
acid long ?-helix, and arranged in close contact to each other [11].
Whereas  published  studies  have concentrated  on  the  enzymatic  activities  of  CDs  [16-22],  no
function of the LDs has been described so far. First evidence for a more pivotal role of the LDs has
come from our phylogenetic analysis done separately on CD and LD of TconTS, in which, only the
LDs of the most active enzymes TconTS1 and TconTS2 group together, whereas the CDs of these
enzymes fall into different branches [21]. For example, the CD of the highly active TconTS2 groups
together with the two less active enzymes TconTS3 and TconTS4, but it is less related to the also
very active TconTS1 [21]. In our recent work we demonstrated the lectin activity of TconTS-LD to
oligomannose and oligogalactose oligosaccharides [23]. Interestingly, oligomannose oligosaccha-
rides are not substrates for the catalytic transfer of Sia  [10,12,24]. However, high-mannose  N-
glycans have been found on glycoproteins or as part of their glycosylphosphatidylinositol (GPI)-
anchor on the parasite's surface [25-31]. Therefore, these potentially serve as ligand structures for
TconTS-LD. Furthermore, also TS were found to be glycosylated, predominantly with N-glycans of
the  high-mannose  type  [3,4],  leading  to  the  suggestion  of  intermolecular  interactions  possibly
mediated  by  TS-LD.  Our  experimental  results  from  size-exclusion  chromatography  analysis
demonstrated the mannose-dependent oligomerisation of recombinant, high-mannosylated TconTS
[23]. Based on this fundamental findings we wanted to investigate a possible role of TconTS-LD on
catalytic activities of the enzymes.
Here we present a strategy to sufficiently swap CDs and LDs from different TconTS and expressed
recombined  chimeric  enzymes  by  E.  coli  as  well  as  fibroblasts  for  subsequent  biochemical
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characterisation regarding enzymatic activities. Homology models of TconTS revealed that amino
acid residues localised at the contact sites between TconTS CD and LD are well conserved in the
TS family. In addition, in silico data of domain swapped TconTS revealed a similar overall topology
with an extended hydrogen bond network at the interface between CD and LD, which was also
found in wild type TconTS. Based on this observation we assumed that recombination of CDs and
LDs from different TconTS would not interfere with correct folding.
Clear Sia transfer and sialidase activities were observed for purified domain swapped recombinant
TconTS expressed by  E. coli  or CHO-Lec1 fibroblasts.  Interestingly,  specific  catalytic  activities
drastically  differed  from  that  of  wild  type  enzymes.  In  addition,  we  have  demonstrated  the
relevance of LD for enzymatic activities of TconTS1 and TconTS2, since in the presence of 1,4-?-
mannotriose these enzymes have a higher Sia transfer to sialidase ratio. Furthermore, epitope
mapping of  the anti  TS mAb 7/23 revealed that  it's  binding epitope is  glycan dependent  and
localised  in  the  lectin  domains  of  both,  TconTS1  and  TconTS2.  Interestingly,  it  has  been
demonstrated that  binding of  this  antibody to  native TS-forms isolated from cultured procyclic
trypomastigotes reduced specific enzymatic activity by 75 % [12].
Understanding the role of TconTS-LD will provide advanced knowledge of their biological functions
in the parasite during pathogenesis and the establishment of chronic infections. Furthermore, new
insights  into  structure-related  TS  functions  are  likely  to  open  new  strategies  for  potent  drug
development targeting TS and will  possibly also provide new opportunities for biotechnological
applications employing trypanosomal TS.
Results
The contact sites between TconTS CD and LD
Using the crystal structure of T. cruzi TS (TcruTS) [11] as template, homology structure models of
TconTS1 through TconTS4 were calculated as described under Methods. Similar to other TS, CD
and LD are localised in immediate vicinity,  connected by an 23 to 25 amino acid long ?-helix
connecting both domains (Figure 1). From these homology models of TconTS, we observed that
the arrangement of CD and LD is stabilised by the relatively broad contact sites between both
4
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domains [23]. The interface between CD and LD from TcruTS [11] and T. rangeli sialidase (TranSA)
[32] were previously determined by Buschiazzo et al. [11] and Amaya et al. [32] to be about 36 to
48 % lager compared to those from other sialidases, such as Vibrio cholerae sialidase (VCS) [33]
and Marcobdella decora intramolecular trans-sialidase (leech IT-sialidase) [34]. Along this line, we
calculated areas of the molecular interfaces for several African TS, namely TconTS1, TconTS2,
TconTS3, TconTS4 and T. brucei TS (TbruTS). Results revealed 33 to 46 % larger areas compared
to that of  VCS and leech IT-sialidase, consistent with Buschiazzo's and Amaya's observations
[11,32] (Table 1).
It can be seen that the overall surface area of the contact site between CD and LD of African TS is
around 2833.55 to 3306.47 Å2 and quite similar in size among the TS family (Table 1). Interestingly,
amino acid sequence alignments of TS illustrated that regions, which are part of the contact site,
are  well  conserved  among  TS  (Figure  1  D).  Further  in  silico analysis  regarding  potential
interactions between amino acids at the contact site of TconTS, revealed a network of hydrogen
bonds formed between both domains, providing a comparative rigid overall conformation of the
enzyme. Interestingly,  calculated structure models revealed two defined locations, in which the
majority of inter-domain hydrogen bonds were located (Figure 1). One site is close to the ?-helix
(Figure 1 B), whereas the second is located at the opposite side of the interface (Figure 1 C).
Amino acids from both domains of TconTS1 through TconTS4, forming hydrogen bonds at the
contact site, where identified and summarised in Table 2.
In total, 13 hydrogen bonds at the interface between CD and LD for TconTS3, 12 for TconTS1 and
11 for TconTS2 as well as for TconTS4, were identified from homology models, also considering
hydrogen bonds between CD/LD and the ?-helix. Moreover, the number of these hydrogen bonds
in each TS seems to be equally distributed over both locations A and B (Figure 1 B and C). Not
surprisingly, amino acid sequence alignments of TS revealed that amino acid residues essential for
hydrogen bond formation in A and B are well  conserved among the TS family (Table 3).  One
exception  represents  TranSA,  which  showed  9  amino  acid  deviations  from  the  consensus
sequence, 5 in CD and 4 in LD (Table 3). 4 of these were also found in TcruTS, which exhibits 5
changes in total, 3 in CD and 2 in LD. For the African trypanosomes, TconTS and TbruTS, only up
to 3 variations in total were identified in comparison to the consensus sequence.
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Interestingly, the 3 amino acid residues Trp (10), Lys (11) and Asp (12) of the ?-helix, essential for
the formation of hydrogen bonds to Glu (6) and Arg (9) of CD and Tyr (15) and Trp (13) of LD in A
(Figure 1 B), are conserved through all TS listed in Table 3, indicating a fundamental role of that
region for enzyme structure stability. In addition, the Gln (18) of LD, which is also well conserved in
the trypanosomal TS family, is located on a loop at the more exposed location B (Figure 1 C). Gln
18 reaches relatively far into the CD, where it forms hydrogen bonds to Gly (4), Lys (7) and Arg (5),
suggesting that Gln 18 is one of the key amino acids for structure stability in B, mainly responsible
for stabilising the contact between CD and LD (Figure 1).
TconTS domain swap
To  investigate  the  influence  of  TconTS-LD  on  enzyme  activity,  we  established  a  strategy  to
exchange  and  recombine  CDs  and  LDs  from  different  TconTS.  In  silico  data  provided  good
evidence that  a  potential  domain swap on a molecular  level  is  possible,  because amino acid
residues at the contact site of TconTS between CD and LD, including those essential for hydrogen
bond network formation are well conserved in TconTS1 through TconTS4 (Figure 1 and Table 3). A
unique endonuclease restriction site was introduced between the regions coding for TconTS CD
and LD, which can subsequently be used to swap domains from different TconTS. At first sight, the
?-helix itself might represent a potential target for the restriction site introduction, but amino acid
sequence alignments of TconTS revealed that the majority of amino acid residues of the ?-helix are
well conserved (Figure 1 D and Figure 2 A). Thus the insertion or exchange of 2 - 3 amino acids
(corresponding to 6 - 9 nucleotides) in the sequence of the ?-helix is expected to interfere with its
structure and or interactions (see above).
However, the crystal structure of TcruTS  [11] revealed a crystallographically unresolved flexible
loop right after the ?-helix between the two domains (Figure 2). This structural hairpin loop, which
is stabilised by a well conserved disulphide bridge (C477 and C487 in TconTS1), does not exhibit
any conserved amino acid residues among TTS (Figure 3 A). Sterically, this loop is more distinct
from the enzyme and not in close contact to CD. In summary, these features together encouraged
us  to  utilise  that  loop  segment  as  a  suitable  target  for  the  introduction  of  an  endonuclease
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restriction site. In addition, this region provides almost the entire LD to be exchanged, without the
disruption of  any potentially  important  structure  elements  such as  ?-sheets,  salt-bridges or  ?-
helices.
A screening was performed to identify endonuclease restriction sites not present in the coding
sequences  of  TconTS1  through  TconTS4,  from which  Eco105I  (TAC'GTA)  was  selected.  The
enzyme generates blunt ends after restriction digest and can therefore also be used to insert any
other  sequence  in  frame,  for  example  spacer  or  other  TS-LD for  further  applications  without
requiring  additional  restriction  sites.  Suitable  sense  and  reverse  primer  for  each  TconTS,
containing the  Eco105I restriction site, were designed (Table S1) and mutagenesis experiments
were performed as described under Methods, inserting the Eco105I site at the appropriate position
in the hairpin loop (Figure 2 B). Restriction digest and recombination of TconTS CD and LD were
performed to generate all 12 possible domain swapped constructs as plasmid preparations, listed
in Table 4 (Nr. 5-16).
Expression and purification of domain swapped TconTS
After introduction of the Eco105I restriction site into the modified pET28a MBP plasmid [23], all four
mutated recombinant TconTS* (TconTS containing Eco105I restriction site) were expressed by E.
coli Rosetta (DE3) pLacI, as described under Methods. A schematic composition of recombinant
domain  swapped  TconTS  expressed  by  bacteria,  is  shown  in  Figure  3  A.  After  expression,
sufficient  amounts  of  mutated  TconTS*  were  obtained  and  characterised  by  SDS-PAGE  and
Western blot analysis (Figure 3 C, ~135 kDa). However, in contrast to the expression of TconTS-
LD constructs, mutated TconTS* as well as wild type TconTS were obtained only in relatively low
amounts (100 – 300 ?g of enzyme per litre of bacterial culture) as soluble protein after tandem
affinity chromatography, employing Ni-NTA and Strep-tag purification (described under Methods).
Even  several  expression  optimisations,  including  variation  of  the  isopropyl-?-D-1-thiogalacto-
pyranoside (IPTG) concentration, as well  as induction time and temperature adjustments,  only
negligibly enhanced yields of about 200 – 500 ?g of purified soluble protein per litre of bacterial
culture were obtained.
7
Results 3.5  
 197 
 
Based on our recent findings that TconTS1 and TconTS2 are highly active, whereas TconTS3 and
TconTS4 exhibited drastically lower enzyme activities [20,21], it was obvious to first swap the LDs
from a highly and a less active TconTS (e.g. TconTS1 and TconTS3) and analyse the resulting
specific activities. Along this line, TconTS3-LD was recombined with TconTS1a-CD to generate the
recombinant domain swapped TconTS1a/TS3 (Table 4, construct 6) as described under Methods.
Concerning  the  differences  in  enzymatic  activities  of  wild  type  TconTS mentioned  above,  we
assumed that if the LD has any effect on enzyme activity, TconTS3-LD might be able to change the
overall enzyme behaviour of TconTS1a/TS3 relative to that of wild type TconTS1a.
The pET28aMBP plasmid encoding TconTS1a/TS3 was transformed into E. coli Rosetta pLacI and
recombinant  protein  was  expressed  and  purified  using  the  same  conditions  described  for
expression of mutated TconTS* as well  as wild type TconTS (described under Methods).  After
tandem affinity purification a major band close to 130 kDa was observed on SDS-PAGE gel (Figure
3 C).
Besides the bacterial expression of domain swapped TconTS, a eukaryotic expression system was
also  established  using  CHO-Lec1  fibroblasts.  Furthermore  we  demonstrated  that  the  enzyme
activity of TconTS expressed by bacteria (E. coli), is drastically lower compared to that of TconTS
expressed by CHO-Lec1 cells [20,21].
For  stable  transfection  in  CHO-Lec1  cells,  DNA sequences  coding  for  recombinant  domain
swapped TconTS1a/TconTS3 and TconTS2/TconTS4 as well as sequences for mutated TconTS1a*
and TconTS2* were subcloned into pDEF, a modified eukaryotic expression vector [20] (described
under Methods). A transin signal peptide for protein secretion was N-terminally fused directly to the
TconTS coding sequence for eukaryotic expression (Figure 3 A) instead of His- and MBP-tags for
TconTS expressed by bacteria (Figure 3 B).  In addition, C-terminal SNAP- and  Strep-tags are
included in both, the bacterial and fibroblast expressed TconTS. Because of the time intensive
work starting from transfection to single clone selected, stable CHO-Lec1 cell lines and finally to a
sufficient amount of  purified recombinant protein for enzyme activity analysis,  only TconTS1a*,
TconTS1a/TS3,  TconTS2* and TconTS2/TS4 were selected for  production.  Stable  transfection,
single clone selection, cultivation of TconTS expressing cells and finally purification of recombinant
proteins  was  done  as  described  under  Methods.  Cells  transfected  with  TconTS1a*  and
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TconTS1a/TS3 respectively, showed relatively high amounts of secreted protein in the cell culture
supernatant (SN) directly after clonal selection. In contrast to that, TconTS2* showed only relatively
low amounts of secreted protein in the SN even after an extended cultivation time (2-3 weeks),
whereas CHO-Lec1 cells transfected with TconTS2/TS4 did not proliferate at all after transfection.
Also repetition of stable transfection, using a dilution series of TconTS2/TS4 plasmid DNA ranging
from 5 to 15 ?g, revealed the same results. Interestingly, bacterial expression of TconTS2/TS4
followed by SDS-PAGE analysis of the lysate revealed a clear band close to 130 kDa (Figure 3 C),
as it was expected based on the calculated molecular weight of TconTS2/TS4. However, reasons
for this surprising observations still remain unclear, although corresponding experiments to further
investigate these findings are part of our current research.
 
Binding epitope determination of the monoclonal anti TS mAb 7/23
Besides  the  anti  Strep-tag  antibody  also  the  anti  TS  mAb  7/23  [12] was  used  for  TconTS
characterisation.  This  mAb  recognises  two  isolated  native  TconTS  forms,  which  where  later
suggested  to  contain  TconTS1  and  TconTS2  [20,21].  In  addition,  this  antibody  was  found  to
precipitate 75% of the TS activity of a native TS from T. congolense cultures [12]. T. Gbem et al.
showed the specific binding of anti TS mAb 7/23 to recombinant TconTS1 and TconTS2, purified
from cell  culture supernatants of  transfected CHO-Lec1 cells,  whereas TconTS3 and TconTS4
were not recognised by the same antibody  [21]. Based on these findings we were interested to
analyse the corresponding binding epitope of this anti TS mAb 7/23, also to employ the antibody in
further applications including characterisation of domain swapped TconTS. 
To analyse and possibly locate the binding epitope,  different  truncated recombinant  TconTS1a
fragments were generated. A schematic overview of these constructs is provided in Figure 4 A. In
total, five TconTS1-CD (Figure 4 A, constructs A-E) and two TconTS1-LD (Figure 4 A, constructs F
and G) fragments,  varying in  length,  were cloned and expressed by  E. coli Rosetta  pLacI  as
described under Methods. Bacterial lysates containing truncated recombinant TconTS fragments
were used for epitope mapping, employing Western blot analysis using anti Strep-tag and anti TS
mAb 7/23.
Results of the corresponding Western blot analysis are illustrated in Figure 4 B-D. It can be seen
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that none of the truncated recombinant TconTS1-CD constructs (A-E) were recognised by the anti
TS mAb 7/23 (Figure 4 B). Wild type TconTS1a, comprising CD and LD, expressed by bacteria
was detected by anti TS mAb 7/23, but with significantly lower signal intensity compared to the
control  TconTS1a expressed by  fibroblasts  (Figure  4  B).  Interestingly,  signal  intensities  of  the
truncated constructs as well as wild type TconTS1a expressed by bacteria, were comparable when
using the anti Strep-tag antibody, indicating that the same amount of each protein was used in both
Western blots. In contrast, when analysing lysates of the two recombinant TconTS1a-LD constructs
A and B, both proteins were detected by the anti TS mAb 7/23 (Figure 4 C), clearly demonstrating
the binding epitope to be localised in the LD. In addition, a similar observation regarding the lower
signal intensity for wild type TconTS1a expressed by bacteria compared to the eukaryotic construct
(Figure 4 C), was obtained as discussed above. Furthermore, when testing the other recombinant,
bacterial wild type TconTS2, TconTS3 and TconTS4 as well as their truncated recombinant LDs
(Figure 4 D), none of them were recognised by the anti TS mAb 7/23. Recombinant proteins were
generated according to TconTS1a, described under Methods. Surprisingly also TconTS2 constructs
(wild type and LD) expressed by bacteria, were not detected by the antibody, which appears in
contrast to previous findings, when using TconTS2 expressed by fibroblasts [21].
Since one of the main differences between protein expression in CHO-Lec1 and  E.coli Rosetta
pLac1  represents  the  missing  glycosylation,  in  case  of  the  latter.  Eukaryotic  TconTS1a  and
TconTS2 were treated with peptide-N-glycosidase F (pNGaseF) to investigate the influence on
antibody binding.  Interestingly,  it  was found that  N-deglycosylation of  TconTS1a and TconTS2
under  native  conditions  drastically  reduced  the  binding  affinity  of  anti  TS  mAb  7/23  to  both
enzymes, indicated by the weak bands at 110 kDa (Figure 4 E). Furthermore, pNGaseF treatment
under denaturing conditions completely eliminated the binding of anti TS mAb 7/23 to TconTS1a as
well as to TconTS2 (Figure 4 E). These observations indicate the N-glycan dependency of the anti
TS mAb 7/23 binding to both, TconTS1a and TconTS2.
 
Biochemical characterisation of domain swapped TconTS
Selected recombinant domain swapped TconTS constructs, expressed by bacteria and fibroblasts
were purified in sufficient amounts and analysed employing SDS-PAGE and Western blot analysis
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as described under Methods. Therefore anti  TS mAb 7/23 was used, which can be utilised to
differentiate mutated and chimeric TconTS constructs expressed by CHO-Lec1, since the binding
epitope  of  anti  TS  mAb  7/23  is  located  in  the  LD  of  TconTS1  and  TconTS2.  For  example,
TconTS1a* and TconTS2* as well as the corresponding wild type TconTS are detectable using the
anti TS mAb 7/23, whereas domain swapped TconTS1a/TS3 and TconTS2/TS4 are not. Figure 3 D
illustrates the results of the corresponding Western blot analysis. Anti TS mAb 7/23 and Strep-tag
antibodies were used separately for detection, although the protein amount was keept constant in
both blots. As expected, TconTS1a and TconTS2 wild type (Figure 3 D) were clearly detected using
both antibodies. In addition, the domain swapped TconTS1a/TS3 was only detectable using the
anti Strep-tag antibody but not with the anti TS mAb 7/23 (Figure 3 D). Surprisingly, compared to
TconTS1a and TconTS2, binding of 7/23 to TconTS1a* and TconTS2* was drastically reduced and
not even detectable for TconTS2* under the conditions used (Figure 3 D). Nevertheless, results
clearly  demonstrate that  the anti  TS mAb 7/23 can be used as a specific  tool  to differentiate
domain swapped TconTS enzymes on protein level. It will be of significant importance to further
analyse  the  reasons  for  the  drastic  reduction  of  anti  TS mAb 7/23  binding  to  TconTS1*  and
TconTS2*.
 
Determination of the influence of TconTS-LD on enzyme activity employing HPAEC-PAD
analysis
TconTS1 and TconTS2 were described as the two most active enzymes with specific activities 100-
to 1000 fold higher compared to those observed for TconTS3 and TconTS4, respectively [20,21].
Therefore,  we  wanted  to  investigate  a  potential  change  in  specific  catalytic  activities  when
exchanging the LD of a highly active (TconTS1 and TconTS2) with that of a lower active TconTS
(TconTS3 and TconTS4). Recombinant domain swapped TconTS1a/TS3 (Table 4) was selected
and  expressed  by  E.  coli Rosetta  pLacI  and  CHO-Lec1  fibroblasts.  To  determine  specific
enzymatic activities, fetuin and lactose were used as Sia donor and acceptor substrates in TS
reactions using standard conditions described under Methods. Reaction products were isolated
and  characterised  employing  high  performance  anion  exchange  chromatography  with  pulsed
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amperometric  detection  (HPAEC-PAD),  a  method  optimised  for  the  analysis  of  carbohydrates
(described under Methods).
In the first instance, we wanted to compare the specific catalytic activities of wild type TconTS
expressed by bacteria or fibroblasts. Therefore, TconTS1a was expressed by E. coli Rosetta pLacI
and subsequently purified as described under Methods. Different amounts of  bacterial,  recom-
binant TconTS1a were incubated with fetuin and lactose as Sia donor and acceptor substrates
under standard conditions for 30 min at 37°C. Reaction products 3-sialyllactose (3'SL) and Neu5Ac
were quantified and data analysis was done as described under Methods (results are illustrated in
Figure 5 A - D). 
3'SL  concentrations  determined  (up  to  8  ?M  3'SL),  using  increasing  amounts  of  enzyme,
suggested that the equilibrium is still not reached, even when using 3 ?g of bacterial TconTS1a
under standard conditions for 30 min of incubation (Figure 5 A). In addition, only relatively low
concentrations  of  free  Neu5Ac  (70  nM)  were  detected  (Figure  5  B).  Along  this  line,  1  ?g  of
TconTS1a was used in  the  following TS activity  time series  under  standard  conditions,  using
different reaction times ranging from 0 to 24 h. Results are presented in Figure 5 C and D. It can
be seen that after 24 h of incubation using 1 ?g enzyme the concentration of 3'SL (approximately
80 ?M 3'SL) is not at equilibrium, which possibly would be reached at about 100 ?M 3'SL (Figure 5
C).  In  addition,  clear  sialidase  activity  was  observed,  indicated  by  the  formation  of  Neu5Ac
reaching 3.8 ?M after 24 h of incubation (Figure 5 D). However, compared to specific catalytic
activities observed for recombinant TconTS1 expressed by CHO-Lec1 cells [20,21], these findings
clearly  demonstrated  approximately  500  to  1700  fold  lower  specific  enzyme  activities  of
recombinant TconTS1a expressed by E. coli Rosetta pLacI (Figure 5 E and Table 5). Nevertheless,
both  recombinant  TconTS1a  enzymes,  expressed  by  bacteria  or  fibroblasts,  exhibited  similar
overall  enzymatic behaviour with higher Sia transfer to sialidase activity rates (Figure 5 E and
Table 5). 
In following experiments, 1 ?g of bacterial expressed and purified TconTS1a, TconTS3 and domain
swapped  TconTS1a/TS3,  were  incubated  with  fetuin  and  lactose  as  Sia  donor  and  acceptor
substrates for 24 h under standard conditions (described under Methods).
Wild type TconTS1a expressed by bacteria produced around 80 ?M 3'SL and 4.24 ?M Neu5Ac
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(Figure 6 A-C). In contrast, wild type TconTS3 from E. coli  generated only 1.2 ?M 3'SL and 2.32
?M Neu5Ac, demonstrating a higher sialidase then Sia transfer activity, which is in sharp contrast
to  TconTS3  expressed  by  CHO-Lec1,  which  did  not  show  detectable  sialidase  activity  [21].
Interestingly,  the  domain  swapped  TconTS1a/TS3  showed  contrary  overall  enzyme  behaviour
compared to wild type TconTS1a, indicated by the formation of 2.5 ?M 3'SL and 4.5 ?M Neu5Ac
(Figure 6 A-C). Hence, demonstrating a drastically decrease in Sia transfer activity, by a factor of
32 compared to  wild  type TconTS1a,  but  two fold  higher  to  wild  type  TconTS3 (Figure  6  C).
Furthermore, a two fold higher sialidase activity for TconTS1a/TS3 (4.5 ?M Neu5Ac) was observed
compared to that found for wild type TconTS3 (2.3 ?M Neu5Ac), but similar to that of wild type
TconTS1a  (4.2  ?M  Neu5Ac).  In  summary,  it  can  be  concluded  that  domain  swapped
TconTS1a/TS3 expressed by bacteria, is double as active as TconTS3 or a modified TconTS1a-
analogue with a drastically reduced Sia transfer activity.
We also wanted to investigate the enzyme activity  of  TconTS1a/TS3 expressed by CHO-Lec1
cells, besides the bacterial domain swapped TconTS1a/TS3. For TS reactions, 50 ng recombinant
TconTS1a/TS3 expressed and purified from CHO-Lec1 were incubated with fetuin and lactose as
Sia  donor  and  acceptor  substrates  for  30  min  under  standard  conditions  (described  under
Methods). The set up for TS reactions of wild type TconTS1a and mutated TconTS1a* expressed
by  CHO-Lec1  cells  was  performed  according  to  that  for  TconTS1a/TS3.  Unfortunately,
TconTS2/TS4  could  not  be  prepared  in  sufficient  amounts  and  purity  for  reasonable  activity
analysis  (see  previous  chapters).  However,  mutated  TconTS2*  was  expressed and purified  in
adequate concentrations and purity and was used to investigate a possible influence of the two
inserted  amino  acid  residues  (Tyr-Val)  on  enzymatic  activities.  Figure  6  D-F  summarise  the
experimental results from HPAEC-PAD analysis of the reaction products 3'SL and Neu5Ac.
82 and 54 ?M 3'SL (Figure 6 D and F) as well as 2.64 and 1.7 ?M Neu5Ac (Figure 6 E and F) were
produced by  wild  type TconTS1a and TconTS2,  respectively.  Surprisingly,  mutated TconTS1a*
showed a drastically reduced production of about 31 ?M 3'SL compared to wild type TconTS1a (82
?M 3'SL). On the other hand, 1.48 ?M Neu5Ac were generated by mutated TconTS1a*, which is
similar to the 1.7 ?M Neu5Ac produced by wild type TconTS2 (Figure 6 E and F). Surprisingly, in
addition to that, domain swapped TconTS1a/TS3 generated only a slightly lower 3'SL concentration
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of about 72 ?M compared to wild type TconTS1a (82 ?M 3'SL), but a clearly reduced Neu5Ac
concentration of 0.47 ?M (Figure 6 D-F). Thus demonstrating a reduction in Sia transfer activity by
only 12 % but a reduction in sialidase activity by even 82 %, compared to wild type TconTS1a
(Figure 6 D-F).
In addition, similar 3'SL concentrations were found for wild type TconTS2 (54 ?M 3SL) and mutated
TconTS2* (55 ?M 3'SL), demonstrating similar Sia transfer activities (Figure 6 D and F). However,
drastic  differences  in  Neu5Ac  production  were  observed  for  wild  type  TconTS2  and  mutated
TconTS2*, whereas 1.7 ?M Neu5Ac were generated by the former and 6.7 ?M by the latter (Figure
6 E and F). In summary, both CHO-Lec1 expressed, mutated enzymes TconTS1a* and TconTS2*
exhibited clear Sia transfer and sialidase activities, but significantly different from that of wild type
TconTS1a  and  TconTS2,  respectively  under  conditions  used.  Interestingly,  domain  swapped
TconTS1a/TS3 showed a more similar Sia transfer (72 ?M 3'SL) then sialidase activity (0.47 ?M
Neu5Ac) compared to wild type TconTS1a (82 ?M 3'SL and 2.64 ?M Neu5Ac).
In summary, taking all  these enzyme activity data together,  it  can be concluded that generally
TconTS  enzymes  expressed  by  CHO-Lec1  cells  exhibit  orders  of  magnitude  higher  overall
enzymatic activities compared to those expressed by E. coli. Furthermore, sialidase activity is more
pronounced for  TconTS expressed by  E. coli  compared to enzymes expressed by CHO-Lec1,
which  exhibited  clearly  higher  Sia  transfer  activities.  Regarding  the  domain  swapped
TconTS1a/TS3, it can be suggested that the LD of TconTS3 in the chimeric enzyme TconTS1a/TS3
suppresses its sialidase activity when expressed by CHO-Lec1 cells. In contrast to that, the exact
contrary  effect  was  observed  for  the  bacterial  domain  swapped  TconTS1a/TS3.  It  was
demonstrated, that the LD of TconTS3 maintain sialidase activity but suppress Sia transfer activity
of recombinant TconTS1a/TS3, when expressed by E. coli.
In addition to the biochemical characterisation of domain swapped TconTS, also the influence of
1,4-?-mannotriose  on  the  enzymatic  activities  of  wild  type  TconTS1a  and  TconTS2  was
investigated. Our previous findings have demonstrated that TconTS-LD is a carbohydrate binding
domain  with  a  specific  affinity  for  oligomannose  oligosaccharides,  besides  serval  other
oligogalactosyl  oligosaccharides  [23].  Hence  it  was  hypothesised  that  due  to  its  carbohydrate
binding ability, the LD of TconTS may additionally bind the same substrate as its CD and therefore
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potentially directly effecting the overall enzyme activity. To investigate this hypothesis, CHO-Lec1
expressed wild type TconTS1a and TconTS2 were incubated with fetuin and lactose as Sia donor
and acceptor substrates under standard conditions for 30 min, in the presence and absence of 5
mM 1,4-?-mannotriose  (described  under  Methods).  Reaction  products  3'SL and Neu5Ac were
analysed and quantified as described under Methods. Indeed, a significant effect on enzymatic
activity for both, TconTS1a and TconTS2, in the presents of 1,4-?-mannotriose could be observed
(Figure 7 A-C). In the absence as well as in the presence of 1,4-?-mannotriose, no significant
change in 3'SL production was observed neither for TconTS1a (66 ?M and 65 ?M) nor TconTS2
(60 ?M and 61 ?M). Interestingly, both enzymes showed a clear decreased Neu5Ac production in
the presence of  1,4-?-mannotriose (TconTS1a:  0.45 ?M, TconTS2:  0.32 ?M) compared to  the
corresponding samples without the addition of 1,4-?-mannotriose (TconTS1a: 2.74 ?M, TconTS2:
1.7 ?M) after 30 min of incubation.
 
Discussion
Based  on  our  findings,  namely  identifying  TconTS-LD as  a  carbohydrate-binding  domain  with
specific  affinities  to  oligomannosyl  oligosaccharides  [23],  we  have  hypothesised  that  the  LD
modulates  TconTS  catalytic  activities,  due  to  additional  binding  of  TconTS-LD  to  the  same
substrate,  influencing  the  overall  binding  affinities  or  catalytic  turnover.  To  investigate  this
hypothesis,  we established a novel strategy to simply and efficiently  swap CDs and LDs from
different TconTS. Chimeric, domain-swapped recombined TconTS were expressed by  E.coli and
CHO-Lec1 cells and subsequently purified to characterise enzymatic activities.
So far, only very minor attention has been payed to the lectin domain of TS. Smith and Eichinger 
described  the  expression  and  characterisation  of  TcruTS/TranSA  hybrid  proteins,  exhibiting
different  Sia  transfer  and sialidase activities  [35].  They found that  the  C-terminal  Fn3 domain
(fibronectin type III), named according to its structural relation to fibronectin type III, is not only
required for expression of enzymatically active TcruTS and TranSA [1,36,37], but also influences
the overall  Sia transfer and sialidase activities  [35]. Amino acid sequence alignments of a well
characterised sialidase from M. viridifaciens [38] with TcruTS revealed that R572 and E578, which
are  known  to  be  essential  for  galactose  binding  of  M.  viridifaciens sialidase  [38],  are  well
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conserved in TcruTS and TranSA [35]. Point mutation of one of these residues resulted in reduced
sialidase  activities  for  both  enzymes and enhanced  Sia  transfer  activity  in  TcruTS  [35].  As  a
consequence of these findings Smith and Eichinger predicted both amino acid residues (R572 and
E578 in TcruTS) to be involved in galactose binding of the acceptor and/or donor substrates, which
would necessarily require an overall protein folding that brings the catalytic domain and the region
containing the Arg and Glu of Fn3 domain (at least R and E) close together  [35]. However, the
resolved crystal structures of TcruTS [11] and TranSA [32] demonstrated that these two amino acid
residues are located far away from the actual Sia binding pocket of the catalytic domain, and
therefore, they are unlikely to be directly involved in substrate binding as proposed by Smith and
Eichinger [35]. Nevertheless, even if these residues do not interact with the galactose moiety of the
acceptor/donor substrate, R611 and E617 of TranSA (correspond to R572 and E578 in TcruTS)
were  found  to  form  a  intramolecular  salt  bridge  at  the  C-terminus  of  the  lectin  domain  [32]
apparently indirectly influencing enzymatic activities, since its disruption was found to change Sia
transfer and sialidase activities, respectively [35]. Interestingly, structural and amino acid sequence
alignments  of  TcruTS  (EMBL:  AAA66352.1),  TbruTS  (EMBL:  AAG32055.1),  TranSA (EMBL:
AAC95493.1) and TconTS revealed that this salt bridge is conserved among all TS used (Figure
S1 A), indicating a possibly essential role in trypanosomal trans-sialidase activities.
Furthermore, our results for TconTS enzymatic activities using mixtures of two different TconTS
enzymes revealed an altered overall enzymatic behaviour compared to that determined for each
TconTS individually (T.T. Gbem, personal communication). Interestingly, none of the four TconTS1
through TconTS4 enzymes was able to efficiently release Sia from methylumbellyferone-Neu5Ac
(MU-Neu5Ac) neither in the presence nor in the absence of a suitable acceptor substrate [21]. In
contrast, if any other TconTS was added to either TconTS1 or TconTS2, cleavage of MU-Neu5Ac
was clearly observed (T.T. Gbem, personal  communication).  This supports our hypothesis of a
potential cooperative interaction of TconTSs, possibly mediated by the lectin domain, leading to
modulation of substrate specificities.
Furthermore, it should be noted that besides the active TconTS described [20,21] three additional
genes were identified, sharing only 20-30 % amino acid sequence identity [21]. They lack most of
the conserved amino acid residues known to be involved in enzymatic activity and therefore, it has
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been assumed that these genes coding for catalytically inactive TconTS, thus they were termed
TconTS-like proteins [21]. Their function is not known but it has been proposed that they serve as
cell adhesion proteins or may just be involved in cooperative interactions with active TconTS to
modulate their enzymatic activities [21].
 
Structural insights into the contact site between CD and LD of TTS
Buschiazzo et al. first observed that the interface between TcruTS CD and LD is significantly larger
(2550 Å2) compared to other bacterial and viral sialidases (1300 – 1600 Å2)  [11]. Furthermore,
Amaya et al. found that also the molecular surface of the contact site in TranSA is more extended
(about 2600 Å) [32]. Along this line, we calculated the area of the molecular interfaces of TconTS1,
TconTS2, TconTS3 and TconTS4 and observed area sizes analogous to those obtained for TcruTS
and TranSA (Table  1).  Slight  difference in  area size between TconTS and TcruTS as well  as
TranSA might be due to different settings used in in silico calculations, but it should be noted that
the relative areas are very similar. In conclusion, in both publications [11,32] the authors predicted
a relatively rigid overall TS core structure precluding a direct involvement of the LD in enzymatic
catalysis, which is in agreement with our hypothesis that the LD is indirectly involved in Sia transfer
activity instead, potentially by modulating the affinities of the enzymes for several donor/acceptor
substrates [23]. In conclusion, the extended interfaces between CD and LD seems to be a typical
feature for trypanosomal TS.
Therefore, we investigated the structural architecture at the contact site between TconTS CD and
LD in more detail. Interestingly, our TconTS homology models revealed that the majority of amino
acids localised at the contact site between CD and LD are well conserved among TconTS family
members (Figure 1 D, Table 3), indicating a high pressure to maintain these during evolution of
these TconTS genes [21]. When calculating the hydrogen bond network formed between residues
at the interface between CD and LD, eleven to thirteen potential hydrogen bonds were observed
for  TconTS1 through TconTS4,  which  is  similar  to  the  number  found for  TranSA and in  clear
contrast  to  other  sialidases,  where  only  about  half  of  this  have  been  found  [32].  Mainly  two
separate locations, A and B (Figure 1), comprise the majority of hydrogen bonds formed, evenly
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distributed over both locations. Area A is located at the region where CD, LD and the ?-helix are in
close contact (Figure 1 A, B), whereas area B is located more closely to the Sia binding pocket of
CD (Figure 1 A, C), opposite of A. We assume that the contacts at area B keep the catalytic grove
of CD close to the hypothesised binding site of LD, thus providing a well defined orientation of both
domains relative to each other and preventing even minor rotations around theoretical axis along
the ?-helix, which would induce a more drastic effect on more distant locations. Interactions in area
A are predicted to stabilise the protein core conformation in a similar manner as described for B.
Strikingly, amino acid residues involved in hydrogen bond network formation at both sites, A and B,
are particularly well conserved (Table 3). For example Gln (18 in Table 3) in the LD, which is part of
area B reaches deep into the CD and forms hydrogen bonds to a conserved Gly (4), to Lys (7),
conserved in all TconTS except TconTS2, where it is replaced by Glu, which also forms a hydrogen
bond, and finally to Arg (5), which is well conserved among African TS including TranSA (Figure 1
A and C, Table 2 and 3). In area A a similar situation was observed, where five essential amino
acid residues, Arg (9), Trp (10), Asp (12), Leu (14) and Tyr (15), are mainly responsible for the
distinct hydrogen bond network in that region (Figure 1 A and B, Table 2 and 3). Since all these
amino acid residues are highly conserved in the TS family despite their different catalytic activities
(e.g. of TranSA), it appears unlikely that this has a direct influence on the catalytic Sia transfer.
Nevertheless, the proposed simultaneous binding of both domains to the same substrate requires
such a stabilised conformation of the two domains as provided by the conserved hydrogen bonding
networks, which thus keep the substrate in an appropriate orientation for a Sia transfer.
 
A novel strategy to efficiently swap catalytic and lectin domains of TS
Based on the fact that the majority of amino acid residues localised at the contact sites between
CD and LD are well conserved in the TconTS family, we rationed that it might be possible to swap
the domains of  different  TconTS to investigate the influence of  LD on enzymatic activities.  To
achieve this we introduced a unique restriction site into the sequence coding for a hairpin loop,
which is located right after the ?-helix, connecting CD and LD. This appeared to be a good location
to join CD and LD from different TS for several structural reasons: (I) This loop seems to be highly
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flexible, since it is not resolved in the crystal structure of TcruTS or TranSA [11,39]. (II) The hairpin
loop segment is not well conserved showing a high amino acid sequence diversity between all
TconTS (Figure 2 A). (III) The loop is sterically distant from the catalytic pocket of CD and the
predicted carbohydrate binding-site of LD. To further investigate the theoretical structure stability of
the chimeric TconTS a structure homology model was generated  in silico, using as example the
domain  swapped  TconTS1a/TS3 comprising  CD of  TconTS1a  and  LD of  TconTS3.  Indeed,  a
homology model of TconTS1a/TS3 (data not shown) was obtained, in which CD and LD exhibited
similar structure topology to CD of wild type TconTS1a and LD of wild type TconTS3, respectively.
Interestingly, when investigating the interface between CD and LD of TconTS1a/TS3, 11 hydrogen
bonds were observed formed by amino acid residues, which were predicted to be essential for
conformation stability of the wild type TconTS as discussed above. These observations underline
the possibility of such a rearrangement of TconTS genes, which would provide an explanation for
the separate evolution of TconTS domains [21].
These considerations encouraged us to employ this strategy for the recombination of CDs and LDs
from  different  active  TconTS.  Expression  of  recombinant  domain  swapped  TconTS1a/TS3  by
bacteria (E. coli Rosetta DE3 pLacI) and fibroblasts (CHO-Lec1) revealed sufficient amounts of
soluble  and  most  notably  active  enzyme,  whereas  catalytic  activities  observed  for  both
recombinant proteins differed by orders of magnitude. TconTS1a/TS3 expressed by CHO-Lec1
cells  showed  500  to  1800  fold  higher  Sia  transfer  and  sialidase  activities  compared  to  that
expressed  by  E.  coli  (Figure  6  A-F).  One  explanation  for  this  effect  might  be  the  missing
glycosylation  of  bacterial  expressed  proteins.  In  addition,  a  high  amount  of  improperly  folded
TconTS1a/TS3 in preparations of bacterial enzymes cannot be excluded. Furthermore, successful
bacterial expression of active CD and LD separately, was already performed and demonstrated the
effective folding of each domain independent of the other [23].
Nevertheless, it can be concluded that in general employing the strategy established in this study
has worked well to exchange LDs from different TconTS enzymes. 
Also the domain swap of CDs and LDs from different TS family members, such as TcruTS, TbruTS,
TranSA or  Trypanosoma vivax TS (TvivTS)  to  further  investigate  the  role  of  LD in  enzymatic
activity, might be of reasonable interest. Smith and Eichinger expressed several TcruTS/TranSA
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hybrid proteins, varying in length, to identify the minimum amino acid sequence, which is required
for Sia transfer activity [35]. Results revealed that Sia transfer activity was increased, ether when
mutating the C-terminal located R642 or E648, which were suggested to be directly involved in
substrate binding [35]. In addition, the relevance of these findings were supported by Amaya et al.,
who demonstrated that both residues form a salt bridge in the LD of TcruTS [40]. Homology models
and amino acid sequence alignments of TS calculated in this study showed that this crucial salt
bridge is well conserved in the TS family (Figure S1 A) and furthermore, suggested that it remains
intact when swapping TS domains, using the strategy presented here.
 
A shared oligosaccharide dependent  epitope for  the anti  TS mAb 7/23 localised in  the LD of
TconTS1 and TconTS2
Tiralongo et al. generated an anti TS mAb 7/23 [12], which was later found to specifically bind both,
recombinant TconTS1 and TconTS2, but not TconTS3 and TconTS4,  [20,21]. Furthermore, also
recombinant TcruTS and TbruTS were not detectable on western blots using the anti TS mAb 7/23
[12], indicating its specificity for TS from T. congolense. Here we partially identified the antibody
binding epitope, using recombinant truncated TconTS1 proteins expressed by bacteria and varying
in length (Figure 4 A). Interestingly, only expression products containing TconTS1-LD (Figure 4 C)
were detectable in Western blot analysis, but none of the truncated TconTS comprising only parts
of CD. These data suggested that the binding epitope is located somewhere in the LD of TconTS1.
Surprisingly, compared to TconTS1 expressed by CHO-Lec1 cells, drastically reduced binding to
bacterial protein was observed, even when applying high amounts of antigen in Western blots. This
effect was not likely to be due to improper folding in the bacteria, since the anti TS mAb 7/23
bound well to TconTS1 denatured under reducing conditions, which consequently indicated a linear
epitope not requiring appropriate folding of the protein for antibody recognition.
In  a  previous  study  we  have  demonstrated  that  oligomerisation  of  TconTS1a  is  mediated  by
binding to N-linked oligomannose glycans, since pNGaseF glycosidase treated TconTS1a reduced
the degree of  oligomerisation  [23].  Surprisingly,  these experiments revealed new insight in  the
binding  epitope  of  the  anti  TS  mAb  7/23.  When  employing  the  anti  TS  mAb  7/23  to  detect
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TconTS1a  after  deglycosylation  with  pNGaseF,  the  corresponding  signal  intensities  drastically
decreased (Figure 4 E). These surprising findings clearly demonstrated that the presence of a N-
glycan is required for efficient binding of anti TS mAb 7/23 to its epitope. However, the fact that
TconTS1a expressed by bacteria, which is not glycosylated, is still detectable with the anti TS mAb
7/23  indicates  that  the  binding  epitope  comprises  an  amino  acid  stretch  containing  a  N-
glycosylation site,  which is present in both, TconTS1a and TconTS2. The observation, that we
could not detect binding of anti TS mAb 7/23 to bacterial TconTS2 might be explained with minor
differences in the amino acid sequence in the epitopes of TconTS1a and TconTS2.
In summary, it can be concluded that the anti TS mAb 7/23 recognises an epitope, which is  N-
glycan dependent and localised in the lectin domain of TconTS1 and TconTS2. Thus, it can be
expected to be a more exposed region in TconTS1-LD and TconTS2-LD, which (I) comprise an N-
glycosylation site,  which (II)  is  not  present  in  TconTS3,  TconTS4,  TcruTS, TbruTS or  TranSA.
Indeed,  when  screening  the  TS  amino  acid  sequence  alignments,  we  found  a  short  stretch
complying with both these criteria (Figure S1 A). Furthermore, in structure homology models of
TconTS1a  and  TconTS2  this  regions  are  relatively  exposed  to  solvent  (Figure  S1  B),  thus
suggesting that this region is at least part of the epitope and that the Asn residue in that sequence
(N657 in TconTS1, N640 in TconTS2) is glycosylated. However, in order to confirm the proposed
binding epitope of anti TS mAb 7/23, it will be necessary to change this region by mutagenesis
experiments, including in particular mutants eliminating the glycosylation motif of N657 and N640
in TconTS1 and TconTS2, respectively.
Interestingly, Tiralongo et al. demonstrated the ability of anti TS mAb 7/23 to immunoprecipitate 75
% of TS activity present in a native TS-containing sample from T. congolense culture supernatants
[12]. Thus, the majority of the TS activity in this TS-containing sample is due to TconTS1 and
possibly TconTS2, but the presence of other TconTS is well possible [21]. Since the anti TS mAb
7/23 has only week inhibitory activity (20%), it will  be interesting to investigate its influence on
recombinant TconTS1 and TconTS2 expressed by CHO-Lec1 cells. Along this line, it will be also
interesting to determine enzymatic activities of mutants where the  N-glycosylation sites at N657
(TconTS1) or N640 ( TconTS2) is changed, to investigate the influence of that N-glycosylation site
on catalytic activities.
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Specific enzymatic activities of domain swapped TconTS demonstrated the complexity of catalytic
mechanisms
The specific enzymatic activities of TconTS1a and TconTS3 expressed by  E. coli was orders of
magnitudes lower (500 to 1800 fold) compared to previously reported activities of these enzymes
expressed by CHO-Lec1 cells [20,21]. Nevertheless, for bacterial TconTS1 the ratio of Sia transfer
to sialidase activities were similar to those reported for the eukaryotic protein [20]. Also the ratio for
specific Sia transfer activities, TconTS1a being about 100-fold more active than TconTS3, was
similar to that for enzymes from CHO-Lec1 cells [21]. However, the opposite ratio for Sia transfer to
sialidase activity was obtained for TconTS3 expressed by E. coli, which surprisingly had a higher
sialidase than TS activity (Table 5). The drastically lower activities of bacterial TconTS compared to
that expressed by CHO-Lec1 cells is most likely due to either inefficient protein folding or lack of
glycosylation, which might influence enzymatic activities, but to our knowledge has never been
investigated in detail. The lack of glycosylation may have a bigger effect on TconTS compared to
TcruTS, since only two N-glycosylation sites were predicted for TcruTS compared to 8-9 potential
sites for TconTS1 through TconTS4, in comparison to TbruTS with 4 and TranSA with 5 predicted
N-glycosylation  sites  [23].  However,  it  should  be  noted  that  only  very  little  is  known  about
glycosylation of native TS so far. TbruTS from procyclic trypanosomes has been found to be  N-
glycosylated with high-mannose type oligosaccharides [3], leading to the assumption of a similar
situation  for  TconTS.  Both  T.  brucei and  T.  congolense  bloodstream  (mammalian  host)  and
procyclic  (tsetse vector)  forms contain high-mannose type  N-glycans on the parasites surface,
linked to amino acid residues of the polypeptide or as part of the GPI (glycosylphosphatidylinositol)
anchor [28-31,41-43].
In  a  next  step,  enzymatic  activities  were  determined  for  domain  swapped  TconTS1a/TS3
expressed by  E. coli.  According to the assumption that the LD of TconTS indirectly influences
enzymatic  activities,  it  was  expected  that  LD  of  the  less  active  TconTS3  may  decrease  the
enzymatic activities, if attached to the CD of a highly active TconTS. Indeed, an over 30-fold lower
3'SL production (2.5 ?M 3'SL) was observed for chimeric TconTS1a/TS3 compared to wild type
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TconTS1a (80 ?M 3'SL), but it was still two-fold higher compared to wild type TconTS3 (1.2 ?M
3'SL) (Figure 6 C). Surprisingly, the situation was different for the sialidase assays, where similar
specific sialidase activities (Figure 6 C) were observed for TconTS1a/TS3 (4.5 ?M Neu5Ac) and
wild type TconTS1a (4.2 ?M Neu5Ac), whereas only the half (2.3 ?M Neu5Ac) was generated by
wild  type  TconTS3.  Summarising  these  findings,  it  can  be  concluded  that  the  exchange  of
TconTS1a-LD with that  from TconTS3 lead to an active chimeric TconTS1a/TS3 expressed by
bacteria, which can be described either as a modified wild type TconTS1a variant with a drastically
lower Sia transfer, but equal sialidase activity, or as a twice as active wild type TconTS3. The
impact  of  the  LD  exchange  in  TconTS1a/TS3  on  enzymatic  activities  becomes  even  more
apparent, when comparing the ratios of Sia transfer/sialidase activities of wild type TconTS1a and
domain swapped TconTS1a/TS3 (Table 5). A ratio of 0.55 for TconTS1a/TS3 illustrated that the
ratio is clearly shifted from primarily Sia transfer in TconTS1a (ratio 109) to primarily sialidase
activity  obtained  for  the  bacterial  chimeric  enzyme.  Thus,  it  can  be  concluded  that,  if  LD  of
TconTS3 is attached to CD of TconTS1a the Sia transfer/sialidase ratio is decreased by the factor
of  200,  or  in  other  words  TconTS3-LD  appears  to  suppress  the  Sia  transfer  activity  in
TconTS1a/TS3, while retaining its sialidase activity.
In the next step enzymatic activities of the domain swapped TconTS1a/TS3 expressed by CHO-
Lec1 cells  were determined.  Interestingly,  a completely different  situation regarding the overall
catalytic activities were observed. For example, similar Sia transfer activities for TconTS1a/TS3
(2409 nmol/(min x mg TS)) and TconTS1a (2732 nmol/(min x mg TS)) were determined, whereas
sialidase activity of domain swapped TconTS1a/TS3 was reduced by 82% relative to that of wild
type TconTS1a (Table 5).  In summary, the domain swap of TconTS1a-CD and TconTS3-LD in
CHO-Lec1  cells  significantly  reduced  the  sialidase  relative  to  the  Sia  transfer  activity  for
TconTS1a/TconTS3 compared to wild type TconTS1a. Regarding the Sia transfer/sialidase activity
ratio for wild type TconTS1a (31) and domain swapped TconTS1a/TS3 (153) expressed by CHO-
Lec1  cells,  it  can  be  concluded  that  TconTS3-LD significantly  suppressed  sialidase  activity  in
TconTS1a/TS3  by  the  factor  of  5,  relative  to  that  of  wild  type  TconTS1a.  Interestingly,  these
findings are exactly contrary to those observed for bacterial expressed enzymes discussed above.
Finally, it can be concluded that TconTS3-LD in TconTS1a/TconTS3 enhanced sialidase activity of
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the chimeric enzyme when expressed by E. coli and suppressed sialidase activity when expressed
by CHO-Lec1 cells. Actually, this completely matches the situation observed for TconTS3 wild type
expressed by bacteria,  predominantly a sialidase (Table 5)  compared to TconTS3 produced in
fibroblasts, for which basically no sialidase activity could be detected [21]. It is tempting to assign
this to the lack of glycosylation, predominantly in the LD of TconTS3, since no such effect was
observed for TconTS1a. However, the associated mechanisms still remain unclear. It should be
also noted that a contribution of misfolding of the bacterial and/or eukaryotic expressed chimeric
TconTS1a/TS3 cannot be completely excluded, and may also contribute to the different activities
determined.
In addition to these findings, an interesting effect was observed for the enzymatic properties of
TconTS1a* mutant expressed by CHO-Lec1 cells, whose only modification is the addition of two
amino acids (Tyr-Val) in the hair-pin loop after the domain connecting ?-helix. In contrast to our
expectations,  both,  Sia  transfer  and  sialidase  activities  were  reduced  by  62  %  and  44  %
respectively, compared to those of wild type TconTS1a (Table 5). Obviously, this is not a general
consequence of loop extension, since no such effect was observed for TconTS2*. In contrast, in
that case the Sia transfer of TconTS2* was not changed, but its sialidase activity was fourfold
higher. A possible reason for this unexpected loss of general enzymatic activities of TconTS1a*
might be an effect on the glycosylation of N657, which is in close sterical vicinity to the crucial salt-
bridge between Arg and Glu in TconTS-LD mentioned above and, possibly more important, close
to the hairpin-loop in which the two additional amino acids were introduced (Figure S1 A and B,
Figure 2).
In this context it is important to note that N657 is the predicted N-glycosylation site in TconTS1a
possibly  contributing  to  the  epitope  of  anti  TS  mAb 7/23.  Western  blot  analysis  of  wild  type
TconTS1a,  mutated  TconTS1a*  and  chimeric  TconTS1a/TS3  expressed  by  CHO-Lec1  cells
revealed  that  anti  TS  mAb  7/23  binds  to  both,  TconTS1a  as  well  as  TconTS1a*,  but  not  to
TconTS1a/TS3 as expected, since the two former comprise the predicted epitope located in their
LD (Figure 3 D). However, the signal intensity for TconTS1a* was clearly decreased compared to
that of wild type TconTS1a (Figure 3 D). A reasonable explanation for this surprising observation is
a  less  effective  or  missing  N-glycosylation  of  N657.  Simple  concentration  differences  can  be
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excluded, since similar signal intensities for wild type TconTS1a and mutated TconTS1a* were
observed, when using anti  Strep-tag mAb (Figure 3 D). Similar results were obtained for anti TS
mAb 7/23 binding to wild type TconTS2 and mutated TconTS2*, where the effect was even more
pronounced, as no signal was detected in case of mutated TconTS2*, when using anti TS mAb
7/23 in Western blots (Figure 3 D). It is in complete agreement with our results with enzymatically
deglycosylated proteins discussed above,  that  the decrease or  complete missing of  mAb 7/23
binding is most likely due to a lack of N-glycosylation in the predicted binding epitope.
In summary it can be concluded that introduction of the two amino acids Tyr-Val may change the
conformation of the hairpin-loop resulting in a sterically more restricted conformation of that region,
which potentially prevents efficient  N-glycosylation of N657. In conclusion, we hypothesise that
differences in  enzymatic  activities  of  mutated  TconTS1a*  and wild  type TconTS1a are  due to
changes in the N-glycosylation pattern of the enzymes.
I this context, it should be noted here that  N-glycan-dependent oligomerisation of TconTS1 has
been demonstrated [23], which might also have an impact on enzymatic activities due to TconTS
cluster  formation  and  consequently  enhanced substrate  binding  as  discussed  for  MU-Neu5Ac
using mixtures of different recombinant TconTS. However, the higher Sia transfer activity of domain
swapped TconTS1a/TS3 expressed by CHO-Lec1 compared to mutated TconTS1a* might be due
to  the  N-glycosylation  site  N667  in  TconTS3-LD.  Interestingly,  from  amino  acid  sequence
alignments of TconTSs (Figure S1 A) it can be seen that the predicted N-glycosylation site N667 in
TconTS3-LD is just 16 amino acids further C-terminally located than N657 of TconTS1a (Figure S1
A). Therefore, we propose that in TconTS1a/TS3 N667 possibly adopts a similar function as N657
in TconTS1a, but is slightly less efficient, which would explain its maintained Sia transfer activity
(Table 5). Furthermore, we assume that a possible N-glycosylation of N667 will not be effected by
the extended hair-pin loop of TconTS1a/TS3, since it is more distantly located from the insertion.
Apparently, for TconTS2 the situation is different in some details, since the introduction of Tyr-Val
as in TconTS2* enhanced sialidase activity, whereas Sia transfer is not effected (Figure 6). Similar
to TconTS1a*, this might be explained by modulation of  N-glycosylation, in this case of N658 in
TconTS2 (Figure S1 A). This  N-glycosylation site corresponds to N667 in TconTS3 and is only
conserved in this two TconTS enzymes (Figure S1 A). Similar to the effect of the maintained Sia
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transfer activity of chimeric TconTS1a/TS3 compared to wild type TconTS1a, we hypothesise that
N658 in TconTS2* adopts the function of N640 (corresponding to N657 in TconTS1a), which was
proposed not  to  be glycosylated in  TconTS2*,  a situation which lead to  a reduction in  overall
enzymatic activity of TconTS1a*. Additionally, considering Sia transfer/sialidase activity ratios of
mutated  TconTS1a*  and  TconTS2*  compared  to  the  corresponding  wild  type  TconTS1a  and
TconTS2 it can be concluded that extending the loop by Tyr-Val shifted the transfer/sialidase ratio
in favour of sialidase activity (Table 5).
The results discussed so far suggest that  N-glycans play important  roles in the modulation of
TconTS activities by the LD. Since at least the LD of TconTS2 and TconTS1a interact with high-
mannose N-glycans, we investigated whether 1,4-?-mannotriose, the binding determinant of these
LD, can influence the activities of TconTS1a and TconTS2 produced in CHO-Lec1 cells. Our results
clearly demonstrated that in the presence of 5 mM 1,4-?-mannotriose sialidase activities of both,
TconTS1a and TconTS2, was reduced by the factor of 6. Obviously, a concentration dependency of
1,4-?-mannotriose on enzymatic activities should be determined, to evaluate this inhibitory effect
further. Interestingly, Sia transfer activities for both enzymes remained unchanged by the presence
of 5 mM 1,4-?-mannotriose (Figure 7 A-C). The effect of 1,4-?-mannotriose on enzyme activities
becomes even more apparent,  when considering Sia transfer/sialidase activity ratios (Table 6).
Ratios for TconTS1a (24) and TconTS2 (34) were shifted in favour to the Sia transfer activity site by
the factor of 6 (144 for TconTS1a and 193 for TconTS2), when 1,4-?-mannotriose was present in
enzyme reactions (Table 6). It should be noted that these ratios are very close to that of domain
swapped TconTS1a/TS3. Therefore, we postulate that TconTS-LD activities are influenced by N-
glycosylation and the presence of 1,4-?-mannotriose, and that this effect is also responsible for the
decrease  of  sialidase  relative  to  Sia  transfer  activity  observed  for  chimeric  TconTS1a/TS3,  if
produced in CHO-Lec1 cells, as well as for TconTS3 wild type, which has a much lower sialidase
activity, if expressed by fibroblasts compared to the bacterial protein.
Summarising these results, the influence of LD and probably N-glycosylation on TconTS enzymatic
activities was demonstrated in this study, indicating a more complexity of catalytic mechanisms as
supposed so far. However, the strategy to swap CD and LD of TconTS presented here, can be
further optimised, for example by mutating appropriate amino acids present in the hairpin-loop
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instead  of  adding  two  additional  residues.  This  approach  might  prevent  sterical  demanding
structure of that region, which appears to result in impaired N-glycosylation.
Nevertheless, it would be also necessary to generate other domain swapped TconTS constructs for
a better understanding of the interplay between CD and LD of trypanosomal trans-sialidases. Also
the  proposed  glycosylation  dependency  of  enzymatic  activities  has  to  be  further  investigated
employing completely degylcosylated TconTS expressed by CHO-Lec1. In conclusion, these new
insights  into  enzymatic  properties  of  TS have opened new perspectives  in  understanding  the
mechanisms of these interesting enzyme reactions and finally may support the development of
new  strategies  using  TS  as  potential  target  in  efforts  towards  the  control  of  African
trypanosomiasis.
 
Methods
Materials
Unless  stated otherwise,  all  chemicals  and reagents  used in  this  study  were  cell  culture  and
analytical grade. Recombinant pNGaseF endoglycosidase was from New England Biolabs, United
Kingdom.  Pfu  and  Taq DNA polymerase,  Eco105I,  HindIII,  BamHI, SalI  and  SpeI  Fast  Digest
restriction enzymes,  T4-DNA ligase,  isopropyl-?-D-1-thiogalactopyranoside (IPTG),  Dithiothreitol
(DTT),  Coomassie  Brilliant  Blue  (Page  Blue),  protein  molecular  weight  marker  (PageRuler),
GeneJET DNA Gel Extraction Kit, BCA Protein Assay Kit, enhanced chemiluminescence system
(ECL-Kit),  Luria  Broth  (LB)  microbial  growth  medium,  were  from Thermo Scientific,  Germany.
Biozym LE Agarose was from Biozyme Scientific, Germany. StrepTactin Sepharose, purification
buffers and anti Strep-tag rabbit polyclonal antibody were from IBA, Germany. ?-D-galactosyl-(1-4)-
?-D-glucose  (4?-lactose),  N-acetyl-neuraminic  acid  (Neu5Ac),  3'sialyllactose  (3'SL),  ?-D-
glucopyranuronic acid (glucuronic acid), lyophilised fetuin from fetal calf serum, polyethylene glycol
sorbitan monolaurate (TWEEN 20),  Ex-cell  CD CHO media,  PEI  (Polyethylenimin)  transfection
reagent were from Sigma-Aldrich, Germany. Hygromycin and gentamycin were purchased from
PAA, Austria.  1-4?-D-mannotriose was from Megazyme, Ireland. Ultrafiltration units Vivacell and
Vivaspin6 were from Sartorius, Germany. X-ray film were purchased from GE Healthcare, Sweden.
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Protino Ni-NTA Agarose and NucleoBond Midi Plasmid DNA Purification Kit were from Macherey-
Nagel, Germany. Polyvinylidenedifluoride (PVDF) membranes were from Millipore, Germany. 96-
well transparent microtitre plate were from Sarstedt, Germany. 6 mL gravity flow columns were
from Biorad, Germany.
Cloning and expression of recombinant, domain swapped TconTS
Cloning of TconTS into modified pET28aMBP bacterial expression vector
DNA sequences encoding for TconTS1 (including truncated CD or LD containing variants, Figure 4
A-G), TconTS2, TconTS3 and TconTS4 as well as their LDs were amplified from modified pDEF
vector  [20,21], using the corresponding set of sense and reverse primer listed in Table S1. The
resulting PCR products  were  subcloned into  modified pET28aMBP vector  [23] via  HindIII  and
BamHI (TconTS1, TconTS2 and TconTS3) or  SalI and BamHI (TconTS4) following instructions of
the manufacturers. 
Introduction of Eco105I restriction site into TconTS
To insert the Eco105I endonuclease restriction site into the appropriate location at the hair-pin loop
following  the  domain-connecting  ?-helix  of  TconTS,  sense  and  reverse  primer  were  designed
annealing at  this  target  location and comprising the  Eco105I  site  (Table S1).  DNA sequences
coding for TconTS-CD-?-helix with the  Eco105I site attached at the 5'-end were amplified using
HindIII (TconTS1, TconTS2 and TconTS3) or SalI (TconTS4) sense primer in combination with the
corresponding  Eco105I  reverse  primer  (Table  S1).  In  addition,  DNA sequences  encoding  the
corresponding TconTS-LD sequence with the  Eco105I site attached to the 3'-end were amplified
using  BamHI  (TconTS1 through TconTS4)  reverse  and  the  appropriate  Eco105I  sense primer
(Table  S1).  Both  PCR products  were  digested  using  Eco105I  Fast  Digest  restriction  enzyme
(Thermo Scientific, Germany), purified using GeneJET DNA Gel Extraction Kit (Thermo Scientific,
Germany) and blunt-end ligated using T4-DNA ligase, following instructions of the manufacturers.
Religated  TconTS  DNA sequences  comprising  the  Eco105I  site were  cloned  into  modified
pET28aMBP expression vector using BamHI (TconTS1, TconTS2 and TconTS3) or SalI (TconTS4)
and  HindIII  restriction  enzymes  according  to  manufacturers  instructions.  All  sequences  and
insertions were confirmed by DNA sequencing at the Max Planck Institute for Marine Microbiology,
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Bremen, Germany.
Recombination of CDs and LDs from different TconTS
To generate domain swapped TconTS constructs, corresponding pET28aMBP plasmids encoding
mutated TconTS enzymes were digested with Eco105I and HindIII Fast Digest restriction enzymes
(Thermo Scientific, Germany) to isolate the LD, which was subsequently cloned into a Eco105I and
HindIII digested pET28aMBP plasmid coding for the CD of a TconTS variant different from that of
the isolated LD, following the manufacturers instructions. 
For expression of secreted TconTS constructs in mammalian fibroblasts, DNA sequences coding
for  mutated  TconTS,  only  comprising  the  Eco105I  endonuclease  restriction  site,  and  domain
swapped TconTS constructs were subcloned into the modified pDEF expression vector using SpeI
and HindIII restriction sites as described previously [20].
Purification  of  recombinant  TconTS  expressed  by  E.  coli  Rosetta  (DE3)  pLacI  or  CHO-Lec1
fibroblasts
Recombinant TconTS constructs were expressed by CHO-Lec1 fibroblasts or E. coli Rosetta (DE3)
pLacI and subsequently purified as described previously [20,23].
In  brief,  for  expression of  TconTS constructs  by  E.  coli Rosetta  (DE3)  pLacI,  colonies  freshly
transformed with pET28aMBP plasmid, encoding the TconTS construct, were used for an overnight
culture in Luria Broth (LB) medium containing 50 ?g/ mL kanamycin, incubated at 37°C and 240
rpm shaking. For large scale, 1 L of LB medium containing 50 ?g/ mL kanamycin was inoculated
with 2 mL of the overnight culture and grown at 37°C and 240 rpm until an optical density of 0.5 at
600 nm was reached. Induction was done using isopropyl-?-D-1-thiogalactopyranoside (IPTG, 0.1
mM  final  concentration)  for  30  min  at  37°C  followed  by  incubation  at  4°C  and  240  rpm  for
additional 14 h.  E. coli Rosetta (DE3) pLacI cultures expressing TconTS-LDs were induced with
IPTG (0.1 mM final concentration) for 2 h at 37°C and 240 rpm. Purification of recombinant TconTS
constructs was done as described previously employing double affinity chromatography using Ni-
NTA and Strep-tag chromatography [23]. Purified proteins were characterised by SDS-PAGE and
Western  blot  analysis  and  quantified  using  BCA  assay  according  to  instructions  of  the
manufacturers.
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Recombinant  TconTS  constructs  expressed  by  CHO-Lec1  fibroblasts  were  purified  employing
Strep-tag chromatography  and  characterised  by  SDS-PAGE  and  Western  blot  analysis  as
described previously [20] and subsequently quantified by BCA assay.
Trans-sialidase  reactions  of  recombinant  TconTS  constructs  expressed  by  E.  coli and
fibroblasts
Purified recombinant TconTS enzymes were assayed for Sia transfer and sialidase activities using
fetuin and lactose as Sia donor and acceptor substrates as described previously [20]. In general,
TconTS reactions  in  50  ?L reaction  volume  containing  10  mM phosphate  buffer  pH  7.4,  the
appropriate amount of recombinant TconTS enzyme (50 ng of TconTS expressed by CHO-Lec1 or
1 ?g of enzyme expressed by  E. coli) as well as fetuin (100 ?g corresponding to 600 ?M fetuin
bound Sia) and lactose (2 mM final concentration) as Sia donor and acceptor substrates were
incubated at 37°C for the times indicated. To determine the influence of  1,4-?-mannotriose on
enzyme activities of  recombinant TconTS1a and TconTS2 expressed by CHO-Lec1 fibroblasts,
0.25 ?mol (5 mM final concentration) of the trisacchride were additionally added to the reaction mix
described  above.  Reaction  products  3'SL  and  Neu5Ac  were  quantified  from  chromatograms
obtained, employing high performance anion exchange chromatography with pulsed amperometric
detection (HPAEC-PAD) utilising a Dionex DX600 system in combination with a CarboPac PA100
column (Dionex/ Thermo Scientific, Germany) as described previously [20].
 
Deglycosylation of TconTS using pNGaseF endogylcosidase
Purified  TconTS  expressed  by  CHO-Lec1  fibroblasts  were  deglycosylated  using  pNGaseF
endoglycosidase  under  native  and  denaturing  conditions  according  to  instructions  of  the
manufacturers  (New  England  Biolabs,  United  Kingdom).  In  brief,  for  degylcosylation  under
denaturing conditions, 10 ?g of TconTS enzyme in 20 ?L of denaturing buffer (0.5 % SDS, 40 mM
DTT) were incubated at 95°C for 10 min. After incubation, NP40 and Na2P4O were added to final
concentrations  of  1  %  (v/v)  and  40  mM,  pH  7.5,  respectively.  Finally,  2  units  of  pNGaseF
endoglycosidase were added and the reaction mix was incubated at 37°C for 4 h. Deglycosylation
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reactions under native conditions were set up according to that under denaturing conditions but
without incubation in denaturing buffer at 95°C.
 
SDS-PAGE and Western Blot analysis
Protein  samples  were  separated  employing  SDS-PAGE  as  described  previously  [44] using  a
MiniProtean III electrophorese Unit (Bio-Rad, Germany) and stained with Coomassie Brilliant Blue
(Thermo Scientific, Germany).
Western blot analysis were performed using primary rabbit anti Strep-tag and mouse anti TS mAb
7/23  for  detection  of  recombinant  TconTS  as  previously  described  [20,23].  After  blotting,
membranes  were  developed  using  enhanced  chemiluminescence  system  (ECL-Kit,  Thermo
Scientific,  Germany)  and X-ray  film (GE Healthcare,  Sweden)  according to  instructions  of  the
manufacturers.
 
Homology Modelling and in silico calculations
Homology models of TconTS-LD containing and lacking the ?-helix were calculated employing the
molecular modelling software Yasara 13.3.26 [45-50] as previously described [20]. In brief, crystal
structure  of  T.  cruzi trans-sialidase  [11] was  used  as  a  template  structure  (PDB:  3b69)  for
calculating  the  models.  Yasara  homology  modeling module  were  modified  manually  from  the
default settings of the program: Modeling speed: slow, PsiBLASTs: 6, EValue Max: 0.5, Templates
total:  1,  Templates  SameSeq:  1,  OligoState:  4,  alignments:  15,  LoopSamples:  50,
TermExtension:10.  The molecular  surface was calculated using the  surface module of  Yasara
Structure with  the  following  parameters:  Force  field:  AMBER96,  Algorithm  used  to  calculate
molecular surface: numeric, Radius of water probe: 1.4 Å, Grid solution: 3.
Amino acid sequences alignments of  TTS were performed employing the  Geneious Alignment
module of the software Geneious 5.5.5, using Blosum62 Cost Matrix [51] with gap openings and
extension 10 and 0.1  respectively.  Adaptations  and modifications  were  made using  the  same
software.  Increasing  darkness  of  sheds  indicates  increasing  number  of  identical  amino  acid
residues at each position (black: 100 %; dark grey: 80 to 100 %; light grey 60 to 80 %; white: less
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then  60  % similarity).  Numbers  on  top  of  each  sequence  indicate  the  corresponding  residue
number for the appropriate TTS sequence.
Author contributions
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performed in silico calculations and epitope mapping of anti TS mAb 7/23, evaluated experimental
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ND significantly contributed to TconTS domain swap experiments and HPAEC-PAD data analysis.
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Figure legends
Figure 1: Hydrogen bond network at the interface between CD and LD of TconTS.  A: The
homology model of TconTS1a, which was calculated using the crystal structure of TcruTS (PDB
code: 3B69) as template structure employing the software Yasara (described under  Methods).
Locations A and B, comprising the majority of conserved hydrogen bonds formed by amino acid
residues at the interface between catalytic domain (CD in grey), ?-helix (blue) and lectin domain
(LD in green) are marked with yellow (A) and red (B) cycles.  B: Enlarged view of  location A
(yellow).  C: Enlarged view of location B (red).  D: Amino acid sequence alignment of TconTS1a
through TconTS4,  T. cruzi TS (TcruTS EMBL: AAA66352.1),  T. rangeli sialidase (TranSA EMBL:
AAC95493.1) and  T, brucei TS (TbruTS EMBL: AAG32055.1) with assigned structural elements
(light blue, dark blue and yellow for CD, ?-helix and LD, respectively). Alignments were calculated
employing the software Geneious (described under Methods). Sequence segments being part of
the  interface  between  CD,  ?-helix  and  LD of  TS  are  marked  with  green  squares.  Increasing
darkness of  background for  each residue indicates increasing number  of  identical  amino acid
residues at the corresponding position (described under Methods).
 
Figure  2:  Insertion of  Eco105I  endonuclease restriction site  into  TconTS.  A: Amino acid
sequence alignment of TconTS1a through TconTS4 with assigned structural elements (light blue,
dark  blue  and yellow for  CD,  ?-helix  and LD,  respectively).  Cysteine  residues forming a  well
conserved disulphide bridge in TS are marked with light blue frames, whereas the resulting hair-pin
loop flanked by these cysteine residues is marked with a red frame.  B: Amino acid sequence
alignment  of  the hair-pin  loop region with the Eco105I  restriction site  inserted (red annotation
above each TconTS sequence).  Alignments were calculated employing the software Geneious
(described under Methods). Numbers on top of each sequence indicate the corresponding residue
number.  TconTS  comprising  the  inserted  Eco105I  restriction  site  are  labelled  (*).  Increasing
darkness of  background for  each residue indicates increasing number  of  identical  amino acid
residues at the corresponding position. C: Homology model of TconTS1a showing a region of the
lectin domain (grey), including the well conserved disulphide bridge (C493 and C505) and the hair-
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pin loop with the Eco105I insertion (red label). TconTS1a homology model was calculated using
the software Yasara (described under Methods).
 
Figure  3:  Recombinant  TconTS  constructs  generated  for  expression  by  CHO-Lec1
fibroblasts  and  E.  coli.  A-B: Schematic  presentation  of  recombinant  TconTS  constructs  for
expression by CHO-Lec1 fibroblasts (A) and E.coli (B). Fusion tags flanking TconTS are: Transin:
translocation signal peptide (only in A), His: poly histidine tag (only in B), MBP: maltose binding
protein tag (only in B), TEV:  tobacco etch virus  protease cleavage site (only in B), 3C: human
rhinovirus 3C protease cleavage site, SNAP: SNAP-tag, Strep: Strep-tag. C: SDS-PAGE of purified
TconTS constructs expressed by E. coli Rosetta pLacI. 1-2 ?g of protein was loaded in each lane
of a 10 % SDS polyacrylamide gel as indicated. The gel was stained with Coomassie Brilliant Blue
after electrophorese. Lane 1-4 contain TconTS constructs with Eco105I insertion as indicated (*).
Lane 5 and 6 comprise domain swapped proteins as labelled (CD/LD). D: Western blot analysis of
TconTS constructs expressed by CHO-Lec1 fibroblasts. 100 ng of  each TconTS construct was
used and detection was done employing anti  Strep-tag mAb and anti TS mAb 7/23 as indicated
(described under Methods).
 
Figure 4: Epitope mapping of anti TS mAb 7/23 binding epitope.  A: Amino acid sequence
alignment of wild type TconTS1a and truncated TconTS1a constructs (A-G, CD: catalytic domain,
LD:  lectin  domain)  used  for  anti  TS  mAb 7/23  epitope  mapping.  Alignments  were  calculated
employing the software Geneious (described under Methods). Numbers on top of each sequence
indicate the length of the corresponding protein. Structural  elements,  such as catalytic domain
(CD),  ?-helix  and  lectin  domain  (LD)  are  labelled.  B-D: Western  blot  analysis  of  TconTS1a
constructs (A-G) using anti TS mAb 7/23 and anti  Strep-tag mAb as indicated (described under
Methods). All TconTS1a constructs were expressed by E. coli Rosetta pLacI and bacterial lysates
were used for SDS polyacrylamide gel electrophorese. 100 ng TconTS1a expressed and purified
from CHO-Lec1 cells was used as a control in Western blot experiments. E: pNGaseF treatment of
purified recombinant TconTS1a and TconTS2 expressed by CHO-Lec1 cells. Both proteins were
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deglycosylated using pNGaseF under native and denaturing conditions (described under Methods)
as indicated. 1 ?g of each TconTS sample was used in SDS-PAGE analysis with subsequent
Coomassie Brilliant Blue staining (upper line) and 100 ng in western blots (lower line) using anti TS
mAb 7/23 and anti Strep-tag for detection (described under Methods).
 
Figure  5:  Enzymatic  activities  of  recombinant  TconTS1a  expressed  by  E.  coli.  A-B:
Production of 3'SL (A) and Neu5Ac (B) using different amounts of purified, bacterial expressed,
recombinant TconTS1a ranging from 0-3 ?g of enzyme. TS reactions were set up as described
under Methods using standard conditions employing fetuin and lactose as Sia donor and acceptor
substrates for 30 min at 37°C. Reaction products 3'SL and Neu5Ac were quantified using HPAEC-
PAD analysis (described under Methods). C-D: Time dependency of TconTS1a activity using 1 ?g
of  purified  bacterial  expressed  enzyme.  Reactions  were  set  up  according  to  TconTS1a
concentration series, using different incubation times ranging from 0-24 h. Data points are means ±
standard deviation of triplicates.
 
Figure  6:  Enzymatic  activities  of  mutated  and  domain  swapped  recombinant  TconTS
enzymes.  A-C: Sia transfer  (A and C) and sialidase activities (B and C) of  purified,  bacterial
expressed,  recombinant  TconTS1a,  TconTS3  and  domain  swapped  TconTS1a/TS3.  1  ?g  of
enzyme was incubated with fetuin and lactose as Sia donor and acceptor substrates, respectively,
under standard conditions (described under Methods) for 24 h at  37°C.  D-F: Sia transfer  and
sialidase  activities  of  recombinant  TconTS1a,  mutated  TconTS1a*,  domain  swapped
TconTS1a/TS3,  TconTS2  and  mutated  TconTS2*  expressed  and  purified  from  CHO-Lec1
fibroblasts. TS reactions were set up according to bacterial expressed TconTS enzymes, whereas
50 ng of  CHO-Lec1 expressed recombinant TconTS were used and incubated under standard
conditions for 30 min at 37°C. Reaction products 3'SL and Neu5Ac were quantified using HPAEC-
PAD  analysis  (described  under  Methods).  Data  points  are  means  ±  standard  deviation  of
triplicates.
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Figure 7: Enzymatic activities of recombinant TconTS1a and TconTS2 in the presence or
absence of 1,4-?-mannotriose. A-C: Sia transfer (A and C) and sialidase activities (B and C) of
recombinant TconTS1a and TconTS2 expressed and purified from CHO-Lec1 fibroblasts. 50 ng of
enzyme were incubated under  standard conditions using fetuin and lactose as Sia donor  and
acceptor substrates for 30 min at 37°C (described under Methods), in the presence or absence of
5 mM 1,4-?-mannotriose as indicated. Reaction products 3'SL and Neu5Ac were quantified using
HPAEC-PAD analysis (described under Methods). Data points are means ± standard deviation of
triplicates.
Supporting Information
Figure  S1.  Predicted  binding epitope  of  the  anti  TS  mAb 7/23.  A: Amino  acid  sequence
alignment of  TconTS1a through TconTS4,  T. cruzi TS (TcruTS EMBL: AAA66352.1),  T. rangeli
sialidase  (TranSA EMBL:  AAC95493.1)  and  T,  brucei TS  (TbruTS  EMBL:  AAG32055.1)  was
calculated using the software Geneious 5.5.5 as described under Methods. Structural elements,
such as predicted N-glycosylation sites, ?-helix, salt-bridge (between arginine and glutamine) and
the predicted anti TS mAb 7/23 binding epitope are marked with red, purple, green and blue labels,
respectively.  Numbers  on  top  of  each  sequence  indicate  the  corresponding  residue  number.
Increasing darkness of background for each residue indicates increasing number of identical amino
acid residues at the corresponding position (described under Methods).  B: Homology model of
TconTS1a showing a detailed view of the lectin domain (LD). Structural elements, such as the C-
terminal ?-helix and the predicted N-glycosylation site are labelled in purple and red, respectively.
The salt-bridge between R704 and E 710, which is well conserved among TS, is illustrated in stick
style.  C: Structural alignment of TconTS2 (homology model), TcruTS (PDB: 3B69) and TranSA
(PDB: 1N1Y) calculated using the software Yasara (described under Methods). The tryptophan
residue, which is part of the Sia donor substrate binding-site is shown in stick style and labelled in
yellow (TconTS2), green (TcruTS) and red (TranSA), respectively. Bound Sia is illustrated in stick
style (light blue). 
Table S1. List of primers used for cloning and Eco105I restriction site insertion.
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Table 1: Calculated molecular surface of the contact site between CD and LD of TTSs.
Area Å2
Enzyme (PDB) CD/LD total surf.
TconTS1 1526.68/1500.01 3026.69
TconTS2 1440.96/1392.59 2833.55
TconTS3 1509.82/1331.59 2841.41
TconTS4 1674.97/1631.50 3306.47
TcruTS (3B69) 1483.04/1509.52 2992.56
TbruTS* 1677.44/1604.22 3281.66
TranSA (1N1S) 1470.99/1563.01 3034.00
VCS (1W0O) 960.88/935.29 1896.17
LeechMD-SA (1SLI) 868.53/918.46 1786.99
* Homology model for TbruTS was calculated using the amino acid sequence: EMBL AAG32055.1
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Table 2: Hydrogen bonds formed by amino acid residues at the contact site between CD and LD of
TconTSs.
TconTS1 TconTS2 TconTS3 TconTS4
Atom A Atom B Distance[Å] Atom A Atom B
Distance
[Å] Atom A Atom B
Distance
[Å] Atom A Atom B
Distance
[Å]
V369-O Q566-N 2.269 V361-O Q559-N 1.955
G349-O N687-N?2 2.400 G419-O N751-N?2 2.183
R423-N?1 N725-O?1 2.164
V354-O Q552-N 2.294 V424-O Q621-N 1.873
G371-O Q564-N?2 2.190 G356-O Q550-N?2 1.974 G363-N Q557-O 1.921 G426-N D620-O?1 1.869
G363-O Q557-N?2 1.944 G426-O Q619-N?2 2.019
R376-N?2 G563-O 2.261 R361-N?1 Q550-O 1.923
R376-N?2 S560-O 2.212 R361-N? Q550-O 2.294
E376-O K468-N? 2.336 E383-O K475-N? 2.386
K402-O Q564-N?2 1.972 E387-O Q550-N?2 1.919 K394-O Q557-N?2 2.119 K457-N? D620-O?2 1.897
K394-N? Q557-O?1 1.983
K394-N? D558-O?2 1.798
N421-O?2 N703-N?2 2.396 N413-O?1 G503-N 1.907 S476-O? L566-O 1.809
R422-N? L511-O 1.836 R414-N? L504-O 1.864 R477-N?1 D541-O?2 1.888
R422-N?1 D486-O?1 1.902 R414-N?1 D478-O?1 1.930 R477-N?2 D541-O?1 1.927
R422-N?2 D486-O?2 2.016 R414-N?2 D478-O?2 1.853
R399-N?1 D551-O?2 2.129
R399-N?2 D551-O?2 2.160
W482-N?1 Y528-O 2.047 W467-N?1 Y513-O 1.981 W474-N?1 Y521-O 1.778 W537-N?1 Y583-O 1.886
Q485-O?1 S726-O? 2.073
D486-O?1 Y528-OH 1.811 D471-O?1 Y513-OH 1.818 D478-O?1 T501-O?1 1.870 D541-O?1 Y583-OH 1.898
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Table 3: Conserved amino acid residues involved in hydrogen bond formation between CD and LD
at the contact site of TSs.
Nr. Consensus TconTS1 TconTS2 TconTS3 TconTS4 TcruTS* TranSA** TbruTS***
CD
1 Gly N364 G349 G356 G419 G269 G291 G376
2 Arg R368 R353 R360 R423 R273 H295 R380
3 Val V369 V354 V361 V424 V274 V296 V381
4 Gly G371 G356 G363 G426 G276 T298 G383
5 Arg R376 R361 R368 R431 S281 S303 R388
6 Glu E391 E376 E383 E446 E296 E318 G410
7 Lys K402 E387 K394 K457 L307 L329 K421
8 Asn N421 N406 N413 S476 Q326 Q348 N440
9 Arg R422 R407 R414 R477 R327 R349 R441
?Hel
10 Trp W482 W467 W474 W537 W386 W408 W501
11 Lys K483 K468 K475 K538 K387 K409 K502
12 Asp D486 D471 D478 D541 D390 D412 D505
LD
13 Thr T508 I493 T501 T563 T417 T439 T528
14 Leu L511 L496 L504 L566 L420 L442 L531
15 Tyr Y528 Y513 Y521 Y583 Y437 Y459 Y548
16 Ser S560 G546 S553 R615 S468 A490 S580
17 Gly G563 G549 G556 G618 G471 G493 G583
18 Gln Q564 Q550 Q557 Q619 Q472 Q494 Q584
19 Asp D565 D551 D558 D620 N473 T495 D585
20 Gln Q566 Q552 Q559 Q621 Q474 R496 Q586
21 Asn N674 N658 N667 N725 D581 D603 H694
22 Asn N703 N687 N696 N751 N610 N632 N723
* TcruTS sequence: EMBL AAA66352.1; ** TranSA sequence: EMBL AAC95493.1; *** TbruTS sequence: EMBL AAG32055.1. It should be
noted that different TbruTS have been identified, which are similar to certain TconTS enzymes, respectively [21].
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Table 4: Possible domain swapped and mutated TconTS constructs.
Construct
Nr.
Catalytic
domain
Lectin
domain Swap construct
1 TconTS1a TconTS1a TconTS1a*
2 TconTS2 TconTS2 TconTS2*
3 TconTS3 TconTS3 TconTS3*
4 TconTS4 TconTS4 TconTS4*
5 TconTS1a TconTS2 TconTS1a/TS2
6 TconTS1a TconTS3 TconTS1a/TS3
7 TconTS1a TconTS4 TconTS1a/TS4
8 TconTS2 TconTS1a TconTS2/TS1a
9 TconTS2 TconTS3 TconTS2/TS3
10 TconTS2 TconTS4 TconTS2/TS4
11 TconTS3 TconTS1a TconTS3/TS1a
12 TconTS3 TconTS2 TconTS3/TS2
13 TconTS3 TconTS4 TconTS3/TS4
14 TconTS4 TconTS1a TconTS4/TS1a
15 TconTS4 TconTS2 TconTS4/TS2
16 TconTS4 TconTS3 TconTS4/TS3
* Mutated TconTS containing the inserted Eco105I restriction site
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Table 5: Specific catalytic activities of different TconTS enzymes expressed by E. coli and CHO-
Lec1 cells.
CHO-Lec1
Enzyme
Trans-sialidase activity
[nmol 3'SL/(min x mg TS)]
Sialidase activity
[nmol Neu5Ac/(min x mg TS)] TS/sialidase
TconTS1a 2732 ± 28 88 ± 1 31
TconTS1a* 1029 ± 41 49 ± 7 21
TconTS1a/TS3 2409 ± 109 16 ± 2 153
TconTS2 1820 ± 204 56 ± 7 32
TconTS2* 1852 ± 107 223 ± 26 8
E. coli
Enzyme
Trans-sialidase activity
[nmol 3'SL/(min x mg TS)]
Sialidase activity
[nmol Neu5Ac/(min x mg TS)] TS/sialidase
TconTS1a 5.22 ± 0.03 0.05 ± 0.01 109
TconTS1a/TS3 0.086 ± 0.004 0.157 ± 0.014 0.55
TconTS3 0.042 ± 0.008 0.081 ± 0.011 0.51
Quantifications of  3'SL and Neu5Ac were done employing HPAEC-PAD analysis  as described under Methods.  *  Mutated TconTS
containing the inserted Eco105I endonuclease restriction site. Data points are means of triplicates ± standard deviation.
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Table  6: Specific  catalytic  activities  of  TconTS1a and TconTS2 expressed by CHO-Lec1 cells
under standard conditions for 30 min in the presence and absence of 5 mM 1-4?-mannotriose.
Trans-sialidase activity
[nmol 3'SL/(min x mg TS)]
Sialidase activity
[nmol Neu5Ac/(min x mg TS)] TS/sialidase
1-4?-
mannotriose - + - + - +
TconTS1a 2213 ± 133 2163 ± 190 91 ± 1 15 ± 1 24 144
TconTS2 1983 ± 26 2038 ± 69 58 ± 7 11 ± 2 34 193
Quantifications of 3'SL and Neu5Ac were done employing HPAEC-PAD analysis as described under Methods. Data points are means of
triplicates ± standard deviation.
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Figure 6
A B
E. coli 3'SL [µM/24 h] Neu5Ac [µM/24 h]
TconTS1a 80 ± 1 4.2 ± 0.6
TconTS1a/TS3 2.5 ± 0.1 4.5 ± 0.4
TconTS3 1.2 ± 0.2 2.3 ± 0.3
C
D E
CHO-Lec1 3'SL [µM/30 min] Neu5Ac [µM/30 min]
TconTS1a 82 ± 1 2.64 ± 0.02
TconTS1a* 31 ± 1 1.48 ± 0.21
TconTS1a/TS3 72 ± 3 0.47 ± 0.07
TconTS2 54 ± 6 1.7 ± 0.2
TconTS2* 55 ± 3 6.7 ± 0.8
F
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Figure 7
A B
C
3'SL [µM/30 min] Neu5Ac [µM/30 min]
1?4?-mannotriose - + - +
TconTS1a 66 ± 4 65 ± 6 2.74 ± 0.02 0.45 ± 0.04
TconTS2 60 ± 1 61 ± 2 1.7 ± 0.2 0.32 ± 0.07
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Table S1. List of primers used for cloning and Eco105I restriction site insertion.
Gene Forward primer (restriction enzyme) Reverse primer (restriction enzyme)
For bacterial expression by E. coli Rosetta (DE3) pLacI
TconTS1a GCAAGCTTCAGTGCTGCGACCACATG (HindIII)
CGGGATCCGTCGCTCCCAGGCAC
ACG (BamHI)
TconTS2 GCAAGCTTGCCCAGTGCATCTCAACG (HindIII)
GCGGATCCAGACACGGGATGCAC
ATC (BamHI)
TconTS3 GCAAGCTTTCTGGAAACGGACGAACG (HindIII)
GCGGATCCGAGGTAAAGTGACTC
CAGTTC (BamHI)
TconTS4 GCGTCGACATCCTACAAGAAAGCTC (SalI)
GCGGATCCCCTTGCTGCTCTTTTA
AGTAAT (BamHI)
For epitope mapping of anti TS mAb 7/23
TconTS1a-CD (A)
GCAAGCTTCAGTGCTGCGACCAC
ATG (HindIII)
CGGGATCCGTCACTCGATTCGAAT
ATC (BamHI)
TconTS1a-CD (B) CGGGATCCATCCGAGCTGCCAGGACCA (BamHI)
TconTS1a-CD (C) CGGGATCCATCACGATAATACGAGCCCT (BamHI)
TconTS1a-CD (D) CGGGATCCGTCCTGTGCCTTCCACACC (BamHI)
TconTS1a-CD (E) CGGGATCCGTCCACAAGGCGCACAAGG (BamHI)
TconTS1a-LD (F) GCAAGCTTGACGAGCTGAAAAGC (HindIII) CGGGATCCGTCGCTCCCAGGCAC
ACG (BamHI)
TconTS1a-LD (G) GCAAGCTTAACTGCCTCCCGGGC(HindIII)
TconTS2-LD GCAAGCTTCTGGAGGATGAGATGGAGG (HindIII)
GCGGATCCAGACACGGGATGCAC
ATC (BamHI)
TconTS3-LD GCAAGCTTCTAGAAGACGAGCTGGAAAGC (HindIII)
GCGGATCCGAGGTAAAGTGACTC
CAGTTC (BamHI)
TconTS4-LD GCGTCGACCTCGCTGACGAACTGAAG (SalI)
GCGGATCCCCTTGCTGCTCTTTTA
AGTAAT (BamHI)
For Eco105I insertion
TconTS1a*-CD (Eco105I) GCAAGCTTCAGTGCTGCGACCACATG (HindIII)
GCTACGTAATCGCCCGGGAGGC
(Eco105I)
TconTS1a*-LD (Eco105I) GCTACGTAAAATATGATCCCGGG(Eco105I)
CGGGATCCGTCGCTCCCAGGCAC
ACG (BamHI)
TconTS2*-CD (Eco105I) GCAAGCTTGCCCAGTGCATCTCAACG (HindIII)
GCTACGTATTTGTTCAGTTGAC
(Eco105I)
TconTS2*-LD (Eco105I) GCTACGTAAAGCGCCGGAGCGGC(Eco105I)
GCGGATCCAGACACGGGATGCAC
ATC (BamHI)
TconTS3*-CD (Eco105I) GCAAGCTTTCTGGAAACGGACGAACG (HindIII)
GCTACGTAACCATCCGGTGAGG
(Eco105I)
TconTS3*-LD (Eco105I) GCTACGTAGATTATACTGAGGG(Eco105I)
GCGGATCCGAGGTAAAGTGACTC
CAGTTC (BamHI)
TconTS4*-CD (Eco105I) GCGTCGACATCCTACAAGAAAGCTC (SalI)
GCTACGTACCCGGTAGTTGCAG
(Eco105I)
TconTS4*-LD (Eco105I) GCTACGTAGATGGCAGCGATTGC(Eco105I)
GCGGATCCCCTTGCTGCTCTTTTA
AGTAAT (BamHI)
Endonuclease restriction sites are underlined.
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4 Summarising discussion 
Trypanosomes are flagellate protozoan parasites belonging to the order of kinetoplastida 
and are mainly found in Latin America and Sub-Saharan Africa. They develop in mammalian 
hosts and insect vectors, although some trypanosomes cause fatal diseases in human, 
comprising American Chagas’ disease caused by T. cruzi [1] and Human African 
Trypanosomiasis (HAT or sleeping sickness in human) caused by T. brucei gambiense and T. 
brucei rhodesiense [2], as well as Animal African Trypanosomiasis (AAT locally also termed 
nagana) caused by T. brucei brucei, T. vivax and T. congolense [3], characterised by similar 
symptoms and pathogenesis. During their life cycle parasites utilise different very efficient 
strategies to evade immune response, ensure their survival and effectively establish infection 
in host and vector [4-6]. These strategies comprise antigenic variation and the expression of 
trans-sialidases (TS). 
TS are generally membrane bound enzymes catalysing the regio and stereo specific 
transfer of terminal sialic acids (Sia) from host sialo-glycoconjugates to galactose or N-
acetylgalactosamine residues of parasites surface glycoproteins, including mucins [7] and 
procyclins such as T. congolense GARP [8] and T. brucei PARP [9]) as well as 
glycosylphosphatidylinositol (GPI)-anchors [10-12]. Since trypanosomes are unable to 
synthesise Sia de novo, they utilize TS to cover their glycocalyx with Sia, resulting in a 
negatively charged surface, protecting parasites from proteolytic digest [5,9,13] and to 
generate ligand structures for host cell interactions [14]. Both mechanisms are essential for the 
establishment of infection and pathogenesis of trypanosomiasis, subsequently characterising 
TS as fundamental virulence factor in trypanosomes [6,15]. In addition, it has been shown that 
TS is expressed in procyclic insect trypomastigotes [11,16], as well as in bloodstream forms of 
the parasite [17-19]. However, many studies have been concentrated on T. cruzi TS, 
investigating the catalytic mechanism as well as the architecture of the active centre in detail 
[20-25], also in respect to develop new strategies for the synthesis of potent TS inhibitors [26]. 
Nevertheless, no specific and satisfying efficient inhibitor has been established so far. In 
contrast to Latin American TcruTS, only little was known about African TconTS before this 
study was initiated [27,28].  
The main subjects of this work focused on the identification, expression and 
biochemical characterisation of TconTS to provide new insight into substrate specificities, as 
well as enhanced knowledge about the biological function. Primal database search using the 
partial sequences of TS-form 1 and 2, published by Tiralongo et al. [28], revealed 14 related 
active and 3 inactive TconTS members in total. All active TconTS have been subsequently 
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cloned and expressed in eukaryotic fibroblasts. Different biochemical and glyco-bioanalytical 
techniques were employed to characterise these recombinant TconTS variants and revealed 
significant differences in their overall enzymatic properties. Besides that, homology model 
structures for each TconTS comprising CD and LD were calculated, which provided a more 
detailed insight into the catalytic centre. In comparison to previously published data on the 
active site of TcruTS, striking differences and essential similarities for several TconTS have 
been observed, which appear to be related to their enzymatic properties determined during the 
course of this work.  
Interestingly, separate phylogenetic analysis of TconTS catalytic domains (CD) and 
lectin-like domains (LD), surprisingly revealed a close relationship of the more active, as well 
as the less active enzymes, when aligning LDs compared to a different situation when 
aligning CDs. This fundamental finding indicated a possibly more relevant role of LD in 
TconTS enzymatic activities than previously thought. Thus, a major subject of this work has 
focused on the biochemical characterisation of TconTS-LDs and their possible influence on 
catalytic activities, since only very limited data has been available in literature and even no 
carbohydrate binding activities or potential functions had been demonstrated for TconTS-LD. 
Within this study, for the first time carbohydrate recognising activities were clearly 
demonstrated for TconTS-LD with distinct ligand specificities. Surprisingly, mannose-
containing oligosaccharides have been identified as prominent ligands for at least two 
TconTS-LDs, namely TconTS1-LD and TconTS2-LD [29] (Chapter 3.4). This was 
unexpected, since previous studies have clearly demonstrated that mannose residues are no 
substrates for sialylation by TconTS-CD [28,30]. Thus, the data presented in Chapter 3.4 
indicated a different, yet unknown, biological function of TconTS [29]. Along this line, our 
oligomerisation studies with TconTS1 and TconTS2 are of particular interest, since they have 
clearly demonstrated that higher order complexes are formed via N-linked oligomannosyl 
oligosaccharide dependent interactions. They are most likely mediated via TconTS-LD, which 
in turn might also be a natural biological function, since native TS have been found to be 
glycosylated with oligosaccharides of the high-mannose type [10,31]. Schenkman et al. had 
isolated native TcruTS from cultured trypomastigotes using ConA affinity chromatography, 
indicating the presence of high-mannose glycans on TcruTS [10]. Furthermore, Engstler et al. 
had isolated native TbruTS from cultured trypomastigotes in a similar way [32]. 
Based on to the mannose binding activity of LDs observed [29] (Chapter 3.4), we 
wanted to investigate the potential influence of LD on TconTS enzyme activities. Using a 
genetic approach, established within the scope of this thesis, the lectin domains between 
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different active TconTS have been swapped and enzymatic activity data of recombinant 
TconTS chimeras revealed significant differences in enzyme overall behaviour, TS and SA 
activities, compared to wild type TconTS (Chapter 3.5).  
Binding and inhibition assay established by Bock and Kelm [33], initially utilised for 
siglec interaction studies, was used as a template method to develop a TconTS-LD 
binding/inhibition assay, which allows the characterisation of TconTS-LD binding specificity 
to high-mannosylated glycoproteins as potent ligand structures [29] (Chapter 3.4). Further 
details will be discussed in following paragraphs. 
4.1 Identification and diversity of TconTS gene products 
First partial characterisation of isolated native TconTS from procyclic T. congolense 
trypomastigotes cultures was described by Tiralongo et al., who isolated two distinct TS 
preparations, termed TS-form 1 and TS-form 2, which exhibited different TS and sialidase 
activities [27,28]. Based on the partial sequence of T. congolense TS1, obtained in these 
studies, open reading frames for 11 TconTS1 variants have been identified in genomic DNA 
from T. congolense STIB 249 which were cloned and sequenced [34] (Chapter 3.1). 
Corresponding DNA sequences characteristic for these variants were also identified in the 
Welcome Trust Sanger Institute (WTSI) database of T. congolense (strain IL3000). Obtained 
results revealed 96.3 % amino acid sequence identity among TconTS1 variants (TconTS1a - 
TconTS1j). Interestingly, the amino acid differences, 25 in total (8 in LD and 17 in CD), are 
not evenly distributed over the whole protein sequence, but are found concentrated in a few 
regions of the protein [34] (Chapter 3.1).  
Besides the 11 TconTS1 variants 6 additional TS-like genes have been identified from 
the WTSI database. Three out of these were suggested to encode for inactive TconTS, since 
they exhibit drastic substitutions of catalytic active amino acid residues (D150 to E or K, 
E324 to N, Y or S and Y438 to F, L or H) at the catalytic centre besides several others, 
essential for substrate binding and enzyme activity. Furthermore these genes share only up to 
~30 % amino acid sequence similarity compared to TconTS1 and therefore termed as 
TconTS-Like1, TconTS-Like2 and TconTS-Like3, respectively [35] (Chapter 3.2). In contrast 
to that, the other three TconTS genes were found to be more closely related sharing about 42 
– 49 % overall amino acid sequence similarities. Almost all crucial amino acid residues 
essential for catalysis and substrate binding were found to be well conserved among all three 
genes and therefore, these were expected to also encode for active TconTS enzymes, 
subsequently termed TconTS2, TconTS3 and TconTS4, respectively [35] (Chapter 3.2). 
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Amino acids, which had been identified to be relevant for TS catalytic activities and 
substrate interaction [24,25] are mostly conserved among all TconTS variants reported in this 
work [34,35] (Chapter 3.1 and 3.2). In the following paragraph amino acid residues of 
TconTS1 will be used as reference to discuss their essential role on enzymatic activities. 
Catalytically active residues, such as D150 (acid/base catalyst corresponding to D59 in 
TcruTS) catalysing the cleavage and formation of Sia-Gal gylcosidic linkage, E324 and Y438 
(correspond to E230 and Y342 in TcruTS) representing the acid/nucleophile pair involved in 
the formation of covalent sialyl-enzyme intermediates, are well conserve among all 14 
TconTS variants [34,35] (Chapter 3.1 and 3.2). Also R126, R339 and R410 (correspond to 
R35, R245 and R314 in TcruTS) forming the arginine triad, stabilising the carboxyl group of 
Sia and maintaining its required positioning for catalysis, as well as D188, W212, Q289, 
D341 and E454 (correspond to D96, W120, Q195, D247 and E357 in TcruTS), known to be 
involved in Sia stabilisation through hydrogen bond formation [23-25,36], and other relevant 
residues at the catalytic centre of TconTS variants are mainly well conserved [34,35] (Chapter 
3.1 and 3.2). In addition, Y211 (correspond to Y119 in TcruTS) being part of the acceptor 
substrate binding-site and involved in stacking interactions (π-π*) with the cyclohexane ring 
of the Gal or aglycon moiety [24,25,36,37], occurs in all TconTS1 forms [34] (Chapter 3.1), as 
well as in TconTS3 and TconTS4 (corresponding to Y203 in TconTS3 and Y268 in TconTS4) 
but is substituted to a proline residue (P196) in TconTS2 [35] (Chapter 3.2), which will be 
discussed in a subsequent paragraph of this Chapter.  
In addition, W312 in TcruTS, which has been demonstrated to be part of the donor 
substrate binding-site (π-π* interactions to lactose), is substituted by Y408 in all TconTS1 
variants and Y463 in TconTS4 [34,35] (Chapter 3.1 and 3.2), but still maintaining potential 
stacking interactions with the cyclohexane ring of the donor substrate. The consistent 
presence of all these amino acid residues in TconTS variants essential for enzymatic activity 
provided strong evidence that these residues are subjects of a high evolutionary conservation 
pressure. According to that, a mutation, which might negatively influence TS activity and 
therefore consequently also affect parasite survival, would not lead to an evolutionary 
dominant species. 
However, also drastic amino acid substitutions have been observed in TconTS enzymes. 
One striking substitution represents the exchange of R144 in TconTS1 (correspond to R53 in 
TcruTS) to a cysteine residue, only observed for the variant TconTS1g [34] (Chapter 3.1). 
This arginine residue has been demonstrated to form hydrogen bonds to the C-4 hydroxyl 
group of Sia in TcruTS [25]. Thus, R144 has been assumed to be involved in donor substrate 
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binding and possibly contribute to Sia stabilisation in the Michaelis-complex and covalent 
intermediate, respectively (Chapter 1.5.4, Figure 5). A more detailed discussion regarding the 
possible influence of the substitution R144C on TconTS1g enzyme activity is provided in the 
subsequent Chapter 4.2.1. 
Another drastic substitution represents the exchange of the well-conserved Y211 in 
TconTS1, TconTS3 and TconTS4 (corresponding to Y203 in TconTS3 and Y268 in 
TconTS4) to a proline residue (P196) in TconTS2 [35] (Chapter 3.2). As mentioned before, 
this tyrosine residue is part of the acceptor substrate binding-site and has been suggested to 
stabilise the Gal or aglycon moiety through stacking interactions with the cyclohexane ring or 
the respective aryl substituent (e.g. in MU-Lac and MU-Gal [28]). Mutagenesis experiments 
on TcruTS exchanging the corresponding Y119 to a serine residue, revealed a drastic decrease 
in both, TS and sialidase activities. Similar to TconTS2, also in TranSA this tyrosine is 
replaced by a serine residue (S141), which was first supposed to be one of the main reasons 
for the lack of TS activity in TranSA. However, Buschiazzo et al. demonstrated that the 
mutation of S141 to tyrosine did not introduce TS activity to TranSA or enhanced its sialidase 
activity [23]. However, this apparent discrepancy could be explained within the context of the 
overall structure of the catalytic pocket. For that purpose, of particular importance is the study 
of Paris et al., who demonstrated the importance of the orientation of W312 in TcruTS for 
enzymatic activity [38]. As already mentioned earlier, W312 is part of the acceptor substrate 
binding-site and needs a well-defined orientation for efficient substrate binding and 
subsequent catalysis. Due to a single substitution of a proline to glutamine (P283 in TcruTS 
corresponding to Q305 in TranSA) in the subjacent loop in TranSA, W334 (corresponding to 
W312 in TcruTS) adopts a completely different orientation compared to W312 of TcruTS, 
because of steric hindrance by Q305 (Chapter 1.5.4, Figure 6). Interestingly, the mutation 
Q305P in TranSA significantly increased the sialidase activity on MU-Neu5Ac and 3’SL, 
indicating the importance and indirect role of Q305 on substrate binding and enzyme activity 
[38]. Furthermore, this proline residue was found to be well conserved in TconTS2 as well as 
in all other TconTS family members [34,35] (Chapter 3.1 and 3.2), leading to the suggestion 
that the adjacent tyrosine (Y408 in TconTS1 and Y463 in TconTS4) or tryptophan residues 
(W393 in TconTS2 and W400 in TconTS3) occupy the positions required for efficient 
substrate binding, similar to W312 in TcruTS [24].  
Typical sialidases and also TS contain the characteristic FRIP (amino acid single letter 
code) motif or conservative modifications thereof and one of the Asp boxes located early at 
the N-terminus of CD were also found in all TconTS variants. R35 (numbering of TconTS1) 
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of the FRIP motif is one of the arginine residues forming the arginine triad, thus positioning 
FRIP as one of the key elements in Sia binding and influencing enzymatic activity, as it has 
been proposed for other TS [39-41]. 
Concerning these findings and all the other amino acid differences in TconTS1-4, it was 
impossible to predict the exact enzymatic properties for each of the 14 active TconTS forms 
just by comparing amino acid sequence data with investigations reported for TcruTS and 
TranSA. Therefore, it was of fundamental importance to determine enzymatic activities and 
kinetic parameters such as KM and vmax values to investigate potential structure-function 
relations of TconTS. Since no crystal structure for TconTS or any other African TS is 
available so far, TconTS structure homology models were calculated based on the crystal 
structure of TcruTS [24] to get deeper insight into understanding catalytic activities, which 
were experimentally determined, in the context of structural differences to TcruTS [34,35] 
(Chapter 3.1 and 3.2). 
4.2 Biochemical characterisation of recombinant TconTS 
All 14 identified genes encoding for active TconTS (11 TconTS1 variants, TconTS2, 
TconTS3 and TconTS4) were cloned into modified pDEF, a eukaryotic expression vector, and 
expressed in fibroblasts as recombinant proteins [34,35] (Chapter 3.1 and 3.2). After 
purification of recombinant TconTS from tissue culture supernatant of CHO-Lec1 cells, 
enzymes were incubated with fetuin and lactose as suitable Sia donor and acceptor substrates 
respectively [34,35] (Methods of Chapters 3.1 and 3.2). To determine enzymatic activities, 
reaction products, such as 3’-sialyllactose (3’SL) and free Neu5Ac were quantified employing 
a high performance liquid chromatography (HPLC) based technique specific for carbohydrate 
analysis termed high performance anion exchange chromatography with pulsed amperometric 
detection [34] (HPAEC-PAD, description under Methods in Chapter 3.1). This method allows 
detection and quantification of the TconTS reaction products 3’SL and Neu5Ac from the 
same chromatogram with a detection limit of about 10 pmol. The kinetic parameters KM and 
vmax for each substrate were determined employing a dilution series of the appropriate 
substrate under standard conditions. Substance-specific constants, KM and vmax were used to 
compare enzymatic activities of different TconTS. Besides fetuin also other molecules have 
been used as Sia donor substrates, such as 3’SL, pNP-Neu5Ac, MU-Neu5Ac and sialo-
glycoconjugates from human blood serum as well as other acceptor substrates besides lactose, 
such as Gal, MU-Gal and sialidase-treated fetuin (asialofetuin, ASF) [34,35] (Chapter 3.1, 3.2 
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and 3.3). In addition, sialidase activities of TconTS were also determined in the absence of 
any suitable acceptor substrates. 
4.2.1 The diversity in enzymatic activities of TconTS 
Using standard conditions, similar overall TS activities for all 11 TconTS1 variants 
were determined except for one, termed TconTS1g [34] (Chapter 3.1). Indeed, this variant 
showed a significantly lower 3’SL production of about 70 % after 24 h incubation using 
standard conditions, compared to other TconTS1 variants (Figure 1 A, Chapter 3.1). As 
mentioned in the previous Chapter 4.1, TconTS1g exhibits a unique substitution R144C close 
to the catalytic centre [34] (Chapter 3.1). It can be suggested that this exchange may lead to 
destabilisation of Sia in the Michaelis-complex due to the loss of hydrogen bonds formed by 
R144 with the C-4 hydroxyl group of Sia, which has been previously proposed for TcruTS 
[25]. A cysteine residue at that position 144, although in principle it is also able to form 
hydrogen bonds, is expected not to reach the C4-hydroxyl group of Sia for efficient hydrogen 
bond formation according to the homology model. The relatively low Vmax value of 
TconTS1g for fetuin-bound Sia compared to that of TconTS1b and TconTS1e-1 supported 
this hypothesis (Table 1). However, it remains unclear whether this mutation represents the 
main reason for the reduced TS activity, and if so, what mechanistic explanation might be 
reasonable. However, the remaining TS activity of TconTS1g indicated that the substitution 
R144C has a pronounced effect on the enzyme activity, but it also shows that R144 is not 
essential for the catalysis of Sia transfer. 
Interestingly, KM values of TconTS1g determined for fetuin-bound Sia (3025 µM) and 
lactose (362 µM, Figure 1 B and C) are more related to those of TconTS1e-1 than TconTS1b 
(Table 1), indicating a shared structural similarity also influencing the catalytic activities. 
Table 1: Kinetic parameters Vmax and KM of TconTS1b and TconTS1g. 
Data for TconTS1b and TconTS1e-1 were taken from Koliwer-Brandl et al. [34] 
(Chapter 3.1). Kinetic para-meters for TconTS1g were calculated using the 
Michaelis-Menten kinetics (Figure 1 A and B) employing Prism6. Data points 
are means ± standard deviation of triplicates. 
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Along this line, we noticed that besides the substitution R144C most of the critical amino acid 
differences comparing TconTS1b with TconTS1e-1 and TconTS1g, are located at the LDs 
[34] (Chapter 3.1 Figure 3). Thus, the LD of TconTS1e-1 is more related to the LD of 
TconTS1g than to the LD of TconTS1b. Furthermore, it can be seen that amino acid residues 
599-602 represent a significant structural element at the LD comprising the most critical and 
subsequent changes [34] (Chapter 3.1 Figure 3). A further discussion regarding this significant 
structure element at TconTS-LD is provided in the following Chapter 4.3.3. 
Since all TconTS1 variants, besides TconTS1g, showed similar overall enzyme 
activities under standard conditions, a more detailed biochemical characterisation of just two 
TconTS1 variants, namely TconTS1b and TconTS1e-1, which mainly differ in their C-
terminal LD, was performed to investigate potential variations in enzymatic activities. In 
addition also substrates, other then fetuin and lactose have been utilised in further enzyme 
activity experiments [34] (Chapter 3.1). Indeed significant differences were observed, when 
fetuin was used as donor substrate under standard reaction conditions, whereas both TconTS1 
variants produced different amounts of 3’SL (product of TS activity) in 30 min. Nevertheless, 
each enzyme generated almost the same amount of 3’SL within 20 h of incubation, when 
equilibrium was reached. 
These findings strongly suggest different substrate affinities of TconTS1 variants for the 
various sialylated oligosaccharides attached to fetuin, which is also reflected by the distinct 
KM values of TconTS1b (359 µM) and TconTS1e-1 (1617 µM) for fetuin-bound Sia [34] 
(Chapter 3.1). In addition, even no TS or sialidase activity was detected using MU-Neu5Ac 
with these two recombinant TconTS1 variants. These observations are in contrast to data 
reported by Tiralongo et al., who determined a KM for Gal-MU approximately 10 fold higher 
compared to TconTS1b and TconTS1e-1 [34] (Chapter 3.1), as well as hydrolytic activity on 
MU-Neu5Ac, when using native TS-form 1 and TS-form 2, preparations isolated from 
procyclic T. congolense trypomastigote cultures [28]. It is important to note that these 
isolated, native TS-forms do not correspond to TconTS1 and TconTS2, described in this 
work. 
However, it should also be mentioned that the presence of a mixture of different 
TconTS variants in TS-form 1 and/or TS-form 2 preparations has been proposed [34] (Chapter 
3.1), since some TconTS enzymes may exhibit higher affinities for MU-Neu5Ac or pNP-
Neu5Ac and efficiently transfer Sia to MU-Gal or hydrolyse the donor substrate. 
Nevertheless, no sialidase activities were detected neither for TconTS1b nor TconTS1e-1 
after 30 min incubation using fetuin and lactose as substrates [34] (Chapter 3.1). Only when 
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enzymes were incubated for 20 h clear sialidase activities were observed, indicated by the 
production of free Neu5Ac in the 
reaction. Interestingly, free Neu5Ac 
was already detected very early in 
TS reactions with 3’SL as donor 
and ASF as acceptor substrate (Sia 
transfer from 3’SL to asialofetuin). 
This finding together with the 
occurrence of free Neu5Ac only in 
extended reactions using fetuin and 
lactose, suggested that free Sia as a 
side product generated by the 
hydrolysis of 3’SL, if it is present in 
sufficient amounts accumulated at 
later stages during standard TS 
reaction with fetuin as donor and 
lactose as acceptor substrates. 
Without any suitable acceptor 
substrate, both, TconTS1b and 
TconTS1e-1, showed similar hydro-
lytic activity on fetuin as well as on 
3’SL. Compared to TconTS1b and 
TconTS1e-1, more drastic differen-
ces in enzyme activities have been 
observed for the other three TconTS 
gene family members TconTS2, 
TconTS3 and TconTS4. 
As discussed in Chapter 4.1, all four 
TconTS1 through TconTS4 contain 
Figure 1: Time dependency of TconTS1 variants and Michaelis-Menten kinetics of TconTS1g 
reactions. A) Time dependent enzymatic activities of TconTS1c, f, g and i were determined using 
standard conditions (100 µg fetuin, 2 mM lactose, 50 ng TconTS incubated at 37°C) and different 
incubation times. B) Varying concentrations of fetuin-bound Sia were used as donor substrate and 
incubated for 30 min with 100 ng TconTS1g under standard conditions. C) 600 µM fetuin-bound Sia 
was used as donor substrate with varying amounts of lactose and 100 ng TconTS1g under standard 
conditions. Data points are means ± standard deviation of triplicates. 3’SL production was quantified 
employing HPAEC-PAD analysis [34] (Chapter 3.1).  
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almost all amino acid residues critical for enzymatic activity, but more drastically differ in 
their overall amino acid sequence similarities. To determine enzymatic activities, recombinant 
TconTS2, TconTS3 and TconTS4 were incubated with fetuin and lactose as donor and 
acceptor substrates under standard conditions. TS activities were detected for all three 
enzymes, clearly presenting them as active TS, although significant variations in catalytic 
activities were observed. High 3’SL production demonstrated that TconTS1 and TconTS2 are 
the most active enzymes with about 100- to 1000-fold higher specific Sia transfer activity 
compared to TconTS3 and TconTS4 under the same reaction conditions [35] (Chapter 3.2). 
Surprisingly, TconTS2 exhibited the highest specific TS activity among all characterised 
TconTS. Tyrosine Y211 in TconTS1, which is assumed to be part of the acceptor substrate 
binding-site (demonstrated for TcruTS [25]), is substituted to a proline residue (P196) in 
TconTS2 (Figure 2). This drastic change was suggested to decrease TS activity in TconTS2 
due to the loss of substrate interaction, whereas experimental data demonstrated the contrary. 
However, since all other amino acid residues involved in Sia transfer activity of 
TconTS2 are conserved relative to those of the also highly active TconTS1 (except the less 
drastic substitution of Y408 in TconTS1 to W393 in TconTS2) further, yet unknown reasons 
have to be responsible for this unexpected observation. One possible explanation arose from 
results obtained by Amaya et al. regarding the Y119 in TcruTS (corresponding to Y211 in 
TconTS1 and P192 in TconTS2), which has been demonstrated to contribute to Sia stability in 
the covalent intermediate through hydrogen bond formation to the C-9 hydroxyl group, 
mediated by subsequent conformational change of the catalytic centre upon substrate binding 
(allosteric effect) [25,37]. Due to the presence of P192, such a hydrogen bond formation 
cannot occur in TconTS2 but might be partially compensated by hydrogen bond formation of 
the conserved residues W197 and Q274 in TconTS2 (corresponding to W120 and Q195 in 
TcruTS), which have also been demonstrated to contribute to the hydrogen bond network of 
the glycerol side chain of Sia in TcruTS [25]. Nevertheless, this substitution in the highly 
active TconTS2 indicates that a tyrosine at this position is not required for enzymatic activity, 
but may even contribute to the high TS activity of TconTS2.  
Along this line, it seems obvious to look for other structural elements, which might be 
responsible for the relatively high catalytic activity of TconTS2. In addition, similar reasons 
might also explain the relatively low TS activities of TconTS3 and TconTS4, since both 
enzymes comprise the well conserved composition of all critical amino acid residues at the 
catalytic centre [35] (Chapter 3.2). 
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Another aspect regarding the specific enzymatic activities of TconTS deals with 
significant environmental changes during parasites life cycle in mammalian host and tsetse 
vector, which is for example characterised by an shift from pH 7 (mammalian blood stream) 
up to pH 10 (tsetse midgut [4]). Therefore, it was important to investigate pH dependency of 
TconTS enzymatic activities, which may provide further insight into the catalytic properties 
of TconTS1 through TconTS4 and moreover, how these may relate to their potential role in 
different host systems.  
Significant differences in TS and sialidase activities of TconTS were determined using 
fetuin and lactose as donor and acceptor substrates under standard conditions at different pH 
values (Chapter 3.3). TconTS1, TconTS3 and TconTS4 exhibit maximum TS activities at pH 
7 and a more or less drastic decrease of their activities towards higher pH values. These 
findings fit to possible roles as active TS in trypomastigote bloodstream forms, since the 
Figure 2. Structural comparison of TconTS1 (red coloured amino acid 
residues) and TconTS2 (yellow coloured amino acid residues). The 
superimposed homology models of TconTS1 in complex with 3’-
sialyllactose (coloured in light blue) and TconTS2 were generated using the 
crystal structure of TcruTS (PDB code: 1SOI) as template employing the 
software Yasara as described under Methods in chapter 3.1. A detailed 
illustration of the catalytic centres of both enzymes is shown. The 
conserved tryptophan residue W393 in TconTS2 (yellow, corresponds to 
334 in TcruTS) is substituted to a tyrosine (red Y408) and occupies the 
same donor substrate binding-site in TconTS1 compared to TconTS2. The 
conserved tyrosine at position 211 (red Y211, corresponds to Y119 in 
TcruTS) in TconTS1, which stabilise the acceptor substrate via stacking 
interactions is substituted to a proline (yellow P196) in TconTS2. Molecular 
Van der Waals surfaces of the illustrated residues and 3’-sialyllactose are 
shown in transparent spheres, respectively. 
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present pH value of 7.4 in blood is very close to the optimal pH of 7.0 determined for 
TconTS1, TconTS3 and TconTS4 (Chapter 3.3 Figure 1). Interestingly, in contrast to that, 
TconTS2 showed a maximum TS activity at pH 9, indicating a potential predominant role as 
TS of procyclic parasites in tsetse midgut with its alkaline environment of about pH 10. 
Furthermore, in the absence of lactose, TconTS4 showed relative significantly enhanced 
sialidase activity (appr. by the factor of 7) at higher pH values (maximum sialidase activity at 
pH 9) compared to the sialidase activity determined for the other enzymes, although the 
amount of free Sia produced by TconTS4 is still less compared to that produced by TconTS1 
and TconTS2 under same conditions, respectively. However, if lactose is present, sialidase 
activity of TconTS4 is almost abolished at pH 9. Nevertheless, this has suggested that 
TconTS4 might be a more prominent sialidase in tsetse midgut, if expressed in procyclic 
trypomastigotes. Nevertheless, it should be noted that the precise expression patterns of 
TconTS in the parasites life cycle, including procyclic trypomastigotes and blood stream 
parasites, is still unknown so far. 
In summary, it has been demonstrated that TconTS1 and TconTS2 exhibit the highest 
TS activities, whereas TconTS3 and TconTS4 have the lowest specific activities. Comparing 
Sia transfer with sialidase activities, TconTS2 has the lowest transfer/hydrolysis ratio and 
TconTS4 the highest among TconTSs under the reaction conditions used [34,35] (Chapter 3.1 
and 3.2). Furthermore, it might be possible that the low Sia transfer activity observed for 
TconTS3 and TconTS4 on substrates tested, is due to higher specific affinities to other donor 
and/or acceptor substrates, such as blood glycoproteins and glycolipids, as well as parasites 
own glycoconjugates [35] (Chapter 3.2). In this context, it should be noted that the T. 
congolense procyclic glutamic acid/ alanine-rich protein (GARP), which is expressed on the 
parasites surface, has been demonstrated to be a suitable substrate for TconTS trans-
sialylation [30], and was found to be relatively strong associated to isolated native TS-forms 
[28]. Thus, additional natural substrates for TconTS reaction have to be identified and 
characterised also to investigate the biological role of TconTS3 and TconTS4. 
4.2.2 Cooperatively mediated specific sialidase activities of TconTS 
Besides critical amino acids at the catalytic centre, which are mostly well conserved 
among TconTSs, other structural features have to exist, which modulate TS and sialidase 
activities in TconTS and possibly their orthologous from other trypanosomes.  
One first surprising evidence for cooperativity between the different TconTS was 
obtained, when mixtures of different recombinant TconTS were tested for enzymatic activities 
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with MU-Neu5Ac as substrate. As mentioned earlier in this Chapter 4.2, recombinant 
TconTS1 and TconTS2 exhibit relatively poor hydrolysing activities on the synthetic donor 
substrate MU-Neu5Ac. A similar behaviour was observed for TconTS3 and TconTS4, which 
did not show any hydrolytic activities on MU-Neu5Ac. However, mixtures of TconTS1 or 
TconTS2 together with any of the other recombinant TconTS (e.g. TconTS3 or TconTS4) 
revealed relatively good hydrolytic activities (TT Gbem, personal communication). In 
contrast, a mixture of TconTS3 and TconTS4 was not able to hydrolyse MU-Neu5Ac under 
the same reaction conditions, leading to the suggestion that TconTS1 and TconTS2 are 
generally able to cleave synthetic substrates such as MU-Neu5Ac, but need the presence of 
another different TconTS, which somehow induce this or other activities of TconTS1 and 
TconTS2. This consideration is in good agreement with the hypothesis that not only one 
TconTS form is expressed at each stage of the parasites life cycle, but a composition of 
different active TS and possibly inactive proteins is responsible for the oveall TS and sialidase 
activities [19,35] (Chapter 3.2). Interestingly, as mentioned earlier in this Chapter, Tiralongo 
et al. demonstrated that native TS-form 1 as well as TS-form 2 isolated from T. congolense 
procyclic trypomastigotes were able to hydrolyse MU-Neu5Ac [28].  
Tiralongo et al. also described an anti TS specific monoclonal antibody (anti-
T.congolense TS mAb 7/23), which was generated against partially purified TS forms and 
recognised both, TS-form 1 and TS-form 2, but precipitated only 75% of the TS activity 
present in T. congolense cell culture supernatnats [28]. In addition, also no cross reactivity 
with recombinant TcruTS or TbruTS has been found [28]. It is important to note that this anti-
TconTS mAb specifically recognises recombinant TconTS1 and TconTS2, but not TconTS3 
and TconTS4 [34,35] (Chapter 3.1 and 3.2). In summary, these findings have suggested that at 
least the native TS-form 1, isolated by Tiralongo et al. might have been a mixture of TconTS1 
and TconTS2, since the anti-TconTS mAb 7/23 obviously recognises an epitope shared by 
both enzymes, TconTS1 and TconTS2. 
In summary, these observations together with the fact that the isolated native TS-forms 
1 and 2 are able to hydrolyse MU-Neu5Ac provided good evidence that both isolated TS-
forms most likely represent mixtures of TconTS1 and TconTS2 enzymes and that the T. 
congolense cell culture supernatnats possibly also contained TconTS3 and/or TconTS4. This 
would eb in good agreement with the hypothesis of a cooperatively regulated sialidase 
activity for MU-Neu5Ac and possibly also other synthetic and yet unknown natural 
substrates. 
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4.3 The lectin domain of TconTS and its influence on enzyme activities 
The majority of studies available in literature regarding the catalytic mechanism and 
structure-function relationships between trypanosomal TS have been focused almost 
exclusively on the catalytic domain, mainly that of TcruTS [23-25,36,37,42,43]. In contrast, 
only very limited data was available addressing potential links between the diversity in 
catalytic activities of different TS and their lectin-like domain (LD) of these unusual enzymes. 
Obviously, differences in TconTS enzymatic activities observed for TconTS1 through 
TconTS4 in this work, cannot be exclusively explained by the composition of critical amino 
acid residues at the catalytic centre. For example, all 12 amino acid residues at the catalytic 
centre known to be essential for substrate binding and catalysis are completely identical in 
TconTS1 and TconTS4 [35] (Chapter 3.2). 
 This observation may lead to the expectation that both enzymes also exhibit similar 
catalytic activities, whereas TconTS1 and TconTS4 drastically differ in their enzymatic 
properties [34,35] (Chapter 3.1 and 3.2). When using fetuin and lactose as Sia donor and 
acceptor substrates under the same standard reaction conditions, TconTS1 was found to be 
highly active (TS activity = 4000 nmol/(min x mg TS), sialidase activity = 60 nmol/(min x mg 
TS)), whereas TconTS4 showed drastically lower TS (9 nmol/(min x mg TS)) and sialidase 
(2,7 nmol/(min x mg TS)) activities, corresponding to reductions by the factors of ~450 and 
~22, respectively. These observations either indicated important roles of other amino acid 
residues at or near the catalytic centre, which are not directly involved in substrate binding 
and catalysis, but indirectly by possibly maintaining the flexibility of loops containing critical 
amino acids and thus contribute to the highly dynamic processes at the CD during catalysis, 
and/or point to different fundamental regions elsewhere in the protein, which have not been 
considered regarding differences in enzymatic activity so far. The later hypothesis is 
supported by the surprising results of a more detailed phylogenetic analysis of TconTS1 
through TconTS4 and the TconTS-Like genes, together with TcruTS, TranSA, TbruTS and 
TvivTS genes [35] (Chapter 3.2). Besides the close relation of African active TS on one hand, 
and American active TS on the other, as well as the distant relation to TconTS-Like genes 
encoding for inactive TconTS, results surprisingly also revealed the grouping of highly active 
TconTS2 together with the less active TconTS3 and its more distant relation to the also highly 
active TconTS1. Interestingly, further phylogenetic analysis only considering TconTS-LDs, 
grouped the highly active TconTS1 and TconTS2 together, as well as the less active TconTS3 
and TconTS4 in another branch [35] (Figure 3 B, Chapter 3.2). These surprising findings, for 
the first time indicated a functional relevance of LD and suggested their potential involvement 
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in modulating enzymatic activities. Since only very limited data were available about 
structure-function relations of the LD of trypanosomal TS, including their possible lectin 
activities, recombinant LDs from TconTS1 through TconTS4 were cloned, expressed and 
biochemically characterised [29] (Chapter 3.4). 
4.3.1 TconTS-LD specific binding to different carbohydrate ligands 
Specific binding of recombinant TconTS-LDs to several carbohydrate structures could 
be demonstrated for the first time, employing specific techniques optimised to analyse and 
characterise protein-ligand interactions, such as glycan array and STD NMR spectroscopy 
[29] (Chapter 3.4). Using the glycan array approach as a rapid and broad screening method to 
identify glycan structures as suitable TconTS-LD ligands, a full library of more than 300 
different glycans was tested. A brief description regarding the principle of this method is 
provided in Chapter 3.4 [29].  
Testing all four TconTS-LDs, predominantly recombinant TconTS2-LD was found to 
bind several galactosyl and lactosyl oligosaccharides, as well as some oligomannosyl glycans 
[29] (Chapter 3.4 Figure 2). In addition, TconTS1-LD was also found to bind galactosyl 
glycans but with significantly lower binding activity and decreased number of glycan 
structures, whereas no binding was determined neither for TconTS3 nor TconTS4 on the 
glycan array. Besides the observed lectin activity of TconTS2-LD for several galactosyl and 
lactosyl oligosaccharides, especially binding to mannose containing glycans was unexpected. 
Interestingly, it had been described that mannose is not a suitable acceptor substrate for trans-
sialylation by TbruTS [11] and TconTS [28,30]. Thus, lectin activities of TconTS-LD to 
Figure 3. Phylogenetic analysis on DNA genes of catalytic and lectin domain of TconTS1-4. 
A) Phylogenetic analysis on TconTS-CDs. The two more inactive TconTS3 and TconTS4 
group together with the highly active TconTS2, which is in turn surprisingly distantly related 
to the also very active TconTS1. B) Phylogenetic analysis on TconTS-LDs. TconTS-LD 
alignment shows TconTS1 and TconTS2 group together as well as TconTS3 with TconTS4. 
Active TconTS are labelled with red cycles. Phylogenetic trees were calculated as described 
under Methods in Chapter 3.2 [35]. The graphic was originally generated and provided by 
Prof. Dr. Sørge Kelm. 
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mannosyl glycans indicate possible non-identified biological functions distinct from that of 
TconTS-CD. 
The missing lectin activity observed for TconTS3-LD and TconTS4-LD might either 
indicate that they are not binding carbohydrates or that suitable ligand structures were not 
present on the glycan array. In addition, it should be noted that, in contrast to common C-type 
lectins [44-46], TconTS-LDs do not require divalent ions, such as Ca2+, for efficient lectin 
activity, suggesting a different mode of ligand binding compared to those mannose binding 
lectins. In conclusion, these preliminary data already provided evidence for a novel, yet 
unknown function of TconTS. 
STD NMR experiments were employed to further characterise TconTS-LD binding to 
mannosyl and lactosyl oligosaccharides using recombinant TconTS2-LD and α-D-lactose 
(Lac) as well as α1-3,α1-6-mannotriose as ligand structures [29] (Chapter 3.4). Results 
revealed that both ligands were clearly bound by TconTS2-LD, indicated by the relatively 
strong STD NMR signals for both molecules compared to the control spectra (off-resonance 
spectra) [29] (Chapter 3.4 Figure 3). Furthermore, the STD NMR signals for the β-GlcH2 and 
GalH4 protons of Lac provided good evidence that both monosaccharide units interact with 
TconTS2-LD. Similar observations were made for α1-3,α1-6-mannotriose [29] (Chapter 3.4 
Figure 3). In summary, these data provided evidence for more extended carbohydrate binding 
sites in TconTS-LD. An important observation was made when adding an equimolar amount 
of Lac to the TconTS2-LD/α1-3,α1-6-mannotriose complex. No evidence for a competition of 
the two ligands was found, since (I) no reduction of the STD NMR signals of α1-3,α1-6-
mannotriose occurred and (II) additional signals from Lac were detected. These surprising 
findings are very good evidence that both ligands bind simultaneously to thermodynamically 
distinct binding sites on TconTS2-LD. It will be interesting to extend such ligand competition 
experiments to further confirm and characterise these distinct binding sites and and the 
binding epitopes for both ligands in detail with series of related ligand molecules. 
4.3.2 TconTS-LD binding to high-mannose N-glycans as a potential 
biological function? 
Microtitre plate-based binding and inhibition assays had been developed by Bock and 
Kelm [33] to characterise siglec-ligand interactions. The principle of this method is generally 
similar to the classical ELISA (enzyme-linked immunosorbent assay), which is commonly 
used in biochemical applications for specific qualitative and quantitative analysis of antigens 
[47]. The primary antibody (capture antibody) in the so called sandwich ELISA is commonly 
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immobilised to a solid phase (surface of a microtitre plate) and utilised to “capture” the target 
antigen, which is in turn detected via a second antigen specific antibody, mostly conjugated to 
a selected detection system (Enzyme, fluorophore etc.). When using the siglec-binding assays, 
this primary antibody was replaced by a Sia containing binding partner, such as the highly 
sialylated glycoprotein fetuin, to quantify the binding of siglecs in the presence and absence 
of a potential inhibitor [33,48]. 
Utilising the principle of this method, a TconTS-LD binding and inhibition assay was 
established to further characterise the lectin activity of LDs to glycoproteins [29] (Chapter 
3.4). The concept comprises the usage of immobilised, high-mannose glycans containing 
glycoproteins as potential TconTS-LD model binding structures, since mannosyl glycans have 
been demonstrated as relatively effective TconTS2-LD ligands. One major difference of this 
binding assay, in contrast to the glycan array performed in this work, was the usage of more 
complex N-linked oligosaccharides. Since glycoproteins expressed in CHO-Lec1 cells are 
glycosylated with N-linked oligosaccharides of the high-mannose type [49] recombinant 
proteins produced by these cells seemed to eb good candidates for TconTS binding and 
therefore, we used these as TconTS-LD binding target structures. 
TconTS-LD binding assay results demonstrated specific binding activity of TconTS2-
LD to immobilised Siglec-2Fc applied as high-mannose glycan carrying glycoprotein. The 
specificity of this interaction for glycan binding was confirmed by competitive inhibition with 
high-mannose oligosaccharides, which were enzymatically released from glycoproteins 
expressed by CHO-Lec1 cells [29] (Chapter 3.4 Figure 4). Interestingly, in contrast to that 
finding no clear inhibition of TconTS2-LD binding has been observed when using the 
monosaccharide α-methyl-mannopyranoside, which is a well known inhibitor for 
concanavalin A (ConA) [50], even at relatively high concentrations of about 50 mM [29] 
(Chapter 3.4 Figure S4). This is a good indicator for the proposed extended binding site of 
TconTS2-LD interacting with more than the final mannose residues. It also points towards a 
preference for oligo- or polyvalent ligands reported for other lectins, which have been 
postulated to prevent unspecific interactions leading to enhanced ligand selectivities [46,51]. 
Recombinant TconTS expressed in CHO-Lec1 cell lines are also glycosylated with N-
linked oligosaccharides of the high-mannose type, which was demonstrated by ConA lectin 
blot analysis [29] (Chapter 3.4 Figure 5). N-glycosylation site predictions revealed eight to 
nine potential sites differently distributed in TconTS1 through TconTS4 with one site being 
conserved [29] (Chapter 3.4 Figure S3). However, it remains unclear which of the predicted 
N-glycosylation sites are used for glycosylation in post-translational modification processes. 
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Furthermore, it should be noted that native TbruTS was shown to contain high-mannose 
oligosaccharides, since it binds to ConA [52], although the glycosylation pattern of these 
enzymes has remained unknown. Along this line, it can be assumed that also native TS from 
T. congolense carries high-mannose glycans. 
Size exclusion chromatography experiments with TconTS1 and TconTS2 produced in 
CHO-Lec1 demonstrated the presence of dimeres and oligomeres for both enzymes, where for 
TconTS1 almost equal quantities of monomers and dimers were found, whereas 
predominantly monomers were detected for TconTS2 [29] (Chapter 3.4 Figure 6). In 
agreement to these findings, Tiralongo et al. observed high molecular weights for native TS-
forms isolated from T. congolense trypomastigotes [28]. Although the TS-form 1 and TS-form 
2 characterised by Tiralongo et al. do not directly correspond to TconTS1 and TconTS2, their 
data are in perfect agreement with the oligomerisation potential of TS from T. congolense 
described in this work. Furthermore, TconTS oligomerisation appears to be N-glycan 
dependent and therefore possibly LD mediated, since EndoH treatment of TconTS1 
significantly shifted the amount of dimeric to monomeric structures. Although the biological 
relevance of TconTS oligomerisation has remained unclear so far, our experimental data have 
provided evidence for a potential role in enzyme stability and/or enhanced substrate affinities 
as well as enzyme activities.  
Additional in vitro experiments addressing stability of TS activity of TconTS1 and 
TconTS2 after storage for a long time period at 37°C revealed that even after four month at 
37°C TconTS1 retained almost full TS activity, whereas TconTS2 completely lost its activity 
(data not shown). In the light of the observed oligomerisation, it can be suggested that the 
relatively high oligomerisation potential of TconTS1 may support its stability and provides 
one possible explanation for the retained TS activity after incubation for four month at 37°C. 
In addition, the relatively low oligomerisation potential of TconTS2 is also in agreement with 
this hypothesis and would explain the loss of TS activity possibly due to enzyme degradation. 
Formation of TconTS homo- (or hetero-) dimers and oligomers thus might play a role for the 
half-life of shed TconTS in the mammalian host and insect vector, although no experimental 
data regarding this theory are available in literature so far. In addition, also the possible 
formation of TconTS hetero-dimers and/or association to other native molecules, such as 
GARP (T. congolense procyclic glutamic acid/ alanine-rich protein [53]), have to be 
considered in respect to potential oligomerisation of TconTS on the parasite and its biological 
relevance. 
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4.3.3 Structural properties of TconTS-LD 
Our results obtained from glycan array, STD NMR spectroscopy, TconTS-LD 
binding/inhibition assay and oligomerisation experiments clearly demonstrated the lectin 
activity of TconTS-LD binding to several different carbohydrate ligands [29] (Chapter 3.4). In 
addition, clear binding preferences of TconTS-LDs towards polymeric and complex ligand 
structures were observed. Accordingly, the specific structural arrangement of TconTS-CD and 
LD relative to each other might provide the simultaneous binding of both domains to the same 
ligand, which could consequently enhance the specific binding affinities and possibly also 
catalytic activities. The fact that both, the catalytic binding pocket of CD as well as the 
proposed carbohydrate binding-site of LD [23,54] are localised on the same site of the enzyme 
(Figure 4 A), supports this hypothesis of simultaneous binding. To investigate this possibility, 
the direct distance between the catalytic tyrosine residue (Y438 in TconTS1, Chapter 3.2 
Table 2) in active centres of TconTS-CD and a phenylalanine residue in the predicted 
carbohydrate binding-site of TconTS-LD was determined from homology models of TconTS1 
through TconTS4 and was found to range from 40.5 to 42.6 Å [29] (Figure 4 A and Chapter 
3.4).  
It should be noted that the phenylalanine residue assumed to be involved in 
carbohydrate binding [54] is well-conserved among TconTS (Figure 4 B-E) with an RMSD 
(root-mean-square deviation) value of 1.1, 1.3 and 1.6 Å for TconTS2, TconTS3 and 
TconTS4 relative to TconTS1, respectively. Interestingly this phenylalanine was also found in 
TbruTS and is substituted by tyrosine in both, TcruTS and TranSA. One interesting and 
significant observation was made when comparing the overall topology of the proposed 
binding-site of TconTS-LDs employing the homology models generated in this work. As 
shown in Figure 4, the predicted binding pocket of TconTS2-LD is more open compared to 
that of TconTS1, TconTS3 and TconTS4 (Figure 4 B-F), due to an overlying loop (labelled in 
green) covering the phenylalanine-containing groove (unpublished data). 
Therefore the flexibility of this loop, defined through its amino acid sequence, might be 
a critical factor for effective lectin activities of TconTS-LD assuming that this location 
participates to the carbohydrate binding-site. Table 2 illustrates the amino acid sequence 
alignment of TconTS1 through TconTS4 of the loop region mentioned above. It can be seen 
that amino acid residues flanking the loop are very diverse among TconTSs (Table 2). 
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TconTS1 and TconTS2
TconTS1 TconTS2
TconTS3 TconTS4
B C
D E
F
TconTS2A
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Table 2: Comparison of amino acid residues from TconTS1 through TconTS4 forming a loop 
structure close to the predicted carbohydrate binding-site of TconTS-LD 
Enzyme Amino acid residue 
TconTS1b R599 E600 G601 K602 V603 
TconTS1e-1 R599 K600 D601 Q602 V603 
TconTS2 N584 E585 - E586 S587 
TconTS3 Y592 E593 G594 E595 T596 
TconTS4 S654 K655 G656 E657 N658 
Conserved amino acid residues are grey shaded 
 
One striking observation comprises the missing glycine residue in TconTS2, which 
shortened the loop but will not drastically reduce its overall flexibility. In addition, only 
TconTS2 and TconTS3 contain two glutamic acid residues in close relation (E585 and E586 
in TconTS2, E593 and E595 in TconTS3), whereas both, TconTS1 variants and TconTS4 
exhibit a relatively drastic substitution from a negatively charged glutamic acid to a positively 
charged lysine residue (K600 in TconTS1e-1, K602 in TconTS1b and K655 in TconTS4). 
This change of the electrostatic potential may influence the flexibility of the loop due to 
repulsive and/or attractive interactions to adjacent amino acid side chains. However, these 
three amino acids have been suggested to play a critical role in the sterical orientation of the 
loop and thus, possibly are indirectly involved in lectin activity of TconTS-LD. 
In this context, it should be mentioned again that experimental results concerning the 
specific enzymatic activities of the two TconTS1 variants, TconTS1b and TconTS1e-1 
revealed significant differences [34] (Chapter 3.1). Interestingly, the only drastic differences 
in the amino acid sequence of these two TconTS1 variants are located exactly in the region of 
the critical loop (599-602) mentioned above and have been proposed to be involved in 
recognition of larger substrate molecules, such as glycoproteins [34] (Chapter 3.1 Figure 3). 
Figure 4. Proposed carbohydrate binding-site of TconTS-LD. A) Homology model of 
TconTS2. The active centre of the catalytic domain (CD) is marked with a yellow ellipse. 
The proposed carbohydrate binding-site of the lectin domain (LD) is marked with a red 
ellipse. B-E) Homology models of TconTS(1-4)-LD showing only the proposed 
carbohydrate binding-site. A flexible loop element proposed to influence lectin activity is 
labelled in green. F) Structural comparison of TconTS1-LD (yellow) and TconTS2-LD 
(blue). Significantly different configurations of a loop element covering the proposed 
binding site are illustrated. Homology models were generated using the crystal structure of 
TcruTS (PDB code: 1SOI) as template employing the software Yasara as described under 
Methods in Chapter 3.1 [34]. The molecular surface of each structure model is shown in 
grey. Amino acid side chains suggested to be involved in carbohydrate recognition are 
presented. 
 
Summarising discussion 
 268 
These findings could explain the observed variations in TS activity of TconTS1b and 
TconTS1e-1 and would support the hypothesis concerning the importance of the loop 
structure in carbohydrate binding activity of LD and consequently catalytic activity of 
TconTS. 
It will be interesting, to perform mutagenesis experiments in future to further 
characterise TconTS-LD binding and to challenge the hypothesis mentioned above. 
4.3.4 The influence of TconTS-LD on enzymatic activity 
The ability of TconTS-LD to bind carbohydrate structures as well as their structural 
significant features and ligand specificities has been discussed in the previous Chapters. 
Based on that, the question arises, whether TconTS-LD plays a direct role in influencing 
enzyme activities including TS/sialidase rates. To address this question a genetic approach 
was used to recombine TconTS-domains from differ, on the DNA level, without the 
disruption of any critical structure elements (Chapter 3.5). In order to introduce a unique 
restriction site two additional amino acids were inserted into a loop segment, which was 
proposed to be the most potent location for such a mutation. This loop element follows the 
domain-connecting α-helix and is neither resolved in the crystal structure of TcruTS [24] nor 
conserved in trypanosomal TS, demonstrating its flexibility and suggesting that it is not 
important for the overall folding of the TS (Chapter 3.5 Figure 2).  
To test this option in theory, homology models of domain swapped TconTS were 
calculated to investigate potential problems of a practical recombination of TconTS-domains. 
The in silico results revealed domain swapped TconTS, exhibiting high overall structure 
similarity to wild type TconTS, without the loss or drastic change of any critical structure 
elements (data not shown). In addition, an extended molecular surface area and a well-defined 
hydrogen bond network at the interface between TconTS-CD and LD of domain swapped 
enzymes was observed, which was also found in wild type TconTS1 through TconTS4 and is 
well-conserved in the TS family (Chapter 3.5 Figure 1 and Tables 1-3). It has been reported 
that this extended contact site together with these hydrogen-bonds is significantly stronger 
pronounced compared to related microbial sialidases [24,43], possibly indicating an enhanced 
interplay of both, TconTS-CD and LD.  
Two out of twelve theoretically possible domain swapped TconTS enzymes were 
selected for cloning and expression, comprising CD of TconTS1a and LD of TconTS3 
(termed TconTS1aTS3) as well as CD from TconTS2 and LD of TconTS4 (termed 
TconTS2TS4). The idea was to recombine the CD of a relatively high active TconTS 
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(TconTS1 or TconTS2) to the LD of a lower active enzyme (TconTS3 or TconTS4) to 
investigate possible changes in TS and sialidase activities. TconTS1aTS3 has been 
successfully cloned and expressed in fibroblasts (CHO-Lec1). Due to time consuming stable 
transfection of CHO-Lec1 cells, TconTS1aTS3 has also been expressed in E. coli (Chapter 
3.5 Figure 3). Thus, preliminary enzyme activity data of TconTS1aTS3 were determined with 
this bacterial protein, clearly demonstrating its TS activity. Interestingly, this activity was 
significantly lower compared to that of TconTS1a wild type expressed by E. coli, but still 
approximately two fold higher than TconTS3 wild type (Chapter 3.5 Figure 6 A and C). In 
contrast, the amount of free Neu5Ac produced by TconTS1aTS3 was similar to that of 
TconTS1a wild type and again double as high as for TconTS3 wild type (Chapter 3.5 Figure 6 
B and C). Thus, TconTS1aTS3 exhibited a rather similar TS activity to TconTS3 and sialidase 
activity to TconTS1a. In summary, it can be concluded that the exchange of LD modified the 
catalytic activity of TconTS1a supporting the correlated hypothesis mentioned above 
regarding a potential influence of LD on enzyme activity. The mechanistic reasons for that are 
still not clear, but it is proposed that the lectin activity of LD to glycoproteins, which serve as 
substrates for Sia transfer activity, enhances the affinity to these substrates and therefore 
supports the catalytic activity of the enzyme. However, it should be kept in mind that the 
enzyme activities of TconTS expressed by bacteria was found to be orders of magnitudes 
lower compared to that of enzymes expressed in fibroblasts [34] (Chapter 3.1 and Chapter 
3.5). 
Interestingly a complete different situation regarding the enzymatic behaviour of 
domain swapped TconTS1aTS3 was found, when the enzyme was expressed by CHO-Lec1 
cells. Experimental data revealed no significant reduction of TS activity for TconTS1aTS3, 
indicated by the amount of 3’SL produced, which is almost the same as that generated by 
TconTS1a wild type (Chapter 3.5 Figure 6 D and F). In contrast, sialidase activity of 
TconTS1aTS3 was drastically reduced of about 85 % compared to TconTS1a wild type 
(Chapter 3.5 Figure 6 E and F,).  
In summary, it seems that TS activity of TconTS1aTS3 is drastically reduced in contrast 
to the retained sialidase activity, when TS is expressed in bacteria, whereas the exact contrary 
enzymatic behaviour was observed when TconTS1aTS3 was expressed in CHO-Lec1 cells. In 
addition, the general overall enzymatic properties (TS/sialidase ratio) of TconTS1a wild type 
remains approximately constant, independent from the expression system used in this work. 
Considering only these results, it can be concluded that another factor, besides the domain-
exchange, influences enzyme activities, which could be either the folding and/or 
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glycosylation of the enzyme, since glycoproteins expressed by CHO-Lec1 fibroblasts are 
glycosylated with high-mannose N-glycans, whereas proteins expressed by E. coli Rosetta 
pLacI completely lack glycosylation.  
Surprisingly, the situation becomes even more complex, when enzymatic activities of 
the control TconTS1a* were considered. TconTS1a* is similar to the wild type but 
additionally comprises the insertion if the two amino acids (Tyr-Val) introduced to facilitate 
the domain swap (Chapter 3.5 Figure 2). It has been observed that both, TS and sialidase 
activities, of TconTS1a* expressed by CHO-Lec1 fibroblasts were drastically reduced 
compared to TconTS1a wild type (Chapter 3.5 Figure 6 D-F). Interestingly, only TS activity 
of TconTS1a* is significantly lower compared to that of domain swapped TconTS1aTS3, 
whereas its sialidase activity was two fold higher then that of TconTS1aTS3. 
Currently, it remains unclear what kind of effect might be induced by the insertion in 
TconTS1a* causing the observed variations in TS and sialidase activities. Referring to this, 
further data regarding the enzymatic activities of TconTS2 and TconTS2* (Chapter 3.5 Figure 
6 D-F), additional in silico data (Chapter 3.5 Figure S1 A), as well as Western blot analysis 
(Chapter 3.5 Figure 3 D) using anti TS mAb 7/23 [28,34,35] (Chapter 3.1 and 3.2) provided 
cumulative evidence for important roles of N-glycosylation at a defined location in TconTS-
LD strerically close to the loop segment carrying the inserted Eco105I endonuclease 
restriction site (Chapter 3.5 Figure S1 B). It was proposed that the inserted two amino acids 
possibly interfere with N-glycosylation of the N657, which is sterically in close vicinity to the 
loop segment comprising the insertion (Chapter 3.5 Figure S1 B). Along this line, it was 
assumed that sufficient N-glycosylation of this site might be essential for proper folding of the 
corresponding region. In addition to this, it has previously been reported that single point 
mutations of amino acid residues (corresponding to E710 and R704 in TconTS1 variants) 
forming a conserved salt bridge close to the N-glycosylation site mentioned above, 
significantly influence enzymatic activities of TcruTS [43,55]. However, it has remained 
unclear what kind of mechanistic effect might be responsible for this change in TS activity. 
Interestingly, this salt bridge is far away from the catalytic centre of TcruTS, thus indicating 
another functional structure element contributing to the hypothesis that LD influences 
TconTS enzymatic activity. 
In conclusion, the relatively high TS activity of domain swapped TconTS1aTS3 clearly 
demonstrated the efficiency and general usability of the TconTS domain-swap strategy, which 
was established and demonstrated in this work. Based on the data obtained in this study, 
additional optimisations appear possible for even better comparability of TconTS catalytic 
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activities when swapping TconTS domains and possibly also LDs from other trypanosomal 
TS. For example, it would be of fundamental interest in future experiments to recombine 
TconTS2-LD with CDs from TconTS1, TconTS3 and TconTS4 as well as the domain swap 
between the eleven TconTS1 variants, since they represent TconTS1 enzymes comprising 
natural mutations in CD and LD [34] (Chapter 3.1). 
4.3.5 TconTS-LD activity opens new strategies towards novel potent TS 
inhibitor synthesis 
Potent TS inhibitors exhibiting selective inhibitory properties in the low µM to nM 
range are not available so far. However, besides all current full synthetic compounds, which 
have only moderate TS inhibitory effects, some natural occurring molecules have been 
identified and successfully tested as relatively potent TcruTS inhibitors [56]. This class 
comprises the family of gangliosides as well as N-linked-type oligosaccharides [56]. For 
example terminal α2-3-linked Sia containing gangliosides, such as GM3 (Neu5Acα2,3-
Galβ1,4-Glc-ceramide) and GSC-31 (Neu5Acα2,3-Galβ1,4-GlcNAcβ1,3-Galβ1,4-Glc-R) 
showed IC50 values in the lower µM range using TcruTS [56]. Furthermore, a tetra-antennary, 
complex N-linked-type oligosaccharide, comprising four terminal sialylated saccharide chains 
of the type (Neu5Acα2,3-Galβ1,4-GlcNAc) exhibit also inhibitory effects in the low µM 
range [56]. Therefore, it was proposed that the enhanced inhibitory properties of GM3 and the 
N-linked-type oligosaccharide compared to other synthetic compounds, is mainly due to their 
ability to occupy both, the donor and the acceptor substrate binding-sites in the catalytic 
centre of TcruTS [56]. According to these findings, a new set of synthetic compounds has 
been synthesised, which should be able to target both binding sites similar to the natural 
ligands mentioned above [57]. Against all expectations, these novel TS inhibitors surprisingly 
showed only minor TS inhibitory properties on TcruTS [57]. Thus, it is still of fundamental 
importance to fully understand the mechanistic of trypanosomal TS activity for more potent 
inhibitor synthesis. 
However, the observed lectin activity of TconTS-LDs on several glycan structures, 
demonstrated in this work (Chapter 3.4) [29], is suggested to bring new light into potent TS 
inhibitor synthesis. The fact that TconTS-LD showed binding preferences towards 
oligosaccharide ligands, strongly suggested that the enhanced inhibitory effect of oligomeric 
glycans on TS activity is due the additional binding of the ligand to the LD of TS, which is in 
agreement with data observed from STD NMR experiments and supports the hypothesis of an 
extended binding site on TconTS-LD [29] (Chapter 3.4). Such a simultaneous binding of a 
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multivalent ligand to TS would possibly significantly increase affinity to TconTS and 
consequently also its inhibitory potential. In theory it would be possible for a relatively long 
ligand to bind both, CD and LD at the same time, since the carbohydrate binding pocket of 
CD and LD are located on the same site of the enzyme and targeted in the same direction 
(Figure 4 A). Furthermore, the distance between the active centre of the catalytic domain and 
the proposed extended binding-site of the lectin domain of TconTS is in the range of 
approximately 40 Å, as it can be seen from Figure 4 A. This value equals approximately the 
length of an oligosaccharide comprising six to seven monosaccharide units, where each 
monosaccharide is about 7 Å long. Therefore it might be of significant importance to consider 
the aspect of TconTS-LD lectin activity for future strategies to establish a class of novel and 
more potent TS inhibitors. The impact of 1-4β-mannotriose on the sialidase activity of 
TconTS1a and TconTS2 (Chapter 3.5) is an example for the potential of addressing the LD to 
modulate the enzymatic activities. Furthermore, blocking of this LD site might have 
significant impact on the supramolecular organisation of the glycoproteins on the parasites 
surface.  
Another aspect refers to the hypothesis that trypanosomal TS and siglecs share ligand-
binding properties for the same type of Sia containing glycan structures. Indeed such an 
correlation between trypanosomes and siglecs from host cells has been reported previously 
[14,58,59]. It has been demonstrated that trypanosomal TS generates sialo-glycoconjugates on 
the parasites surface, which were specifically bound by Siglec-E expressed on host 
phagocytic and antigen-presenting cells (macrophages), respectively [60]. However, it can be 
hypothesised that TS generates sialo-glycans on the parasite surface, which might also 
specifically interact with other related receptors for example from the siglec family [61], such 
as Siglec-1 (sialoadhesin, Sn [62]), Siglec-2 (CD22 [63]) and Siglec-4 (myelin associated 
glycoprotein, MAG [64]), which are expressed on macrophages, oligodendrocytes and other 
cell types [34] (Chapter 3.1). Indeed specific interaction of sialoadhesin (Sn), expressed on 
macrophages, to sialo-glycoconjugates of cultured T.cruzi trypomastigotes and epimastigotes 
has been demonstrated [65]. With respect to these findings and the hypothesis made above it 
can be further concluded that potent siglec inhibitors in general may also serve as promising 
TS inhibitors, since both proteins obviously recognise (compete) the same ligands on host 
cells [59]. Therefore, it will be interesting to test known siglec inhibitors, such as the novel C-
4 and C-9 disubstituted Neu5Ac derivatives reported by Kelm et al., which have been 
demonstrated to be relatively strong Siglec-2 inhibitors with affinities in the sub-µM range 
[48], for their inhibition potential on TconTSs.  
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In summary, it might be of significant importance to consider both aspects regarding 
TconTS ligand properties discussed in this Chapter, (1) the extended length to simultaneously 
bind to TconTS-CD and LD and (2) novel C-4, C-9 and/or other substitutions at the terminal 
Neu5Ac residue. These new strategies may provide a novel generation of potent TS inhibitors 
comprising affinities potentially in the lower µM to nM range. 
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5 Outlook 
Main achievements of this work comprise the detailed biochemical characterisation of 
trans-sialidases from T. congolense and the carbohydrate-binding activities of TconTS-LD. 
The results obtained are novel and provide important and enhanced knowledge about TS in 
general and their biological role in T. congolense during parasite’s developmental life cycle in 
host and vector. Thus, based on this study new strategies can be developed for anti-TS drug 
design and possibly other new therapy forms against Trypanosomiasis in human and animal.  
The diversity of active and non-active TconTS genes, described in this study, presents 
the relatively complex situation in the African T. congolense. Furthermore, biochemical 
characterisations of TconTS, performed in this work demonstrated striking differences in 
enzymatic activities of TconTS utilizing several combinations of Sia acceptor and donor 
substrates and different physical reaction conditions. These findings together with recent 
mRNA isolation experiments from blood stream forms of T. congolense provided evidence 
for a well-defined Sia transfer machinery of the parasite in both the mammalian host and 
insect vector. Since the previously reported anti TS mAb 7/23, which was further 
biochemically characterised in this work, recognises TconTS1 as well as TconTS2, it cannot 
be efficiently used to investigate the expression pattern of the different TconTS proteins in 
vivo. Therefore, it would be of significant importance to generate antibodies specific for each 
TconTS enzyme as potential tools for their detection and differentiation during the 
development of trypanosomiasis and establishment of disease control measures. 
Glycosylation of trypanosomal TS was previously demonstrated by ConA affinity 
purification of native TS from T. cruzi and T. brucei procyclic trypomastigotes. 8-9 potential 
N-glycosylation sites were predicted for TconTS in contrast to only 2-4 for TcruTS and 
TranSA, indicating a possible, more complex glycosylation pattern in the African 
trypanosomal TS. Oligomerisation experiments of TconTS performed in this study 
demonstrated the high-mannose N-glycan dependency of this process. In addition to that, 
experimental data obtained, provided good evidence for the direct influence of N-
glycosylation on enzymatic activities. However, only limited data is available regarding the 
glycosylation pattern of trypanosomal TS and their direct or indirect influence on enzyme 
activities so far. Additional MALDI-MS and mutagenesis experiments should provide further 
insight into glycosylation of TconTS and the role in enzymatic catalysis. 
Finally, carbohydrate binding of TconTS lectin domain to mannosyl oligosaccharides 
was demonstrated for the first time and presented in this work. Distinct lectin activities of 
TconTS1 through TconTS4 to different carbohydrate ligands together with experimental data 
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obtained from domain swap experiments provided strong evidence for a direct role of 
TconTS-LD on enzymatic activities. However, ligand specificities as well as the location and 
topology of the binding sites of TconTS-LD still remain to be investigated. Therefore, it is of 
fundamental importance to further characterise the specific TconTS-LD-ligand interactions 
through subsequent biophysical methods, such as SPR (surface plasmon resonance), ITC 
(isothermal titration calorimetry), STD NMR and crystallisation experiments. It can be 
suggested that enhanced knowledge about TconTS-LD ligand affinities and specificities 
provide new insight into TS enzymatic activities, their biological functions and possibly 
represents TconTS-LD as a biotechnological tool for specific carbohydrate detection and/or 
cell traffic inhibition in several applications. 
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